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1.1 Transition Metal-Catalyzed C−H Activation 
In the past decades, transition metal-catalyzed cross-coupling reactions have been considered 
as one of the most useful and reliable tools for carbon−carbon (C−C) or carbon−heteroatom 
(C−Het) bond formation,[1] including Kumada-Corriu,[2] Negishi,[3] Suzuki-Miyaura,[4] Migita-
Kosugi-Stille,[5] Hiyama,[6] Mizoroki-Heck[7] and Sonogashira-Hagihara[8] cross-couplings. 
These reactions have been employed in the synthesis of pharmaceuticals, natural products, 
agrochemicals, polymers and feedstock commodity chemicals.[9] Despite the enormous 
progress achieved by cross-coupling reactions,[10] they still show some opportunities for 
improvement, especially the necessity for pre-functionalized substrates is a major limitation. 
These pre-functionalization steps are accompanied with the generation of stoichiometric 
amounts of undesired byproducts and metal containing wastes. As a more atom- and step-
economical alternative,[11] direct C−H functionalization has recently emerged as a powerful tool 
allowing the transformation of otherwise unreactive C−H bonds, which bears the potential for 
the construction of C−C or C−Het bonds without pre-functionalization steps.[12] Furthermore, 
the direct formation of C−C bonds by activating two C−H bonds, including C(sp3)−H bonds,[13] 
which was termed cross-dehydrogenative coupling (CDC), has also been extensively studied 
(Scheme 1.1.1).[14] 
 




The key step, the C–H metalation can be accomplished depending on the nature of the transition 
metal species LnM. Five generally accepted pathways of these mechanisms have been 
summarized by Ackermann[12n] as well as Eisenstein and co-workers,[15] which is shown in 
Scheme 1.1.2. The mechanistic modes include (a) oxidative addition with electron-rich and 
low-valent late transition metals, (b) σ-bond metathesis with early transition metals and 
lanthanides, (c) electrophilic substitution with electron-deficient late transition metals, (d) 1,2-
addition onto unsaturated M−X bonds, and (e) the base-assisted deprotonation, called either 
concerted metalation-deprotonation (CMD) or ambiphilic metal ligand activation (AMLA) 
(Scheme 1.1.2). 
 
Scheme 1.1.2 Plausible mechanisms for C−H activations. 
The concerted metalation-deprotonation (CMD)[16] or ambiphilic metal ligand activation 
(AMLA)[17] is based on a six-membered transition state. Metals with alkoxy ligands favors an 
internal electrophilic substitution (IES), which is based on a four-membered transition state.[18] 
Recently, a related base-assisted internal electrophilic substitution (BIES) has been proposed 





Scheme 1.1.3 Proposed transition states for the base-assisted metalation. 
In 1955, an early example of directed C–H functionalization reactions was reported by 
Murahashi. The treament of imine 1 with catalytic amounts of cobalt at high temperature and 
pressure of CO led to the formation of 2-phenylisoindolin-1-one (2) (Scheme 1.1.4).[20] 
 
Scheme 1.1.4 Cobalt-catalyzed C–H carbonylation. 
Thereafter, a variety of transition metal-catalyzed C–H functionalizations have been explored, 
using 4d and 5d transition metals, for instance by palladium, platinum, rhodium, ruthenium and 
iridium, as well as the inexpensive, naturally abundant 3d base metals, such as iron, cobalt, 
nickel and copper.[12, 21] 
1.2 Nickel-Catalyzed C−H Activation 
During the past decade, catalytic reactions based on inexpensive naturally abundant base metals 
have become a significant research area, driven by declining natural resources of precious 
metals and their enormous price increases. Therefore, C–H functionalization using nickel 
catalysts has recently received considerable attention from synthetic chemists because nickel 
catalysts are more cost effective than noble transition metal catalysts, in particular palladium.[22] 
The cost of nickel (10 €/kg) in its elemental form is roughly 0.04% of the price of palladium 
(24017 €/kg).[23] Moreover, unlike palladium, nickel has specified key properties, such as facile 





Important contributions to nickel-catalyzed C–H activation were made as early as the 1960s. 
Indeed, an adduct of a C–H bond of azobenzene (3) onto a nickel complex 4 was reported by 
Dubeck and Kleiman in 1963 (Scheme 1.2.1a).[25] Thereafter, Liang and coworkers disclosed 
the pincer nickel complex 6 could react with benzene (7) to achieve complex 8 under mild 
conditions via the oxidative addition of the C–H bond of benzene without any directing group 
(Scheme 1.2.1b).[26] 
 
Scheme 1.2.1 Stoichiometric C–H activation using nickel complexes. 
Early examples of catalytic C–H activation focused on electronically-biased azole substrates as 
investigated by the groups of Miura, Itami, Hu and Ackermann.[27] These C–H functionalization 
reactions include arylations, alkenylations, alkylations as well as alkynylations. The latter two 
reactions will be described in the following sections separately. 
(a) Nickel-Catalyzed C–H Activation without Directing Group 
In 2009, examples of nickel-catalyzed C–H arylation of 1,3-azoles 9 with aryl halides 10 to 
synthesize 2-ary-1,3-azoles 11 were reported.[27d, 27e] In both reactions, it was essential to use 
the strong base LiOt-Bu. The Itami group developed the nickel-catalyzed C–H/C–O coupling 
of 1,3-azoles 9 and phenol derivatives 12,[28] while cobalt-catalyzed direct arylation and 
benzylation through C–H/C–O bond cleavage were reported by Ackermann.[29] Interestingly, 
1,2-bis(dicyclohexylphosphino)ethane (dcype) as the ligand was key success for this 
transformation, while other ligands did not deliver the desired products. The Ni(cod)2/dcype 




carbonates, sulfamates, triflates, tosylates, and mesylates. However, the Ni(cod)2/dcype catalyst 
was limited by a narrow substrate scope, as imidazoles were unreactive under these reaction 
conditions. More recently, Itami and Yamaguchi reported a method for the C–H arylation of 
imidazoles with aryl carbamates using nickel(II) instead of nickel(0), which is a less expensive 
complex [Ni(OTf)2/dcype] as compared to [Ni(cod)2/dcype] (Scheme 1.2.2).[30] 
 
Scheme 1.2.2 C–H arylation of azoles 9 with aryl electrophiles 10 and 12. 
Nickel-catalyzed oxidative C–H arylations using organometallic species as the aryl source have 
also been reported in recent years (Scheme 1.2.3). In 2010, Miura and coworkers developed an 
oxidative direct arylation of 1,3-azoles with arylsilanes[31] or arylboronic acids[32] in the 
presence of copper salts or air as the oxidants. These reports could be regarded as a significant 
finding because oxidative C–H arylation with arylsilanes were rare.[33] One year later, nickel-






Scheme 1.2.3 C–H arylation of azoles with organosilicon, boron, and Grignard reagents. 
Miura’s oxidative arylation strategy (see Scheme 1.2.3) could also be applied for the C–H 
alkenylation of oxazole with alkenylsilanes and alkenylboronic acids, as shown in Scheme 
1.2.4a.[31] The oxidative alkenylation was observed in moderate yield at high temperature. 
Likewise, Itami’s conditions for the C–H arylation (see Scheme 1.2.2) were suitable for the  
C–H/C–O alkenylation with enol derivatives as coupling partners using nickel/dcype or 
nickel/dcypt catalytic system in good yields (Scheme 1.2.4b).[30, 35] 
 
Scheme 1.2.4 C–H alkenylation of azoles with organosilicon, boron and carbamate reagents. 
In 2012, Itami discovered the nickel-catalyzed decarbonylative C–H biaryl coupling of azoles 
and aryl esters (Scheme 1.2.5a).[36] Under a catalytic system similar to the aforementioned 
nickel-catalyzed C–H/C–O coupling (see Scheme 1.2.2), the decarbonylative C–H arylation of 
oxazole 9 with heteroaromatic esters 15 proceeded efficiently to afford the corresponding 
coupling products 13. Additionally, these reaction conditions could be applied to the 




Thereafter, Ge and coworkers reported a nickel-catalyzed decarboxylative coupling using α-
oxoglyoxylic acids 16 as coupling partners (Scheme 1.2.5b).[37] In the meantime, Zhang and 
coworkers performed a nickel-catalyzed decarboxylative coupling of benzoxazoles and 
carboxylic acid derivatives 18 employing nickel(II) catalyst in conjunction with N-heterocyclic 
carbene (NHC) IPr·HCl as the ligand (Scheme 1.2.5c).[38] Although the nickel-catalyzed 
decarboxylation needed harsh conditions, including stoichiometric silver salts used and high 
reaction temperature), it was still the first example of this type of reaction using a nickel catalyst. 
 
Scheme 1.2.5 Nickel-catalyzed decarbonylative and decarboxylative C–H activation of 
azoles. 
As early as 2006, Nakao, Hiyama, and coworkers developed a nickel-catalyzed hydroarylation 
of alkynes with heteroarenes.[39] In recent years, the catalytic hydroarylation system was 
improved by Nakao and Hiyama using nickel(0) and phosphine ligands. This nickel-catalyzed 
hydroarylation was applicable not only for five-membered heteroarenes 19 such as benzoxazole, 
thiazole,[39] oxadiazole,[40] pyrazole[41] and imidazole,[42] but also electron-deficient arenes 22, 
such as azine-N-oxide,[43] pyridine[44] and pentafluorobenzene.[45] Notably, the nickel-catalyzed 
hydroarylation occured in high regioselectively at the C2 position on pyridines with the addition 
of Lewis acids such as ZnMe2 or ZnPh2 instead of using N-oxides. In contrast, a nickel-




coworkers. They showed that the complexation of amino-NHC (24) and AlMe3 activated a  C–
H bond on pyridine at the C4 position.[46] 
 
Scheme 1.2.6 Hydroarylation of alkynes 20 with heteroarenes. 
The hydroarylations were not only applicable for alkynes 20, but also for alkenes 25 (Scheme 
1.2.7). The groups of Nakao, Hiyama,[47] Hartwig[48] and Ong[49] mainly contributed to these 
achievements. Similar to the hydroarylation of alkynes 20, the hydroarylation of alkenes only 
worked well for the electron-deficient aromatics such as pyridine (occurred at C4 postion)[50] 
and 1,3-bis(trifluoromethyl)benzene.[51] 
 
Scheme 1.2.7 Hydroarylation of alkenes 25 with heteroarenes. 
As to mechanism, nickel-catalyzed hydroarylation C–H functionalization typically starts with 
the coordination of the alkyne to the nickel(0) species. Then, an aromatic C–H bond reacts with 




nickel(II)–alkenyl intermediate 27b, which then undergoes reductive elimination to furnish 
hydroarylation products 23 (Scheme 1.2.8).[39] 
 
Scheme 1.2.8 Hydroarylation-type C–H functionalization. 
(b) Nickel-Catalyzed C–H Activation under Chelation-Assistance 
Despite these important contributions, all the aforementioned C–H transformations were 
applicable only for the activation of relatively acidic C–H bonds on heteroaromatic and specific 
arenes. In the case of simple arenes, such as benzoic acid derivatives and anilines, the utilization 
of a chelation assistance for site-selective nickel-catalyzed C–H functionalization was achieved, 
after the conception of bidentate auxiliaries by the group of Daugulis for palladium-catalyzed 
C–H activations.[12d] Based on these findings, Chatani and coworkers attempted a nickel-
catalyzed annulation of inert C–H bonds of benzamides containing a 2-pyridylaminomethane 
moiety as a bidentate directing group.[52] More recently, nickel-catalyzed C–H arylation,[53] 
carbonylation,[54] sulfonylation,[55] thiolation,[55a, 56] amidation,[57] amination,[58] halogenation,[59] 
alkenylation,[60] allylation,[61] alkylation[62] and alkynyltation[63] of benzamides were reported 
using bidentate auxiliaries such as 8-aminoquinoline (Q) and (pyridin-2-yl)isopropyl (PIP) 





Scheme 1.2.9 Selected examples of nickel-catalyzed C–H activation under bidentate 
assistance. 
The bidentate directing group strategy has remained most widely used within directed nickel-
catalyzed C–H functionalization. However, scarce examples involving monodentate 
approaches have been reported. One example is the nickel-catalyzed oxidative annulation of 
oximes 36 developed by Matsubara (Scheme 1.2.10a).[64] Another is the nickel-catalyzed alkyne 
annulation of electron-rich anilines 38 to form substituted indoles with removable directing 
groups performed by Ackermann (Scheme 1.2.10b).[65] It is noteworthy that the C–H/N–H bond 






Scheme 1.2.10 Nickel-catalyzed C–H functionalization with monodentate auxiliaries. 
1.2.1 Nickel-Catalyzed C–H Alkylation 
Compounds bearing alkyl groups have attracted significant attention in organic chemistry.[66] 
This is due to their abundance in natural products, and their effect on the pharmacokinetic of 
drug moleculars in medicinal chemistry.[67] Therefore, aliphatic substrates with various 
substituents and functional groups can be commonly found in a wide range of top-selling drugs 
(Scheme 1.2.1.1).[68] 
 
Scheme 1.2.1.1 Selection of bioactive compounds containing aliphatic groups. 
Regarding transition metal-catalyzed direct C–H alkylations two approaches have been 
commonly followed: hydroarylation of alkenes, which has been discussed above (Scheme 1.2.7 




which was first developed by Ackermann in 2009 using ruthenium catatalysis (Scheme 
1.2.1.2b).[70] 
 
Scheme 1.2.1.2 Strategies for transition metal-catalyzed C–H alkylation. 
Recently, nickel-catalyzed C–H alkylations of 1,3-azoles with alkyl halides were reported 
independently by the groups of Miura,[71] Hu[27c] and Ackermann (Scheme 1.2.1.3).[72] Direct 
C–H activation using alkyl halides is relatively rare compared to hydroarylation of olefins due 
to the facile β-hydrogen elimination of alkylmetal reagents.[70i] 
 




To suppress ß-hydrogen elimination, the Miura group developed a C–H alkylation of 
benzoxazole with alkyl hydrazones 54 as the alkylating reagent instead of alkyl halides 
(Scheme 1.2.1.4a).[73] Furthermore, an intramolecular C–H alkylation of arenes via a radical 
pathway was reported by Lei in 2013 (Scheme 1.2.1.4b).[74] 
 
Scheme 1.2.1.4 Nickel-catalyzed aromatic C–H alkylation. 
Intermolecular C–H alkylation of benzamides through nickel catalysis was achieved using a 
bidentate directing group by Chatani and coworkers (Scheme 1.2.1.5).[62b] Although, only 
primary alkyl bromides reacted in the presence of Ni(OTf)2/PPh3, the reaction conditions could 
be applied to methylation when using MeOTs and NaI or PhMe3NI as the methylating 
reagent.[62c] 
 
Scheme 1.2.1.5 C–H Alkylation with primary alkyl halides 58. 
In 2014, Ackermann group realized the nickel-catalyzed C–H alkylation of unreactive arenes 




(BDMAE) was found to be an effective ligand for secondary alkylation as well as for C–H 
trifluoroethylations. 
 
Scheme 1.2.1.6 C–H Alkylation with secondary alkyl halides. 
The Ge group reported the direct alkylation of unactivated C(sp3)–H bonds of aliphatic amides 
via nickel catalysis under the assistance of the 8-aminoquinoline directing group (Scheme 
1.2.1.7).[62d] The reaction favored the C–H bonds of methyl groups over the methylene C–H 
bonds and tolerated various functional groups. However, the reaction was specific with regard 
to the structure of substrates, thus limiting its application to only aliphatic amides bearing a 
quaternary α-carbon and containing at least one β-methyl group. In this catalytic system, the 
authors proposed a mechanism through a nickel(II)/nickel(III) manifold from the oxidation of 
the nickel(II) species generated after the concerted metalation-deprotonation (CMD) by an 
alkyl radical. 
 
Scheme 1.2.1.7 Nickel-catalyzed C(sp3)–H alkylation of aliphatic amides 34. 
Indeed, in nickel-catalyzed alkylation chemistry several readily available oxidation states 
involved in catalytic cycles need to be recognized as 2-electron changes, these being 
nickel(0)/nickel(II) but also nickel(I)/nickel(III) as well as nickel(II)/nickel(IV), with the latter 




1.2.2 Nickel-Catalyzed C–H Alkynylation 
Alkynes are versatile building blocks in organic synthesis. Consequently, C–H alkynylations 
have been identified as increasingly powerful alternatives to the conventional Sonogashira–
Hagihara cross-coupling reaction.[76] An early example of nickel-catalyzed C–H alkynylation 
of oxazoles 9 was reported by Miura and coworkers in 2009 (Scheme 1.2.2.1),[77] where 
bromoalkynes 61 were used as the electrophiles to afford the corresponding alkynyl products 
62. 
 
Scheme 1.2.2.1 Nickel-catalyzed alkynylation of oxazoles. 
Instead of bromoalkynes, the more stable and easier accessible gem-dibromoalkenes 63 were 
also used for the alkynylation of 1,3-azoles, as mainly described by the groups of Ackermann,[78] 
Piguel[79] and Das (Scheme 1.2.2.2).[80] 
 
Scheme 1.2.2.2 C–H Alkynylations with gem-dibromoalkenes. 
Such a promising methodology has not yet been used for nickel. However, nickel-catalyzed 
oxidative C–H functionalization involving terminal alkynes 64 directly without pre-
functionalization, was achieved by Miura group,[81] for the dehydrogenative C–H alkynylation 
of oxazoles 9 under aerobic conditions (Scheme 1.2.2.3). 
 




As discussed above, directing groups are often not necessary for transition metal-catalyzed 
direct functionalizations in the more acidic C2 position of 1,3-azoles and related compounds, 
which is not the case for carbocyclic arenes. In 2015, the groups of Shi,[63a] Li,[82] and 
Balaraman[83] independently disclosed the C–H alkynylation of six-membered arenes with 
alkynyl bromides using chelation-assisted groups to give the corresponding ortho-substituted 
products in good yields (Scheme 1.2.2.4). 
 
Scheme 1.2.2.4 Nickel-catalyzed direct C–H alkynylation under bidentate assistance. 
Thereafter, Shi and coworkers developed an oxidative C–H alkynylation of arylamides 
containing PIP moiety in the presence of NiI2 and NaI under an oxygen atmosphere. (Scheme 
1.2.2.5).[63b] 
 
Scheme 1.2.2.5 Oxidative C–H alkynylation of benzamides. 
1.3 Manganese-Catalyzed C–H Functionalization 
The recent few years have witnessed the emergence of 3d transition metals for C–H bond 





Manganese, which is the twelfth most abundant element and the third most abundant transition 
metal after iron and titanium in the earth’s crust, is found as an essential trace element for life 
on the earth.[84] Furthermore, the low toxicity[85] and low cost of manganese[86] present a useful 
alternative for catalytic C–H activation to the typically used 4d or 5d transition metal catalysts 
derived from platinum, palladium, rhodium, or ruthenium.[21b] 
In 1970, an early report of stoichiometric direct C–H manganesation of arene was reported by 
Stone, Bruce and co-workers, where manganacycle 68 was isolated from the reaction of 
azobenzene (3) with MnMe(CO)5 (Scheme 1.3.1).[87] Following similar cyclomanganation 
protocols, a variety of manganacycle complexes could later on be obtained.[88] 
 
Scheme 1.3.1 Stoichiometric manganese-mediated C–H activation. 
1.3.1 Addition to C–Het Multiple Bonds 
Based on pioneering stoichiometric transformations, manganese(I)-catalyzed C–H bond 
activation has been investigated, with major contributions performed by the groups of 
Kuninobu/Takai, Wang and Ackermann.[89] Especially, early progress in manganese(I)-
catalyzed C–H activation was achieved by the group of Kuninobu/Takai in 2007.[90] Thus, they 
revealed the manganese(I)-catalyzed aromatic C–H bond addition onto the polar C=O bond of 
aldehydes 72 with imidazole as a directing group, initiated by probing the stoichiometric C–H 
manganesation (Scheme 1.3.2a). Notably, the use of Et3SiH (73) as additive was found to be 
crucial, as only trace amounts of the C=O bond insertion product was observed in the absence 
of additive 73 (Scheme 1.3.2b). Furthermore, manganese(I)-catalyzed diastereo-selective C–H 






Scheme 1.3.2 Manganese(I)-catalyzed C–H addition to aldehydes 72. 
A plausible catalytic cycle for the C–H activation was proposed by Kuninobu/Takai, which is 
initiated by oxidative addition of the aromatic C–H bond to the manganese center, thereby 
delivering the manganese(III) intermediate 77. Subsequent insertion of a C=O bond into the 
manganese-carbon bond forms the seven-membered manganacycle 78. Finally, the treatment 
of Et3SiH (73) furnishes the desired product 74 via the release of H2 (Scheme 1.3.3). 
 
Scheme 1.3.3 Proposed catalytic cycle for manganese(I)-catalyzed C–H  




In 2015, Wang and coworkers developed a manganese(I)-catalyzed nucleophilic addition of 
C(sp2)–H to aldehydes 72 or nitriles 81 to access the alcohols 79 or ketones 82 with good yields 
and excellent positional and stereoselectivity (Scheme 1.3.4).[91] Compared to the work of 
Kuninobu/Takai, the achievement of Wang circumvented the use of external silanes to 
guarantee catalytic turnover by the aid of ZnMe2 and ZnBr2. Importantly, ZnMe2 was found to 
be indispensable for the C–H activation step to form manganacycle complex 80, whereas 
Lewis-acid ZnBr2 was essential to the aldehyde-activation step. 
 
Scheme 1.3.4 Manganese(I)-catalyzed C–H addition to aldehydes 72 and nitriles 81. 
The first example of manganese(I)-catalyzed C–H amidation by using isocyanates 84 was 
accomplished by Ackermann and co-workers (Scheme 1.3.5),[92] constituting a competent 
alternative to processes involving relatively expensive rhodium,[93] rhenium,[94] ruthenium[95] or 
Cp*-containing cobalt(III) catalysts.[96] The C–H aminocarbonylation of heteroarenes 83 were 
well tolerated with both aryl and alkyl isocyanates 84, leading to the formation of 
aminocarbonylated products 85, which could be easily converted into substituted 






Scheme 1.3.5 Manganese(I)-catalyzed C–H aminocarbonylation of heteroarenes. 
A catalytic cycle for the manganese(I)-catalyzed C–H aminocarbonylation was proposed to be 
initiated by the precoordination of the substrate’s pyridine moiety. The subsequent C–H 
metalation formed the cyclometalated complex 88, followed by coordination and rate 
determining insertion of isocyanate 84. Finally, the desired product 85 is released by proto-
demetalation (Scheme 1.3.6). 
 
Scheme 1.3.6 Proposed catalytic cycle for manganese(I)-catalyzed C–H aminocarbonylation. 
Thereafter, a significant advance was achieved by Ackermann and coworkers, for the 
unprecedented additive-free manganese(I)-catalyzed hydroarylation of C=Het multiple bonds 




functionalizations with aldehydes, ketones and imines, overcoming the innate substrate 
selectivity. 
 
Scheme 1.3.7 Additive-free manganese(I)-catalyzed C=Het hydroarylation. 
1.3.2 Addition to C–C Multiple Bond 
Manganese(I)-catalyzed C–H activation was not limited to additions onto polar C=Het bonds. 
Indeed, Wang reported a manganese(I)-catalyzed C–H alkenylation via hydroarylation of 
alkynes 64 in the presence of HNCy2 as the additive. However, the C–H alkenylation was thus 
far largely restricted to terminal alkynes (Scheme 1.3.8). The reaction was suggested to be 
initiated by base-assisted deprotonative C–H activation resulting in the five-membered 
manganacycle 80.[98] 
 
Scheme 1.3.8 Manganese(I)-catalyzed C–H alkenylation with terminal alkynes 64 
A similar work on manganese(I)-catalyzed C–H alkenylation with highly extended substrate 
scope was later performed by Li and coworkers (Scheme 1.3.9).[99] Compared to the previous 
work from Wang, the C–H olefination was not limited to terminal alkynes 64 but also the 
internal alkynes 20, furnishing various indolyl-alkenes products, by using a catalytic amount of 
acid as additive. Interestingly, carbazoles 98 were formed in low yields via a [2+2+2] 
cycloaddition pathway in the absence of the acid (Scheme 1.3.9b). The additive PhCO2H was 





Scheme 1.3.9 Manganese(I)-catalyzed C–H alkenylation and cyclization of indoles 83 
The C–H addition strategy was also applicable to alkenes, as demonstrated by Wang and 
coworkers, with a manganese(I)-catalyzed C–H addition to α,β-unsaturated carbonyls 99 in the 
presence of catalytic MnBr(CO)5 and HNCy2 as base (Scheme 1.3.10).[100] 
 
Scheme 1.3.10 Manganese(I)-catalyzed C–H addition to α,β-unsaturated carbonyls 99. 
(c) Annulation 
The synthesis of isoquinoline derivatives 102 was accomplished by Wang and coworkers via 
dehydrogenative [4+2] annulation of N−H free imines 101 with alkynes 20 in the presence of 
MnBr(CO)5 (Scheme 1.3.11).[101] Compared to other well-known isoquinoline synthesis 
process,[102] this highly atom-economical and user-friendly strategy only produced H2 as the 
byproduct without any oxidants, ligands, or additives. Importantly, the five-membered 





Scheme 1.3.11 Manganese(I)-catalyzed C−H annulation of N−H imines 101 with alkynes 20. 
In 2015, Ackermann and co-workers illustrated the first manganese(I)-catalyzed step-
economical C−H annulation of imines 104 with acrylates 105 in DCE or toluene as the solvents. 
The valuable carbocyclic β-amino acids 106 were provided by the annulation with either 
terminal alkenes or more challenging internal alkenes 105 in high efficacy, good functional 
group tolerance and high cis-diastereoselectivity (Scheme 1.3.12).[103] 
 
Scheme 1.3.12 Manganese(I)-catalyzed C–H annulation of iminines 104 with acrylates 105. 
Recently, Kuninobu and co-workers developed the preparation of isobenzofuranones 109 from 
aromatic esters 107 and oxiranes 108 via manganese-catalyzed C−H bond activation with the 
assistance of Lewis-acid BPh3 at high temperature (Scheme 1.3.13a).[104] Indeed, key to success 
was constituted by using BPh3 as the additive, which was found to be indispensable for 






Scheme 1.3.13 Manganese(I)-catalyzed isobenzofuranones synthesis and the effect of BPh3. 
1.3.4 Substitutive C−H Functionalization and others 
The manganese-catalyzed C–H cyanation on indoles, pyrroles and tryptophans by means of 
synergistic manganese and ZnCl2 as co-catalyst was presented by Ackermann and coworkers 
(Scheme 1.3.14).[105] The role of the Lewis-acid ZnCl2 was the first time illustrated by 
experimental mechanistic studies and DFT calculations, which disclosed the synergistic effect 
of the catalysis through stabilizing coordinative interactions of the zinc(II) additive on the 
cyclomanganated transition state. 
 
Scheme 1.3.14 Manganese(I)-catalyzed C–H cyanation on indoles. 
In 2016, Ackermann and co-workers established an unprecedented manganese(I)-catalyzed 
substitutive C−H allylation with allyl carbonates 110 (Scheme 1.3.15). This example constitutes 
the first manganese(I)-catalyzed C−H activation of imines and heterocycles to give the linear 
allylation products 111 through general C−H metalation, migratory insertion, ß-oxygen 





Scheme 1.3.15 Manganese(I)-catalyzed substitutive C−H allylation imines. 
Based on the previous work, Ackermann and co-workers consistently realized manganese(I)-
catalyzed dispersion-enabled C−H/C−C activation of indole with vinylcyclopropane substrates 
112 (Scheme 1.3.16).[107] The silver-free C−H/C−C transformations led to the obtention of 
allylated heterocycle 113 in high yields and with excellent (E)-diastero-selectivities that was 
complementary to the one observed with the Cp*Co(III)/Ag catalytic system.[108] Moreover, the 
robustness of the manganese(I) catalyst set the stage for the first application of C−H/C−C 
functionalization strategy to the late-stage diversification of amino acids under racemization-
free reaction conditions. 
 
Scheme 1.3.16 Manganese(I)-catalyzed C−H/C−C activation 
Inspired by the robustness of manganese catalysis in C−H activation, an air- and water-tolerant 
manganese(I)-catalyzed decarboxylative C−H/C−O activation of indoles, ketimines and 
tryptophan derivatives with dioxolanone 114 was accomplished by the group of Ackermann,[109] 
as well as other related work were reported by other groups (Scheme 1.3.17).[110] 
 
Scheme 1.3.17 Air- and H2O-tolerant manganese(I)-catalyzed C−H/C−O activation 
Very recently, Ackermann and co-workers reported the first examples of manganese-catalyzed 




allylations and alkenylations (Scheme 1.3.18).[111] These manganese-catalyzed C−H activation 
involved a base-assisted C−H metalation, and insertion of unsaturated multiple bonds into the 
Mn−C bond via an overall isohypsic mode of action. 
 
Scheme 1.3.18 Manganese(I)-catalyzed C−H/C−F activation 
1.4 Ruthenium-Catalyzed meta-Selective C−H Functionalization 
Achieving site-selectivity is of great importance in C–H functionalization chemistry. The arenes 
of interest bear many C–H bonds with comparable dissociation energies and therefore 
controlling chemo- and regioselectivity can be a significant challenge. Several strategies have 
been developed to achieve site-selectivity between various chemically similar C–H bonds. 
These include the assistance of a Lewis-basic directing group facilitate the activation in the 
ortho-position (Scheme 1.4.1a); and catalyst-based control (Scheme 1.4.1b).[112] 
 
Scheme 1.4.1 Site-selectivity in C−H functionalization. 
Despite significant recent advances, the chelation-assisted C−H activations provided mainly 
access to a plethora of ortho-functionalized products.[12b-n, 113] In stark contrast, general 
approaches for meta-selective C−H transformations continue to be scare.[112, 114] Notable 
exceptions for remote C−H functionalizations are exploiting the inherent steric features of 




workers installed rationally designed auxiliaries, which bring the metal in close proximity to 
the meta position (Scheme 1.4.2b).[116] However, the synthesis and installation of these 
auxiliaries requires additional steps. Recently, Kanai and coworkers developed an approach 
based on a linker installed on the ligand which coordinates to the substrate via covalent or 
secondary hydrogen interactions and thus resulting the metal chelation to the meta-C–H bond 
(Scheme 1.4.2c).[117] Another catalytic strategy is based on the Catellani reaction, where a 
transient mediator, for example, norbornene, set the stage for meta-selective C−H activation, as 
reported by Yu and Dong (Scheme 1.4.2d).[118] In contrast, ruthenium catalysis was recently 
shown to facilitate meta-selective C−H activations by means of chelation-assisted 
cyclometalation (Scheme1.4.2e).[114d] 
 
Scheme 1.4.2 Strategies for meta-selective C−H functionalization. 
Frost and co-workers discovered that ruthenium catalysis led to meta-functionalization in direct 
C−H sulfonation of 2-phenylpyridine derivatives (95a) (Scheme 1.4.3).[119] To account for the 
regioselectivity of ruthenium, the authors hypothesized that the chelating group facilitates the 
formation of a stable cyclometalated ruthenium complex containing a Ru-Caryl σ-bond that 





Scheme 1.4.3 meta-Sulfonation of phenylpyridine. 
In 2008, the group of Ackermann first introduced carboxylates as ligands for robust and 
effective ruthenium(II)-catalyzed C−H bond arylations,[120] followed by oxidative 
alkenylations,[19d, 121] alkyne annulations[102c, 122] as well as primary alkylations,[70a, 70b, 123] which 
occurred exclusively at the ortho-position. In 2011, the same group devised the first direct C−H 
bond alkylations of arenes with unactivated alkyl halides 47 under mild reaction conditions 
(Scheme 1.4.4), while detailed mechanistic studies provided strong evidence for an initial 
ortho-C−H cyclometalation with subsequent remote meta-functionalization.[124] 
 
Scheme 1.4.4 meta-Selective direct alkylation of phenylpyridine. 
Very recently, Ackermann has developed a system for meta-selective tert-alkylation on 
electron-rich aniline derivatives with versatile removable directing groups (Scheme 1.4.5).[125] 
Interestingly, mono protected amino acids (MPAAs) were shown to be the best ligands for this 
ruthenium(II)-catalyzed remote C−H functionalizations. The robust nature of the versatile 
ruthenium(II)-MPAA system was mirrored by challenging remote C−H activations with tertiary 
alkyl halides 124 on anilines 123 as well as pyridyl-, pyrimidyl- and pyrazolyl-substituted 
arenes.[125] The authors also provided experimental evidence for an initial reversible C−H 





Scheme 1.4.5 meta-Selective C−H tert-alkylation of anilines 123. 
At the same time Frost and coworkers presented the meta-C–H tert-alkylation of 
phenylpyridines with a somewhat narrow substrate scope.[126] Furthermore, recent progress has 
been made in meta-selective bromination[127] and nitration[128] of phenylpyridines as well as 
meta-alkylation[129] and sulfonation[130] of azoarenes. 
However, these strategies for ruthenium-catalyzed meta-C–H functionalization continue to be 
restricted to strongly coordinating heteroaromatic pyridyl, pyrazolyl, imidazolyl or pyrimidy 
directing groups, which are difficult to modify or remove. To address these limitation, 
Ackermann and coworkers developed a powerful ruthenium(II)-catalysis manifold that 
facilitated efficient secondary and tertiary C–H alkylations of easily accessible ketimines 104a 
with exceptional levels of meta-selectivity. The transformative feature of this approach was 
emphasized by the preparation of a variety of meta-substituted arenes, including ketones, 
amines, indoles, acids and phenols through late-stage diversification (Scheme 1.4.6).[131] 
 




Remarkably, in 2017, Ackermann and coworkers reported the first remote meta-C–H 
bromination on purine bases by a heterogeneous ruthenium catalyst, which could be easily 
recovered and reused (Scheme 1.4.7).[132] 
 





Remarkable advances in transition metal-catalyzed C–H bond functionalization have been 
achieved by the group of Prof. Dr. Ackermann, especially in the chemo-, site- and 
enantioselective direct construction of C–C and C–Het bonds, with applications to material 
sciences, drug discovery and peptide assembly.[1c, 12i, 12n, 89, 124, 133] In this context, major efforts 
were made to develop novel C–H activation reactions by user-friendly nickel, manganese and 
ruthenium catalysis. 
At the outset of this thesis, Ackermann and coworkers had developed a novel nickel-catalyzed 
C–H alkylation of benzamides with bidentate auxiliaries,[62a] as well as an efficient indole 
synthesis from 2-pyrimidyl anilines by nickel catalysis via alkyne annulation.[65] In 
consideration of the importance of 2-pyrimidyl anilines as structural motifs of bioactive 
compounds relevant to crop protection and medicinal chemistry,[134] the direct C–H 
functionalization of anilines 123 bearing a monodentate directing group with alkyl halides 58 
was to be investigated (Scheme 2.1). 
 
Scheme 2.1 Nickel-catalyzed C–H alkylation of anilines 123. 
Likewise, purines represent an important and attractive structural motif in drug discovery,[135] 
and viable possibilities[136] of nucleobase modification are highly desired in synthetic chemistry. 
Therefore, the development of a protocol for versatile nickel-catalyzed C–H activation of 6-
anilinopurines 134 with alkyl halides 58 was devised (Scheme 2.2). 
 




Compared to the palladium-catalyzed Sonogashira-Hagihara reaction, direct C–H alkynylations 
have been identified as more environment friendly alternatives.[76] In recent years, despite 
remarkable advances in nickel-catalyzed C–H alkynylations,[77, 137] most nickel-catalyzed C–H 
alkynylations were limited to the acidic C–H bonds of azoles or electron-deficient benzamide 
derivatives bearing N,N-bidentate auxiliaries. Thus, the development of novel strategies for 
nickel-catalyzed C–H alkynylations of electron-rich aniline derivatives 123 or 134 with alkynyl 
bromides 61 was to be achieved (Scheme 2.3). 
 
Scheme 2.3 Nickel-catalyzed C–H alkynylation of anilines 123/134. 
Based on research in transition-metal catalyzed C–H alkynylation, less toxic manganese has 
recently gained interest in C–H activation, yet limited to the insertion reactions of multiple C–
Het or C–C bonds.[89] Therefore, it was of great interest to establish a novel approach for 
manganese-catalyzed substitutive C–H alkynylation with organic halides 61 (Scheme 2.4). 
 
Scheme 2.4 Manganese-catalyzed C–H alkynylation of indoles 83. 
The introduction of fluorine into bioactive compounds uniquely affects their properties, 
including solubility, bioavailability, and metabolic behavior.[138] For instance, fluorine atoms 
can be found in 30% of all agrochemicals and 20% of all marketed drugs.[138-139] As a result, 
suitable methodologies for the synthesis of fluorinated molecules are still strongly needed.[140] 
Based on the recent advances by the group of Ackermann on ruthenium(II)-catalyzed C–H 
activation by phosphorus ligand-acceleration,[12e, 120d, 122c, 141] and meta-C–H alkylations by a 
single-electron transfer (SET) pathway,[124-125] we set out to develop a strategy for the 
installation of fluorine through ruthenium-catalyzed remote C–H (di)fluoromethylation by 





Scheme 2.5 Ruthenium(II)-catalyzed meta-C–H mono- and difluoromethyaltions. 
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3 Results and Discussion 
3.1 Nickel-Catalyzed C–H Alkylation of Anilines 
2-Pyrimidyl anilines are privileged structural motifs of numerous bioactive compounds found 
in crop protection and medicinal chemistry, such as the anticancer drug Gleevec (Figure 
3.1.1).[134, 142] In view of these biological importance, it is important to develop new methods 
for the direct preparation of ortho-functionalized aniline derivatives. 
 
Figure 3.1.1 2-Pyrimidyl anilines in drugs and bioactive compounds. 
3.1.1 Optimization of Nickel-Catalyzed C–H Alkylation with Anilines 
We initiated our studies for the envisioned C–H alkylation of aniline 123a, which contains a 
monodentate N-pyrimidyl directing goup, with alkyl bromide 58a (Table 3.1.1). Catalytic 
systems previously reported for the nickel-catalyzed direct C–H alkylations of benzamides with 
primary alkyl halides, using bidentate directing groups, provided unsatisfactory results along 
with N-alkylation byproducts (entries 1–3). Likewise, the use of various N-heterocyclic carbene 
preligands resulted in just moderate yields (entries 4–6). In sharp contrast, extensive and 
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detailed optimization studies revealed that vicinal secondary diamines to be particularly 
suitable ligands for the transformation (entries 7-9). While tertiary amines, such as TMEDA 
gave undesired results, the secondary diamine Dt-BEDA (143) showed high conversion to the 
desired product 133aa. The optimal results were achieved in 1,4-dioxane as the solvent of 
choice at slightly reduced temperatures without forming side-product 133aa’ (entries 10–11). 
The control experiments verified the essential role of the nickel catalyst, while the C–H 
functionalization proceeded in a similar manner in the absence of an additional ligand (entries 
12–13). It is noteworthy that the optimized nickel catalysis derived from vicinal diamine 143 
was not limited to C–H activation with primary alkyl halides. Indeed, the versatile nickel 
catalyst set the stage for a general C–H alkylation strategy, also enabling C–H transformation 
with secondary alkyl halide 58b under otherwise identical reaction conditions (Table 3.1.1, right 
column). 
Table 3.1.1 Optimization of nickel-catalyzed C–H alkylation with anilines 123[a] 
 
Entry [Ni] Ligand 
Yield [%] 
133aa    133aa’    142bb 
1 [(DME)NiCl2] - 18[b] 0 --- 
2 Ni(OTf)2 PPh3 19[b] 8 5[c,d] 
3 [(DME)NiCl2] PPh3 26[b] 17 --- 
4 [(DME)NiCl2] L1 40[b] 4 66[c,d] 
5 [(DME)NiCl2] L2 54 8 --- 
6 [(DME)NiCl2] L3 22[b] 4 --- 
7 [(DME)NiCl2] L4 43 0 --- 
8 [(DME)NiCl2] L5 31[b] 7 --- 
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9 [(DME)NiCl2] L6 84 0 18[c,d] 
10 [(DME)NiCl2] TMEDA 33[b] 0 19[c] 
11 [(DME)NiCl2] Dt-BEDA (143) 87 0 99[c] 
12 - Dt-BEDA (143) 0 12 0 
13 [(DME)NiCl2] - 45 0 24[c,d] 
[a] Reaction conditions: 123a or 123b (0.50 mmol), 58a or 58b (1.0 mmol), [Ni] (5.0 mol %), ligand 
(10 mol %), LiOt-Bu (2.0 equiv), 1,4-dioxane (1.5 mL), 120 °C, 16 h; yields of isolated products are 
given. [b] [Ni] (10 mol %), ligand (20 mol %), PhMe (1.5 mL), 160 °C. [c] [Ni] (2.5 mol %), ligand (5.0 
mol %), 1,4-dioxane (1.5 mL), 100 °C. [d] 19F NMR analysis with C6F6 as internal standard, performed 
by Dr. Sebastian Lackner. 
 
Figure 3.1.2 Ligands employed for C‒H alkylation. 
3.1.2 Scope of Nickel-Catalyzed C‒H Activation with Primary Alkyl Halides 
With the optimized catalytic system in hand, we probed the C–H alkylation with a wide variety 
of aniline derivatives 123 with primary alkyl halides 58 (Scheme 3.1.1). The nickel-catalyzed 
C–H activation strategy enabled highly chemo-selective transformations of ortho- and para-
substituted arenes 123a–123e and 123k–123o, giving moderate to high yields of mono-
alkylated products 133. Moreover, we were particularly delighted to observe that meta-
substituted substrates 123f–123j containing useful ester functional groups, reacted exclusively 
at the sterically less hindered C–H bond. Furthermore, a variety of functionalized alkyl halides 
58c–58j, for instance, ether or nitrile, were well tolerated as well as various alkyl chain lengths. 
Remarkably, a sterically hindered neopentyl group could be directly introduced by the nickel-
catalyzed C–H functionalization method to furnish product 133bk in good selectivity and 
excellent yield. 




Scheme 3.1.1 Scope of nickel-catalyzed C‒H alkylation with primary alkyl halides 58. 
3.1.3 Scope of Nickel-Catalyzed C‒H Activation with Secondary Alkyl Halides 
Thereafter, we probed the efficacy of the optimized nickel(II) catalysis derived from ligand 143 
in challenging transformations with secondary alkyl halides (Scheme 3.1.2). The robustness of 
our approach was reflected by successful C–H activation with a broad range of different 
substituted anilines 123 with secondary alkyl bromide 58b. Furthermore, the reactions could be 
performed on gram scale, which furnished the desired product in high efficiency as 96% 
isolated yield. The reactions with secondary alkyl halides proved to be in a site-selective fashion 
with ortho-, meta-, and para-substituted anilines, displaying halo, ether, ester and acetal 
substituents. Moreover, the user-friendly nickel catalysis system could not only be used for 
reactions with cyclic alkyl halide 58b, but also acyclic electrophile 58l. Obviously, the versatile 
nickel-catalyzed C–H functionalization with secondary alkyl halides could be performed with 
lower catalyst loading even at a lower temperature than that described in previous report.[62a, 62b] 




Scheme 3.1.2 Scope of nickel-catalyzed C‒H alkylation with secondary alkyl halides 58. 
3.1.4 Mechanistic Studies 
Considering the uniquely versatile of the nickel-catalyzed C–H alkylation process by 
monodentate chelation, mechanistic experiments were performed. To this end, the nickel-
catalyzed C–H alkylations were performed in the presence of stoichiometric amounts of 
TEMPO. Primary alkyl halide 58a or secondary alkyl halide 58b led to catalyst inhibition by 
the radical scavenger without radical adduct formation. Howerver, by the use of alkyl halide 
58g in the presence of the radical scavenger TEMPO, the adduct 144 was observed. The 
detection of 144 might be contributed to the radical stabilized by the phenoxyl group of (3-
bromopropoxy)benzene (58g) (Scheme 3.1.3).[143] 




Scheme 3.1.3 C‒H Alkylation in the presence of radical scavenger. 
In good agreement with these observations, experiments with the radical clock 
cyclopropylmethyl bromide (58m) exclusively afforded alkylation products, resulting from a 
cyclopropylmethyl/homoallyl rearrangement with the notable formation of the 2-substituted 
tetrahydroquinoline 133bm’. Likewise, 6-bromohexene (58n) delivered the mixtures of 
alkylated products 133bn with retention of double bond, and 133bn’ of partial cyclization of 
substrate 58n. Moreover, the well-defined cis- and trans-isomers of 58o were utilized as 
electrophiles in two independent C–H alkylations, furnishing the same diastereomeric product 
mixture 142bo. This epimerization can be rationalized in terms of a homolytic C–X cleavage 
process (Scheme 3.1.4). 




Scheme 3.1.4 Key mechanistic findings for the C‒X cleavage process. 
Additionally, an intermolecular competition experiment between electron-rich and electron-
deficient anilines were conducted (Scheme 3.1.5). The results clearly showed substituents with 
electron-withdrawing groups to react preferentially, being indicative of the C–H bond acidity 
might be crucial for this type reaction. 
 
Scheme 3.1.5 Intermolecular competition experiment. 
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3.1.5 Proposed Catalytic Cycle 
Based on our preliminary mechanistic findings, we propose a plausible catalytic cycle to be 
initiated by deprotonation of substrate 123, followed by reversible C‒H nickelation, delivering 
the six-membered[144] metallacycle 145 (Scheme 3.1.6). Thereafter, the nickel species is 
suggested to trigger the formation of the alkyl radical, which is followed by radical rebound to 
generate intermediate 146. Finally, reductive elimination delivers the desired product and 
regenerates the active catalyst species. Whereas the formation of nickel(IV) species by the 
action of organic electrophiles,[75c, 75d, 145] radical addition[74] or NiI/NiIII mechanisms[62b, 75b] 
cannot be ruled out at this stage. 
 
Scheme 3.1.6 Proposed catalytic cycle. 
3.1.6 Removal of the Directing Group 
Finally, we illustrated the synthetic utility of our approach by the facile removal of the 
pyrimidyl group in a traceless fashion, yielding the corresponding anilines 147 in good yields 
(Scheme 3.1.7). 




Scheme 3.1.7 Facile removal of the pyrimidyl group. 
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3.2 Nickel-Catalyzed C‒H Alkylation of Purine Bases 
Purines represent a privileged structural motif found in various biologically active compounds 
with inter alia anti-retroviral, anti-cancer and anti-malaria activities (Figure 3.2.1).[135] Thus, 
within our own program on nickel-catalyzed C–H alkylation, it is useful to further develop 
novel strategies for the preparation of non-natural purine analogs by atom-economical chemical 
syntheses. 
 
Figure 3.2.1 Representative pharmaceutically bioactive purine bases. 
3.2.1 Optimization of Nickel-Catalyzed C–H Alkylation with Purine Bases 
At the outset of our studies, we explored a representative set of ligands for the envisioned 
nickel-catalyzed C–H alkylation of 6-anilinopurine 134a with secondary alkyl bromide 58b in 
1,4-dioxane as the solvent (Table 3.2.1). While typical phosphine, N-heterocyclic carbene, or 
bipyridine ligands yielded desired product 135ab with unsatisfactory results (entries 1−4). 
Interestingly, the vicinal diamine Dt-BEDA (143) was identified as being the optimal ligand to 
afford the desired product 135ab in 98% yield (entry 5). The conversion of substrate 134a was 
not achieved with Na2CO3 or K2CO3 as the base (entries 6 and 7). Notably, the C−H 
transformation proceeded in a similar manner in the absence of an additional ligand, albeit with 
moderate efficiency (entry 8). However, the reaction temperature could be reduced to 100 °C 
(entry 9). Additionally, a control experiment verified the essential role of the nickel catalyst 
(entry 10). 
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Table 3.2.1. Optimization of C−H alkylation with purine 134a.[a] 
 
Entry Ligand Base T [°C] 3aa [%] 
1 PPh3 LiOt-Bu 120 47 
2 IPr·HCl LiOt-Bu 120 70 
3 IMes·HCl LiOt-Bu 120 trace 
4 Dt-BBPY LiOt-Bu 120 0 
5 Dt-BEDA (143)  LiOt-Bu 120 98 
6 Dt-BEDA (143)  Na2CO3 120 0 
7 Dt-BEDA (143)  K2CO3 120 0 
8 - LiOt-Bu 120 68 
9 Dt-BEDA (143)  LiOt-Bu 100 85 
10 Dt-BEDA (143)  LiOt-Bu 120 0b 
[a] Reaction conditions: 134a (0.30 mmol), 58b (2.0 equiv), [(DME)NiCl2] (10 mol %), ligand (20 mol %), 
base (2.0 equiv), 1,4-dioxane (1.5 mL), under N2, 16 h. [b] Without [Ni]. Dt-BBPY = 4,4’-di-tert-butyl-
2,2’-dipyridyl. 
3.2.2 Scope of Nickel-Catalyzed C–H Alkylation with Purine Bases 
With the optimized condition in hand, we probed its versatility in the C–H alkylation of various 
substituted purine derivatives 134 (Scheme 3.2.1). The nickel-catalyzed C–H activation proved 
widely applicable and enabled highly chemo-selective transformations of ortho- and para-
substituted arenes 134. meta-Substituted anilines 134d-134h furnished the desired products 135 
with excellent regio selectivity control, which was governed by steric interactions. Moreover, 
the robustness of the user-friendly nickel catalyst was highlighted by fully tolerating both 
electron-rich groups as well as synthetically valuable electron-deficient functional groups, such 
as fluoro, chloro and ester substituents. Substrates displaying different N-substituents afforded 
the C–H alkylated products 135kb–135mb in good yields. Furthermore, the strategy of the 
nickel-catalyzed C–H alkylation also enable the efficient transformation of purine nucleoside 
134n. 




Scheme 3.2.1 C–H Alkylation of purine nucleoside 134. 
3.2.3 Scope of Nickel-Catalyzed C–H Alkylation with Alkyl Halides 
Subsequently, we probed the scope of various unactivated primary and secondary alkyl halides 
58 in the nickel-catalyzed C–H functionalization manifold (Scheme 3.2.2). The robustness of 
our method was highlighted by successful C–H alkylations with viable functionalized primary 
alkyl halides 58, displaying ester or ether groups, among others. Furthermore, the inexpensive 
nickel catalyst could not only be applied for couplings with cyclic alkyl halide 58r in excellent 
yield, but also the acyclic electrophile 58l, which afforded the desired product 135al in a 
chemoselective manner. Moreover, the C–H alkylation with a norbornyl bromide 58s furnished 
the exo product 135as with retention of configuration. Interestingly, the prominent synthetic 
utility of the nucleobase C–H transformation was demonstrated by introducing a pyrene 
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fluorescent label in a user-friendly fashion, highlighting the potential for the fluorescent 































Scheme 3.2.2 C–H Alkylation of purine base 134a with alkyl halides 58 and fluorescence 
spectra of 134a and 135at. 
3.2.4 Mechanistic Studies 
In consideration of the unique efficiency of the nickel catalysis regime, we became intrigued 
by rationalizing its mode of action. To this end, intermolecular competition experiments 
between differently meta-substituted arenes 134 emphasized that electron-deficient groups 
significant favors this reaction (Scheme 3.2.3a). Moreover, an intermolecular competition 
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experiment between the purinyl and the pyrimidyl groups revealed the former to be more 
powerful in the nickel-catalyzed C–H activation process (Scheme 3.2.3b). 
 
Scheme 3.2.3 Intermolecular competition experiments. 
Thereafter, the nickel-catalyzed C–H functionalization was performed in the presence of a 
series of radical scavengers. As a result, the reaction was completely suppressed by the addition 
of typical radical scavengers (Scheme 3.2.4a), which can be rationalized in terms of SET-type 
processes being of key relevance. With good concurrence with this finding, the involvement of 
radical intermediates was confirmed through the partial cyclization of 6-bromohexene (58n) 
(Scheme 3.2.4b). 




Scheme 3.2.4 Key mechanistic findings supporting SET-based mechanism. 
Moreover, we performed the nickel-catalyzed C–H alkylation of the labeled [D]5-134c, which 
revealed a reversible H/D exchange reaction, as observed by the reisolation of [D]5-134c and 
the labeled alkylated product (Scheme 3.2.5). 
 
Scheme 3.2.5 H/D Exchange experiment. 
In addition, the intermolecular kinetic isotope effect (KIE) was found to be minor (kH/kD≈1.3) 
in independent experiments, being indicative of a facile C–H metalation manner (Scheme 3.2.6). 




Scheme 3.2.6 Independent KIE studies. 
3.2.5 Removal of the Protecting Group 
Finally, the versatile synthetic utility of our strategy was demonstrated by the removal of the 
protecting group, yielding the corresponding alkylated product 148 of NH-free 6-anilinopurine 
in excellent yields (Scheme 3.2.7). 
 
Scheme 3.2.7 Traceless removal of the THP group 
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3.3 Nickel-Catalyzed C–H Alkynylation of Anilines: Expedient Access to 
Functionalized Indoles and Purine Nucleobases 
3.3.1 Optimization of Nickel-Catalyzed C–H Alkynylation with Anilines 
We initiated our studies by probing a variety of nickel catalysts for the envisioned C–H 
alkynylation of the 2-pyrimidyl substituted aniline 123a with alkyne halide 61a (Table 3.3.1). 
Thus, the user-friendly complex (DME)NiCl2 proved to be highly effective while the Ni(cod)2 
gave unsatisfied results (entries 1–5). Among a set of represent ligands, such as mono-/di-
phosphines, N-heterocyclic carbene, binaphthol and diamines, Dt-BEDA (143) was identified 
once more as being optimal and powerful (entries 6–16), thereby leading to a significantly 
reduced catalyst loading (entry 5). Different solvents were tested, and ethereal solvents were 
found to be ideal (entries 17–23). Unfortunately, other bases, such as Na2CO3, K2CO3, LiHMDS 
and KHMDS failed to afford desired product, while KOt-Bu gave only trace amounts of the 
desired product 136aa (entries 24–28). Control experiments showed that the C–H activation 
performed in a similar manner in the absence of an additional ligand with moderate efficiency, 
while the C–H functionalization failed to occur in the absence of a nickel complex (entries 29 
and 30). 
Table 3.3.1 Optimization of nickel-catalyzed C−H alkynylation with aniline 123a.[a] 
 
Entry [Ni] Ligand Solvent T [℃] 136aa [%] 
1 (DME)NiBr2 Dt-BEDA (143) 1,4-dioxane 100 53 
2 Ni(acac)2 Dt-BEDA (143) 1,4-dioxane 100 53 
3 Ni(OTf)2 Dt-BEDA (143) 1,4-dioxane 100 51 
4 Ni(cod)2 PPh3 1,4-dioxane 100 46 
5 (DME)NiCl2 Dt-BEDA (143) 1,4-dioxane 100 61 (68)[b] 
6 (DME)NiCl2 Dt-BEDA (143) 1,4-dioxane 85 56 
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7 (DME)NiCl2 Dt-BEDA (143) 1,4-dioxane 120 53 
8 (DME)NiCl2 BDMAE 1,4-dioxane 100 43 
9 (DME)NiCl2 Mes·HCl 1,4-dioxane 100 46 
10 (DME)NiCl2  1,4-dioxane 100 36 
11 (DME)NiCl2  1,4-dioxane 100 44 
12 (DME)NiCl2 PPh3 1,4-dioxane 100 60 
13 (DME)NiCl2 dppe 1,4-dioxane 100 35 
14 (DME)NiCl2 BINOL 1,4-dioxane 100 45 
15 (DME)NiCl2 PCy3 1,4-dioxane 100 46 
16 (DME)NiCl2 X-phos 1,4-dioxane 100 46 
17 (DME)NiCl2 Dt-BEDA (143) toluene 100 23 
18 (DME)NiCl2 Dt-BEDA (143) DCE 100 3 
19 (DME)NiCl2 Dt-BEDA (143) MeCN 100 0 
20 (DME)NiCl2 Dt-BEDA (143) DME 100 56 
21 (DME)NiCl2 Dt-BEDA (143) THF 100 57 
22 (DME)NiCl2 Dt-BEDA (143) DMF 100 0 
23 (DME)NiCl2 Dt-BEDA (143) NMP 100 0 
24c (DME)NiCl2 Dt-BEDA (143) 1,4-dioxane 100 0 
25d (DME)NiCl2 Dt-BEDA (143) 1,4-dioxane 100 0 
26e (DME)NiCl2 Dt-BEDA (143) 1,4-dioxane 100 0 
27f (DME)NiCl2 Dt-BEDA (143) 1,4-dioxane 100 0 
28g (DME)NiCl2 Dt-BEDA (143) 1,4-dioxane 100 trace 
29 (DME)NiCl2 - 1,4-dioxane 100 53 
30 - Dt-BEDA (143) 1,4-dioxane 100 0 
[a] Reaction conditions: 123a (0.50 mmol), 61a (2.0 equiv), [Ni] (10 mol %), ligand (20 mol %), LiOt-Bu 
(2.0 equiv), 1,4-dioxane (1.5 mL), 16h. [b] 123a (0.50 mmol), 61a (3.0 equiv), [Ni] (2.5 mol %), ligand 
(5.0 mol %), LiOt-Bu (2.0 equiv), 1,4-dioxane (1.5 mL), 100 °C, 16h. [c] Na2CO3. [d] K2CO3. [e] LiHMDS. 
[f] KHMDS. [g] KOt-Bu. 
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3.3.2 Scope of Nickel-Catalyzed C−H Alkynylation with Anilines 
With the optimized catalytic condition in hand, we explored the scope of the nickel-catalyzed 
C–H alkynylation with diversely decorated anilines 123 (Scheme 3.3.1). Hence, under the 
optimized catalytic system, the conversion of unsubstituted as well as ortho- and para-
substituted anilines (123a–123c, 123l) was enabled in high efficacy and chemo-selectivity. 
Moreover, C–H functionalizations with meta-substituted arenes 123 occurred at the less sterical 
C–H bond with high levels of positional control. The robustness of the user-friendly nickel 
catalyst was specifically reflected by fully tolerating valuable functional groups, including 
chloro, bromo, ketone, ester, or amino substituents (123j, 123q, 123u–123w). Furthermore, the 
heterocyclic substrate 123x afforded the desired product 136xa with high levels of regio-control 
in moderate yield. Notably, the corresponding N-pyridin-2-yl-substituted aniline, as well as the 
pyrimidin-2-yl-substituted phenol, failed to afford the C–H alkynylation, revealing the unique 
nature of the deprotonable pyrimidyl aniline motif. 
 
Scheme 3.3.1 Scope of C−H Alkynylation of Anilines 123. 
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3.3.3 Scope of Nickel-Catalyzed C−H Alkynylation with Alkynes 
Moreover, the robustness of nickel catalysis derived from ligand 143 was demonstrated by the 
C–H transformation with different alkynyl halides 61, such as alkynyl chloride, as well as 
different silyl groups, with best results being achieved with alkynyl bromides 61a–61c (Scheme 
3.3.2). However, the 1-octyne was not a viable substrate for the nickel-catalyzed C–H 
alkynylation under otherwise identical reaction conditions. 
 
Scheme 3.3.2 Scope of C−H alkynylation with alkynes 61. 
3.3.4 Mechanistic Studies 
In consideration of the efficient performance of the optimized nickel(II) precatalyst, we became 
inquisitive to delineating its mode of action. To this end, intermolecular competition 
experiments between electron-rich and electron-deficient anilines 123 did not show a 
significant difference in relative reaction efficacy (Scheme 3.3.3). 




Scheme 3.3.3 Intermolecular competition between different anilines. 
The C–H transformation was found to be almost unaltered in the presence of stoichiometric 
amounts of TEMPO, rendering a SET-type mechanism unlikely to be operative here, while the 
addition of typical radical scavengers led to diminished yields somehow of product 136aa 
(Scheme 3.3.4). 
 
Scheme 3.3.4 C−H Alkynylation in the presence of radical scavengers. 
Furthermore, in contrast to aforementioned nickel-catalyzed C–H alkylation of anilines 123 
(Chapters 3.1 & 3.2), the C–H alkynylation of isotopically labeled substrate [D5]-123c was not 
accompanied by a H/D exchange reaction in different reaction times (Scheme 3.3.5a). This 
observation is in consistence with a kinetic isotope effect (KIE) of kH/kD ≈ 2.6 (Scheme 3.3.5b) 
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in independent experiments between substrates 123c and [D5]-123c, which is indicative of a 
kinetically relevant C–H metalation step. 
 
Scheme 3.3.5 H/D Exchange and KIE experiments 
3.3.5 Proposed Catalytic Cycle 
Based on our mechanistic studies and previous reports,[137b, 137c] we propose a plausible catalytic 
cycle as shown in Scheme 3.3.6. Initially coordination of substrate 123 to nickel(II) was 
followed by a ligand exchange and C–H cyclometalation to form complex 145. The oxidative 
addition of alkynyl bromide 61a afforded the intermediate 146b, which underwent reductive 
elimination and protonation to furnish the alkynylated product 136 with regeneration of the 
nickel(II) catalyst. 




Scheme 3.3.6 Proposed catalytic cycle 
3.3.6 Nickel-Catalyzed C–H Alkynylation of Purine Bases 
Likewise, the versatile nickel-catalyzed C–H functionalization approach developed by us was 
also highlighted by performing the first C–H alkynylation with purine nucleobases 134 
(Scheme 3.3.7). Thus, the C–H activation of the adenines 134 occurred exclusively by the 
N1-chelation assistance on the aniline moiety, while the significantly more acidic imidazole 
and pyrimidine C–H bonds remained unactivated. Thereby, the sole products 137 were achieved 
by the alkynylation of purines 134, which should prove instrumental for future applications to 
DNA and RNA chemistry. 




Scheme 3.3.7. Nickel-catalyzed C–H alkynylation of purine bases 134 
Interestingly, the purinyl moiety proved again to be a more powerful directing group in the 
nickel-catalyzed C–H activation process through an intermolecular competition experiment 
between the pyrimidyl and the purinyl substituted anilines (Scheme 3.3.8). 
 
Scheme 3.3.8 Directing group ability. 
3.3.7 Diversification of C–H Alkynylation Products 
Finally, we illustrated the synthetic utility of our approach by the facile removal of the 
protecting group in traceless fashion. Additionally, the unprecedented nickel-catalyzed C–H 
alkynylation of NH-free anilines 123 sets the stage for the expedient synthesis of diversely 
decorated indoles 149 in good yields via a copper-catalyzed intramolecular hydroamination[147] 
approach (Scheme 3.3.9). 




Scheme 3.3.9 (a) Diversification and (b) preparation of indoles 149. 
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3.4 Manganese(I)-Catalyzed C‒H Alkynylation: Expedient Peptide Synthesis and 
Modification of Peptides 
3.4.1 Optimization of Manganese(I)-Catalyzed C‒H Alkynylation 
At the outset of our studies, we probed the effect of representative bases and solvents on the 
envisioned manganese(I)-catalyzed C‒H alkynylation of indoles 83 with silyl bromoalkyne 61a 
(Table 3.4.1). Among a variety of organic and inorganic bases, dicyclohexyl amine afforded 
satisfactory results at 120 °C with 1,4-dioxane as the solvent while inorganic bases such as 
NaOAc and Na2CO3 resulted in unsatisfactory yields (entries 1‒7). DCE was identified as the 
optimal solvent for the C‒H alkynylation with reduced catalyst loadings and reaction 
temperatures as low as 60 °C (entries 10‒13). Further control experiments verified the essential 
role of the manganese catalyst and the amine base likewise (entries 14 and 15). 
Table 3.4.1 Optimization of manganese(I)-catalyzed C‒H alkynylation. 
 
Entry X Mn (mol %) Base Solvent T [°C] Yield [%][b] 
1 CH 10.0 Cy2NH 1,4-dioxane 120 93 
2 CH 5.0 Cy2NH 1,4-dioxane 100 78 
3 CH 5.0 Cy2NH DCE 80 85 
4 N 10.0 Cy2NH 1,4-dioxane 120 94 
5 N 5.0 Cy2NH 1,4-dioxane 120 71 
6 N 5.0 NaOAc 1,4-dioxane 120 41[c] 
7 N 5.0 Na2CO3 1,4-dioxane 120 33[c] 
8 N 5.0 Cy2NH TFE 120 15[c] 
9 N 5.0 Cy2NH DCE 120 96 
10 N 2.5 Cy2NH DCE 120 71 
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11 N 5.0 Cy2NH DCE 100 92 
12 N 5.0 Cy2NH DCE 80 95 (99)[d] 
13 N 5.0 Cy2NH DCE 60 71 
14 N - Cy2NH DCE 80 0 
15 N 5.0 - DCE 80 < 5 
[a] Reaction conditions: 83a or 83b (0.50 mmol), 61a (0.75 mmol), MnBr(CO)5 (Y mol %), base (1.0 
mmol), solvent (1.0 mL), T °C, 16 h. [b] Yield of isolated product. [c] Determined by GC conversion using 
n-dodecane as internal standard. [d] 61a (0.60 mmol). 
3.4.2 Scope of Manganese(I)-Catalyzed C‒H Alkynylation 
With the optimized catalytic system in hand, we explored the viability of indole substrates in 
the managanese(I)-catalyzed C‒H alkynylation with TIPS-alkyne 61a (Scheme 3.4.1). Thus, 
the manganese catalysis performed with excellent levels of site-selectivity with various indoles, 
displaying different substituted directing groups. Additionally, valuable functionalities, 
including sensitive bromo and cyano groups, were fully tolerated in this transformation, which 
could serve as a handle for future late-stage modifications. 
 
Scheme 3.4.1 Scope of manganese(I)-catalyzed C‒H alkynylation with indoles 83. 
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Likewise, different silyl-substituted alkynyl halides 61 were tested in the C‒H functionalization 
of indoles 83b, illustrating excellent levels of catalytic efficacy (Scheme 3.4.2). In this regard, 
it is particularly noteworthy that the corresponding alkynyl chloride 61a’’ was identified as a 
suitable electrophilic substrate. 
 
Scheme 3.4.2 Manganese-catalyzed C–H alkynylation with silyl haloalkynes. 
3.4.3 Scope of Manganese(I)-Catalyzed C‒H Alkynylation with Aryl and Alkyl Alkynes 
Thus far, base metal-catalyzed C–H alkynylations, were particularly restricted to the use of 
activated alkynes featuring a silyl protecting group. Thereby, in consideration of the step- and 
atom-economical nature of the C–H activation strategy, we were delighted to observe that the 
manganese(I) catalysis enabled C–H alkynylations with aryl alkyne 61g (Table 3.4.2). Here, 
the key to success was the addition of triphenylborane as the pivotal cocatalytic additive, while 
other Lewis-acidic additives, including zinc(II) salts (entries 4 and 5), yielded only traces of the 
product (entries 2–6). It is notable that the BPh3 loading could be reduced to 0.05 mol % at a 
low manganese loading of 2.5 mol % (entry 7). 
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Table 3.4.2 Optimization of manganese-catalyzed C‒H alkynylation with aryl alkyne 61g.[a] 
 
Entry mol % additive additive Yield [%][b] 
1 - - 0 
2 5.0 BPh3 61 
3 5.0 BPh3 0[c] 
4 5.0 ZnBr2 trace 
5 5.0 ZnCl2 trace 
6 0.05 BPh3 92 (95) [d] 
7 0.05 BPh3 86[e] 
[a] Reaction conditions: 83b (0.5 mmol), 61g (0.6 mmol), MnBr(CO)5 (5.0 mol %), Cy2NH (1.0 mmol), 
DCE (1.0 mL), 80 °C, 16 h. [b] Yields of isolated product. [c] Without [Mn]. [d] 1 h. [e] [Mn] (2.5 mol %). 
With the optimized catalytic system in hand, the remarkable versatility of the manganese(I)-
catalyzed C–H alkynylation not only enabled the step-economic conversion of various aryl 
alkynes, but also alkyl alkynes, such as primary, secondary and tertiary alkyl alkynes, 
displaying synthetically meaningful functional groups (Scheme 3.4.3a). The practical utility of 
our strategy was further illustrated by smoothly introducing the desired C–H transformation 
with substrates bearing an enantiomerically pure amino acid (150bn), a fluorescent tag (150bo), 
or a complex steroid motif (150bp). Notably, the pyrimidyl group could be cleaved in a traceless 
fashion, yielding the corresponding alkynylated indole 151 (Scheme 3.4.3b). 




Scheme 3.4.3 (a) Manganese-catalyzed C–H alkynylation with aryl and alkyl alkynes 61g–
61p. [a] 1 h. [b] [Mn] (2.5 mol %). (b) Removal of pyrimidine. 
3.4.4 Mechanistic Studies 
In consideration of the outstanding versatility of the C–H alkynylation we became attracted to 
clarifying its mode of action. To this end, intermolecular competition experiments between 
electron-rich and electron-deficient substituted indoles 83 revealed a slight preference for the 
more electron-deficient substrate, which contrasts with previous observations (Scheme 
3.4.4).[92, 105-106]  




Scheme 3.4.4 Intermolecular competition experiment. 
Moreover, C–H alkynylation experiments performed in the presence of D2O as cosolvent 
unraveled a facile C–H metalation, as showed by the reisolation of the isotopically labeled 
substrate [D]n-83b with significant H/D exchange at the C2 position as well as the labeled 
product [D]n-83ba. The H/D scrambling at C3 was also observed due to an electrophilic 
substitution which is even operative in the absence of the metal catalyst (Scheme 3.4.5a).[76] In 
good agreement with this finding, a negligible KIE of kH/kD  1.0 was determined by 
independent experiments (Scheme 3.4.5b). 
 
Scheme 3.4.5 (a) H/D Exchange and (b) KIE experiments. 
Results and Discussion 
65 
 
Furthermore, the well-defined organometallic complex 152 could be prepared by the reaction 
of substrate 83b with stoichiometric amounts of MnBr(CO)5 (Scheme 3.4.6a). Thus, the 
manganese complex 152 delivered the C–H alkynylated product 138ba both in a stoichiometric 
as well as a catalytic setting, suggesting the organometallic complex 152 to be a key on-cycle 
intermediate of the C–H activation regime (Scheme 3.4.6b–c). 
 
Scheme 3.4.6 C–H Alkynylations with cyclometalated complex 152. 
In addition, conducting the manganese-catalyzed C–H alkynylation under an atmosphere of air 
or in the presence of the radical scavenger TEMPO led to a significantly diminished catalytic 
efficacy, indicating a distinct mode of action. (Scheme 3.4.7) 
 
Scheme 3.4.7 C–H Alkynylation under air or in the presence of radical scavenger. 
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3.4.5 Proposed Catalytic Cycle 
Based on our experimental mechanistic studies we propose a plausible catalytic cycle to be 
initiated by a reversible and fast organometallic C–H bond activation (Scheme 3.4.8). 
Thereafter, a migratory insertion delivers the seven-membered metallacycle [Mn]-I, which 
undergoes ß-elimination, forming the desired product. Alternatively, a mechanism through 
oxidative addition and reductive elimination cannot be ruled out based on current limited 
mechanistic studies.  
 
Scheme 3.4.8 Plausible proposed catalytic cycle. 
3.4.6 Peptide Modification and Assembly by Manganese-Catalyzed C–H Alkynylation 
The notably versatile transformation of the manganese-catalyzed C–H alkynylation finally set 
the stage for the efficient late-stage diversification of acyclic peptides 153 with high chemo and 
positional selectivity. Henceforth, the manganese-catalyzed C–H functionalization provided 
step-economical access to novel peptides for biochemistry, medicinal chemistry and drug 
discovery (Scheme 3.4.9a). In this context, viable alkynes especially alkyl alkynes featuring 
steroid moiety can be elegantly introduced by the robust manganese catalysis regime. It is 
particularly noteworthy that the azido-substituted peptide (154c) and a tryptophan-containing 
pentapeptide 154d were fully tolerated in this protocol, which should prove invaluable for 
potential applications to bioorthogonal tag-and-modify approaches[148] or click chemistry[149] 
for peptide modification in living systems. 
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Finally, we were particularly delighted to develop the first intramolecular macrocyclization[150] 
by manganese(I)-catalyzed C–H activation. Hence, the manganese-catalyzed C–H alkynylation 
of substrate 155 under high-dilution conditions delivered the 21-membered cyclic peptide 156, 
which enriched the database of novel peptidomimetic drugs with, for instance, antibacterial 
activities (Scheme 3.4.9b). Here, the addition of catalytic BPh3 proved again essential to realize 
the challenging assembly of macrocycle 156. 
 
Scheme 3.4.9 Peptide modification and assembly by manganese-catalyzed C–H alkynylation. 
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3.5 Ruthenium(II)-Catalyzed meta-C–H Mono- and Difluoromethylations by 
Phosphine/Carboxylate Cooperation 
3.5.1 Optimization of Ruthenium-Catalyzed C–H Difluoromethylation 
We initiated our optimization studies by probing the effect of various additives on the 
envisioned ruthenium(II)-catalyzed C–H difluoromethylation on arene 95a with 
bromodifluoroester 139a (Table 3.5.1). Based on our recent findings on SET-type processes,[125] 
different nickel cocatalysts were tested and the desired C–H functionalization was proved to be 
highly effective by using Ni(PPh3)2Cl2 as an addictive (entries 1–4). However, control 
experiments uncovered the crucial importance of phosphine ligands, furnishing the product 
140aa with excellent levels of meta-selectivity (entries 5–7). Thus, whereas a variety of 
electron-rich phosphines, phosphites, N-heterocyclic carbene precursors, N-protected amino 
acid provided unsatisfactory results (entries 8–18), triaryl phosphines showed outstanding 
catalytic efficacy for the meta-C–H activation (entries 7, 19, and 20). Here, the best catalytic 
performance was realized by employing the electron-deficient P(4-C6H4CF3)3 as the ligand with 
Na2CO3 as the base of choice, along with 1,4-dioxane as the optimal solvent (entry 19). The 
key importance of the synergistic phosphine/carboxylate assistance within the remote C–H 
functionalization regime was highlighted by the simple ruthenium complexes RuCl3·(H2O)n and 
[RuCl2(p-cymene)]2 failing in the challenging meta-C–H functionalization under otherwise 
identical reaction conditions (entries 21 and 22). Hence, the best results were obtained with the 
ruthenium(II)-biscarboxylate complex [Ru(O2CMes)2(p-cymene)] (entry 19). 
Table 3.5.1 Optimization of ruthenium-catalyzed C−H difluoromethylation.[a] 
 
Entry [Ru] Additive Yield[%] 
1 [Ru(O2CMes)2(p-cymene)] - ˂ 5 
2 [Ru(O2CMes)2(p-cymene)] Ni(PPh3)2Cl2 72 
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3 [RuCl2(p-cymene)]2 Ni(PPh3)2Cl2 --- 
4 - Ni(PPh3)2Cl2 --- 
5 [Ru(O2CMes)2(p-cymene)] NiCl2 ˂ 5 
6 [Ru(O2CMes)2(p-cymene)] NiCl2 + PPh3 71 
7 [Ru(O2CMes)2(p-cymene)] PPh3 62 
8 [Ru(O2CMes)2(p-cymene)] PCy3 12[b] 
9 [Ru(O2CMes)2(p-cymene)] IPr.HCl --- 
10 [Ru(O2CMes)2(p-cymene)] Xantphos --- 
11 [Ru(O2CMes)2(p-cymene)] P(1-Ad)2n-Bu ˂ 5 
12 [Ru(O2CMes)2(p-cymene)] P(n-Bu)3 7 
13 [Ru(O2CMes)2(p-cymene)] P(OEt)3 --- 
14 [Ru(O2CMes)2(p-cymene)] X-Phos --- 
15 [Ru(O2CMes)2(p-cymene)] P(p-Tol)3 ˂ 5 
16 [Ru(O2CMes)2(p-cymene)] Ph2P(O)H --- 
17 [Ru(O2CMes)2(p-cymene)] Piv-Val-OH ˂ 5 
18 [Ru(O2CMes)2(p-cymene)] Ac-Val-OH ˂ 5 
19 [Ru(O2CMes)2(p-cymene)] P(4-C6H4CF3)3 71 
20 [Ru(OAc)2(p-cymene)] P(4-C6H4CF3)3 63 
21 [RuCl2(p-cymene)]2 P(4-C6H4CF3)3 --- 
22 [RuCl3·(H2O)n] P(4-C6H4CF3)3 --- 
[a] Reaction conditions: 95a (0.5 mmol), 139a (3.0 equiv), [Ru] (10 mol %), additive ([Ni]: 10 mol % or 
[P]: 20 mol %), Na2CO3 (2.0 equiv), 1,4-dioxane (2.0 mL), 60 °C, 18 h, isolated yield. [b] Conversion was 
determined by 19F NMR using C6F6 as the internal standard. 
3.5.2 Scope of Ruthenium(II)-Catalyzed C−H Difluoromethylation with Arenes 
With the optimized catalytic systems in hand, we explored versatility in the meta-C–H 
difluoromethylation of heteroarenes 95 (Scheme 3.5.2). We were delighted to observe that a 
variety of pyridyl-substituted substrates 95a–95h provided the meta-C–H difluoromethylation 
products 140 with high chemo-selectivity and good yields. Thereby, a variety of electron-
donating and electron-withdrawing functional groups, such as methoxy, fluoro, chloro and ester 
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substituents, were fully tolerated. The remote functionalization strategy was not limited to 
pyridyl-guided reactivity. Indeed, pyrimidine, indazole and pyrazole containing substrates 
delivered the desired products 140ia–140ma with high levels of meta-selectivity as well. 
Notably, in some cases, Ni(PPh3)2Cl2 as the additive led to improved yields of products 140, 
which could either be due to a low concentration of free phosphine or a heterobimetallic regime. 
 
Scheme 3.5.1 Scope of ruthenium(II)-catalyzed C−H difluoromethylation with arenes 95. 
3.5.3 Scope of Ruthenium-Catalyzed C−H Difluoromethylation with Purine Bases 
Likewise, the versatile ruthenium(II)-catalyzed direct remote C–H functionalization strategy 
sets the stage for the modification of purine nucleobases, which is significant for the preparation 
of bioactive compounds as well as the labelling of biologically relevant molecules. Thus, we 
were delighted to observe that various aryl purines 131 displaying synthetically useful groups, 
such as chloro, ketone, and ester as well as a nucleoside base, were site-selectively meta-
difluoromethylated by the action of the versatile ruthenium(II)-regime (Scheme 3.5.2). It is 
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noteworthy that the C–H functionalization did not take place at the kinetically C–H acidic C8 
position of the purine motif. 
 
Scheme 3.5.2 Scope of ruthenium-catalyzed C−H difluoromethylation with purine bases 131. 
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3.5.4 Mechanistic Studies 
In consideration of the distinct selectivity of the ruthenium(II) catalyst, we became attracted to 
elucidating its mode of action (Scheme 3.5.3). To this end, intermolecular competition 
experiments between para-methoxy- and fluoro-substituted arenes 95 did not show a 
significantly electronic effect in this meta-C–H transformation. However, more extensive 
studies revealed that electron-rich substrates were inherently more reactive (Scheme 3.5.3a), 
which contrasts previous findings on meta-C–H alkylations.[125] Moreover, the challenging 
nature of the remote difluoromethylation reaction was reflected by intermolecular competition 
experiments between difluoromethyl- and dimethyl-substituted substrates 139a and 124a, 
exclusively affording the tert-alkylated product 157aa as the sole product (Scheme 3.5.3b). 




Scheme 3.5.3 Intermolecular competition experiments. 
Furthermore, ruthenium(II)-catalyzed meta-C–H functionalizations was conducted in the 
presence of deuterated cosolvent D2O (Scheme 3.5.4). The results showed a significant H/D 
scrambling in the ortho-position, revealing the reversible nature of the C–H metalation 
elementary step, while at the same time highlighting the robustness of the water-tolerant C–H 
activation.  




Scheme 3.5.4 H/D Exchange experiment. 
In addition, reactions performed in the presence of the typical radical scavenger TEMPO led to 
complete inhibition of the catalytic activity in both P(4-C6H4CF3)3 and Ni(PPh3)2Cl2 ruthenium 
regime, with TEMPO adduct 150 being isolated in low yields (Scheme 3.5.5). This observation 
can be rationalized by a radical-involving C–X cleavage. 
 
Scheme 3.5.5 meta-C–H Difluoromethylation in the presence of TEMPO. 
As to the nature of the catalytically active species, the remote C–H functionalization was 
conducted with the structurally well-defined cyclometalated complex 159 as catalyst (Scheme 
3.5.6a). The complex 159 was identified as being competent albeit in low yield in the C–H 
transformations with phosphine ligand. The key importance of the synergistic 
phosphine/carboxylate assistance in the meta-C–H activation regime was highlighted by the 
attempted meta-C–H difluoromethylations with the carboxylate-free ruthenium(II)phosphine 
complex 160,[151] which failed to yield the desired product (Scheme 3.5.6b). However, the 
catalytic efficacy could be restored by the simple addition of cocatalytic amounts of the proton 
shuttle MesCO2H. However, the investigation for more detailed mechanistic study is currently 
underway. 




Scheme 3.5.6 meta-C–H Difluoromethylation with complexes 159 and 160. 
3.5.5 Ruthenium(II)-Catalyzed meta-C–H mono-Fluoromethylation 
Finally, the synthetic utility of our strategy was demonstrated by enabling the positionally 
selective meta-C–H monofluorometylation under otherwise identical reaction conditions 
(Scheme 3.5.7). Indeed, the unprecedented remote C–H mono-fluoromethylation was achieved 
with wide range of substrates, including pyridyl, pyrimidyl, pyrazolyl and even purinyl 
substituted arenes, furnishing the desired products 162a–162d in high efficacy. 




Scheme 3.5.7 meta-C–H Monofluoromethylation 
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4 Summary and Outlook 
Transition metal-catalyzed C–H functionalizations have recently emerged as a reliable tool for 
the efficient chemo- and site-selective construction of C–C and C–Het bonds, which is of major 
importance for the preparation of pharmaceuticals, agrochemicals and functional materials. 
Within this thesis, efforts have been devoted to developing new step-economic synthetic 
methods employing versatile nickel-, manganese(I)-, or ruthenium(II)-catalyzed C–H 
activation. 
First, the C–H alkylation of aniline derivatives with alkyl halides was achieved with a versatile 
nickel catalyst through monodentate chelation assistance (Scheme 4.1). The nickel catalyst 
derived from the vicinal diamine ligand Dt-BEDA set the stage for a unified strategy for C–H 
alkylations of 2-pyrimidyl anilines with primary and secondary alkyl halides. The 
corresponding products are key structural motifs of numerous bioactive compounds including 
anticancer drugs. A facile C–H activation step and SET-type C–X bond cleavage in this nickel 
catalyst regime were also revealed by detailed mechanistic studies. 
 
Scheme 4.1 Nickel-catalyzed C–H alkylation of anilines 123. 
Second, based on the achievement of the nickel-catalyzed C–H alkylation of anilines, we were 
motivated to enable the C–H functionalization of more useful and challenging purine moieties. 
Therefore, C–H primary and secondary alkylations of purine nucleosides were achieved by 
means of user-friendly nickel catalysis with excellent positional selectivity, ample substrate 
scope and high functional group tolerance, providing access to key structural motifs of 
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numerous bioactive compounds and marketed drugs (Scheme 4.2). The novel synthetic strategy 
of the nickel catalysis regime also enabled the direct fluorescent labeling of nucleobases, 
highlighting the potential of our methodology for late stage diversification. 
 
Scheme 4.2 Nickel-catalyzed C–H activation of purine bases 134 with alkyl halides 58. 
Third, the first nickel-catalyzed C–H alkynylation of electron-rich arenes was developed 
(Scheme 4.3). Thus, anilines were directly functionalized with high positional selectivity, ample 
scope and high functional group tolerance. Moreover, a kinetically relevant C–H metalation 
was disclosed by mechanistic studies. Thereby, the C–H alkynylation strategy set the stage for 
a novel step-economical synthesis of highly substituted indole, and modifications of purine 
nucleobases. 
 
Scheme 4.3 Nickel-catalyzed C–H alkynylation of anilines. 
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Fourth, in continuation of our nickel-catalyzed C–H alkynylation, we devised a versatile C–H 
alkynylation by less toxic manganese(I) catalysis with silyl, aryl, alkenyl, and alkyl haloalkynes 
(Scheme 4.4). The transformative nature of the manganese(I) catalysis manifold facilitated the 
C–H coupling of alkynes featuring fluorescent labels, steroids, and amino acids. The versatility 
of the powerful C–H alkynylation approach set the stage for peptide ligation as well as the 
efficient modification and assembly of cyclic and acyclic peptides. 
 
Scheme 4.4 Manganese-catalyzed C–H alkynylation 
Fifth, we have developed a ruthenium(II)-catalyzed remote C–H mono- and 
difluoromethylation through cooperation of phosphine and carboxylate ligands (Scheme 4.5). 
Thereby, a versatile ruthenium(II) carboxylate catalyst modified with arylphosphines enabled 
expedient and meta-selective C–H functionalization of diversely decorated pyridyl, pyrimidyl, 
pyrazolyl, and purinyl arenes. Mechanistic studies were indicative of a radical-involved C–X 
cleavage process by facile organometallic ortho-C–H activation. 










5 Experimental Section 
5.1 General Remarks 
Unless otherwise noticed, all reactions were performed under N2 atmosphere using pre-dried 
glassware and standard Schlenk techniques.  
Solvents 
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and stored 
under inert atmosphere (N2) according to the following standard procedures.  
 
1,2-Dichloroethane was dried over CaH2 for 8 h, degassed and distilled under reduced pressure. 
Dimethylacetamide was dried over CaH2 for 8 h, degassed and distilled under reduced 
pressure. 
1,2-Dimethoxyether was used as supplied by Merck or stirred over sodium chips for 5 h at 
120 °C and then distilled at ambient pressure. 
Dichloromethane was purified using a solvent purification system (SPS-800) from M. BRAUN. 
Diethyl ether was purified using a solvent purification system (SPS-800) from M. BRAUN. 
Tetrahydrofuran was purified using a solvent purification system (SPS-800) from M. BRAUN. 
1,4-Dioxane was distilled from sodium benzophenone ketyl. 
Di-(n-butyl)-ether was distilled from sodium benzophenone ketyl. 
Methanol was stirred over magnesium turnings at 65 °C for 3 h prior to distillation from 
Mg(OMe)2. 
N-Methyl-2-pyrrolidone was stirred over CaH2 at 200 °C for 4 h and distilled under reduced 
pressure. 
Toluene was pre-dried over KH followed by distillation from sodium benzophenone ketyl. 
N-Methyl-2-pyrrolidone was dried over CaH2 for 4 h at 150 °C and subsequently distilled 
under reduced pressure. 





Water was degased by repeated Freeze-Pump-Thaw degasing procedure. 
 
Vacuum  
The following pressures were measured on the used vacuum pump and were not corrected: 
membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar.  
Melting Points (M. p.)  
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from 
BARLOWORLD SCIENTIFIC. Reported values are uncorrected.  
Chromatography and HPLC-Chromatography 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates were 
visualized under UV-light or developed by treatment with a KMnO4 solution followed by 
carefully applying a heat gun. Chromatographic purification of products was accomplished by 
column chromatography on MERCK silica gel, grade 60 (0.040–0.063 mm and 0.063–0.200 
mm). Analytical High-Performance-Liquid-Chromatography (HPLC) for determination of 
enantiomeric excess was conducted on an AGILENT 1260 Infinity system with Chiralpak IC-3 
and IF-3 as columns. 
Gas Chromatograpgy (GC)  
The conversion of the reactions was monitored applying coupled gas chromatography/mass 
spectrometry using G1760C GCD plus with mass detector HP 5971, 5890 Series II with mass 
detector HP 5972 from HEWLETT-PACKARD and 7890A GC-System with mass detector 
5975C (Triplex-Axis-Detector) from AGILENT TECHNOLOGIES equipped with HP-5MS 
columns (30 m × 0.25 mm × 0.25 m) were used. 
Gel permeation chromatography (GPC)  
GPC purifications were performed on a JAI system (JAI-LC-9260 II NEXT) equipped with two 
sequential columns (JAIGEL-2HR, gradient rate: 5.000; JAIGEL-2.5HR, gradient rate: 20.000; 
internal diameter: 20 mm; length: 600 mm; Flush rate = 10.0 mL/min and chloroform (HPLC-






The fluorescence-emission spectra were recorded on a JASCO FP-6200 spectroscope with an 
ETC 27 LCT heater. Spectra were recorded as 1.0 mg/L-solutions of sample in EtOAc. Analyses 
of the recorded spectra was carried out using Origin Pro 8.5G. 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy was performed at 300, 400 or 600 MHz (1H 
NMR), 75 or 125 MHz (13C NMR, APT) and 283 MHz (19F NMR) on BRUKER AM 250, 
VARIAN Unity-300 and Inova 500 instruments. Chemical shifts are reported as δ-values in 
ppm relative to the residual proton peak of the deuterated solvent or its carbon atom, 
respectively, or the standard tetramethylsilane (TMS) resonance. For characterization of the 
observed resonance multiplicities the following abbreviations were used: s (singlet), d (doublet), 
t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt (doublet of triplet), or analogue 
representations. The coupling constants J are reported in Hertz (Hz). 
Infrared Spectroscopy (IR) 
Infrared spectra were recorded on a BRUKER Alpha-P ATR-spectrometer. Liquid probes were 
measured as film and solid samples neat. Analysis of the spectral data was done by using the 
OPUS 6. Absorption (ṽ) is given in wave numbers (cm–1). Spectra were recorded in the range 
of 4000 to 400 cm–1. 
Mass Spectrometry (MS) 
MS (EI) and HR-MS (EI) were measured on a Time-of-Flight mass spectrometer AccuTOF 
from JOEL. ESI-mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from 
FINNIGAN or on a Time-of-Flight mass spectrometer microTOF from BRUKER. ESI-HR-MS 
spectra were recorded on a BRUKER APEX IV or a BRUKER DALTONIC, Fourier Transform 
Ion Cyclotron Resonance (FTICR)] mass spectrometer. The ratios of mass to charge (m/z) are 
indicated, intensities relative to the base peak (I = 100) are written in parentheses. 
Reagents 
Chemicals obtained from commercial sources with purity above 95% were used without further 
purification. The following compounds are known and were synthesized according to 





N-(pyrimidine-2-yl)anilines 1a–1w,[152] 1x,[153] [D]5-1c,[65] purine bases 134a–134m,[154] 
134n,[155] alkynes 61a–61g,[156] 61h–61p,[156-157] indoles 83,[158] 153,[105, 156, 159] 155, [105, 156, 159] 
95,[160] 131,[161] cyclometalated complex 159,[162] {RuCl2(p-cymene)[P(4-C6H4CF3)3]} (160).[163] 
5.2 General Procedures 
General Procedure A: Nickel-Catalyzed C–H Alkylation of Anilines 
Anilines 123 (0.50 mmol), [(DME)NiCl2] (5.5 mg, 5.0 mol %) and LiOt-Bu (80 mg, 1.0 mmol) 
were placed in a 25 mL Schlenk tube. The tube was degassed and purged with N2 three times. 
Dt-BEDA (143) (11.0 µL, 10 mol %), alkyl bromides 58 (1.0 mmol) and 1,4-dioxane (1.5 mL) 
were then added, and the mixture was stirred at 120 °C for 16 h. At ambient temperature, 
CH2Cl2 (2 mL) was added, and the reaction mixture was transferred into a round flask with 
CH2Cl2 and concentrated under reduced pressure, purified by column chromatography on silica 
gel to afford the desired products 133 or 142. 
 
General Procedure B: Nickel-Catalyzed C–H Alkylation of Anilines 
Anilines 123 (1.0 mmol), [(DME)NiCl2] (5.5 mg, 2.5 mol %) and LiOt-Bu (160 mg, 2.0 mmol) 
were placed in a 25 mL Schlenk tube. The tube was degassed and purged with N2 three times. 
Dt-BEDA (143) (11.0 µL, 5.0 mol %), alkyl bromides 58 (2.0 mmol) and 1,4-dioxane (2.0 mL) 
were then added, and the mixture was stirred at 100 °C for 16 h. At ambient temperature, 
CH2Cl2 (2 mL) was added, and the reaction mixture was transferred into a round flask with 
CH2Cl2 and concentrated under reduced pressure, purified by column chromatography on silica 
gel to afford the desired products 142. 
 
General Procedure C: Nickel-Catalyzed C–H Alkylation of Purine Bases 
6-Anilinopurines 134 (0.30 mmol), [(DME)NiCl2] (6.6 mg, 10 mol %) and LiOt-Bu (48 mg, 
0.60 mmol) were placed in a 25 mL Schlenk tube. The tube was degassed and purged with N2 
three times. Dt-BEDA (143) (13 µL, 20 mol %), alkyl bromides 58 (0.60 mmol) and 1,4-
dioxane (1.5 mL) were then added, and the mixture was stirred at 120 °C for 16 h. At ambient 





flask with CH2Cl2 and concentrated under reduced pressure, purified by column 
chromatography on silica gel to afford the desired products 135. 
 
General Procedure D: Nickel-Catalyzed C–H Alkylation of Purine Bases 
6-Anilinopurines 134 (0.30 mmol), [(DME)NiCl2] (3.3 mg, 5.0 mol %) and LiOt-Bu (48 mg, 
0.60 mmol) were placed in a 25 mL Schlenk tube. The tube was degassed and purged with N2 
three times. Dt-BEDA (143) (6.5 µL, 10 mol %), alkyl bromides 58 (0.60 mmol) and 1,4-
dioxane (1.5 mL) were then added, and the mixture was stirred at 120 °C for 16 h. At ambient 
temperature, CH2Cl2 (2.0 mL) was added, and the reaction mixture was transferred into a round 
flask with CH2Cl2 and concentrated under reduced pressure, purified by column 
chromatography on silica gel to afford the desired products 135. 
 
General Procedure E: Nickel-Catalyzed C‒H Alkynylation of Anilines 
Anilines 123 (0.50 mmol) or purine bases 134 (0.50 mmol), [(DME)NiCl2] (2.8 mg, 2.5 mol %) 
and LiOt-Bu (80.0 mg, 1.00 mmol) were placed in a 25 mL Schlenk tube. The tube was 
degassed and purged with N2 three times. Dt-BEDA (143) (5.5 µL, 5.0 mol %), alkyne 61 (1.50 
mmol) and 1,4-dioxane (1.5 mL) were then added, and the mixture was stirred at 90‒100 °C 
for 16 h. At ambient temperature, CH2Cl2 (2.0 mL) was added, and the reaction mixture was 
transferred into a round flask with CH2Cl2 and concentrated under reduced pressure, purified 
by column chromatography on silica gel to afford the desired products 136 or 137. 
 
General Procedure F: Manganese-Catalyzed C‒H Alkynylation 
To a solution of substrates 83 (0.50 mmol) or 153 (0.50 mmol), MnBr(CO)5 (6.9 mg, 5.0 mol %) 
and Cy2NH (181 mg, 1.0 mmol) in DCE (1.0 mL), silyl bromoalkynes 61 (0.6 mmol) was added. 
The mixture was stirred at 80 °C for 16 h. After completion of the reaction, CH2Cl2 (3.0 mL) 
was added at ambient temperature and the volatiles were removed in vacuo. Purification by 
chromatography on silica gel afforded the desired products 138 or 154. 
 





To a solution of substrates 83 (0.50 mmol) or 153 (0.50 mmol), MnBr(CO)5 (6.9 mg, 5.0 mol %), 
Cy2NH (181 mg, 1.0 mmol) and BPh3 (25 μL, 0.05 mol %, 0.01 M stock solution in DCE) in 
DCE (1 mL), aryl or alkyl bromoalkynes 61 (0.6 mmol) was added. The mixture was stirred at 
80 °C for 16 h. After completion of the reaction, CH2Cl2 (3 mL) was added at ambient 
temperature and the volatiles were removed in vacuo. Purification by chromatography on silica 
gel afforded the desired products 150 or 154. 
 
General Procedure H: Ruthenium(ІІ)-Catalyzed meta-C‒H mono- and di-
Fluoromethylation 
To a solution of substrates 95 (0.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), 
P(4-C6H4CF3)3 (46.7 mg, 20 mol %) and Na2CO3 (106 mg, 1.0 mmol) in 1,4-dioxane (2.0 mL), 
bromodifluoroester 139a (304 mg, 1.5 mmol) or bromofluoroester 161 (278 mg, 1.5 mmol) was 
added. The mixture was stirred at 60 °C for 18 h. After completion of the reaction, CH2Cl2 (3.0 
mL) was added at ambient temperature and the volatiles were removed in vacuo. Purification 
by chromatography on silica gel afforded the desired products 140 or 162. 
 
General Procedure I: Ruthenium(ІІ)-Catalyzed meta-C‒H mono- and di-
Fluoromethylation 
To a solution of purine substrates 131 (0.25 mmol), [Ru(O2CMes)2(p-cymene)] (14.0 mg, 10 
mol %), P(4-C6H4CF3)3 (23.4 mg, 20 mol %) and Na2CO3 (53.0 mg, 0.50 mmol) in 1,4-dioxane 
(2.0 mL), bromodifluoroester 139a (152 mg, 0.75 mmol) or bromofluoroester 161 (139 mg, 
0.75 mmol) was added. The mixture was stirred at 60 °C for 18 h. After completion of the 
reaction, CH2Cl2 (3.0 mL) was added at ambient temperature and the volatiles were removed 






5.3.1 Characterization Data: Nickel-Catalyzed C–H Alkylation of Anilines 
 
N-(2-n-Butyl-6-methylphenyl)pyrimidin-2-amine (133aa): The general procedure A was 
followed using substrate 123a (93 mg, 0.50 mmol) and bromide 58a (107 μL, 1.0 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 133aa (105 mg, 87%) as 
a yellow solid. 
M. p. = 59–61 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.28 (d, J = 4.8 Hz, 2H), 7.21–7.04 (m, 4H), 6.56 (t, J = 4.8, 
1H), 2.59 (t, J = 7.7 Hz, 2H), 2.22 (s, 3H), 1.58–1.43 (m, 2H), 1.36–1.20 (m, 2H), 0.82 (t, J = 
7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ = 161.8 (Cq), 158.3 (CH), 140.7 (Cq), 136.8 (Cq), 134.9 (Cq), 
128.3 (CH), 127.3 (CH), 127.2 (CH), 111.1 (CH), 32.6 (CH2), 31.7 (CH2), 22.5 (CH2), 18.6 
(CH3), 13.9 (CH3). 
IR (neat): 3223, 2951, 2924, 2860, 1576, 1519, 1445, 1406, 800 cm-1. 
MS (EI) m/z (relative intensity) 241 (24) [M+], 212 (36), 184 (100). 
HR-MS (EI) m/z calcd for C15H19N3 [M+] 241.1579, found 241.1581. 
 
 
N-n-Butyl-N-(o-tolyl)pyrimidin-2-amine (133aa’): Side product 133aa’ as a yellow solid.  
M. p. = 51–52 °C.  
1H NMR (500 MHz, CDCl3) δ = 8.28 (d, J = 4.8 Hz, 2H), 7.33–7.28 (m, 1H), 7.28–7.19 (m, 
2H), 7.18–7.13 (m, 1H), 6.47 (t, J = 4.8 Hz, 1H), 4.13–3.87 (m, 1H), 3.74–3.56 (m, 1H), 2.11 





13C NMR (125 MHz, CDCl3) δ = 161.5 (Cq), 157.7 (CH), 142.8 (Cq), 136.4 (Cq), 131.0 (CH), 
128.6 (CH), 127.0 (CH), 126.9 (CH), 109.9 (CH), 50.2 (CH2), 30.0 (CH2), 20.3 (CH2), 18.1 
(CH3), 14.1 (CH3).  
IR (neat): 2964, 2928, 1572, 1547, 1472, 1369, 798, 765, 622 cm-1.  
MS (EI) m/z (relative intensity) 241 (15) [M+], 226 (100), 198 (70), 170 (35).  
HR-MS (EI) m/z calcd for C15H19N3 [M+] 241.1579, found 241.1587. 
 
 
N-(2-n-Butyl-6-fluorophenyl)pyrimidin-2-amine (133ba): The general procedure A was 
followed using substrate 123b (95 mg, 0.50 mmol) and bromide 58a (107 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 133ba (110 mg, 90%) as 
a yellow solid.  
M. p. = 53–54 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.29 (d, J = 4.9 Hz, 2H), 7.91 (s, 1H), 7.18 (ddd, J = 8.0, 8.0, 
5.4 Hz, 1H), 7.06 (d, J = 7.7 Hz, 1H), 6.99 (ddd, J = 9.6, 8.2, 1.4 Hz, 1H), 6.60 (t, J = 4.8 Hz, 
1H), 2.61 (t, J = 7.8 Hz, 2H), 1.69–1.46 (m, 2H), 1.33–1.25 (m, 2H), 0.83 (t, J = 7.4 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 161.5 (Cq), 158.6 (Cq, 1JC-F = 248.0 Hz), 158.0 (CH), 142.6 
(Cq), 127.4 (CH, 3JC-F = 8.7 Hz), 124.7 (CH, 4JC-F = 3.3 Hz), 124.4 (Cq, 2JC-F = 12.6 Hz), 113.3 
(CH, 2JC-F = 20.8 Hz), 111.9 (CH), 32.4 (CH2), 31.2 (CH2, JC-F = 2.4 Hz), 22.5 (CH2), 13.9 
(CH3).  
19F NMR (283 MHz, CDCl3) δ = -119.6 (dd, J = 9.6, 5.5 Hz).  
IR (neat): 3220, 2959, 2929, 1576, 1521, 1443, 1357, 1225, 968, 783, 638, 495 cm-1.  
MS (EI) m/z (relative intensity) 245 (45) [M+], 226 (20), 216 (100), 188 (76).  







The general procedure A was followed using substrate 123c (86 mg, 0.50 mmol) and bromide 
58a (59 μL, 0.55 mmol). After 8 h, isolation by column chromatography (n-hexane/EtOAc: 8/1) 
yielded 133ca (71 mg, 62%) as a colorless liquid and 133ca’ (20 mg, 14%) as a white solid.  
N-(2-n-Butylphenyl)pyrimidin-2-amine (133ca):  
1H NMR (500 MHz, CDCl3) δ = 8.36 (d, J = 4.8 Hz, 2H), 7.85 (dd, J = 8.0, 1.0 Hz, 1H), 7.23–
7.18 (m, 2H), 7.07 (ddd, J = 7.5, 7.5, 1.0 Hz, 1H), 6.92 (br s, 1H), 6.65 (t, J = 4.8 Hz, 1H), 2.63 
(t, J = 7.9 Hz, 2H), 1.62–1.55 (m, 2H), 1.41–1.32 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 160.8 (Cq), 157.9 (CH), 136.4 (Cq), 134.1 (Cq), 129.5 (CH), 
126.4 (CH), 124.3 (CH), 123.2 (CH), 112.1 (CH), 32.0 (CH2), 31.4 (CH2), 22.6 (CH2), 14.0 
(CH3).  
IR (neat): 3231, 2955, 2928, 1578, 1518, 1439, 1400, 797, 748, 639 cm-1.  
MS (EI) m/z (relative intensity) 227 (52) [M+], 198 (85), 170 (100).  
HR-MS (EI) m/z calcd for C14H17N3 [M+] 227.1422, found 227.1432. 
 
N-(2,6-Di-n-butylphenyl)pyrimidin-2-amine (133ca’):  
M. p. = 73–74 °C.  
1H NMR (500 MHz, CDCl3) δ = 8.28 (d, J = 4.8 Hz, 2H), 7.19 (dd, J = 8.4, 6.7 Hz, 1H), 7.13 
(dd, J = 8.4, 1.1 Hz, 2H), 6.68 (br s, 1H), 6.56 (t, J = 4.8 Hz, 1H), 2.50 (t, J = 7.9 Hz, 4H), 1.54–
1.46 (m, 4H), 1.31–1.23 (m, 4H), 0.82 (t, J = 7.4 Hz, 6H).  
13C NMR (125 MHz, CDCl3) δ = 162.1 (Cq), 158.3 (CH), 141.2 (Cq), 134.4 (Cq), 127.4 (CH), 
127.3 (CH), 111.2 (CH), 32.5 (CH2), 31.7 (CH2), 22.6 (CH2), 13.9 (CH3).  
IR (neat): 3231, 2956, 2927, 2859, 1573, 1517, 1444, 1404, 799, 638 cm-1.  
MS (ESI) m/z (relative intensity) 284 [M+H+].  







N-(3-n-Butylbiphenyl-2-yl)pyrimidin-2-amine (133da): The general procedure A was 
followed using substrate 123d (124 mg, 0.50 mmol) and bromide 58a (107 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 133da (119 mg, 78%) as 
a white solid.  
M. p. = 104–105 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.19 (d, J = 4.8 Hz, 2H), 7.37–7.15 (m, 8H), 6.80 (s, 1H), 6.48 
(t, J = 4.8 Hz, 1H), 2.63 (t, J = 7.9 Hz, 2H), 1.67–1.53 (m, 2H), 1.36–1.27 (m, 2H), 0.85 (t, J = 
7.3 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ = 161.8 (Cq), 158.0 (CH), 141.3 (Cq), 140.3 (Cq), 140.1 (Cq), 
133.6 (Cq), 129.0 (CH), 128.8 (CH), 128.3 (CH), 127.9 (CH), 127.1 (CH), 126.9 (CH), 111.2 
(CH), 32.3 (CH2), 31.7 (CH2), 22.6 (CH2), 13.9 (CH3).  
IR (neat): 3216, 2952, 2927, 2869, 1576, 1525, 1445, 1408, 756, 670 cm-1.  
MS (EI) m/z (relative intensity) 303 (40) [M+], 274 (41), 261 (27), 246 (100), 182 (10).  
HR-MS (EI) m/z calcd for C20H21N3 [M+] 303.1735, found 303.1735. 
 
 
N-(2-tert-Butyl-6-n-butylphenyl)pyrimidin-2-amine (133ea): The general procedure A was 
followed using substrate 123e (114 mg, 0.50 mmol) and bromide 58a (107 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 133ea (92 mg, 65%) as a 
yellow solid.  
M. p. = 128–129 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.30 (d, J = 4.8 Hz, 2H), 7.34 (dd, J = 7.6, 2.0 Hz, 1H), 7.24–
7.16 (m, 2H), 6.77 (s, 1H), 6.54 (t, J = 4.8 Hz, 1H), 2.50–2.38 (m, 2H), 1.60–1.47 (m, 2H), 1.35 





13C NMR (100 MHz, CDCl3) δ = 162.2 (Cq), 158.5 (CH), 158.2 (CH), 147.9 (Cq), 143.2 (Cq), 
134.7 (Cq), 127.9 (CH), 127.6 (CH), 124.8 (CH), 111.0 (CH), 35.4 (Cq), 32.3 (CH2), 31.6 (CH2), 
31.1 (CH3), 22.7 (CH2), 13.9 (CH3).  
IR (neat): 3212, 2951, 2863, 1594, 1527, 1448, 1410, 1265, 779, 648 cm-1.  
MS (EI) m/z (relative intensity) 283 (3) [M+], 226 (100), 183 (12).  
HR-MS (EI) m/z calcd for C18H25N3 [M+] 283.2048, found 283.2048. 
 
 
N-(2-n-Butyl-5-methylphenyl)pyrimidin-2-amine (133fa): The general procedure A was 
followed using substrate 123f (93 mg, 0.50 mmol) and bromide 58a (107 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 133fa (70 mg, 58%) as a 
colorless liquid.  
1H NMR (500 MHz, CDCl3) δ = 8.35 (d, J = 4.8 Hz, 2H), 7.64 (s, 1H), 7.09 (d, J = 7.7 Hz, 
1H), 6.92 (br s, 1H), 6.90 (dd, J = 7.7, 1.2 Hz, 1H), 6.64 (t, J = 4.8 Hz, 1H), 2.58 (t, J = 7.9 Hz, 
2H), 2.33 (s, 3H), 1.60–1.51 (m, 2H), 1.39–1.30 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 161.0 (Cq), 158.1 (CH), 136.3 (Cq), 136.1 (Cq), 131.6 (Cq), 
129.5 (CH), 125.4 (CH), 124.1 (CH), 112.0 (CH), 32.2 (CH2), 30.9 (CH2), 22.5 (CH2), 21.2 
(CH3), 13.9 (CH3).  
IR (neat): 3233, 2954, 2927, 2859, 1577, 1525, 1443, 1400, 797 cm-1.  
MS (EI) m/z (relative intensity) 241 (51) [M+], 212 (73), 184 (100).  







N-(2-n-Butyl-5-methoxyphenyl)pyrimidin-2-amine (133ga): The general procedure A was 
followed using substrate 123g (101 mg, 0.50 mmol) and bromide 58a (107 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 133ga (93 mg, 72%) as a 
colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 8.37 (d, J = 4.8 Hz, 2H), 7.67 (d, J = 2.7 Hz, 1H), 7.08 (d, J 
= 8.4 Hz, 1H), 6.99 (s, 1H), 6.67 (t, J = 4.8 Hz, 1H), 6.61 (dd, J = 8.4, 2.7 Hz, 1H), 3.79 (s, 3H), 
2.57 (t, J = 7.9 Hz, 2H), 1.62–1.49 (m, 2H), 1.42–1.29 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ = 160.6 (Cq), 158.2 (Cq), 158.0 (CH), 137.5 (Cq), 130.0 (CH), 
125.4 (Cq), 112.3 (CH), 109.2 (CH), 108.3 (CH), 55.2 (CH3), 32.1 (CH2), 30.6 (CH2), 22.5 
(CH2), 13.9 (CH3).  
IR (neat): 3232, 2955, 2929, 2870, 1578, 1523, 1442, 1257, 1164, 796 cm-1.  
MS (EI) m/z (relative intensity) 257 (53) [M+], 228 (42), 214 (100), 200 (70), 170 (40). 
HR-MS (EI) m/z calcd for C15H19N3O [M+] 257.1528, found 257.1530. 
 
 
N-[2-n-Butyl-5-(trifluoromethyl)phenyl]pyrimidin-2-amine (133ha): The general 
procedure A was followed using substrate 123h (120 mg, 0.50 mmol) and bromide 58a (107 
μL, 1.00 mmol) at 100 °C. Isolation by column chromatography (n-hexane/EtOAc: 10/1→5/1) 
yielded 133ha (114 mg, 77%) as a colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 8.39 (d, J = 4.8 Hz, 2H), 8.36 (s, 1H), 7.36 (br s, 1H), 7.29–
7.28 (m, 2H), 6.71 (t, J = 4.8 Hz, 1H), 2.67 (t, J = 7.9 Hz, 2H), 1.66–1.56 (m, 2H), 1.43–1.31 
(m, 2H), 0.91 (t, J = 7.3 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 160.4 (Cq), 158.1 (CH), 137.3 (Cq), 136.9 (Cq, d, 4JC-F = 1.0 
Hz), 129.8 (CH), 128.8 (Cq, q, 2JC-F = 32.3 Hz), 124.2 (Cq, q, 1JC-F = 272.0 Hz), 120.2 (CH, q, 
3JC-F = 3.8 Hz), 119.1 (CH, q, 3JC-F = 3.9 Hz), 112.8 (CH), 31.4 (CH2), 31.2 (CH2), 22.5 (CH2), 





19F NMR (283 MHz, CDCl3) δ = -62.3 (s).  
IR (neat): 3445, 3273, 2959, 2873, 1578, 1427, 1327, 1161, 1116, 1074, 797 cm-1.  
MS (EI) m/z (relative intensity) 295 (45) [M+], 266 (100), 238 (95), 183 (10).  
HR-MS (EI) m/z calcd for C15H16F3N3 [M+] 295.1296, found 295.1291. 
 
 
Ethyl 4-n-butyl-3-(pyrimidin-2-ylamino)benzoate (133ia): The general procedure A was 
followed using substrate 123i (122 mg, 0.50 mmol) and bromide 58a (107 μL, 1.00 mmol) at 
100 °C. Isolation by column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 133ia (86 
mg, 57%) as a colorless liquid.  
1H NMR (500 MHz, CDCl3) δ = 8.50 (d, J = 1.8 Hz, 1H), 8.35 (d, J = 4.8 Hz, 2H), 7.74 (dd, J 
= 8.0, 1.8 Hz, 1H), 7.25 (br s, 1H), 7.24 (d, J = 8.0 Hz, 1H), 6.66 (t, J = 4.8 Hz, 1H), 4.33 (q, J 
= 7.1 Hz, 2H), 2.65 (t, J = 7.9 Hz, 2H), 1.65–1.50 (m, 2H), 1.36–1.29 (m, 5H), 0.86 (t, J = 7.3 
Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 166.4 (Cq), 160.8 (Cq), 158.1 (CH), 139.8 (Cq), 136.8 (Cq), 
129.5 (CH), 128.9 (Cq), 125.4 (CH), 124.7 (CH), 112.4 (CH), 60.7 (CH2), 31.6 (CH2), 31.3 
(CH2), 22.4 (CH2), 14.3 (CH3), 13.8 (CH3). 
IR (neat): 3222, 2957, 2931, 2871, 1713, 1577, 1444, 1288, 1221, 1099, 798 cm-1.  
MS (EI) m/z (relative intensity) 299 (40) [M+], 270 (92), 242 (100), 182 (20).  
HR-MS (EI) m/z calcd for C17H21N3O2 [M+] 299.1634, found 299.1646. 
 
 
tert-Butyl 4-n-butyl-3-(pyrimidin-2-ylamino)benzoate (133ja): The general procedure A 





Isolation by column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 133ja (105 mg, 
64%) as a white solid.  
M. p. = 108–109 °C.  
1H NMR (500 MHz, CDCl3) δ = 8.48 (d, J = 1.8 Hz, 1H), 8.37 (d, J = 4.8 Hz, 2H), 7.70 (dd, J 
= 7.9, 1.8 Hz, 1H), 7.27–7.22 (m, 2H), 6.67 (t, J = 4.8 Hz, 1H), 2.66 (t, J = 7,9 Hz, 2H), 1.62–
1.54 (m, 11H), 1.41–1.26 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 165.5 (Cq), 160.8 (Cq), 158.1 (CH), 139.4 (Cq), 136.6 (Cq), 
130.5 (Cq), 129.4 (CH), 125.4 (CH), 124.5 (CH), 112.3 (CH), 80.6 (Cq), 31.6 (CH2), 31.3 (CH2), 
28.1 (CH3), 22.4 (CH2), 13.8 (CH3).  
IR (neat): 3225, 2968, 2930, 2862, 1704, 1583, 1447, 1305, 1126, 800 cm-1.  
MS (EI) m/z (relative intensity) 327 (23) [M+], 271 (45), 242 (98), 214 (100), 182 (16).  
HR-MS (EI) m/z calcd for C19H25N3O2 [M+] 327.1947, found 327.1948. 
 
 
The general procedure A was followed using substrate 123k (93 mg, 0.50 mmol) and bromide 
58a (59 μL, 0.55 mmol). Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 
133ka (75 mg, 62%) and 133ka’ (18 mg, 12%) as yellow solids.  
N-(2-n-Butyl-4-methylphenyl)pyrimidin-2-amine (133ka):  
M. p. = 57–58 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.32 (d, J = 4.8 Hz, 2H), 7.61–7.53 (m, 1H), 7.05–7.01 (m, 
2H), 6.97 (br s, 1H), 6.61 (t, J = 4.8 Hz, 1H), 2.58 (t, J = 7.9 Hz, 2H), 2.30 (s, 3H), 1.61–1.51 
(m, 2H), 1.40–1.28 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ = 161.4 (Cq), 158.1 (CH), 135.6 (Cq), 134.5 (Cq), 133.8 (Cq), 
130.3 (CH), 127.1 (CH), 124.5 (CH), 111.7 (CH), 32.2 (CH2), 31.3 (CH2), 22.6 (CH2), 21.0 
(CH3), 13.9 (CH3).  





MS (EI) m/z (relative intensity) 241 (56) [M+], 212 (82), 184 (100).  
HR-MS (EI) m/z calcd for C15H19N3 [M+] 241.1579, found 241.1576. 
N-(2,6-Di-n-butyl-4-methylphenyl)pyrimidin-2-amine (133ka’):  
M. p. = 99–100 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.27 (d, J = 4.8 Hz, 2H), 6.93 (s, 2H), 6.58 (br s, 1H), 6.54 (t, 
J = 4.8 Hz, 1H), 2.50 (t, J = 7.9 Hz, 4H), 1.55–1.42 (m, 4H), 1.38–1.17 (m, 4H), 0.82 (t, J = 7.3 
Hz, 6H).  
13C NMR (100 MHz, CDCl3) δ = 162.3 (Cq), 158.3 (CH), 145.0 (Cq), 136.9 (Cq), 131.7 (Cq), 
128.2 (CH), 111.0 (CH), 32.6 (CH2), 31.7 (CH2), 22.7 (CH2), 21.2 (CH3), 13.9 (CH3).  
IR (neat): 3223, 2955, 2925, 2857, 1577, 1447, 1407, 1260, 800, 639 cm-1.  
MS (EI) m/z (relative intensity) 297 (35) [M+], 240 (100), 210 (25), 197 (15).  
HR-MS (ESI) m/z calcd for C19H27N3 [M+H+] 298.2283, found 298.2278. 
 
 
The general procedure A was followed using substrate 123l (95 mg, 0.50 mmol) and bromide 
58a (59 μL, 0.55 mmol). After 4 h, isolation by column chromatography (n-hexane/EtOAc: 
10/1) yielded 133la (86 mg, 70%) and 133la’ (20mg, 13%) as white solids.  
N-(2-n-Butyl-4-fluorophenyl)pyrimidin-2-amine (133la):  
M. p. = 63–64 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.32 (d, J = 4.8 Hz, 2H), 7.67–7.58 (m, 1H), 7.04 (br s, 1H), 
6.96–6.85 (m, 2H), 6.63 (t, J = 4.8 Hz, 1H), 2.59 (t, J = 7.9 Hz, 2H), 1.65–1.49 (m, 2H), 1.40–
1.27 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 161.1 (Cq), 160.0 (Cq, 1JC-F = 244.0 Hz), 158.0 (CH), 138.3 
(Cq, 3JC-F = 7.5 Hz), 132.3 (Cq, 4JC-F = 2.7 Hz), 126.3 (CH, 3JC-F = 8.3 Hz), 115.9 (CH, 2JC-F = 
22.6 Hz), 113.0 (CH, 2JC-F = 22.6 Hz), 112.0 (CH), 31.8 (CH2), 31.3 (CH2, 4JC-F = 1.1 Hz), 22.5 





19F NMR (283 MHz, CDCl3) δ = -117.7 (ddd, J = 8.7, 8.7, 5.4 Hz).  
IR (neat): 3234, 2957, 2930, 2870, 1582, 1518, 1446, 1192, 990, 864 cm-1.  
MS (EI) m/z (relative intensity) 245 (51) [M+], 216 (100), 203 (40), 188 (81).  
HR-MS (EI) m/z calcd for C14H16FN3 [M+] 245.1328, found 245.1331. 
N-(2,6-Di-n-butyl-4-fluorophenyl)pyrimidin-2-amine (133la’):  
M. p. = 75–76 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.24 (d, J = 4.8 Hz, 2H), 7.30 (br s, 1H), 6.83 (d, J = 9.3 Hz, 
2H), 6.55 (t, J = 4.8 Hz, 1H), 2.55 (t, J = 7.9 Hz, 4H), 1.55–1.45 (m, 4H), 1.32–1.20 (m, 4H), 
0.81 (t, J = 7.3 Hz, 6H).  
13C NMR (125 MHz, CDCl3) δ = 162.1 (Cq), 161.4 (Cq, 1JC-F = 245.4 Hz), 158.2 (CH), 143.6 
(Cq, 3JC-F = 8.3 Hz), 130.3 (Cq, 4JC-F = 2.9 Hz), 113.6 (CH, 2JC-F = 22.0 Hz), 111.1 (CH), 32.2 
(CH2), 31.7 (CH2, 4JC-F = 1.2 Hz), 22.5 (CH2), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -115.4 (t, J = 9.2 Hz).  
IR (neat): 3214, 2957, 2927, 2860, 1581, 1520, 1446, 1409, 990, 800 cm-1.  
MS (EI) m/z (relative intensity) 301 (40) [M+], 244 (100), 201 (25).  
HR-MS (EI) m/z calcd for C18H24FN3 [M+] 301.1954, found 301.1951. 
 
 
The general procedure A was followed using substrate 123m (103 mg, 0.50 mmol) and bromide 
58a (59 μL, 0.55 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 
133ma (75 mg, 57%) and 133ma’ (24 mg, 15%) as yellow solids.  
N-(2-n-Butyl-4-chlorophenyl)pyrimidin-2-amine (133ma):  
M. p. = 57–58 °C.  
1H NMR (500 MHz, CDCl3) δ = 8.35 (d, J = 4.8 Hz, 2H), 7.82 (d, J = 9.3 Hz, 1H), 7.19–7.16 
(m, 2H), 7.00 (br s, 1H), 6.67 (t, J = 4.8 Hz, 1H), 2.59 (t, J = 7.9 Hz, 2H), 1.56–1.54 (m, 2H), 





13C NMR (125 MHz, CDCl3) δ = 160.7 (Cq), 158.1 (CH), 136.1 (Cq), 135.2 (Cq), 129.4 (CH), 
129.3 (Cq), 126.4 (CH), 124.5 (CH), 112.4 (CH), 31.6 (CH2), 31.1 (CH2), 22.5 (CH2), 13.8 
(CH3).  
IR (neat): 3054, 1649, 1547, 1462, 1437, 1294, 1181, 1121, 757, 690, 546, 505 cm-1.  
MS (EI) m/z (relative intensity) 261 (45) [M+] (35Cl), 263 (15) [M+] (37Cl), 232 (100) (35Cl), 
234 (33) (37Cl), 204 (81), 183 (22).  
HR-MS (EI) m/z calcd for C14H16ClN3 [M+] 261.1033, found 261.1041. 
 
N-(2,6-Di-n-butyl-4-chlorophenyl)pyrimidin-2-amine (133ma’):  
M. p. = 97–98 °C.  
1H NMR (500 MHz, CDCl3) δ = 8.28 (d, J = 4.8 Hz, 2H), 7.11 (s, 2H), 6.59 (t, J = 4.8 Hz, 1H), 
6.57 (br s, 1H), 2.51 (t, J = 7.9 Hz, 4H), 1.52–1.44 (m, 4H), 1.31–1.21 (m, 4H), 0.82 (t, J = 7.3 
Hz, 6H).  
13C NMR (125 MHz, CDCl3) δ = 162.0 (Cq), 158.4 (CH), 143.2 (Cq), 133.1 (Cq), 132.9 (Cq), 
127.3 (CH), 111.6 (CH), 32.2 (CH2), 31.6 (CH2), 22.5 (CH2), 13.8 (CH3).  
IR (neat): 3222, 2955, 2927, 2857, 1580, 1519, 1445, 1408, 799, 638 cm-1.  
MS (EI) m/z (relative intensity) 317 (40) [M+], 288 (65), 260 (100), 217 (20).  
HR-MS (EI) m/z calcd for C18H24ClN3 [M+] 317.1659, found 317.1665. 
 
 
N-(2-n-Butyl-4-fluoro-6-methylphenyl)pyrimidin-2-amine (133na): The general procedure 
A was followed using substrate 123n (102 mg, 0.50 mmol) and bromide 58a (107 μL, 1.00 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 133na (127 
mg, 98%) as a white solid.  





1H NMR (300 MHz, CDCl3) δ = 8.27 (d, J = 4.8 Hz, 2H), 7.03 (br s, 1H), 6.82 (vd, J = 9.3 Hz, 
2H), 6.57 (t, J = 4.8 Hz, 1H), 2.56 (t, J = 7.9 Hz, 2H), 2.20 (s, 3H), 1.55–1.42 (m, 2H), 1.35–
1.19 (m, 2H), 0.82 (t, J = 7.3 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 161.9 (Cq), 161.2 (Cq, JC-F = 245.4 Hz), 158.4 (CH), 143.2 
(Cq, 3JC-F = 8.1 Hz), 139.2 (Cq, 3JC-F = 8.7 Hz), 130.9 (Cq, 4JC-F = 2.8 Hz), 114.8 (CH, 2JC-F = 
22.0 Hz), 113.7 (CH, 2JC-F = 21.8 Hz), 111.3 (CH), 32.2 (CH2), 31.7 (CH2, 4JC-F = 1.3 Hz), 22.4 
(CH2), 18.7 (CH3, 4JC-F = 1.5 Hz), 13.8 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -115.8 (dd, J = 9.2. 9.2 Hz).  
IR (neat): 3219, 2954, 2926, 2870, 1578, 1519, 1446, 1261, 1128, 995, 801, 535 cm-1.  
MS (EI) m/z (relative intensity) 259 (50) [M+], 230 (80), 202 (100).  
HR-MS (EI) m/z calcd for C15H18FN3 [M+] 259.1485, found 259.1481. 
 
 
N-(2-n-Butyl-4,6-difluorophenyl)pyrimidin-2-amine (133oa): The general procedure A was 
followed using substrate 123o (104 mg, 0.50 mmol) and bromide 58a (107 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→5/1) yielded 133oa (119 mg, 
90%) as a colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 8.28 (d, J = 4.8 Hz, 2H), 7.59 (s, 1H), 6.83–6.69 (m, 2H), 6.61 
(t, J = 4.8 Hz, 1H), 2.61 (t, J = 7.9 Hz, 2H), 1.57–1.47 (m, 2H), 1.33–1.21 (m, 2H), 0.82 (t, J = 
7.3 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 161.6 (Cq), 160.8 (Cq, dd, JC-F = 247.2, 12.9 Hz), 158.9 (Cq, 
dd, JC-F = 249.4, 13.0 Hz), 158.0 (CH), 144.4 (Cq, dd, JC-F = 9.0, 1.2 Hz), 120.8 (Cq, dd, JC-F = 
12.9, 3.9 Hz), 111.9 (CH), 111.4 (CH, dd, JC-F = 21.7, 3.4 Hz), 101.9 (CH, dd, JC-F = 26.1, 25.1 
Hz), 32.0 (CH2), 31.2 (CH2, dd, JC-F = 2.0, 2.0 Hz), 22.4 (CH2), 13.8 (CH3).  






IR (neat): 3223, 2958, 2871, 1583, 1444, 1118, 993, 799, 535 cm-1.  
MS (EI) m/z (relative intensity) 263 (40) [M+], 234 (100), 206 (60), 181 (5).  
HR-MS (EI) m/z calcd for C14H15F2N3 [M+] 263.1234, found 263.1230. 
 
 
N-(2-Ethyl-6-fluorophenyl)pyrimidin-2-amine (133bc): The general procedure A was 
followed using substrate 123b (95 mg, 0.50 mmol) and iodoethane 58c (80 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 133bc (87 mg, 
80%) as a white solid.  
M. p. = 108–109 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.30 (d, J = 4.8 Hz, 2H), 7.56 (br s, 1H), 7.20 (ddd, J = 8.0, 
8.0, 5.5 Hz, 1H), 7.10–7.06 (m, 1H), 7.00 (ddd, J = 9.6, 6.3, 1.4 Hz, 1H), 6.61 (t, J = 4.8 Hz, 
1H), 2.68 (q, J = 7.6 Hz, 2H), 1.17 (t, J = 7.6 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ = 161.7 (Cq), 158.6 (Cq, 1JC-F = 248.0 Hz), 158.2 (CH), 143.9 
(Cq), 127.6 (CH, 3JC-F = 8.6 Hz), 124.4 (Cq, 2JC-F = 12.7 Hz), 124.0 (CH, 4JC-F = 3.3 Hz), 113.4 
(CH, 2JC-F = 20.8 Hz), 111.9 (CH), 24.5 (CH2, 4JC-F = 2.5 Hz), 14.3 (CH3). 
19F NMR (376 MHz, CDCl3) δ = -119.9 (dd, J = 9.6, 5.5 Hz).  
IR (neat): 3223, 2971, 2933, 1579, 1524, 1446, 1410, 918, 640 cm-1.  
MS (EI) m/z (relative intensity) 217 (40) [M+], 202 (10), 188 (62).  
HR-MS (EI) m/z calcd for C12H12FN3 [M+] 217.1015, found 217.1021. 
 
 
N-(2-Fluoro-6-iso-butylphenyl)pyrimidin-2-amine (133bd): The general procedure A was 





Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 133bd (109 mg, 
89%) as a white solid.  
M. p. = 76–77 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.29 (d, J = 4.8 Hz, 2H), 7.21–7.14 (m, 2H), 7.05–6.92 (m, 
2H), 6.61 (t, J = 4.8 Hz, 1H), 2.52 (d, J = 7.2 Hz, 2H), 1.94–1.76 (m, 1H), 0.85 (d, J = 6.6 Hz, 
6H).  
13C NMR (125 MHz, CDCl3) δ = 161.5 (Cq), 158.6 (Cq, 1JC-F = 248.0 Hz), 158.0 (CH), 141.4 
(Cq), 127.2 (CH, 3JC-F = 8.6 Hz), 125.7 (CH, 4JC-F = 3.3 Hz), 124.8 (Cq, 2JC-F = 12.5 Hz), 113.5 
(CH, 2JC-F = 20.8 Hz), 111.9 (CH), 40.8 (CH2, JC-F = 2.3 Hz), 29.5 (CH2), 22.5 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -119.0 (dd, J = 9.4, 5.4 Hz). 
IR (neat): 3224, 2959, 2869, 1581, 1529, 1448, 1413, 1265, 799 cm-1. 
MS (EI) m/z (relative intensity) 245 (40) [M+], 230 (55), 202 (45), 182 (15), 170 (7). 
HR-MS (EI) m/z calcd for C14H16FN3 [M+] 245.1328, found 245.1326. 
 
 
N-(2-Fluoro-6-n-octylphenyl)pyrimidin-2-amine (133be): The general procedure A was 
followed using substrate 123b (95 mg, 0.50 mmol) and bromide 58e (173 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 133be (119 mg, 
79%) as a colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 8.29 (d, J = 4.8 Hz, 2H), 7.53 (s, 1H), 7.24–7.14 (m, 1H), 
7.08–6.93 (m, 2H), 6.61 (t, J = 4.8 Hz, 1H), 2.68–2.59 (m, 2H), 1.60–1.50 (m, 2H), 1.26–1.18 
(m, 10H), 0.83 (t, J = 6.8 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ = 161.6 (Cq), 158.6 (Cq, 1JC-F = 248.0 Hz), 158.0 (CH), 142.6 
(Cq), 127.3 (CH, 3JC-F = 8.6 Hz), 124.7 (CH, 4JC-F = 3.2 Hz), 124.5 (Cq, 2JC-F = 12.6 Hz), 113.3 
(CH, 2JC-F = 20.8 Hz), 111.8 (CH), 31.8 (CH2), 31.6 (CH2, 4JC-F = 2.3 Hz), 30.2 (CH2), 29.5 
(CH2), 29.4 (CH2), 29.2 (CH2), 22.6 (CH2), 14.1 (CH3). 





IR (neat): 3224, 2924, 2854, 1581, 1523, 1445, 1409, 1269, 782 cm-1.  
MS (EI) m/z (relative intensity) 301 (50) [M+], 216 (100), 188 (83), 142 (12).  
HR-MS (EI) m/z calcd for C18H24FN3 [M+] 301.1954, found 301.1943. 
 
 
N-(2-Fluoro-6-phenethylphenyl)pyrimidin-2-amine (133bf): The general procedure A was 
followed using substrate 123b (95 mg, 0.50 mmol) and bromide 58f (137 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 133bf (105 mg, 
88%) as a white solid.  
M. p. = 107–108 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.31 (d, J = 4.8 Hz, 2H), 7.32 (br s, 1H), 7.26–7.14 (m, 4H), 
7.10–7.06 (m, 3H), 7.04 (ddd, J = 9.6, 6.3, 1.5 Hz, 1H), 6.62 (t, J = 4.8 Hz, 1H), 3.02–2.95 (m, 
2H), 2.93–2.86 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ = 161.7 (Cq), 158.8 (Cq, 1JC-F = 248.0 Hz), 158.2 (CH), 141.6 
(Cq), 141.3 (Cq), 128.4 (CH), 128.3 (CH), 127.6 (CH, 3JC-F = 8.6 Hz), 126.0 (CH), 124.9 (CH, 
4JC-F = 3.3 Hz), 124.8 (Cq, 2JC-F = 12.8 Hz), 113.8 (CH, 2JC-F = 20.8 Hz), 112.0 (CH), 36.5 (CH2), 
33.6 (CH2, 4JC-F = 2.4 Hz). 
19F NMR (376 MHz, CDCl3) δ = -119.4 (dd, J = 9.6, 5.5 Hz). 
IR (neat): 3220, 3026, 2928, 2861, 1579, 1524, 1442, 1412, 781, 719, 642 cm-1. 
MS (EI) m/z (relative intensity) 293 (40) [M+], 202 (100), 188 (25), 170 (15). 
HR-MS (EI) m/z calcd for C18H16FN3 [M+] 293.1328, found 293.1321. 
 
 
N-[2-Fluoro-6-(3-phenoxypropyl)phenyl]pyrimidin-2-amine (133bg): The general 





1.00 mmol). Isolation by column chromatography (n-hexane/EtOAc: 8/1→5/1) yielded 133bg 
(150 mg, 93%) as a yellow solid.  
M. p. = 92–93 °C. 
1H NMR (300 MHz, CDCl3) δ = 8.29 (d, J = 4.8 Hz, 2H), 7.58 (br s, 1H), 7.27–7.16 (m, 3H), 
7.12–7.09 (m, 1H), 7.02 (ddd, J = 9.6, 8.1, 1.6 Hz, 1H), 6.93–6.87 (m, 1H), 6.85–6.83 (m, 1H), 
6.82–6.80 (m, 1H), 6.60 (t, J = 4.8 Hz, 1H), 3.89 (t, J = 6.2 Hz, 2H), 2.92–2.85 (m, 2H), 2.12–
2.02 (m, 2H). 
13C NMR (125 MHz, CDCl3) δ = 161.4 (Cq), 158.6 (Cq, 1JC-F = 248.0 Hz), 158.6 (Cq), 158.0 
(CH), 141.2 (Cq), 129.2 (CH), 127.4 (CH, 3JC-F = 8.6 Hz), 124.8 (Cq, 2JC-F = 12.8 Hz), 124.8 
(CH, 4JC-F = 3.3 Hz), 120.4 (CH), 114.4 (CH), 113.7 (CH, 2JC-F = 20.8 Hz), 112.0 (CH), 66.5 
(CH2), 29.6 (CH2), 27.8 (CH2, 4JC-F = 2.3 Hz). 
19F NMR (283 MHz, CDCl3) δ = -119.0 (dd, J = 9.6, 5.5 Hz). 
IR (neat): 3226, 3163, 2931, 2875, 1587, 1527, 1445, 1241, 1033, 690 cm-1. 
MS (EI) m/z (relative intensity) 323 (55) [M+], 216 (100), 188 (75), 170 (15). 
HR-MS (EI) m/z calcd for C19H18FN3O [M+] 323.1434, found 323.1435. 
 
 
5-[3-Fluoro-2-(pyrimidin-2-ylamino)phenyl]pentanenitrile (133bh): The general procedure 
A was followed using substrate 123b (95 mg, 0.50 mmol) and bromide 58h (117 μL, 1.00 mmol) 
at 160 °C. Isolation by column chromatography (n-hexane/EtOAc: 5/1→2/1) yielded 133bh 
(96 mg, 71%) as a colorless liquid. 
1H NMR (400 MHz, CDCl3) δ = 8.30 (d, J = 4.8 Hz, 2H), 7.26 (br s, 1H), 7.72–7.17 (m, 1H), 
7.07–6.96 (m, 2H), 6.65 (t, J = 4.8 Hz, 1H), 2.68 (t, J = 7.5 Hz, 2H), 2.24 (t, J = 7.0 Hz, 2H), 
1.78–1.67 (m, 2H), 1.65–1.55 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ = 161.7 (Cq), 158.8 (Cq, 1JC-F = 248.0 Hz), 158.2 (CH), 141.4 





(Cq), 113.9 (CH, 2JC-F = 20.9 Hz), 112.3 (CH), 30.5 (CH2, 4JC-F = 2.4 Hz), 28.9 (CH2), 24.9 
(CH2), 16.9 (CH2). 
19F NMR (376 MHz, CDCl3) δ = -119.55 (dd, J = 9.5, 5.5 Hz). 
IR (neat): 3223, 2933, 2867, 2250, 1580, 1509, 1443, 1405, 1270, 785, 637 cm-1. 
MS (EI) m/z (relative intensity) 270 (30) [M+], 216 (100), 188 (65), 170 (5). 
HR-MS (EI) m/z calcd for C15H15FN4 [M+] 270.1281, found 270.1280. 
 
 
N-[2-(Cyclopentylmethyl)-6-fluorophenyl]pyrimidin-2-amine (133bi): The general 
procedure A was followed using substrate 123b (95 mg, 0.50 mmol) and 
(iodomethyl)cyclopentane 58i (131 μL, 1.00 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 10/1→8/1) yielded 133bi (134 mg, 99%) as a white solid.  
M. p. = 89–90 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.30 (d, J = 4.8 Hz, 2H), 7.19–7.14 (m, 2H), 7.05 (ddd, J = 
7.8, 1.5, 0.8 Hz, 1H), 6.98 (ddd, J = 9.7, 7.8, 1.5 Hz, 1H), 6.62 (t, J = 4.8 Hz, 1H), 2.65 (d, J = 
7.4 Hz, 2H), 2.13–1.96 (m, 1H), 1.70–1.51 (m, 4H), 1.51–1.37 (m, 2H), 1.19–1.03 (m, 2H).  
13C NMR (100 MHz, CDCl3) δ = 161.6 (Cq), 160.0 (Cq, 1JC-F = 248.0 Hz), 158.1 (CH), 142.1 
(Cq), 127.3 (CH, 3JC-F = 8.6 Hz), 125.3 (CH, 4JC-F = 3.3 Hz), 124.6 (Cq, 2JC-F = 12.5 Hz), 113.4 
(CH, 2JC-F = 20.8 Hz), 111.9 (CH), 40.8 (CH), 37.3 (CH2, 4JC-F = 2.2 Hz), 32.5 (CH2), 24.7 
(CH2). 
19F NMR (376 MHz, CDCl3) δ = -119.2 (dd, J = 9.6, 5.4 Hz). 
IR (neat): 3208, 2944, 2863, 1583, 1527, 1445, 1409, 1270, 786, 648 cm-1. 
MS (EI) m/z (relative intensity) 271 (40) [M+], 203 (65), 188 (100), 170 (5). 







2-{5-[3-Fluoro-2-(pyrimidin-2-ylamino)phenyl]pentyl}isoindoline-1,3-dione (133bj): The 
general procedure A was followed using substrate 123b (95 mg, 0.50 mmol) and bromide 58j 
(296 mg, 1.00 mmol). Isolation by column chromatography (n-hexane/EtOAc: 5/1→2/1) 
yielded 133bj (182 mg, 90%) as a white solid.  
M. p. = 147–148 °C. 
1H NMR (300 MHz, CDCl3) δ = 8.30 (d, J = 4.8 Hz, 2H), 7.81 (dd, J = 5.4, 3.1 Hz, 2H), 7.68 
(dd, J = 5.5, 3.1 Hz, 2H), 7.15 (ddd, J = 7.9, 7.9, 5.4 Hz, 1H), 7.02 (d, J = 7.7, 1H), 6.95 (ddd, 
J = 9.6, 8.1, 1.5 Hz, 1H), 6.71–6.53 (m, 2H), 3.62 (t, J = 7.2 Hz, 2H), 2.62 (t, J = 7.9 Hz, 2H), 
1.77–1.49 (m, 4H), 1.38–1.23 (m, 2H). 
13C NMR (125 MHz, CDCl3) δ = 168.4 (Cq), 161.6 (Cq), 158.8 (Cq, 1JC-F = 248 Hz), 158.2 (CH), 
142.4 (Cq), 133.8 (CH), 132.1 (Cq), 127.6 (CH, 3JC-F = 8.6 Hz), 124.9 (CH, 4JC-F = 3.3 Hz), 
124.4 (Cq, 2JC-F = 12.7 Hz), 123.2 (CH), 113.5 (CH, 2JC-F = 20.8 Hz), 112.2 (CH), 37.7 (CH2), 
31.4 (CH2, 4JC-F = 2.4 Hz), 29.6 (CH2), 28.2 (CH2), 26.4 (CH2). 
19F NMR (283 MHz, CDCl3) δ = -119.5 (dd, J = 9.6, 5.5 Hz). 
IR (neat): 3326, 2936, 2862, 1705, 1508, 1440, 1367, 1406, 796, 718, 519 cm-1. 
MS (EI) m/z (relative intensity) 404 (50) [M+], 216 (100), 188 (65). 
HR-MS (EI) m/z calcd for C23H21FN4O2 [M+] 404.1649, found 404.1643. 
 
 
N-(2-Fluoro-6-neopentylphenyl)pyrimidin-2-amine (133bk): The general procedure A was 
followed using substrate 123b (95 mg, 0.50 mmol) and bromide 58k (126 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 133bk (117 mg, 
90%) as a white solid.  





1H NMR (300 MHz, CDCl3) δ = 8.29 (d, J = 4.8 Hz, 2H), 7.24 (br s, 1H), 7.16 (ddd, J = 8.0, 
8.0, 5.5 Hz, 1H), 7.06–6.94 (m, 2H), 6.60 (t, J = 4.8 Hz, 1H), 2.59 (s, 2H), 0.89 (s, 9H).  
13C NMR (125 MHz, CDCl3) δ = 161.4 (Cq), 158.8 (Cq, 1JC-F = 248.0 Hz), 158.1 (CH), 139.3 
(Cq), 127.4 (CH, 4JC-F = 3.3 Hz), 126.6 (CH, 3JC-F = 8.6 Hz), 125.4 (Cq, 2JC-F = 12.4 Hz), 113.8 
(CH, 2JC-F = 20.9 Hz), 111.9 (CH), 44.5 (CH2, 4JC-F = 2.2 Hz), 32.9 (Cq), 29.5 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -117.8 (dd, J = 9.6, 5.6 Hz). 
IR (neat): 3452, 3236, 2950, 2864, 1578, 1520, 1440, 1406, 1240, 797, 751 cm-1. 
MS (EI) m/z (relative intensity) 241 (35) [M+], 184 (100), 170 (40). 
HR-MS (EI) m/z calcd for C15H19N3 [M+] 241.1579, found 241.1576. 
 
N-(2-Cyclohexyl-6-methylphenyl)pyrimidin-2-amine (142ab): The general procedure B was 
followed using substrate 123a (185 mg, 1.0 mmol) and bromide 58b (246 μL, 2.00 mmol) at 
120 °C. Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 142ab 
(254 mg, 95%) as a white solid. 
M. p. = 113–114 °C. 
1H NMR (400 MHz, CDCl3) δ = 8.28 (d, J = 4.8 Hz, 2H), 7.23–7.17 (m, 2H), 7.12 (dd, J = 7.0, 
2.6 Hz, 1H), 6.89 (br s, 1H), 6.56 (t, J = 4.8 Hz, 1H), 2.80 (tt, J = 11.9, 3.0 Hz, 1H), 2.21 (s, 
3H), 1.80–1.64 (m, 5H), 1.45–1.15 (m, 5H). 
13C NMR (100 MHz, CDCl3) δ = 162.1 (Cq), 158.3 (CH), 145.7 (Cq), 136.8 (Cq), 134.1 (Cq), 
128.1 (CH), 127.5 (CH), 124.4 (CH), 111.2 (CH), 39.1 (CH), 33.9 (CH2), 26.9 (CH2), 26.2 
(CH2), 18.8 (CH3). 
IR (neat): 3220, 2922, 2852, 1578, 1519, 1446, 1407, 1262, 993, 781, 641 cm-1. 
MS (EI) m/z (relative intensity) 267 (15) [M+], 184 (100), 170 (5). 







N-(2-Cyclohexyl-6-fluorophenyl)pyrimidin-2-amine (142bb): The general procedure B was 
followed using substrate 123b (189 mg, 1.0 mmol) and bromide 58b (246 μL, 2.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 142bb (270 mg, 
99%) as a yellow solid.  
M. p. = 93–94 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.31 (d, J = 4.8 Hz, 2H), 7.21 (ddd, J = 8.0, 8.0, 4.0 Hz, 1H), 
7.10 (d, J = 7.9 Hz, 1H), 6.97 (ddd, J = 9.6, 8.2, 1.3 Hz, 1H), 6.85 (s, 1H), 6.63 (t, J = 4.8 Hz, 
1H), 2.85–2.78 (m, 1H), 1.83–1.73 (m, 4H), 1.72–1.65 (m, 1H), 1.43–1.33 (m, 2H), 1.33–1.15 
(m, 3H). 
13C NMR (125 MHz, CDCl3) δ = 161.9 (Cq), 158.6 (Cq, 1JC-F = 248.0 Hz), 158.2 (CH), 147.5 
(Cq), 127.8 (CH, 3JC-F = 8.6 Hz), 123.6 (Cq, 2JC-F = 12.4 Hz), 122.0 (CH, 4JC-F = 3.3 Hz), 113.2 
(CH, 2JC-F = 20.8 Hz), 112.1 (CH), 38.8 (CH, 4JC-F = 2.1 Hz), 33.7 (CH2), 26.8 (CH2), 26.1 
(CH2). 
19F NMR (283 MHz, CDCl3) δ = -118.8 (dd, J = 9.8, 5.4 Hz). 
IR (neat): 3224, 2935, 2851, 1582, 1523, 1446, 1413, 1256, 958, 776, 641 cm-1. 
MS (EI) m/z (relative intensity) 271 (60) [M+], 188 (100), 170 (5). 
HR-MS (EI) m/z calcd for C16H18FN3 [M+] 271.1485, found 271.1486. 
 
 
The general procedure A was followed using substrate 123c (86 mg, 0.50 mmol) and bromide 
58b (68 μL, 0.55 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) 






M. p. = 93–94 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.33 (d, J = 4.8 Hz, 2H), 7.70 (dd, J = 7.9, 1.4 Hz, 1H), 7.34 
(br s, 1H), 7.30 (dd, J = 7.7, 1.7 Hz, 1H), 7.22 (ddd, J = 7.9, 7.5, 1.7 Hz, 1H), 7.16 (ddd, J = 
7.7, 7.5, 1.4 Hz, 1H), 6.62 (t, J = 4.8 Hz, 1H), 2.78 (tt, J = 11.8, 2.9 Hz, 1H), 1.87–1.67 (m, 
5H), 1.49–1.18 (m, 5H). 
13C NMR (125 MHz, CDCl3) δ = 161.2 (Cq), 157.9 (CH), 140.4 (Cq), 135.5 (Cq), 126.3 (CH), 
126.0 (CH), 125.1 (CH), 124.6 (CH), 111.8 (CH), 38.5 (CH), 33.56 (CH2), 26.9 (CH2), 26.2 
(CH2). 
IR (neat): 3224, 2922, 2848, 1571, 1516, 1442, 1402, 1253, 799, 752, 638 cm-1. 
MS (EI) m/z (relative intensity) 253 (25) [M+], 170 (100), 93 (15). 
HR-MS (EI) m/z calcd for C16H19N3 [M+] 253.1579, found 253.1584. 
 
N-(2,6-Dicyclohexylphenyl)pyrimidin-2-amine (142cb’): 
M. p. = 204–205 °C. 
1H NMR (400 MHz, CDCl3) δ = 8.27 (d, J = 4.8 Hz, 2H), 7.30 (dd, J = 8.2, 7.2 Hz, 1H), 7.19 
(dd, J = 8.2, 0.6 Hz, 2H), 6.88 (s, 1H), 6.55 (t, J = 4.8 Hz, 1H), 2.75 (tt, J = 11.6, 2.9 Hz, 2H), 
1.78–1.66 (m, 10H), 1.42–1.15 (m, 10H). 
13C NMR (100 MHz, CDCl3) δ = 162.8 (Cq), 158.2 (CH), 146.0 (Cq), 132.8 (Cq), 127.9 (CH), 
124.3 (CH), 111.0 (CH), 39.4 (CH), 34.5 (CH2), 33.3 (CH2), 26.9 (CH2), 26.2 (CH2). 
IR (neat): 3222, 2921, 2847, 1601, 1578, 1527, 1445, 1412, 777, 659 cm-1. 
MS (EI) m/z (relative intensity) 335 (10) [M+], 252 (100). 
HR-MS (EI) m/z calcd for C22H29N3 [M+] 335.2361, found 335.2356. 
 
 
N-(3-Cyclohexylbiphenyl-2-yl)pyrimidin-2-amine (142db): The general procedure A was 





[(DME)NiCl2] (2.8 mg, 2.5 mol %) and Dt-BEDA (5.5 μL, 5.0 mol %) at 100 °C. Isolation by 
column chromatography (n-hexane/EtOAc: 4/1) yielded 142db (156 mg, 95%) as a white solid.  
M. p. = 215–216 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.19 (d, J = 4.8 Hz, 2H), 7.41–7.31 (m, 2H), 7.27–7.17 (m, 
6H), 6.49 (t, J = 4.8 Hz, 1H), 6.39 (s, 1H), 2.74 (tt, J = 11.9, 3.1 Hz, 1H), 1.89–1.63 (m, 6H), 
1.44–1.38 (m, 2H), 1.28–1.16 (m, 2H). 
13C NMR (125 MHz, CDCl3) δ = 162.1 (Cq), 158.0 (CH), 146.1 (Cq), 140.3 (Cq), 140.2 (Cq), 
132.7 (Cq), 128.9 (CH), 128.2 (CH), 127.9 (CH), 127.5 (CH), 126.9 (CH), 126.4 (CH), 111.3 
(CH), 39.2 (CH), 33.8 (CH2), 26.9 (CH2), 26.2 (CH2). 
IR (neat): 3205, 2923, 2849, 1593, 1520, 1441, 1410, 794, 756, 693, 644 cm-1. 
MS (EI) m/z (relative intensity) 329 (20) [M+], 246 (100), 169 (10). 
HR-MS (EI) m/z calcd for C22H23N3 [M+] 329.1892, found 329.1890. 
 
 
N-(2-tert-Butyl-6-cyclohexylphenyl)pyrimidin-2-amine (142eb): The general procedure A 
was followed using substrate 123e (114 mg, 0.50 mmol), bromide 58b (123 μL, 1.00 mmol), 
(DME)NiCl2 (2.8 mg, 2.5 mol %) and Dt-BEDA (5.5 μL, 5.0 mol %) at 100 °C. Isolation by 
column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 142eb (82 mg, 53%) as a white 
solid.  
M. p. = 175–176 °C. 
1H NMR (300 MHz, CDCl3) δ = 8.26 (d, J = 4.8 Hz, 2H), 7.35 (dd, J = 6.9, 2.7 Hz, 1H), 7.32 
(s, 1H), 7.28–7.23 (m, 2H), 6.52 (t, J = 4.8 Hz, 1H), 2.61 (tt, J = 11.8, 3.2 Hz, 1H), 1.81–1.55 
(m, 5H), 1.37 (s, 9H), 1.29–0.85 (m, 5H). 
13C NMR (75 MHz, CDCl3) δ = 162.8 (Cq), 158.4 (CH), 158.0 (CH), 147.8 (Cq), 147.7 (Cq), 
134.0 (Cq), 127.7 (CH), 125.5 (CH), 124.6 (CH), 110.8 (CH), 39.2 (CH), 35.5 (Cq), 35.4 (CH2), 
32.9 (CH2), 31.1 (CH3), 27.1 (CH2), 26.9 (CH2), 26.2 (CH2). 





MS (EI) m/z (relative intensity) 309 (1.4) [M+], 252 (100), 226 (80), 170 (5).  
HR-MS (ESI) m/z calcd for C20H28N3 [M + H+] 310.2283, found 310.2278. 
 
 
N-(2-Cyclohexyl-6-methoxyphenyl)pyrimidin-2-amine (142pb): The general procedure A 
was followed using substrate 123p (101 mg, 0.50 mmol), bromide 58b (123 μL, 1.00 mmol), 
[(DME)NiCl2] (2.8 mg, 2.5 mol %) and Dt-BEDA (5.5 μL, 5.0 mol %) at 100 °C. Isolation by 
column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 142pb (120 mg, 85%) as a 
white solid. 
M. p. = 129–130 °C. 
1H NMR (300 MHz, CDCl3) δ = 8.29 (d, J = 4.8 Hz, 2H), 7.23 (dd, J = 8.2, 7.9 Hz, 1H), 6.95 
(dd, J = 7.9, 1.0 Hz, 1H), 6.78 (dd, J = 8.2, 1.1 Hz, 1H), 6.63 (br s, 1H), 6.58 (t, J = 4.8 Hz, 
1H), 3.73 (s, 3H), 2.78 (tt, J = 11.8, 3.2 Hz, 1H), 1.88–1.61 (m, 5H), 1.48–1.16 (m, 5H).  
13C NMR (75 MHz, CDCl3) δ = 162.6 (Cq), 158.0 (CH), 155.0 (Cq), 146.9 (Cq), 127.6 (CH), 
124.6 (Cq), 118.8 (CH), 111.5 (CH), 108.6 (CH), 55.6 (CH3), 39.0 (CH), 33.6 (CH2), 26.8 (CH2), 
26.2 (CH2). 
IR (neat): 3207, 2920, 2849, 1576, 1519, 1446, 1404, 1264, 1065, 779, 640 cm-1. 
MS (EI) m/z (relative intensity) 283 (20) [M+], 252 (100), 200 (30), 170 (8). 
HR-MS (EI) m/z calcd for C17H21N3O [M+] 283.1685, found 283.1691. 
 
 
N-(2-Cyclohexyl-5-methylphenyl)pyrimidin-2-amine (142fb): The general procedure A was 
followed using substrate 123f (93 mg, 0.50 mmol) and bromide 58b (123 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 142fb (115 mg, 





M. p. = 89–90 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.33 (d, J = 4.8 Hz, 2H), 7.49 (s, 1H), 7.37 (br s, 1H), 7.20 (d, 
J = 7.9 Hz, 1H), 7.00 (d, J = 7.9 Hz, 1H), 6.61 (t, J = 4.8 Hz, 1H), 2.74 (tt, J = 11.9, 3.1 Hz, 
1H), 2.34 (s, 3H), 1.87–1.67 (m, 5H), 1.48–1.17 (m, 5H). 
13C NMR (125 MHz, CDCl3) δ = 161.5 (Cq), 158.0 (CH), 138.0 (Cq), 135.6 (Cq), 135.3 (Cq), 
126.3 (CH), 126.3 (CH), 125.5 (CH), 111.6 (CH), 38.2 (CH), 33.6 (CH2), 26.8 (CH2), 26.1 
(CH2), 21.0 (CH3). 
IR (neat): 3209, 2923, 2847, 1595, 1526, 1447, 1416, 1278, 998, 800, 644, 564 cm-1. 
MS (EI) m/z (relative intensity) 267 (25) [M+], 184 (100), 107 (20). 
HR-MS (EI) m/z calcd for C17H21N3 [M+] 267.1735, found 267.1745. 
 
 
N-(2-Cyclohexyl-5-methoxyphenyl)pyrimidin-2-amine (142gb): The general procedure A 
was followed using substrate 123g (101 mg, 0.50 mmol) and bromide 58b (123 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 142gb (106 mg, 
75%) as a white solid.  
M. p. = 106–107 °C.  
1H NMR (500 MHz, CDCl3) δ = 8.35 (d, J = 4.8 Hz, 2H), 7.45 (d, J = 2.7 Hz, 1H), 7.23 (br s, 
1H), 7.17 (d, J = 8.6 Hz, 1H), 6.69 (dd, J = 8.6, 2.7 Hz, 1H), 6.64 (t, J = 4.8 Hz, 1H), 3.77 (s, 
3H), 2.65 (tt, J = 11.9, 3.1 Hz, 1H), 1.85–1.66 (m, 5H), 1.45–1.17 (m, 5H).  
13C NMR (125 MHz, CDCl3) δ = 161.0 (Cq), 158.0 (CH), 157.6 (Cq), 136.5 (Cq), 131.8 (Cq), 
126.9 (CH), 112.0 (CH), 110.2 (CH), 109.4 (CH), 55.1 (CH3), 37.9 (CH), 33.7 (CH2), 26.9 
(CH2), 26.1 (CH2).  
IR (neat): 3222, 2923, 2849, 1754, 1499, 1419, 1308, 1172, 995, 791, 726 cm-1.  
MS (EI) m/z (relative intensity) 283 (30) [M+], 200 (100), 170 (6).  






N-[2-Cyclohexyl-5-(trifluoromethyl)phenyl]pyrimidin-2-amine (142hb): The general 
procedure A procedure was followed using substrate 123h (120 mg, 0.50 mmol) and bromide 
58b (123 μL, 1.00 mmol) at 100 °C. Isolation by column chromatography (n-hexane/EtOAc: 
10/1→6/1) yielded 142hb (153 mg, 95%) as a white solid. 
M. p. = 79–81 °C. 
1H NMR (400 MHz, CDCl3) δ = 8.37 (d, J = 4.8 Hz, 2H), 8.18 (s, 1H), 7.53 (br s, 1H), 7.42–
7.30 (m, 2H), 6.69 (t, J = 4.8 Hz, 1H), 2.78 (tt, J = 11.6, 2.7 Hz, 1H), 1.91–1.68 (m, 5H), 1.49–
1.19 (m, 5H). 
13C NMR (100 MHz, CDCl3) δ = 160.8 (Cq), 158.1 (CH), 143.1 (Cq), 136.3 (Cq), 128.4 (Cq, 
2JC-F = 32.4 Hz), 126.8 (CH), 124.2 (Cq, 1JC-F = 272.0 Hz), 121.1 (CH, 3JC-F = 3.7 Hz), 120.6 
(CH, 3JC-F = 3.9 Hz), 112.7 (CH), 38.6 (CH), 33.2 (CH2), 26.7 (CH2), 26.0 (CH2). 
19F NMR (376 MHz, CDCl3) δ = -62.3 (s).  
IR (neat): 3215, 2926, 2851, 1585, 1529, 1450, 1414, 1328, 1121, 798, 645 cm-1. 
MS (EI) m/z (relative intensity) 321 (30) [M+], 238 (100), 198 (5). 
HR-MS (EI) m/z calcd for C17H18F3N3 [M+] 321.1453, found 321.1445. 
 
 
Ethyl 4-cyclohexyl-3-(pyrimidin-2-ylamino)benzoate (142ib): The general procedure A was 
followed using substrate 123i (122 mg, 0.50 mmol) and bromide 58b (123 μL, 1.00 mmol) at 
100 °C. Isolation by column chromatography (n-hexane/EtOAc: 8/1→5/1) yielded 142ib (99 
mg, 61%) as a white solid.  





1H NMR (500 MHz, CDCl3) δ = 8.36 (d, J = 1.8 Hz, 1H), 8.33 (d, J = 4.8 Hz, 2H), 7.80 (dd, J 
= 8.2, 1.8 Hz, 1H), 7.33 (d, J = 8.2 Hz, 1H), 7.33 (br s, 1H), 6.64 (t, J = 4.8 Hz, 1H), 4.32 (q, J 
= 7.1 Hz, 2H), 2.78 (tt, J = 11.7, 2.9 Hz, 1H), 1.85–1.65 (m, 5H), 1.49–1.13 (m, 8H). 
13C NMR (125 MHz, CDCl3) δ = 166.3 (Cq), 161.2 (Cq), 158.1 (CH), 145.7 (Cq), 135.8 (Cq), 
128.5 (Cq), 126.5 (CH), 126.2 (CH), 125.9 (CH), 112.2 (CH), 60.7 (CH2), 38.8 (CH), 33.2 (CH2), 
26.7 (CH2), 26.0 (CH2), 14.2 (CH3). 
IR (neat): 3222, 2979, 2851, 1713, 1615, 1524, 1446, 1220, 1107, 761 cm-1. 
MS (EI) m/z (relative intensity) 325 (25) [M+], 242 (100), 214 (30). 
HR-MS (EI) m/z calcd for C19H23N3O2 [M+] 325.1790, found 325.1797. 
 
 
tert-Butyl 4-cyclohexyl-3-(pyrimidin-2-ylamino)benzoate (142jb): The general procedure A 
was followed using substrate 123j (136 mg, 0.50 mmol) and bromide 58b (123 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→6/1) yielded 142jb (152 mg, 
86%) as a white solid.  
M. p. = 122–123 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.35 (d, J = 4.8 Hz, 2H), 8.34 (d, J = 1.8 Hz, 1H), 7.75 (dd, J 
= 8.2, 1.8 Hz, 1H), 7.31 (dd, J = 8.2 Hz, 1H), 7.03 (br s, 1H), 6.67 (t, J = 4.8 Hz, 1H), 2.75 (tt, 
J = 11.7, 2.9 Hz, 1H), 1.82–1.71 (m, 5H), 1.55 (s, 9H), 1.47–1.19 (m, 5H). 
13C NMR (125 MHz, CDCl3) δ = 165.5 (Cq), 161.2 (Cq), 158.2 (CH), 145.1 (Cq), 135.7 (Cq), 
130.1 (Cq), 126.4 (CH), 126.1 (CH), 125.5 (CH), 112.4 (CH), 80.7 (Cq), 38.8 (CH), 33.3 (CH2), 
28.2 (CH3), 26.8 (CH2), 26.1 (CH2). 
IR (neat): 2926, 2851, 1709, 1578, 1446, 1404, 1298, 1164, 1112, 798, 766 cm-1. 
MS (EI) m/z (relative intensity) 309 (2) [M+], 252 (100), 226 (80), 170 (5). 







N-(5-Chloro-2-cyclohexylphenyl)pyrimidin-2-amine (142qb): The general procedure A was 
followed using substrate 123q (103 mg, 0.50 mmol) and bromide 58b (123 μL, 1.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 142qb (144 mg, 
86%) as a colorless liquid.  
1H NMR (500 MHz, CDCl3) δ = 8.36 (d, J = 4.8 Hz, 2H), 7.93 (d, J = 2.2 Hz, 1H), 7.24 (br s, 
1H), 7.17 (d, J = 8.4 Hz, 1H), 7.07 (dd, J = 8.4, 2.2 Hz, 1H), 6.68 (t, J = 4.8 Hz, 1H), 2.68 (tt, 
J = 11.9, 3.1 Hz, 1H), 1.88–1.68 (m, 5H), 1.44–1.18 (m, 5H).  
13C NMR (125 MHz, CDCl3) δ = 160.6 (Cq), 158.1 (CH), 137.4 (Cq), 136.8 (Cq), 131.4 (Cq), 
127.4 (CH), 124.4 (CH), 123.2 (CH), 112.6 (CH), 38.2 (CH), 33.4 (CH2), 26.8 (CH2), 26.0 
(CH2).  
IR (neat): 3231, 2927, 2851, 1579, 1516, 1446, 1412, 798 cm-1.  
MS (EI) m/z (relative intensity) 287 (25) [M+], 204 (100), 161 (15).  
HR-MS (EI) m/z calcd for C16H18ClN3 [M+] 287.1189, found 287.1192. 
 
 
The general procedure A was followed using substrate 123k (93 mg, 0.50 mmol) and bromide 
58b (68 μL, 0.55 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1→6/1) 
yielded 142kb (98 mg, 73%) and 142kb’ (19 mg, 11%) as white solids. 
N-(2-Cyclohexyl-4-methylphenyl)pyrimidin-2-amine (142kb):  





1H NMR (500 MHz, CDCl3) δ = 8.31 (d, J = 4.8 Hz, 2H), 7.46 (d, J = 8.1 Hz, 1H), 7.10 (d, J 
= 1.7 Hz, 1H), 7.10 (br s, 1H), 7.02 (dd, J = 8.1, 1.7 Hz, 1H), 6.59 (t, J = 4.8 Hz, 1H), 2.74 (tt, 
J = 11.8, 3.0 Hz, 1H), 2.33 (s, 3H), 1.85–1.67 (m, 5H), 1.48–1.21 (m, 5H). 
13C NMR (125 MHz, CDCl3) δ = 161.7 (Cq), 158.1 (CH), 141.3 (Cq), 135.2 (Cq), 132.9 (Cq), 
127.2 (CH), 126.9 (CH), 125.5 (CH), 111.6 (CH), 38.5 (CH), 33.6 (CH2), 26.9 (CH2), 26.2 
(CH2), 21.2 (CH3).  
IR (neat): 3223, 2927, 2848, 1597, 1520, 1447, 1410, 797, 639 cm-1. 
MS (EI) m/z (relative intensity) 267 (30) [M+], 184 (100), 107 (20). 
HR-MS (EI) m/z calcd for C17H21N3 [M+] 267.1735, found 267.1747. 
 
N-(2,6-Dicyclohexyl-4-methylphenyl)pyrimidin-2-amine (142kb’):  
M. p. = 270–271 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.26 (d, J = 4.8 Hz, 2H), 6.98 (s, 2H), 6.55 (t, J = 4.8 Hz, 1H), 
6.46 (s, 1H), 2.69 (tt, J = 11.6, 2.8 Hz, 2H), 2.33 (s, 3H), 1.74–1.63 (m, 10H), 1.44–1.02 (m, 
10H). 
13C NMR (125 MHz, CDCl3) δ = 162.9 (Cq), 158.3 (CH), 145.6 (Cq), 137.2 (Cq), 130.1 (Cq), 
125.3 (CH), 111.0 (CH), 39.4 (CH), 34.6 (CH2), 33.3 (CH2), 27.0 (CH2), 26.2 (CH2), 21.7 (CH3). 
IR (neat): 3202, 2921, 2848, 1585, 1517, 1447, 1410, 1240, 787, 640 cm-1. 
MS (ESI) m/z (relative intensity) 350 [M+H+]. 
HR-MS (ESI) m/z calcd for C23H31N3 [M+H+] 350.2596, found 350.2594. 
 
 
The general procedure A was followed using substrate 123r (101 mg, 0.50 mmol) and bromide 
58b (68 μL, 0.55 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1→6/1) 
yielded 142rb (112 mg, 79%) and 142rb’ (24 mg, 13%) as white solids. 





M. p. = 122–123 °C.  
1H NMR (500 MHz, CDCl3) δ 8.29 (d, J = 4.8 Hz, 2H), 7.39 (d, J = 8.7 Hz, 1H), 6.94 (s, 1H), 
6.84 (d, J = 3.0 Hz, 1H), 6.75 (dd, J = 8.7, 3.0 Hz, 1H), 6.57 (t, J = 4.8 Hz, 1H), 3.78 (s, 3H), 
2.73 (tt, J = 11.8, 3.1 Hz, 1H), 1.83–1.64 (m, 5H), 1.43–1.16 (m, 5H). 
13C NMR (125 MHz, CDCl3) δ 161.9 (Cq), 158.0 (CH), 157.6 (Cq), 144.1 (Cq), 128.4 (Cq), 
127.5 (CH), 112.6 (CH), 111.4 (CH), 110.9 (CH), 55.3 (CH3), 38.9 (CH), 33.6 (CH2), 26.9 
(CH2), 26.2 (CH2). 
IR (neat): 3206, 2929, 2850, 1581, 1519, 1445, 1411, 1206, 1034, 799 cm-1. 
MS (EI) m/z (relative intensity) 283 (45) [M+], 200 (100), 185 (5), 79 (8). 
HR-MS (EI) m/z calcd for C17H21N3O [M+] 283.1685, found 283.1684. 
 
N-(2,6-Dicyclohexyl-4-methoxyphenyl)pyrimidin-2-amine (142rb’):  
M. p. = 267–268 °C.  
1H NMR (500 MHz, CDCl3) δ = 8.26 (d, J = 4.8 Hz, 2H), 6.71 (s, 2H), 6.55 (s, 1H), 6.54 (t, J 
= 4.8 Hz, 1H), 3.79 (s, 3H), 2.70 (tt, J = 11.5, 2.9 Hz, 2H), 1.78–1.56 (m, 10H), 1.40–1.01 (m, 
10H).  
13C NMR (125 MHz, CDCl3) δ = 162.9 (Cq), 158.7 (Cq), 158.1 (CH), 147.3 (Cq), 125.6 (Cq), 
110.9 (CH), 109.8 (CH), 55.1 (CH3), 39.7 (CH), 34.6 (CH2), 33.3 (CH2), 27.0 (CH2), 26.9 (CH2), 
26.2 (CH2).  
IR (neat): 3216, 2920, 2847, 1576, 1519, 1446, 1410, 1257, 803, 640 cm-1.  
MS (EI) m/z (relative intensity) 365 (15) [M+], 282 (100).  







The general procedure A was followed using substrate 123l (95 mg, 0.50 mmol) and bromide 
58b (68 μL, 0.55 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1→6/1) 
yielded 142lb (95 mg, 70%) and 142lb’ (35 mg, 20%) as white solids. 
N-(2-Cyclohexyl-4-fluorophenyl)pyrimidin-2-amine (142lb):  
M. p. = 121–122 °C. 
1H NMR (400 MHz, CDCl3) δ = 8.30 (d, J = 4.8 Hz, 2H), 7.52 (dd, J = 8.8, 5.6 Hz, 1H), 7.22 
(br s, 1H), 6.98 (dd, J = 10.2, 3.0 Hz, 1H), 6.89 (ddd, J = 8.7, 7.9, 3.0 Hz, 1H), 6.61 (t, J = 4.8 
Hz, 1H), 2.74 (tt, J = 10.5, 1.5 Hz, 1H), 1.84–1.63 (m, 5H), 1.44–1.14 (m, 5H). 
13C NMR (100 MHz, CDCl3) δ = 161.6 (Cq), 160.7 (Cq, 1JC-F = 244.0 Hz), 158.2 (CH), 144.2 
(Cq, 3JC-F = 7.0 Hz), 131.4 (Cq, 4JC-F = 2.8 Hz), 127.3 (CH, 3JC-F = 8.3 Hz), 113.3 (CH, 2JC-F = 
22.6 Hz), 112.9 (CH, 2JC-F = 22.3 Hz), 111.9 (CH), 38.7 (CH, 4JC-F = 1.1 Hz), 33.4 (CH2), 26.7 
(CH2), 26.0 (CH2).  
19F NMR (376 MHz, CDCl3) δ = -116.4 (ddd, J = 9.2, 7.3, 5.3 Hz). 
IR (neat): 3232, 2924, 2850, 1575, 1518, 1445, 1403, 1259, 1191, 799, 638, 552, 457 cm-1.  
MS (EI) m/z (relative intensity) 271 (40) [M+], 188 (100), 111 (10).  
HR-MS (EI) m/z calcd for C20H21N3 [M+] 271.1485, found 271.1476. 
N-(2,6-Dicyclohexyl-4-fluorophenyl)pyrimidin-2-amine (142lb’):  
M. p. = 222–223 °C. 
1H NMR (400 MHz, CDCl3) δ = 8.26 (d, J = 4.8 Hz, 2H), 6.87 (d, J = 9.8 Hz, 2H), 6.86 (br s, 
1H), 6.56 (t, J = 4.8 Hz, 1H), 2.73 (tt, J = 10.2, 1.5 Hz, 2H), 1.75–1.64 (m, 10H), 1.44–1.00 (m, 
10H). 
13C NMR (100 MHz, CDCl3) δ = 162.8 (Cq), 162.3 (Cq 1JC-F = 244.4 Hz), 158.3 (CH), 148.6 
(Cq, 3JC-F= 7.6 Hz), 128.6 (Cq, 4JC-F= 2.7 Hz), 111.3 (CH), 111.2 (CH, 2JC-F= 22.5 Hz), 39.6 (CH, 
4JC-F = 1.4 Hz), 34.4 (CH2), 33.1 (CH2), 26.8 (CH2), 26.0 (CH2). 
19F NMR (376 MHz, CDCl3) δ = -113.8 (t, J = 9.7 Hz). 
IR (neat): 3222, 2922, 2848, 1583, 1525, 1445, 1412, 856, 802, 642 cm-1. 
MS (EI) m/z (relative intensity) 353 (10) [M+], 270 (100). 







The general procedure A was followed using substrate 123m (103 mg, 0.50 mmol) and bromide 
58b (68 μL, 0.55 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1→6/1) 
yielded 142mb (88 mg, 61%) and 142mb’ (35 mg, 19 %) as white solids. 
N-(4-Chloro-2-cyclohexylphenyl)pyrimidin-2-amine (142mb): 
M. p. = 147–148 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.35 (d, J = 4.6 Hz, 2H), 7.68 (d, J = 8.6 Hz, 1H), 7.23 (d, J 
= 2.5 Hz, 1H), 7.16 (dd, J = 8.6, 2.5 Hz, 1H), 6.97 (br s, 1H), 6.67 (t, J = 4.6 Hz, 1H), 2.75–
2.63 (m, 1H), 1.86–1.65 (m, 5H), 1.47–1.17 (m, 5H). 
13C NMR (125 MHz, CDCl3) δ = 161.1 (Cq), 158.1 (CH), 142.0 (Cq), 134.2 (Cq), 130.3 (Cq), 
126.7 (CH), 126.2 (CH), 125.7 (CH), 112.4 (CH), 38.6 (CH), 33.4 (CH2), 26.8 (CH2), 26.0 
(CH2). 
IR (neat): 3205, 2927, 2849, 1579, 1523, 1443, 1264, 994, 800, 644, 456 cm-1. 
MS (EI) m/z (relative intensity) 287 (45) [M+], 204 (100), 127 (15). 
HR-MS (EI) m/z calcd for C16H18ClN3 [M+] 287.1189, found 287.1195. 
 
N-(4-Chloro-2,6-dicyclohexylphenyl)pyrimidin-2-amine (142mb’): 
M. p. = 273–274 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.27 (d, J = 4.8 Hz, 2H), 7.13 (s, 2H), 6.58 (t, J = 4.8 Hz, 1H), 
6.57 (br s, 1H), 2.69 (tt, J = 11.5, 2.8 Hz, 2H), 1.73–1.68 (m, 10H), 1.41–0.97 (m, 10H). 
13C NMR (125 MHz, CDCl3) δ = 162.6 (Cq), 158.3 (CH), 148.0 (Cq), 133.7 (Cq), 131.4 (Cq), 
124.8 (CH), 111.5 (CH), 39.5 (CH), 33.4 (CH2), 33.1 (CH2), 26.8 (CH2), 26.1 (CH2). 
IR (neat): 3206, 2923, 2848, 1581, 1525, 1439, 1406, 1004, 800, 644 cm-1. 
MS (EI) m/z (relative intensity) 369 (10) [M+], 286 (100). 







N-(2-Cyclohexyl-4-fluoro-6-methylphenyl)pyrimidin-2-amine (142nb): The general 
procedure A was followed using substrate 123n (102 mg, 0.50 mmol), bromide 58b (123 μL, 
1.00 mmol), [(DME)NiCl2] (2.8 mg, 2.5 mol %) and Dt-BEDA (5.5 μL, 5.0 mol %). Isolation 
by column chromatography (n-hexane/EtOAc: 10/1→6/1) yielded 142nb (134 mg, 94%) as a 
white solid. 
M. p. = 137–138 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.25 (d, J = 4.8 Hz, 2H), 7.38 (br s, 1H), 6.87 (dd, J = 10.0, 
2.9 Hz, 1H), 6.81 (dd, J = 8.8, 2.9 Hz, 1H), 6.55 (t, J = 4.8 Hz, 1H), 2.81 (tt, J = 11.0, 1.1 Hz, 
1H), 2.20 (s, 3H), 1.82–1.59 (m, 5H), 1.39–1.12 (m, 5H). 
13C NMR (125 MHz, CDCl3) δ = 162.1 (Cq), 161.6 (Cq, 1JC-F = 245.0 Hz), 158.3 (CH), 148.2 
(Cq, 3JC-F = 7.8 Hz), 139.1 (Cq, 3JC-F = 8.6 Hz), 130.0 (Cq, 4JC-F = 2.8 Hz), 114.6 (CH, 2JC-F = 
22.1 Hz), 111.4 (CH), 111.1 (CH, 2JC-F = 22.1 Hz), 39.2 (CH, 4JC-F = 1.3 Hz), 33.7 (CH2), 26.7 
(CH2), 26.0 (CH2), 18.8 (CH3, 4JC-F = 1.6 Hz). 
19F NMR (283 MHz, CDCl3) δ = -115.0 (dd, J = 9.7, 9.1 Hz). 
IR (neat): 3208, 2926, 2852, 1580, 1519, 1442, 1409, 1262, 952, 786 cm-1. 
MS (EI) m/z (relative intensity) 285 (20) [M+], 202 (100), 125 (10). 
HR-MS (EI) m/z calcd for C17H20FN3 [M+] 285.1641, found 285.1648. 
 
 
N-(2-Cyclohexyl-4,6-difluorophenyl)pyrimidin-2-amine (142ob): The general procedure A 
was followed using substrate 123o (104 mg, 0.50 mmol), bromide 58b (123 μL, 1.00 mmol), 





column chromatography (n-hexane/EtOAc: 10/1→6/1) yielded 142ob (133 mg, 92%) as a 
white solid.  
M. p. = 111–112 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.29 (d, J = 4.8 Hz, 2H), 7.09 (br s, 1H), 6.83 (ddd, J = 9.9, 
2.8, 1.7 Hz, 1H), 6.72 (ddd, J = 9.6, 8.3, 2.9 Hz, 1H), 6.63 (t, J = 4.8 Hz, 1H), 2.84 (tt, J = 10.1, 
1.1 Hz, 1H), 1.84–1.61 (m, 5H), 1.38–1.13 (m, 5H).  
13C NMR (100 MHz, CDCl3) δ = 162.0 (Cq), 161.4 (Cq, dd, JC-F = 247.0, 13.0 Hz), 158.4 (Cq, 
dd, JC-F = 250.0, 13.5 Hz), 158.2 (CH), 149.3 (Cq, JC-F = 8.4 Hz), 120.0 (Cq, dd, JC-F = 12.8, 3.9 
Hz), 112.1 (CH), 109.0 (CH, dd, JC-F = 22.2, 3.4 Hz), 101.8 (CH, dd, JC-F = 26.3, 25.1 Hz), 39.0 
(CH, dd, JC-F = 1.3, 1.3 Hz), 33.5 (CH2), 26.6 (CH2), 26.0 (CH2).  
19F NMR (283 MHz, CDCl3) δ = -111.5 (dd, J = 16.6, 8.2 Hz), -114.5 (ddd, J = 9.6, 6.9, 1.6 
Hz).  
IR (neat): 3222, 2926, 2853, 1577, 1520, 1445, 1260, 1116, 994, 640 cm-1.  
MS (EI) m/z (relative intensity) 289 (25) [M+], 206 (40), 166 (4).  
HR-MS (EI) m/z calcd for C16H17F2N3 [M+] 289.1391, found 289.1396. 
 
 
N-(2-Cyclohexylnaphthalen-1-yl)pyrimidin-2-amine (142sb): The general procedure A was 
followed using substrate 123s (111 mg, 0.50 mmol), bromide 58b (123 μL, 1.00 mmol), 
[(DME)NiCl2] (2.8 mg, 2.5 mol %) and Dt-BEDA (5.5 μL, 5.0 mol %). Isolation by column 
chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 142sb (147 mg, 97%) as a white solid.  
M. p. = 80–81 °C. 
1H NMR (600 MHz, CDCl3) δ = 8.25 (br s, 2H), 7.99–7.94 (m, 1H), 7.86–7.80 (m, 2H), 7.58 
(s, 1H), 7.54 (d, J = 8.6 Hz, 1H), 7.45–7.39 (m, 2H), 6.56 (t, J = 4.8 Hz, 1H), 3.08 (tt, J = 12.0, 





13C NMR (125 MHz, CDCl3) δ = 162.8 (Cq), 158.2 (CH), 142.8 (Cq), 132.9 (Cq), 131.6 (Cq), 
130.2 (Cq), 128.0 (CH), 127.8 (CH), 126.3 (CH), 125.2 (CH), 124.9 (CH), 123.4 (CH), 111.3 
(CH), 39.6 (CH), 33.7 (CH2), 26.9 (CH2), 26.3 (CH2). 
IR (neat): 3206, 3059, 3005, 2922, 2849, 1584, 1507, 1446, 1375, 1261, 800, 747, 641 cm-1. 
MS (EI) m/z (relative intensity) 303 (5) [M+], 220 (40), 180 (2), 143 (2). 
HR-MS (EI) m/z calcd for C20H21N3 [M+] 303.1735, found 303.1739. 
 
 
N-[2-Cyclohexyl-5-(2-methyl-1,3-dioxolan-2-yl)phenyl]pyrimidin-2-amine (142tb): The 
general procedure A was followed using substrate 123t (129 mg, 0.50 mmol) and bromide 58b 
(123 μL, 1.00 mmol). Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 
142tb (152 mg, 67%) as a white solid. 
M. p. = 129–130 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.33 (d, J = 4.8 Hz, 2H), 7.80 (s, 1H), 7.28–7.19 (m, 2H), 7.06 
(br s, 1H), 6.63 (t, J = 4.8 Hz, 1H), 4.03–3.96 (m, 2H), 3.84–3.77 (m, 2H), 2.71 (tt, J = 11.8, 
2.9 Hz, 1H), 1.86–1.68 (m, 5H), 1.66 (s, 3H), 1.47–1.18 (m, 5H). 
13C NMR (125 MHz, CDCl3) δ = 161.3 (Cq), 158.1 (CH), 141.0 (Cq), 139.9 (Cq), 135.4 (Cq), 
126.3 (CH), 122.1 (CH), 121.5 (CH), 112.0 (CH), 108.7 (Cq), 64.4 (CH2), 38.4 (CH), 33.5 (CH2), 
27.4 (CH3), 26.9 (CH2), 26.1 (CH2). 
IR (neat): 3241, 2928, 2851, 1580, 1528, 1448, 1396, 1196, 1032, 799, 628 cm-1. 
MS (EI) m/z (relative intensity) 339 (30) [M+], 294 (60), 256 (100), 169 (10). 







N-(2-sec-Butyl-6-fluorophenyl)pyrimidin-2-amine (142bl): The general procedure B was 
followed using substrate 123b (189 mg, 1.0 mmol) and bromide 58l (220 μL, 2.00 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1→8/1) yielded 142bl (228 mg, 
93%) as a white solid.  
M. p. = 98–99 °C. 
1H NMR (300 MHz, CDCl3) δ = 8.31 (d, J = 4.8 Hz, 2H), 7.29–7.18 (m, 1H), 7.07 (d, J = 7.9 
Hz, 1H), 6.98 (ddd, J = 9.5, 8.2, 1.4 Hz, 1H), 6.70 (br s, 1H), 6.63 (t, J = 4.8 Hz, 1H), 2.97 (qt, 
J = 7.0, 7.0 Hz, 1H), 1.67–1.42 (m, 2H), 1.17 (d, J = 6.9 Hz, 3H), 0.77 (t, J = 7.4 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ = 161.8 (Cq), 158.4 (Cq, 1JC-F = 248.2 Hz), 158.3 (CH), 147.7 
(Cq), 128.0 (CH, 3JC-F = 8.6 Hz), 124.1 (Cq, 2JC-F = 12.5 Hz), 121.8 (CH, 4JC-F = 3.3 Hz), 113.2 
(CH, 2JC-F = 20.8 Hz), 112.1 (CH), 35.3 (CH, 4JC-F = 2.1 Hz), 30.6 (CH2), 21.1 (CH3), 12.1 
(CH3). 
19F NMR (283 MHz, CDCl3) δ = -119.1 (dd, J = 9.6, 5.6 Hz). 
IR (neat): 3209, 2958, 2930, 2871, 1581, 1524, 1447, 1413, 1270, 786, 501 cm-1. 
MS (EI) m/z (relative intensity) 245 (40) [M+], 188 (65), 138 (15).  




Reactions with TEMPO 
 
N-(2-Fluorophenyl)pyrimidin-2-amine (123b) (95 mg, 0.5 mmol), [(DME)NiCl2] (5.5 mg, 5.0 
mol %), TEMPO (78 mg, 0.5 mmol) and LiOtBu (80 mg, 1.0 mmol) were placed in a 25 mL 
Schlenk tube. The tube was degassed and purged with N2 three times. Dt-BEDA (143) (11 µL, 
10 mol %), 1-bromobutane (58a) (107 µL, 1.0 mmol) and 1,4-dioxane (1.5 mL) were then 





CH2Cl2 (2 mL) was added. No conversion was observed by GC-MS and 1H NMR analysis of 
the crude reaction mixture. 
 
 
N-(2-Fluorophenyl)pyrimidin-2-amine (123b) (95 mg, 0.5 mmol), [(DME)NiCl2] (5.5 mg, 5.0 
mol %), TEMPO (78 mg, 0.5 mmol) and LiOt-Bu (80 mg, 1.0 mmol) were placed in a 25 mL 
Schlenk tube. The tube was degassed and purged with N2 three times. Dt-BEDA (143) (11.0 
µL, 10 mol %), bromocyclohexane (58b) (123 µL, 1.0 mmol) and 1,4-dioxane (1.5 mL) were 
then added, and the mixture was stirred at 120 °C for 16 h. After cooling to ambient temperature, 
CH2Cl2 (2 mL) was added. No conversion was observed by GC-MS and 1H NMR analysis of 
the crude reaction mixture. 
 
 
N-(2-Fluorophenyl)pyrimidin-2-amine (123b) (95 mg, 0.5 mmol), [(DME)NiCl2] (11 mg, 10 
mol %), TEMPO (78 mg, 0.5 mmol) and LiOt-Bu (80 mg, 1.0 mmol) were placed in a 25 mL 
Schlenk tube. The tube was degassed and purged with N2 three times. Dt-BEDA (143) (22.0 
µL, 20 mol %), (3-bromopropoxy)benzene (58g) (158 µL, 1.0 mmol) and 1,4-dioxane (1.5 mL) 
were then added, and the mixture was stirred at 120 °C for 16 h. After cooling to ambient 
temperature, CH2Cl2 (2 mL) was added. TEMPO adduct 144 was observed as minor side-
product by GC-MS analysis, while alkylated product 133bg could not be observed. The 









2-amine (123b) (95 mg, 0.5 mmol), [(DME)NiCl2] (110 mg, 0.5 mmol), TEMPO (78 mg, 0.5 
mmol) and LiOt-Bu (80 mg, 1.0 mmol) were placed in a 25 mL Schlenk tube. The tube was 
degassed and purged with N2 three times. Dt-BEDA (143) (215 µL, 1.0 mmol), (3-
bromopropoxy)benzene (58g) (158 µL, 1.0 mmol) and 1,4-dioxane (1.5 mL) were then added, 
and the mixture was stirred at 120 °C for 16 h. After cooling to ambient temperature, CH2Cl2 
(2 mL) was added, the reaction mixture was transferred into a round flask with CH2Cl2 and 
concentrated under reduced pressure. Isolation by column chromatography (n-pentane/Et2O: 
200/1) yielded 144 (19 mg, 13%) as a colorless liquid.  
1H NMR (500 MHz, CDCl3) δ = 7.29–7.23 (m, 2H), 6.94–6.87 (m, 3H), 4.07 (t, J = 6.6 Hz, 
2H), 3.90 (t, J = 6.2 Hz, 2H), 2.00 (tt, J = 6.4, 6.4 Hz, 2H), 1.59–1.35 (m, 6H), 1.14 (s, 6H), 
1.07 (s, 6H).  
13C NMR (125 MHz, CDCl3) δ = 158.9 (Cq), 129.3 (CH), 120.5 (CH), 114.5 (CH), 72.8 (CH2), 
65.0 (CH2), 59.7 (Cq), 39.6 (CH2), 33.0 (CH3), 28.8 (CH2), 20.1 (CH3), 17.1 (CH2).  
IR (neat): 2974, 2930, 2871, 1600, 1497, 1470, 1243, 1062, 751, 690 cm-1.  
MS (EI) m/z (relative intensity) 291 (10) [M+], 276 (100), 156 (30).  
HR-MS (EI) m/z calcd for C18H29NO2 [M+] 291.2198, found 291.2188. 
 
Reaction with (bromomethyl)cyclopropane (58m) 
 
The general procedure A was followed using substrate 123b (95 mg, 0.5 mmol) and 
(bromomethyl)cyclopropane 58m (97 μL, 1.0 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 20/1→5/1) yielded 133bm (40 mg, 33%) as a colorless liquid and 133bm’ (45 







N-[2-(But-3-enyl)-6-fluorophenyl]pyrimidin-2-amine (133bm):  
1H NMR (600 MHz, CDCl3) δ = 8.30 (d, J = 4.8 Hz, 2H), 7.42 (s, 1H), 7.19 (ddd, J = 8.0, 8.0, 
5.5 Hz, 1H), 7.06 (d, J = 7.7 Hz, 1H), 7.00 (ddd, J = 9.2, 8.0, 1.4 Hz, 1H), 6.62 (t, J = 4.8 Hz, 
1H), 5.78 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 4.99–4.88 (m, 2H), 2.75 (t, J = 7.5 Hz, 2H), 2.35–
2.29 (m, 2H).  
13C NMR (125 MHz, CDCl3) δ = 161.6 (Cq), 158.7 (Cq, 1JC-F = 248.0 Hz), 158.2 (CH), 141.7 
(Cq), 137.6 (CH), 127.6 (CH, 3JC-F = 8.3 Hz), 124.9 (CH, 4JC-F = 3.3 Hz), 124.6 (Cq, 2JC-F = 12.6 
Hz), 115.3 (CH2), 113.7 (CH, 2JC-F = 20.8 Hz), 112.2 (CH), 34.2 (CH2), 31.0 (CH2, 4JC-F = 2.4 
Hz).  
19F NMR (283 MHz, CDCl3) δ = -119.5 (ddd, J = 9.5, 5.5, 0.6 Hz). 
IR (neat): 3223, 2929, 1579, 1520, 1443, 1406, 1268, 911, 783, 638 cm-1. 
MS (EI) m/z (relative intensity) 243 (52) [M+], 202 (100), 188 (45), 148 (15). 




1H NMR (600 MHz, CDCl3) δ = 8.36 (d, J = 4.7 Hz, 2H), 7.05 (ddd, J = 7.9, 5.1, 5.1 Hz, 1H), 
6.98–6.91 (m, 2H), 6.62 (t, J = 4.7 Hz, 1H), 5.76 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.00 (tt, J = 
6.8, 6.1 Hz, 1H), 4.95 (ddt, J = 17.1, 2.4, 1.6 Hz, 1H), 4.89 (ddt, J = 10.2, 2.3, 1.2 Hz, 1H), 
2.75–2.69 (m, 1H), 2.69–2.62 (m, 1H), 2.27 (ddt, J = 20.2, 7.0, 6.2 Hz, 1H), 2.10–2.02 (m, 2H), 
1.68–1.61 (m, 2H), 1.51–1.43 (m, 3H).  
13C NMR (125 MHz, CDCl3) δ = 160.9 (Cq), 157.6 (CH), 157.2 (Cq, 1JC-F = 251.5 Hz), 138.8 
(CH), 135.8 (Cq, 3JC-F = 2.4 Hz), 126.7 (Cq, 2JC-F = 11.5 Hz), 125.0 (CH, 3JC-F = 8.3 Hz), 123.1 
(CH, 4JC-F = 3.1 Hz), 114.3 (CH2), 113.4 (CH, 2JC-F = 20.3 Hz), 111.9 (CH), 53.5 (CH), 33.6 





19F NMR (283 MHz, CDCl3) δ = -114.7 (dd, J = 10.6, 5.1 Hz).  
IR (neat): 2930, 1578, 1550, 1484, 1417, 1261, 780 cm-1. 
MS (EI) m/z (relative intensity) 297 (35) [M+], 228 (100), 208 (30), 148 (15).  
HR-MS (EI) m/z calcd for C18H20FN3 [M+] 297.1641, found 297.1632. 
 
Reaction with 6-bromohex-1-ene (58n) 
 
The general procedure A was followed using substrate 123b (95 mg, 0.5 mmol) and 6-
bromohex-1-ene (58n) (134 μL, 1.0 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 10/1) yielded a mixture of 133bn and 133bn’ as a colorless liquid (120 mg, 
88%). 19F NMR analysis disclosed the ratio of 133bn/133bn’ to be 1.0:1.0. Purification by GPC 
yielded isomer 133bn (56 mg, 41%) as a colorless liquid and 133bn’ (59 mg, 42%) as a white 
solid. The spectral data of 133bn’ was identical to those reported above. 
 
 
N-[2-Fluoro-6-(hex-5-enyl)phenyl]pyrimidin-2-amine (133bn):  
1H NMR (500 MHz, at -25°C, CDCl3) δ = 8.30 (d, J = 4.6 Hz, 2H), 8.24 (s, 1H), 7.20 (ddd, J 
= 8.1, 7.8, 5.6 Hz, 1H), 7.07 (d, J = 7.8 Hz, 1H), 7.01 (dd, J = 9.6, 8.1 Hz, 1H), 6.64 (t, J = 4.6 
Hz, 1H), 5.68 (ddt, J = 16.9, 10.1, 6.7 Hz, 1H), 4.89 (dd, J = 17.1, 1.7 Hz, 1H), 4.84 (dd, J = 
10.1, 1.7 Hz, 1H), 2.64 (t, J = 7.8 Hz, 2H), 1.98–1.93 (m, 2H), 1.54 (dt, J = 15.7, 7.8 Hz, 2H), 
1.38–1.29 (m, 2H).  
13C NMR (125 MHz, CDCl3) δ = 161.7 (Cq), 158.8 (Cq, 1JC-F = 249.0 Hz), 158.1 (CH), 142.5 
(Cq), 138.6 (CH), 127.5 (CH, 3JC-F = 8.6 Hz), 124.8 (CH, 4JC-F = 3.2 Hz), 124.5 (Cq, 2JC-F = 12.6 
Hz), 114.4 (CH2), 113.5 (CH, 2JC-F = 21.2 Hz), 112.1 (CH), 34.4 (CH2), 31.4 (CH2, 4JC-F = 2.1 





19F NMR (283 MHz, CDCl3) δ = -119.5 (dd, J = 9.5, 5.5 Hz).  
IR (neat): 3226, 2932, 2861, 1580, 1444, 1270, 782, 638 cm-1.  
MS (EI) m/z (relative intensity) 271 (35) [M+], 188 (100), 148 (15).  
HR-MS (EI) m/z calcd for C16H18FN3 [M+] 271.1485, found 271.1481. 
 
Reaction with trans-58o 
 
The general procedure A was followed using substrate 123b (95 mg, 0.50 mmol), trans- 58o 
(239 mg, 1.00 mmol), [(DME)NiCl2] (2.8 mg, 2.5 mol %) and Dt-BEDA (143) (5.5 μL, 5.0 
mol %) at 100 °C. Isolation by column chromatography (n-hexane/EtOAc: 4/1) yielded a 
mixture of trans-142bo and cis-142bo (1H NMR ratio 74:26, 173 mg, 99%) as a white solid. 
IR (neat): 3215, 2931, 2852, 1579, 1529, 1445, 1413, 1274, 954, 699 cm-1.  
MS (EI) m/z (relative intensity) 347 (85) [M+], 188 (100), 91 (25).  
HR-MS (EI) m/z calcd for C22H22FN3 [M+] 347.1798, found 347.1794. 
 
For major diastereomer trans-58o:  
M. p. = 146–147 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.34 (d, J = 4.8 Hz, 2H), 7.27–7.26 (m, 3H), 7.22–7.15 (m, 
5H), 7.04–6.99 (m, 1H), 6.65 (t, J = 4.8 Hz, 1H), 2.97 (tt, J = 11.9, 2.8 Hz, 1H), 2.59 (tt, J = 
12.0, 2.8 Hz, 1H), 1.98 (d, J = 11.3 Hz, 4H), 1.64 (dt, J = 12.5, 7.1 Hz, 2H), 1.54 (dt, J = 12.5, 
7.2 Hz, 2H).  
13C NMR (125 MHz, CDCl3) δ = 162.0 (Cq), 158.7 (Cq, 1JC-F = 249.8 Hz), 158.2 (CH), 147.2 
(Cq), 147.1 (Cq), 128.3 (CH), 128.0 (CH, 3JC-F = 8.6 Hz), 126.7 (CH), 125.9 (CH), 124.0 (Cq, 
2JC-F = 12.5 Hz), 121.9 (CH, 4JC-F = 3.2 Hz), 113.4 (CH, 2JC-F = 20.9 Hz), 112.1 (CH), 44.0 (CH), 
38.3(CH, 4JC-F = 1.9 Hz), 34.3 (CH2), 33.7(CH2).  






For minor diastereomer cis-58o:  
M. p. = 116–118 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.34 (d, J = 4.8 Hz, 2H), 7.36–7.29 (m, 4H), 7.20–7.15 (m, 
2H), 7.05 (d, J = 7.9 Hz, 1H), 6.96 (ddd, J = 9.5, 8.2, 1.3 Hz, 1H), 6.67 (t, J = 4.8 Hz, 1H), 6.48 
(s, 1H), 3.06–3.02(m, 1H), 3.02–2.99 (m, 1H), 2.23–2.16 (m, 2H), 1.84 (m, 2H), 1.74–1.68 (m, 
4H).  
13C NMR (125 MHz, CDCl3) δ = 162.0 (Cq), 159.0 (Cq, 1JC-F = 247.6 Hz), 157.7 (CH), 147.0 
(Cq), 145.0 (Cq), 128.2 (CH), 127.8 (CH, 3JC-F = 8.7 Hz), 127.5 (CH), 125.5 (CH), 123.5 (Cq, 
2JC-F = 12.5 Hz), 122.4 (CH, 4JC-F = 3.2 Hz), 113.41 (CH, 2JC-F = 21.0 Hz), 112.2 (CH), 37.6 
(CH, 4JC-F = 1.9 Hz), 37.3 (CH), 30.2 (CH2), 29.0 (CH2).  
19F NMR (283 MHz, CDCl3) δ = -118.8 (dd, J = 9.6, 5.6 Hz). 
 
Reaction with cis-58o 
 
The general procedure A was followed using substrate 123b (95 mg, 0.50 mmol), cis-58o (239 
mg, 1.00 mmol), [(DME)NiCl2] (2.8 mg, 2.5 mol %) and Dt-BEDA (143) (5.5 μL, 5.0 mol %) 
at 100 °C. Isolation by column chromatography (n-hexane/EtOAc: 4/1) yielded a mixture of 
trans-142bo and cis-142bo (1H NMR ratio 74:26, 165 mg, 99%) as a white solid. 
 
Intermolecular Competition Experiment between 123f and 123h 
 
 
N-m-Tolylpyrimidin-2-amine (123f) (93 mg, 0.5 mmol), N-[3-
(trifluoromethyl)phenyl]pyrimidin-2-amine (123h) (120 mg, 0.5 mmol), [(DME)NiCl2] (5.5 





tube was degassed and purged with N2 for three times. Dt-BEDA (143) (11 µL, 10 mol %), 
alkyl bromides 58b (49 μL, 0.4 mmol) and 1,4-dioxane (1.5 mL) were then added, and the 
mixture was stirred at 120 °C for 16 h. At ambient temperature, CH2Cl2 (2 mL) was added, and 
the reaction mixture was transferred into a round flask with CH2Cl2 and concentrated under 
reduced pressure. Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1→5/1) to afford 142hb (58 mg, 61%) as the sole product. 
 
Removal of the Directing Group  
 
 
2-Cyclohexylaniline (147a): ortho-Alkylated compound 142cb (55mg, 0.22 mmol) was 
dissolved in aqueous HCl (37%, 1.5 mL) in a microwave vial. The vial was heated up to 150 °C 
(40 W) for 3 h in the microwave oven. The reaction mixture was allowed to cool to ambient 
temperature and poured into EtOAc (10 mL), and then saturated aqueous NaHCO3 solution was 
added until the pH was adjusted to 7. The aqueous layer was extracted with EtOAc (3 × 10 mL), 
the combined organic layers were dried with Na2SO4 and concentrated in vacuo affording 147a 
(31 mg, 81%) as a colorless liquid.  
1H NMR (500 MHz, CDCl3) δ = 7.10 (dd, J = 7.7, 1.4 Hz, 1H), 7.00 (ddd, J = 7.6, 7.6, 1.5 Hz, 
1H), 6.77 (ddd, J = 7.6, 7.6, 1.2 Hz, 1H), 6.67 (dd, J = 7.9, 1.2 Hz, 1H), 3.62 (s, 2H), 2.49 –
2.43 (m, 1H), 1.93–1.80 (m, 4H), 1.79–1.70 (m, 1H), 1.47–1.35 (m, 4H), 1.33–1.19 (m, 1H).  
13C NMR (125 MHz, CDCl3) δ = 143.3 (Cq), 131.9 (Cq), 126.4 (CH), 126.0 (CH), 119.0 (CH), 
115.8 (CH), 38.4 (CH), 32.8 (CH2), 27.1 (CH2), 26.3 (CH2).  
IR (neat): 3462, 3374, 2922, 2850, 1618, 1494, 1448, 1292, 1254, 744 cm-1.  
MS (EI) m/z (relative intensity) 175 (82) [M+], 106 (100), 91 (20).  
HR-MS (EI) m/z calcd for C12H17N [M+] 175.1361, found 175.1362.  








2-Butyl-4-fluoroaniline (147b): ortho-Alkylated compound 133la (79 mg, 0.32 mmol) was 
dissolved in aqueous HCl (37%, 1.5 mL) in a microwave vial. The vial was heated up to 150 °C 
(40 W) for 3 h in the microwave oven. The reaction mixture was allowed to cool to ambient 
temperature and poured into to EtOAc (10 mL), and then saturated aqueous NaHCO3 solution 
was added until the pH was adjusted to 7. The aqueous layer was extracted with EtOAc (3 × 10 
mL), the combined organic layers were dried with Na2SO4 and concentrated in vacuo affording 
147b (44 mg, 82%) as a colorless liquid.  
1H NMR (500 MHz, CDCl3) δ = 6.76 (dd, J = 9.6, 3.0 Hz, 1H), 6.71 (ddd, J = 8.6, 8.4, 3.0 Hz, 
1H), 6.58 (dd, J = 8.6, 5.0 Hz, 1H), 3.45 (br s, 2H), 2.44–2.41 (m, 2H), 1.62 –1.53 (m, 2H), 
1.46–1.35 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 156.4 (Cq, 1JC-F = 235.7 Hz), 140.0 (Cq, 4JC-F = 2.2 Hz), 128.6 
(Cq, 3JC-F = 6.4 Hz), 116.2 (CH, 3JC-F = 7.2 Hz), 115.6 (CH, 2JC-F = 22.6 Hz), 112.8 (CH, 2JC-F = 
22.5 Hz), 30.9 (CH2, 4JC-F = 1.2 Hz), 30.6 (CH2), 22.6 (CH2), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -126.6 (ddd, J = 9.6, 8.3, 5.0 Hz).  
IR (neat): 3460, 3375, 2957, 2862, 1624, 1498, 1232, 1147, 864, 809 cm-1.  
MS (EI) m/z (relative intensity) 167 (28) [M+], 124 (100), 77 (6).  
HR-MS (EI) m/z calcd for C10H14FN [M+] 167.1110, found 167.1116. 
 
 
2-Cyclohexyl-4-fluoroaniline (147c): ortho-Alkylated compound 142lb (41 mg, 0.15 mmol) 
was dissolved in aqueous HCl (37%, 1 mL) in a microwave vial. The vial was heated up to 
150 °C (40 W) for 3 h in the microwave oven. The reaction mixture was allowed to cool to 
ambient temperature and poured into to EtOAc (10 mL), and then saturated aqueous NaHCO3 
solution was added until the pH was adjusted to 7. The aqueous layer was extracted with EtOAc 
(3 × 10 mL), the combined organic layers were dried with Na2SO4 and concentrated in vacuo 





1H NMR (400 MHz, CDCl3) δ = 6.81 (dd, J = 10.4, 2.9 Hz, 1H), 6.70 (ddd, J = 8.6, 8.2, 2.9 
Hz, 1H), 6.59 (dd, J = 8.6, 5.1 Hz, 1H), 3.48 (s, 2H), 2.44 (t, J = 10.7 Hz, 1H), 1.90– 1.82 (m, 
4H), 1.80–1.72 (m, 1H), 1.48–1.21 (m, 5H).  
13C NMR (100 MHz, CDCl3) δ = 156.9 (Cq, 1JC-F = 235.8 Hz), 139.2 (Cq, 4JC-F = 2.1 Hz), 133.8 
(Cq, 3JC-F = 6.2 Hz), 116.6 (CH, 3JC-F = 7.9 Hz), 112.7 (CH, 2JC-F = 22.6 Hz), 112.6 (CH, 2JC-F = 
22.5 Hz), 38.6 (CH, 4JC-F = 1.5 Hz), 32.7 (CH2), 27.0 (CH2), 26.2 (CH2).  
19F NMR (376 MHz, CDCl3) δ = -125.6 (dddd, J = 9.8, 8.4, 5.1, 1.0 Hz).  
IR (neat): 3464, 3373, 2924, 2852, 1624, 1494, 1272, 1150, 949, 862, 807 cm-1.  
MS (EI) m/z (relative intensity) 193 (95) [M+], 124 (100), 77 (6).  
HR-MS (EI) m/z calcd for C12H16FN [M+] 1193.1267, found 193.1263. 
5.3.2 Characterization Data: Nickel-Catalyzed C–H Alkylation of Purine Bases 
 
N-(2-Cyclohexyl-6-fluorophenyl)-9-iso-propyl-9H-purin-6-amine (135ab): The general 
procedure C was followed using substrate 134a (81 mg, 0.30 mmol) and bromide 58b (74 μL, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 135ab 
(104 mg, 98%) as a white solid.  
M. p. = 90 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.37 (s, 1H), 7.78 (s, 1H), 7.63 (s, 1H), 7.26 (ddd, J = 8.2, 7.9, 
5.5 Hz, 1H), 7.13 (d, J = 7.9 Hz, 1H), 6.99 (ddd, J = 9.5, 8.2, 1.4 Hz, 1H), 4.83 (hept, J = 6.8 
Hz, 1H), 2.82 (tt, J = 12.0, 3.2 Hz, 1H), 1.81–1.74 (m, 2H), 1.73–1.70 (m, 2H), 1.67–1.61 (m, 
1H), 1.58 (d, J = 6.8 Hz, 6H), 1.41–1.34 (m, 2H), 1.24–1.16 (m, 3H).  
13C NMR (125 MHz, CDCl3) δ = 158.6 (Cq, 1JC-F = 247.6 Hz), 154.1 (Cq), 152.8 (CH), 149.4 
(Cq), 147.9 (Cq), 137.9 (CH), 128.3 (CH, 3JC-F = 8.5 Hz), 122.8 (Cq, 2JC-F = 12.7 Hz), 122.0 (CH, 
4JC-F = 3.3 Hz), 120.2 (Cq), 113.2 (CH, 2JC-F = 20.8 Hz), 47.1 (CH), 39.0 (CH, 4JC-F = 2.2 Hz), 





19F NMR (283 MHz, CDCl3) δ = -118.7 (dd, J = 9.6, 5.5 Hz).  
IR (neat): 3181, 2925, 2850, 1607, 1468, 1223, 648 cm-1.  
MS (ESI) m/z (relative intensity) 354 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C20H25FN5 [M+H+] 354.2089, found 354.2089. 
 
 
N-(2-Cyclohexyl-6-methylphenyl)-9-iso-propyl-9H-purin-6-amine (135bb): The general 
procedure D was followed using substrate 134b (80 mg, 0.30 mmol) and bromide 58b (74 μL, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 135bb 
(81 mg, 77%) as a white solid.  
M. p. = 156–157 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.38 (s, 1H), 8.36 (s, 1H), 7.51 (s, 1H), 7.36–7.20 (m, 2H), 
7.16 (dd, J = 6.5, 2.2 Hz, 1H), 4.82 (hept, J = 6.8 Hz, 1H), 2.83 (tt, J = 12.1, 3.2 Hz, 1H), 2.20 
(s, 3H), 1.89–1.60 (m, 5H), 1.57 (d, J = 6.8 Hz, 6H), 1.48–1.31 (m, 2H), 1.21–1.17 (m, 3H).  
13C NMR (75 MHz, CDCl3) δ = 154.4 (Cq), 153.3 (CH), 149.1 (Cq), 146.2 (Cq), 137.5 (CH), 
136.9 (Cq), 133.4 (Cq), 128.1 (CH), 127.9 (CH), 124.5 (CH), 119.8 (Cq), 47.0 (CH), 39.2 (CH), 
34.0 (CH2), 26.9 (CH2), 26.2 (CH2), 22.7 (CH3), 18.9 (CH3).  
IR (neat): 3228, 2925, 2850, 1606, 1468, 1217, 649 cm-1.  
MS (ESI) m/z (relative intensity) 350 (100) [M+H+].  







The general procedure C was followed using substrate 134c (76 mg, 0.30 mmol) and bromide 
58b (41 μL, 0.33 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) 
yielded 135cb (80 mg, 80%) as a colorless oil and 135cb’ (7 mg, 5%) as a white solid. 
N-(2-Cyclohexylphenyl)-9-iso-propyl-9H-purin-6-amine (135cb):  
1H NMR (400 MHz, CDCl3) δ = 8.41 (s, 1H), 7.81 (s, 1H), 7.77–7.69 (m, 2H), 7.32 (dd, J = 
7.3, 2.1 Hz, 1H), 7.27–7.17 (m, 2H), 4.84 (hept, J = 6.8 Hz, 1H), 2.80 (tt, J = 11.7, 3.2 Hz, 1H), 
1.88–1.74 (m, 4H), 1.73–1.63 (m, 1H), 1.60 (d, J = 6.8 Hz, 6H), 1.50–1.15 (m, 5H).  
13C NMR (125 MHz, CDCl3) δ = 153.5 (Cq), 152.8 (CH), 149.2 (Cq), 141.5 (Cq), 137.9 (CH), 
134.7 (Cq), 126.6 (CH), 126.2 (CH), 126.1 (CH), 125.7 (CH), 120.5 (Cq), 47.0 (CH), 38.7 (CH), 
33.6 (CH2), 26.8 (CH2), 26.1 (CH2), 22.7 (CH3).  
IR (neat): 3235, 2925, 2851, 1606, 1467, 1220, 648 cm-1.  
MS (ESI) m/z (relative intensity) 336 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C20H26N5 [M+H+] 336.2183, found 336.2183. 
N-(2,6-Dicyclohexylphenyl)-9-iso-propyl-9H-purin-6-amine (135cb’):  
M. p. = 220 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.31 (s, 1H), 7.73 (s, 1H), 7.41 (br s, 1H), 7.32 (dd, J = 7.7, 
7.7 Hz, 1H), 7.21 (d, J = 7.7 Hz, 2H), 4.85 (hept, J = 6.8 Hz, 1H), 2.71 (tt, J = 11.9, 3.2 Hz, 
2H), 1.85–1.58 (m, 16H), 1.40–1.31 (m, 4H), 1.24–1.16 (m, 6H).  
13C NMR (100 MHz, CDCl3) δ = 154.9 (Cq), 153.2 (CH), 149.1 (Cq), 146.1 (Cq), 137.6 (CH), 
131.9 (Cq), 128.3 (CH), 124.4 (CH), 119.7 (Cq), 47.0 (CH), 39.5 (CH), 34.6 (CH2), 33.4 (CH2), 
26.9 (CH2), 26.1 (CH2), 22.8 (CH3).  
IR (neat): 3180, 2921, 2849, 1612, 1470, 1226, 649 cm-1.  
MS (ESI) m/z (relative intensity) 418 (100) [M+H+].  







N-(2-Cyclohexyl-5-methylphenyl)-9-iso-propyl-9H-purin-6-amine (135db): The general 
procedure C was followed using substrate 134d (80 mg, 0.30 mmol) and bromide 58b (74 μL, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 135db 
(86 mg, 82%) as a white solid.  
M. p. = 126 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.42 (s, 1H), 7.78 (s, 1H), 7.68 (br s, 1H), 7.51 (d, J = 1.8 Hz, 
1H), 7.21 (d, J = 8.0 Hz, 1H), 7.02 (dd, J = 8.0, 1.8 Hz, 1H), 4.83 (hept, J = 6.8 Hz, 1H), 2.74 
(tt, J = 11.8, 3.2 Hz, 1H), 2.32 (s, 3H), 1.86–1.64 (m, 5H), 1.59 (d, J = 6.8 Hz, 6H), 1.47–1.15 
(m, 5H).  
13C NMR (75 MHz, CDCl3) δ = 153.6 (Cq), 152.9 (CH), 149.2 (Cq), 138.8 (Cq), 137.8 (CH), 
135.8 (Cq), 134.5 (Cq), 127.1 (CH), 126.5 (CH), 126.4 (CH), 120.5 (Cq), 47.0 (CH), 38.4 (CH), 
33.7 (CH2), 26.9 (CH2), 26.1 (CH2), 22.7 (CH3), 21.0 (CH3).  
IR (neat): 3211, 2924, 2851, 1604, 1468, 1223, 649 cm-1.  
MS (ESI) m/z (relative intensity) 350 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C21H28N5 [M+H+] 350.2339, found 350.2339. 
 
 
N-(2-Cyclohexyl-5-methoxyphenyl)-9-iso-propyl-9H-purin-6-amine (135eb): The general 
procedure C was followed using substrate 134e (85 mg, 0.30 mmol) and bromide 58b (74 μL, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 135eb 
(89 mg, 81%) as a white solid.  
M. p. = 130 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.44 (s, 1H), 7.83 (s, 1H), 7.61 (br s, 1H), 7.50 (d, J = 2.7 Hz, 
1H), 7.20 (d, J = 8.6 Hz, 1H), 6.75 (dd, J = 8.6, 2.7 Hz, 1H), 4.84 (hept, J = 6.8 Hz, 1H), 3.78 
(s, 3H), 2.70 (tt, J = 11.1, 3.0 Hz, 1H), 1.95–1.64 (m, 5H), 1.60 (d, J = 6.8 Hz, 6H), 1.51–1.12 





13C NMR (75 MHz, CDCl3) δ = 157.7 (Cq), 153.2 (Cq), 152.7 (CH), 149.3 (Cq), 138.0 (CH), 
135.6 (Cq), 132.8 (Cq), 127.1 (CH), 120.7 (Cq), 111.4 (CH), 110.3 (CH), 55.2 (CH3), 47.1 (CH), 
38.2 (CH), 33.8 (CH2), 26.9 (CH2), 26.2 (CH2), 22.7 (CH3).  
IR (neat): 3241, 2925, 2850, 1602, 1467, 1224, 649 cm-1.  
MS (ESI) m/z (relative intensity) 366 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C21H27N5O [M+H+] 366.2288, found 366.2288. 
 
 
N-[2-Cyclohexyl-5-(trifluoromethyl)phenyl]-9-iso-propyl-9H-purin-6-amine (135fb): The 
general procedure C was followed using substrate 134f (96 mg, 0.30 mmol) and bromide 58b 
(74 μL, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 
135fb (120 mg, 99%) as a white solid.  
M. p. = 68 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.43 (s, 1H), 8.14 (s, 1H), 8.09 (br s, 1H), 7.76 (s, 1H), 7.42–
7.41 (m, 2H), 4.83 (hept, J = 6.8 Hz, 1H), 2.93–2.68 (m, 1H), 1.92–1.67 (m, 5H), 1.57 (d, J = 
6.8 Hz, 6H), 1.50–1.15 (m, 5H).  
13C NMR (125 MHz, CDCl3) δ = 152.9 (Cq), 152.5 (CH), 149.4 (Cq), 144.3 (Cq), 138.2 (CH), 
135.5 (Cq), 128.4 (q, 2JC-F = 32.6 Hz, Cq), 127.0 (CH), 124.0 (q, 1JC-F = 271.7 Hz, Cq), 122.0 (q, 
3JC-F = 4.1 Hz, CH), 121.9 (q, 3JC-F = 4.1 Hz, CH), 120.7 (Cq), 47.2 (CH), 38.9 (CH), 33.4 (CH2), 
26.8 (CH2), 26.1 (CH2), 22.7 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -62.3 (s).  
IR (neat): 2928, 2853, 1607, 1328, 1118, 1010, 648 cm-1.  
MS (ESI) m/z (relative intensity) 404 (100) [M+H+].  







N-(5-Chloro-2-cyclohexylphenyl)-9-iso-propyl-9H-purin-6-amine (135gb): The general 
procedure D was followed using substrate 134g (86 mg, 0.30 mmol) and bromide 58b (74 μL, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 135gb 
(90 mg, 81%) as a colorless oil.  
1H NMR (600 MHz, CDCl3) δ = 8.46 (s, 1H), 7.95 (d, J = 2.2 Hz, 1H), 7.82 (s, 1H), 7.75 (br s, 
1H), 7.22 (d, J = 8.4 Hz, 1H), 7.13 (dd, J = 8.4, 2.2 Hz, 1H), 4.84 (hept, J = 6.8 Hz, 1H), 2.74 
(tt, J = 11.7, 3.2 Hz, 1H), 1.83–1.77 (m, 4H), 1.73–1.67 (m, 1H), 1.57 (d, J = 6.8 Hz, 6H), 1.43–
1.28 (m, 4H), 1.26–1.18 (m, 1H).  
13C NMR (125 MHz, CDCl3) δ = 152.8 (Cq), 152.5 (CH), 149.4 (Cq), 138.7 (Cq), 138.2 (CH), 
136.0 (Cq), 131.4 (Cq), 127.5 (CH), 125.4 (CH), 124.5 (CH), 120.6 (Cq), 47.2 (CH), 38.8 (CH), 
33.5 (CH2), 26.8 (CH2), 26.1 (CH2), 22.7 (CH3).  
IR (neat): 2925, 2851, 1612, 1464, 1220, 1009, 646 cm-1.  
MS (ESI) m/z (relative intensity) 370 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C20H25ClN5 [M+H+] 370.1793, found 370.1806. 
 
 
tert-Butyl 4-cyclohexyl-3-[(9-iso-propyl-9H-purin-6-yl)amino]benzoate (135hb): The 
general procedure C was followed using substrate 134h (106 mg, 0.30 mmol) and bromide 58b 
(74 μL, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 
135hb (84 mg, 64%) as a white solid.  





1H NMR (300 MHz, CDCl3) δ = 8.41 (s, 1H), 8.29 (d, J = 1.8 Hz, 1H), 8.05 (br s, 1H), 7.82 
(dd, J = 8.2, 1.8 Hz, 1H), 7.74 (s, 1H), 7.36 (d, J = 8.2 Hz, 1H), 4.81 (hept, J = 6.8 Hz, 1H), 
2.91–2.73 (m, 1H), 1.86–1.62 (m, 5H), 1.56 (d, J = 6.8 Hz, 6H), 1.53 (s, 9H), 1.36–1.13 (m, 
5H).  
13C NMR (125 MHz, CDCl3) δ = 165.2 (Cq), 153.4 (Cq), 152.6 (CH), 149.3 (Cq), 146.7 (Cq), 
138.0 (CH), 134.8 (Cq), 130.2 (Cq), 127.0 (CH), 127.0 (CH), 126.5 (Cq), 120.4 (CH), 80.7 (Cq), 
47.1 (CH), 39.0 (CH), 33.4 (CH2), 28.2 (CH3), 26.7 (CH2), 26.1 (CH2), 22.7 (CH3).  
IR (neat): 2977, 2927, 2852, 1710, 1604, 1298, 648 cm-1.  
MS (ESI) m/z (relative intensity) 436 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C25H33N5O2Na [M+Na+] 458.2526, found 458.2533. 
 
 
The general procedure C was followed using substrate 134i (81 mg, 0.30 mmol) and bromide 
58b (41 μL, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) 
yielded 135ib (76 mg, 72%) and 135ib’ (23 mg, 17%) as white solids. 
N-(2-Cyclohexyl-4-fluorophenyl)-9-iso-propyl-9H-purin-6-amine (135ib):  
M. p. = 137 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.38 (s, 1H), 7.83 (br s, 1H), 7.74 (s, 1H), 7.54 (dd, J = 8.8, 
5.6 Hz, 1H), 7.01 (dd, J = 10.2, 3.0 Hz, 1H), 6.91 (ddd, J = 8.8, 7.8, 3.0 Hz, 1H), 4.82 (hept, J 
= 6.8 Hz, 1H), 2.86–2.71 (m, 1H), 1.87–1.62 (m, 5H), 1.58 (d, J = 6.8 Hz, 6H), 1.47–1.10 (m, 
5H).  
13C NMR (125 MHz, CDCl3) δ = 161.0 (Cq, 1JC-F = 244.1 Hz), 153.7 (Cq), 152.7 (CH), 149.2 
(Cq), 145.1 (Cq, 3JC-F = 7.2 Hz), 137.9 (CH), 130.6 (Cq), 128.1 (CH, 3JC-F = 8.4 Hz), 120.3 (Cq), 
113.4 (CH, 2JC-F = 22.7 Hz), 113.0 (CH, 2JC-F = 22.6 Hz), 47.1 (CH), 39.0 (CH), 33.5 (CH2), 





19F NMR (283 MHz, CDCl3) δ = -115.5 (dd, J = 7.9, 2.2 Hz).  
IR (neat): 3235, 2927, 2852, 1606, 1468, 1221, 649 cm-1.  
MS (ESI) m/z (relative intensity) 354 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C20H24FN5 [M+H+] 354.2089, found 354.2104. 
 
N-(2,6-Dicyclohexyl-4-fluorophenyl)-9-iso-propyl-9H-purin-6-amine (135ib’):  
M. p. = 250 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.31 (s, 1H), 7.72 (s, 1H), 7.38 (br s, 1H), 6.89 (d, J = 9.8 Hz, 
2H), 4.85 (hept, J = 6.8 Hz, 1H), 2.73–2.65 (m, 2H), 1.87–1.50 (m, 16H), 1.39–0.91 (m, 10H).  
13C NMR (75 MHz, CDCl3) δ = 162.6 (Cq, 1JC-F = 244.8 Hz), 154.9 (Cq), 153.2 (CH), 149.1 
(Cq), 148.8 (Cq, 3JC-F = 7.5 Hz), 137.8 (CH), 127.6 (Cq), 119.8 (Cq), 111.4 (CH, 2JC-F = 22.6 Hz), 
47.0 (CH), 39.6 (CH, 4JC-F = 1.6 Hz), 34.5 (CH2), 33.2 (CH2), 26.7 (CH2), 26.0 (CH2), 22.7 
(CH3).  
19F NMR (283 MHz, CDCl3) δ = -113.6 (t, J = 9.7 Hz).  
IR (neat): 3178, 2926, 2850, 1609, 1470, 1224, 650 cm-1.  
MS (ESI) m/z (relative intensity) 436 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C26H34FN5Na [M+Na+] 458.2690, found 458.2695. 
 
 
The general procedure C was followed using substrate 134j (85 mg, 0.30 mmol) and bromide 
58b (41 μL, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) 
yielded 135jb (64 mg, 58%) and 135jb’ (20 mg, 15%) as white solids. 
N-(2-Cyclohexyl-4-methoxyphenyl)-9-iso-propyl-9H-purin-6-amine (135jb):  





1H NMR (300 MHz, CDCl3) δ = 8.36 (s, 1H), 7.76 (s, 1H), 7.73 (s, 1H), 7.41 (d, J = 8.7 Hz, 
1H), 6.86 (d, J = 2.9 Hz, 1H), 6.76 (dd, J = 8.7, 2.9 Hz, 1H), 4.81 (hept, J = 6.8 Hz, 1H), 3.79 
(s, 3H), 2.80–2.70 (m, 1H), 1.83–1.61 (m, 5H), 1.57 (d, J = 6.8 Hz, 6H), 1.45–1.11 (m, 5H).  
13C NMR (75 MHz, CDCl3) δ = 158.2 (Cq), 154.3 (Cq), 153.0 (CH), 149.1 (Cq), 144.9 (Cq), 
137.7 (CH), 128.2 (CH), 127.6 (Cq), 120.2 (Cq), 112.7 (CH), 111.0 (CH), 55.3 (CH3), 47.0 (CH), 
38.9 (CH), 33.6 (CH2), 26.8 (CH2), 26.1 (CH2), 22.7 (CH3).  
IR (neat): 3242, 2926, 2851, 1612, 1469, 1223, 649 cm-1.  
MS (ESI) m/z (relative intensity) 366 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C21H27N5O [M+H+] 366.2288, found 366.2299. 
N-(2,6-Dicyclohexyl-4-methoxyphenyl)-9-iso-propyl-9H-purin-6-amine (135jb’):  
M. p. = 210 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.31 (s, 1H), 7.77 (s, 1H), 7.21 (s, 1H), 6.73 (s, 2H), 4.85 
(hept, J = 6.8 Hz, 1H), 3.81 (s, 3H), 2.78–2.59 (m, 2H), 1.76–1.56 (m, 16H), 1.36–1.04 (m, 
10H).  
13C NMR (75 MHz, CDCl3) δ = 159.1 (Cq), 155.2 (Cq), 153.3 (CH), 149.0 (Cq), 147.5 (Cq), 
137.6 (CH), 124.6 (Cq), 119.8 (Cq), 109.9 (CH), 55.1 (CH3), 47.0 (CH), 39.6 (CH), 34.6 (CH2), 
33.3 (CH2), 26.8 (CH2), 26.1 (CH2), 22.8 (CH3).  
IR (neat): 3225, 2925, 2850, 1611, 1468, 1227, 650 cm-1.  
MS (ESI) m/z (relative intensity) 448 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C27H37N5O [M+H+] 448.3071, found 448.3084. 
 
 
N-(2-Cyclohexylnaphthalen-1-yl)-9-iso-propyl-9H-purin-6-amine (135kb): The general 
procedure C was followed using substrate 134k (91 mg, 0.30 mmol) and bromide 58b (74 μL, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 135kb 





M. p. = 120 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.56 (br s, 1H), 8.29 (s, 1H), 7.94–7.78 (m, 3H), 7.56 (d, J = 
8.7 Hz, 1H), 7.51 (s, 1H), 7.40 (ddd, J = 8.0, 6.8, 1.3 Hz, 1H), 7.32 (ddd, J = 8.2, 6.8, 1.4 Hz, 
1H), 4.74 (hept, J = 6.8 Hz, 1H), 3.04 (tt, J = 12.4, 2.8 Hz, 1H), 1.85–1.52 (m, 7H), 1.47 (d, J 
= 6.8 Hz, 6H), 1.31–1.07 (m, 3H).  
13C NMR (125 MHz, CDCl3) δ = 155.0 (Cq), 153.2 (CH), 149.1 (Cq), 143.3 (Cq), 137.6 (CH), 
132.8 (Cq), 131.4 (Cq), 129.3 (Cq), 128.0 (CH), 127.9 (CH), 126.2 (CH), 125.2 (CH), 124.8 
(CH), 123.3 (CH), 119.8 (Cq), 46.9 (CH), 39.6 (CH), 33.5 (CH2), 26.8 (CH2), 26.2 (CH2), 22.6 
(CH3).  
IR (neat): 3179, 2926, 2851, 1711, 1605, 1220, 648 cm-1.  
MS (ESI) m/z (relative intensity) 386 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C24H28N5 [M+H+] 386.2339, found 386.2348. 
 
 
9-Benzyl-N-(2-cyclohexyl-6-fluorophenyl)-9H-purin-6-amine (135lb): The general 
procedure C was followed using substrate 134l (96 mg, 0.30 mmol) and bromide 58b (74 μL, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 135lb 
(106 mg, 88%) as a white solid.  
M. p. = 95 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.41 (s, 1H), 7.72 (br s, 1H), 7.65 (s, 1H), 7.42–7.21 (m, 6H), 
7.12 (d, J = 7.9 Hz, 1H), 6.98 (ddd, J = 9.5, 8.1, 1.4 Hz, 1H), 5.34 (s, 2H), 2.81 (tt, J = 12.0, 
3.2 Hz, 1H), 1.84–1.52 (m, 5H), 1.50–0.96 (m, 5H).  
13C NMR (75 MHz, CDCl3) δ = 158.7 (Cq, 1JC-F = 248.0 Hz), 154.3 (Cq), 153.4 (CH), 150.0 
(Cq), 148.0 (Cq), 140.3 (CH), 135.4 (Cq), 129.0 (CH), 128.4 (CH, 3JC-F = 8.9 Hz), 128.3 (CH), 
127.9 (CH), 122.8 (Cq, 2JC-F = 12.7 Hz), 122.1 (CH, 4JC-F = 3.3 Hz), 119.8 (Cq), 113.2 (CH, 2JC-





19F NMR (283 MHz, CDCl3) δ = -118.7 (dd, J = 9.6, 5.6 Hz).  
IR (neat): 3180, 2925, 2851, 1605, 1469, 1295, 649 cm-1.  
MS (ESI) m/z (relative intensity) 402 (100) [M+H+].  




(135mb): The general procedure C was followed using substrate 134m (94 mg, 0.30 mmol) 
and bromide 58b (74 μL, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
2/1→1/1) yielded 135mb (117 mg, 99%) as a white solid.  
M. p. = 97 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.36 (s, 1H), 7.93 (s, 1H), 7.77 (br s, 1H), 7.26 (ddd, J = 8.1, 
7.9, 6.0 Hz, 1H), 7.12 (dd, J = 7.9, 1.4 Hz, 1H), 6.98 (ddd, J = 9.5, 8.1, 1.4 Hz, 1H), 5.69 (dd, 
J = 9.8, 2.8 Hz, 1H), 4.13 (ddd, J = 12.9, 2.9, 2.9 Hz, 1H), 3.74 (ddd, J = 11.5, 2.9, 2.9 Hz, 1H), 
2.80 (tt, J = 12.0, 3.2 Hz, 1H), 2.20–1.94 (m, 3H), 1.84–1.54 (m, 8H), 1.50–1.30 (m, 2H), 1.26–
1.13 (m, 3H).  
13C NMR (125 MHz, CDCl3) δ = 158.6 (Cq, 1JC-F = 247.8 Hz), 154.1 (Cq), 153.1 (CH), 149.1 
(Cq), 147.9 (Cq), 138.2 (CH), 128.3 (CH, 3JC-F = 8.5 Hz), 122.7 (Cq, 2JC-F = 12.7 Hz), 122.0 (CH, 
4JC-F = 3.3 Hz), 119.8 (Cq), 113.1 (CH, 2JC-F = 20.7 Hz), 81.8 (CH), 68.7 (CH2), 39.0 (CH, 4JC-F 
= 2.1 Hz), 33.7 (CH2), 31.8 (CH2), 26.7, (CH2), 26.1 (CH2), 24.9 (CH2), 22.8 (CH2).  
19F NMR (283 MHz, CDCl3) δ = -118.8 (dd, J = 9.5, 5.6 Hz).  
IR (neat): 3183, 2926, 2852, 1711, 1449, 1221, 649 cm-1.  
MS (ESI) m/z (relative intensity) 396 (100) [M+H+]. 








tetrahydrofuran-2-yl}-N-(2-cyclohexyl-6-methylphenyl)-9H-purin-6 amine (135nb): The 
general procedure C was followed using substrate 134n (171 mg, 0.30 mmol) and bromide 58b 
(74 μL, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 
135nb (160 mg, 82%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.33 (s, 1H), 8.06 (br s, 1H), 7.23–7.18 (m, 2H), 7.13 (dd, J = 
7.0, 2.0 Hz, 1H), 6.45 (dd, J = 6.5, 6.5 Hz, 1H), 4.62 (m, 1H), 4.01 (m, 1H), 3.85 (dd, J = 11.3, 
4.4 Hz, 1H), 3.76 (dd, J = 11.2, 3.4 Hz, 1H), 2.89–2.62 (m, 2H), 2.42 (ddd, J = 13.1, 6.1, 3.6 
Hz, 1H), 2.19 (s, 3H), 1.82–1.56 (m, 5H), 1.40–1.33 (m, 2H), 1.25–1.19 (m, 3H), 0.90 (s, 19H), 
0.10 (s, 6H), 0.07 (d, J = 2.6 Hz, 6H).  
13C NMR (100 MHz, CDCl3) δ = 154.2 (CH), 153.5 (Cq), 149.1 (Cq), 145.9 (CH), 138.7 (Cq), 
136.8 (Cq), 133.1 (Cq), 128.2 (CH), 128.0 (CH), 124.5 (CH), 120.0 (Cq), 87.9 (CH), 84.3 (CH), 
72.1 (CH), 62.9 (CH2), 41.0 (CH2), 39.2 (CH), 33.9 (CH2), 26.8 (CH2), 26.1 (CH2), 25.9 (CH3), 
25.8 (CH3), 18.8 (CH3), 18.4 (Cq), 18.0 (Cq), -4.7 (CH3), -4.8 (CH3), -5.4 (CH3), -5.5 (CH3).  
IR (neat): 2954, 2925, 2856, 1712, 1612, 1360, 1219, 835 cm-1.  
MS (ESI) m/z (relative intensity) 652 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C35H58N5O3Si2 [M+H+] 652.4073, found 652.4068. 
 
 
Ethyl-6-{3-fluoro-2-[(9-iso-propyl-9H-purin-6-yl)amino]phenyl}hexanoate (135ap): The 





(134 mg, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) 
yielded 135ap (67 mg, 54%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.34 (s, 1H), 8.15 (s, 1H), 7.69 (s, 1H), 7.21 (ddd, J = 8.0, 7.7, 
4.8 Hz, 1H), 7.05 (d, J = 7.7 Hz, 1H), 6.99 (ddd, J = 9.6, 8.0, 1.5 Hz, 1H), 4.79 (hept, J = 6.6 
Hz, 1H), 4.02 (q, J = 7.1 Hz, 2H), 2.62 (t, J = 7.7 Hz, 2H), 2.12 (t, J = 7.5 Hz, 2H), 1.54 (d, J 
= 6.6 Hz, 6H), 1.50–1.42 (m, 4H), 1.26–1.21 (m, 2H), 1.17 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ = 173.5 (Cq), 158.8 (Cq, 1JC-F = 248.0 Hz), 154.0 (Cq), 152.8 
(CH), 149.4 (Cq), 142.9 (Cq), 138.0 (CH), 128.1 (CH, 3JC-F = 8.6 Hz), 124.7 (CH, 4JC-F = 3.3 
Hz), 123.8 (Cq, 2JC-F = 13.1 Hz), 120.2 (Cq), 113.5 (CH, 2JC-F = 20.7 Hz), 60.0 (CH2), 47.0 (CH), 
34.0 (CH2), 31.2 (CH2, 4JC-F = 2.4 Hz), 29.6 (CH2), 28.7 (CH2), 24.6 (CH2), 22.5 (CH3), 14.1 
(CH3).  
19F NMR (283 MHz, CDCl3) δ = -119.4 (dd, J = 9.5, 5.6 Hz).  
IR (neat): 3179, 2933, 2861, 1606, 1467, 1223, 649 cm-1.  
MS (ESI) m/z (relative intensity) 414 (100) [M+H+].  




amine (135aq): The general procedure C was followed using substrate 134a (81 mg, 0.30 mmol) 
and bromide 58q (143 mg, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
2/1→1/1) yielded 135aq (80 mg, 62%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.38 (s, 1H), 8.17 (br s, 1H), 7.81 (s, 1H), 7.19 (ddd, J = 8.2, 
8.0, 5.3 Hz, 1H), 7.07–7.01 (m, 2H), 4.82 (hept, J = 6.8 Hz, 1H), 3.83 (t, J = 6.1 Hz, 2H), 2.89 
(t, J = 6.1 Hz, 2H), 1.57 (d, J = 6.8 Hz, 6H), 0.79 (s, 9H), -0.05 (s, 6H).  
13C NMR (100 MHz, CDCl3) δ = 158.4 (Cq, 1JC-F = 249.1 Hz), 153.3 (Cq), 152.6 (CH), 149.5 





2JC-F = 12.8 Hz), 120.6 (Cq), 114.2 (CH, 2JC-F = 20.7 Hz), 64.8 (CH2), 46.9 (CH), 34.9 (CH2, 
4JC-F = 2.3 Hz), 25.9 (CH3), 22.6 (CH3), 18.4 (Cq), -5.6 (CH3).  
19F NMR (376 MHz, CDCl3) δ = -117.4 (dd, J = 9.6, 5.3 Hz).  
IR (neat): 3172, 2926, 2854, 1611, 1470, 1228, 833, 649 cm-1.  
MS (ESI) m/z (relative intensity) 430 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C22H33FN5OSi [M+H+] 430.2433, found 430.2437. 
 
 
N-(2-Cyclopentyl-6-fluorophenyl)-9-iso-propyl-9H-purin-6-amine (135ar): The general 
procedure C was followed using substrate 134a (81 mg, 0.30 mmol) and bromide 58r (89 mg, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 135ar 
(100 mg, 98%) as a white solid.  
M. p. = 145 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.38 (s, 1H), 7.79 (s, 1H), 7.55 (br s, 1H), 7.26 (ddd, J = 8.1, 
8.0, 5.6 Hz, 1H), 7.16 (dd, J = 8.0, 1.5 Hz, 1H), 7.00 (ddd, J = 9.5, 8.1, 1.5 Hz, 1H), 4.83 (hept, 
J = 6.8 Hz, 1H), 3.25 (p, J = 8.4 Hz, 1H), 2.04–1.87 (m, 2H), 1.86–1.68 (m, 2H), 1.59 (d, J = 
6.8 Hz, 6H), 1.57–1.47 (m, 4H).  
13C NMR (125 MHz, CDCl3) δ = 158.7 (Cq, 1JC-F = 247.7 Hz), 154.0 (Cq), 152.8 (CH), 149.4 
(Cq), 147.0 (Cq), 138.0 (CH), 128.3 (CH, 3JC-F = 8.7 Hz), 123.4 (Cq, 2JC-F = 12.9 Hz), 121.9 (CH, 
4JC-F = 3.3 Hz), 120.3 (Cq), 113.2 (CH, 2JC-F = 20.7 Hz), 47.1 (CH), 40.4 (CH, 4JC-F = 2.2 Hz), 
34.2 (CH2), 25.7 (CH2), 22.8 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -119.2 (dd, J = 9.4, 5.5 Hz).  
IR (neat): 3189, 2945, 1605, 1470, 1222, 1006, 649 cm-1.  
MS (ESI) m/z (relative intensity) 340 (100) [M+H+]. 







N-[2-(sec-Butyl)-6-fluorophenyl]-9-iso-propyl-9H-purin-6-amine (135al): The general 
procedure C was followed using substrate 134a (81 mg, 0.30 mmol) and bromide 58l (82 mg, 
0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1→1/1) yielded 135al 
(84 mg, 86%) as a white solid. 
M. p. = 180 °C. 
1H NMR (300 MHz, CDCl3) δ = 8.36 (s, 1H), 7.79 (br s, 1H), 7.75 (s, 1H), 7.28 (ddd, J = 8.1, 
8.0, 5.5 Hz, 1H), 7.09 (dd, J = 8.0, 1.4 Hz, 1H), 7.00 (ddd, J = 9.5, 8.1, 1.4 Hz, 1H), 4.81 (hept, 
J = 6.8 Hz, 1H), 2.96 (m, 1H), 1.65–1.40 (m, 8H), 1.13 (d, J = 6.9 Hz, 3H), 0.69 (t, J = 7.4 Hz, 
3H). 
13C NMR (125 MHz, CDCl3) δ = 158.7 (d, J = 247.4 Hz), 154.2 (Cq), 152.7 (CH), 149.3 (Cq), 
148.2 (Cq), 137.8 (CH), 128.4 (CH, 3JC-F = 8.5 Hz), 123.4 (Cq, 2JC-F = 12.8 Hz), 121.7 (CH, 4JC-
F = 3.3 Hz), 120.2 (Cq), 113.2 (CH, 2JC-F = 20.7 Hz), 47.0 (CH), 35.4 (CH, 4JC-F = 2.0 Hz), 30.5 
(CH2), 22.7 (CH3), 21.1 (CH3), 12.1 (CH3). 
19F NMR (283 MHz, CDCl3) δ = -119.1 (dd, J = 9.5, 5.6 Hz). 
IR (neat): 3180, 2962, 2931, 1610, 1470, 1224, 649 cm-1. 
MS (ESI) m/z (relative intensity) 328 (100) [M+H+].  









bromide 58s (105 mg, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
2/1→1/1) yielded 135as (100 mg, 91%) as a white solid.  
M. p. = 92 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.39 (s, 1H), 7.76 (s, 1H), 7.73 (s, 1H), 7.26 (ddd, J = 8.1, 8.0, 
5.5 Hz, 1H), 7.16 (dd, J = 8.0, 1.4 Hz, 1H), 7.01 (ddd, J = 9.5, 8.1, 1.5 Hz, 1H), 4.83 (hept, J = 
6.8 Hz, 1H), 2.92 (dd, J = 8.9, 5.7 Hz, 1H), 2.41 (d, J = 2.6 Hz, 1H), 2.25 (d, J = 4.3 Hz, 1H), 
1.70 (ddd, J = 12.0, 9.1, 2.3 Hz, 1H), 1.59 (d, J = 6.8 Hz, 6H), 1.53–1.43 (m, 4H), 1.26–1.09 
(m, 3H).  
13C NMR (75 MHz, CDCl3) δ = 159.1 (Cq, 1JC-F = 248.9 Hz), 153.9 (Cq), 152.8 (CH), 149.6 
(Cq), 147.5 (Cq), 138.1 (CH), 128.0 (CH, 3JC-F = 8.5 Hz), 123.5 (Cq, 2JC-F = 12.6 Hz), 121.2 (CH, 
4JC-F = 3.1 Hz), 120.3 (Cq), 113.3 (CH, 2JC-F = 20.6 Hz), 47.1 (CH), 42.6 (CH, 4JC-F = 2.1 Hz), 
41.3 (CH), 39.3 (CH2), 36.9 (CH), 36.4 (CH2), 30.2 (CH2), 28.7 (CH2), 22.7 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -118.2 (dd, J = 9.4, 5.5 Hz).  
IR (neat): 3226, 2950, 2870, 1711, 1468, 1220, 649 cm-1.  
MS (ESI) m/z (relative intensity) 366 (100) [M+H+].  




(135at): The general procedure C was followed using substrate 134a (81 mg, 0.30 mmol) and 
bromide 58t (74 μL, 0.60 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
2/1→1/1) yielded 135at (90 mg, 54%) as a white solid.  
M. p. = 110 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.41 (s, 1H), 8.27 (d, J = 9.2 Hz, 1H), 8.16–8.13 (m, 2H), 
8.09–8.04 (m, 3H), 8.00 (d, J = 0.7 Hz, 2H), 7.97 (dd, J = 7.5, 7.5 Hz, 1H), 7.92 (d, J = 7.8 Hz, 





(hept, J = 6.7 Hz, 1H), 3.47 (t, J = 6.1 Hz, 2H), 2.65 (t, J = 7.5 Hz, 2H), 1.71–1.53 (m, 4H), 
1.49 (d, J = 6.8 Hz, 6H).  
13C NMR (100 MHz, CDCl3) δ = 158.8 (Cq, 1JC-F = 247.9 Hz), 153.9 (Cq), 152.7 (CH), 149.5 
(Cq), 142.8 (Cq), 138.0 (CH), 131.6 (Cq), 131.1 (Cq), 131.0 (Cq), 130.7 (Cq), 129.1 (Cq), 128.1 
(CH, 3JC-F = 8.5 Hz), 127.5 (CH), 127.3 (CH), 127.2 (CH), 126.7 (CH), 125.8 (CH), 125.1 (CH), 
125.0 (CH), 124.8 (CH, 4JC-F = 3.2 Hz), 124.8 (Cq), 124.6 (Cq), 124.4 (CH), 123.7 (Cq, 2JC-F = 
13.1 Hz), 123.4 (CH), 120.2 (Cq), 113.5 (CH, 2JC-F = 20.7 Hz), 71.3 (CH2), 70.0 (CH2), 47.0 
(CH), 31.1 (CH2, 4JC-F = 2.3 Hz), 29.4 (CH2), 26.6 (CH2), 22.5 (CH3).  
19F NMR (376 MHz, CDCl3) δ = -119.3 (dd, J = 9.3, 5.5 Hz).  
IR (neat): 3039, 2929, 2858, 1606, 1467, 845, 648 cm-1.  
MS (ESI) m/z (relative intensity) 558 (100) [M+H+].  




Intermolecular Competition Experiment between 134d and 134f 
 
 
9-iso-Propyl-N-(m-tolyl)-9H-purin-6-amine (134d) (80 mg, 0.30 mmol), 9-iso-propyl-N-[3-
(trifluoromethyl)phenyl]-9H-purin-6-amine (134f) (96 mg, 0.30 mmol), [(DME)NiCl2] (6.6 mg, 
10 mol %) and LiOt-Bu (48 mg, 0.60 mmol) were placed in a Schlenk tube. The tube was 
degassed and purged with N2 for three times. Dt-BEDA (143) (13 µL, 20 mol %), alkyl bromide 
58b (49 mg, 0.30 mmol) and 1,4-dioxane (1.5 mL) were then added, and the mixture was stirred 





mixture was transferred into a round flask with CH2Cl2 and concentrated under reduced 
pressure. Purification by column chromatography on silica gel (n-hexane/EtOAc: 2/1→1/1) to 
afford 135fb (16 mg, 13%) as the sole product, and the starting materials 134d (77 mg, 96%) 
and 134f (76 mg, 79%) were reisolated. 
 
Intermolecular Competition Experiment between Different Directing Groups 
 
 
N-(2-Fluorophenyl)-9-iso-propyl-9H-purin-6-amine (134a) (81 mg, 0.30 mmol), N-(2-
fluorophenyl)pyrimidin-2-amine (123b) (57 mg, 0.30 mmol), [(DME)NiCl2] (6.6 mg, 10 mol %) 
and LiOt-Bu (48 mg, 0.60 mmol) were placed in a Schlenk tube. The tube was degassed and 
purged with N2 for three times. Dt-BEDA (143) (13 µL, 20 mol %), alkyl bromide 58b (49 mg, 
0.30 mmol) and 1,4-dioxane (1.5 mL) were then added, and the mixture was stirred at 120 °C 
for 16 h. After cooling to ambient temperature, the GC conversions were determined by using 
n-dodecane (51 mg, 0.30 mmol) as internal standard. 
 








N-(2-Fluorophenyl)-9-iso-propyl-9H-purin-6-amine (134a) (81 mg, 0.30 mmol), [(DME)NiCl2] 
(6.6 mg, 10 mol %), TEMPO (47 mg, 0.30 mmol) and LiOt-Bu (48 mg, 0.6 mmol) were placed 
in a 25 mL Schlenk tube. The tube was degassed and purged with N2 three times. Dt-BEDA 
(143) (13 µL, 20 mol %), bromocyclohexane (58b) (74 µL, 0.6 mmol) and 1,4-dioxane (1.5 
mL) were then added, and the mixture was stirred at 120 °C for 16 h. After cooling to ambient 
temperature, CH2Cl2 (2 mL) was added. No conversion was observed by GCMS and 1H NMR 
analysis of the crude reaction mixture. Starting material 1a (80 mg, 98%) and TEMPO (45 mg, 
96%) were reisolated by column chromatography on silica gel (n-hexane/EtOAc: 200/1→1/1). 
 
(b) 
N-(2-Fluorophenyl)-9-iso-propyl-9H-purin-6-amine (134a) (81 mg, 0.30 mmol), [(DME)NiCl2] 
(6.6 mg, 10 mol %), BHT (66 mg, 0.30 mmol) and LiOt-Bu (48 mg, 0.6 mmol) were placed in 
a Schlenk tube. The tube was degassed and purged with N2 three times. Dt-BEDA (143) (13 
µL, 20 mol %), bromocyclohexane (58b) (74 µL, 0.6 mmol) and 1,4-dioxane (1.5 mL) were 
then added, and the mixture was stirred at 120 °C for 16 h. At ambient temperature, CH2Cl2 (2 
mL) was added, and the reaction mixture was transferred into a round flask with CH2Cl2 and 
concentrated under reduced pressure. Purification by column chromatography on silica gel (n-
hexane/EtOAc: 2/1→1/1) to afford 135ab (55 mg, 52%). 
 
(c) 
N-(2-Fluorophenyl)-9-iso-propyl-9H-purin-6-amine (134a) (81 mg, 0.30 mmol), [(DME)NiCl2] 
(6.6 mg, 10 mol %), Galvinoxyl (127 mg, 0.30 mmol) and LiOt-Bu (48 mg, 0.6 mmol) were 
placed in a Schlenk tube. The tube was degassed and purged with N2 three times. Dt-BEDA 
(143) (13 µL, 20 mol %), bromocyclohexane (58b) (74 µL, 0.6 mmol) and 1,4-dioxane (1.5 
mL) were then added, and the mixture was stirred at 120 °C for 16 h. After cooling to ambient 
temperature, CH2Cl2 (2.0 mL) was added. Trace conversion was observed by GCMS analysis 
of the crude reaction mixture. 







N-(2-Fluorophenyl)-9-iso-propyl-9H-purin-6-amine (134a) (81 mg, 0.30 mmol), [(DME)NiCl2] 
(6.6 mg, 10 mol %) and LiOt-Bu (48 mg, 0.6 mmol) were placed in a 25 mL Schlenk tube. The 
tube was degassed and purged with N2 three times. Dt-BEDA (143) (13 µL, 20 mol %), 6-
bromohexene (58n) (98 mg, 0.6 mmol) and 1,4-dioxane (1.5 mL) were then added, and the 
mixture was stirred at 120 °C for 16 h. At ambient temperature, CH2Cl2 (2 mL) was added, and 
the reaction mixture was transferred into a round flask with CH2Cl2 and concentrated under 
reduced pressure. Isolation by GPC (CHCl3) yielded 135an (32 mg, 30%) and 135an’ (26 mg, 
25%) as colorless oils. 
 
N-[2-Fluoro-6-(hex-5-en-1-yl)phenyl]-9-iso-propyl-9H-purin-6-amine (135an):  
1H NMR (300 MHz, CDCl3) δ = 8.33 (s, 1H), 7.78 (s, 1H), 7.71 (br s, 1H), 7.18 (ddd, J = 8.1, 
7.2, 5.5 Hz, 1H), 7.03 (d, J = 7.2 Hz, 1H), 6.97 (ddd, J = 9.6, 8.1, 1.5 Hz, 1H), 5.59 (ddt, J = 
16.9, 10.2, 6.6 Hz, 1H), 4.83 (dd, J = 17.1, 1.7 Hz, 1H), 4.78 (dd, J = 10.1, 1.7 Hz, 1H), 4.75 
(hept, J = 6.9 Hz, 1H), 2.60 (t, J = 7.8 Hz, 2H), 1.88 (q, J = 7.1 Hz, 2H), 1.54 (d, J = 6.8 Hz, 
6H), 1.52–1.42 (m, 2H), 1.26 (p, J = 7.5 Hz, 2H).  
13C NMR (125 MHz, CDCl3) δ = 158.7 (Cq, 1JC-F = 247.6 Hz), 153.9 (Cq), 152.7 (CH), 149.4 
(Cq), 142.9 (Cq), 138.4 (CH), 138.1(CH), 128.1 (CH, 3JC-F = 8.5 Hz), 124.8 (CH, 4JC-F = 3.2 Hz), 
123.6 (Cq, 2JC-F = 12.9 Hz), 120.3 (Cq), 114.3 (CH2), 113.5 (CH, 2JC-F = 20.6 Hz), 47.2 (CH), 
33.5 (CH2), 31.5 (CH2), 29.6 (CH2), 28.6 (CH2), 22.7 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -119.4 (dd, J = 9.5, 5.5 Hz).  
IR (neat): 3198, 2977, 2930, 1612, 1470, 1227, 668 cm-1.  
MS (ESI) m/z (relative intensity) 354 (100) [M+H+].  






N-[2-(Cyclopentylmethyl)-6-fluorophenyl]-9-iso-propyl-9H-purin-6-amine (135an’):  
1H NMR (300 MHz, CDCl3) δ = 8.34 (s, 1H), 7.75 (s, 1H), 7.58 (s, 1H), 7.17 (ddd, J = 8.1, 7.1, 
5.3 Hz, 1H), 7.04 (d, J = 7.1 Hz, 1H), 6.97 (ddd, J = 9.6, 8.1, 1.5 Hz, 1H), 4.79 (hept, J = 6.9 
Hz, 1H), 2.61 (d, J = 7.4 Hz, 2H), 2.12–1.87 (m, 1H), 1.68–1.40 (m, 10H), 1.39–1.32 (m, 2H), 
1.11–0.93 (m, 2H).  
13C NMR (125 MHz, CDCl3) δ = 158.7 (Cq, 1JC-F = 247.7 Hz), 153.8 (Cq), 152.7 (CH), 149.5 
(Cq), 142.5 (Cq), 138.1(CH), 127.9 (CH, 3JC-F = 8.4 Hz), 125.3 (CH, 4JC-F = 3.0 Hz), 123.68 (Cq, 
2JC-F = 13.0 Hz), 120.3 (Cq), 113.4 (CH, 2JC-F = 20.6 Hz), 47.2 (CH), 40.8 (CH), 37.5 (CH2), 
32.6 (CH2), 24.8 (CH2), 22.8 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -119.2 (dd, J = 9.5, 5.5 Hz).  
IR (neat): 3181, 2948, 2867, 1608, 1468, 1225, 649 cm-1.  
MS (ESI) m/z (relative intensity) 354 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C20H25FN5 [M+H+] 354.2089, found 354.2090. 
 
H/D Exchange Experiments with [D]5-134c as the Substrate: 
 
Substrate [D]5-134c (77 mg, 0.3 mmol), [(DME)NiCl2] (6.6 mg, 10 mol %) and LiOt-Bu (48 
mg, 0.60 mmol) were placed in a Schlenk tube. The tube was degassed and purged with N2 
three times. Dt-BEDA (143) (13 µL, 20 mol %), bromocyclohexane (58b) (41 µL, 0.33 mmol) 
and 1,4-dioxane (1.5 mL) were then added, and the mixture was stirred at 120 °C for 1.5 h. At 
ambient temperature, CH2Cl2 (2.0 mL) was added, and the reaction mixture was transferred 
into a round flask with CH2Cl2 and concentrated under reduced pressure. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 2/1→1/1) to afford [D]4-135cb (65 mg, 














KIE Experiments with 134c and [D]5-134c as the Substrates 
 
Independent reactions of 134c or [D]5-134c with 58b were performed to determine the 
corresponding KIE value. Following general procedure C, 134c (76 mg, 0.3 mmol) or [D]5-
134c (77 mg, 0.3 mmol) were reacted with 58b (41µL, 0.33 mmol). After cooling to ambient 
temperature, the GC conversions were determined using n-dodecane (51 mg, 0.30 mmol) as 
internal standard: 
T [min] 25 30 35 40 
5ca/% 28 36 43 53 




y = 1.64x - 13.3
R² = 0.9947

































Removal of the THP Group  
 
 
N-(2-Cyclohexyl-6-fluorophenyl)-9H-purin-6-amine (148): To a solution of 135mb (79mg, 
0.20 mmol) in MeOH (1.0 mL), aqueous HCl (1N, 1.0 mL) was added and stirred for 3 h at 
23 °C. The reaction mixture was poured into EtOAc (10 mL), and then saturated aqueous 
Na2CO3 solution was added until the pH was adjusted to 8. The aqueous layer was extracted 
with EtOAc (3 × 10 mL), the combined organic layers were dried with Na2SO4 and concentrated 
in vacuo to afford 148 (62 mg, 99%) as a white solid.  
M. p. = 270 °C.  
1H NMR (500 MHz, DMSO-d6) δ = 9.14 (br s, 1H), 8.16 (s, 1H), 8.10 (s, 1H), 7.28 (ddd, J = 
8.0, 7.8, 5.6 Hz, 1H), 7.15 (dd, J = 7.8, 1.4 Hz, 1H), 7.05 (ddd, J = 9.7, 8.1, 1.4 Hz, 1H), 3.34 
(br s, 1H), 2.84 (tt, J = 12.1, 3.1 Hz, 1H), 1.79–1.56 (m, 5H), 1.43–1.24 (m, 2H), 1.23–1.10 (tt, 
J = 11.6, 5.9 Hz, 3H).  
13C NMR (125 MHz, DMSO-d6) δ = 158.6 (Cq, 1JC-F = 245.5 Hz), 153.6 (Cq), 151.9 (CH), 
151.5 (Cq), 147.9 (Cq), 140.1 (CH), 127.6 (CH, 3JC-F = 8.8 Hz), 124.2 (Cq, 2JC-F = 13.0 Hz), 
121.7 (CH, 4JC-F = 3.1 Hz), 118.2 (Cq), 112.7 (CH, 2JC-F = 21.0 Hz), 38.1 (CH, 4JC-F = 2.1 Hz), 
32.9 (CH2), 26.4 (CH2), 25.5 (CH2).  
19F NMR (471 MHz, DMSO-d6) δ = -118.9 (dd, J = 9.8, 5.6 Hz).  
IR (neat): 3197, 2929, 2850, 1611, 1591, 1246, 649 cm-1.  
MS (ESI) m/z (relative intensity) 312 (100) [M+H+].  





5.3.3 Characterization Data: Nickel-Catalyzed C–H Alkynylation of Anilines 
 
N-{2-Methyl-6-[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136aa): The general 
procedure E was followed using substrate 123a (93 mg, 0.50 mmol) and 
(bromoethynyl)triisopropylsilane (61a) (392 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 136aa (124 mg, 68%) as a yellow solid. 
M. p. = 96–97 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.31 (d, J = 4.8 Hz, 2H), 7.39 (dd, J = 7.6, 1.2 Hz, 1H), 7.23 
(dd, J = 7.6, 1.2 Hz, 1H), 7.11 (dd, J = 7.6, 7.6 Hz, 1H), 7.00 (s, 1H), 6.60 (t, J = 4.8 Hz, 1H), 
2.26 (s, 3H), 1.02–0.99 (m, 21H).  
13C NMR (125 MHz, CDCl3) δ = 161.4 (Cq), 158.1 (CH), 138.5 (Cq), 136.2 (Cq), 131.0 (CH), 
130.6 (CH), 126.1 (CH), 121.5 (Cq), 111.9 (CH), 104.0 (Cq), 95.8 (Cq), 18.7 (CH3), 18.5 (CH3), 
11.2 (CH).  
IR (neat): 3233, 2940, 2862, 2142, 1574, 1528, 1457, 1404, 1246, 882 cm-1.  
MS (EI) m/z (relative intensity) 365 (20) [M+], 322 (100).  
HR-MS (EI) m/z calcd for C22H31N3Si [M+] 365.2287, found 365.2293. 
Analytical data for compound 136aa was consistent with the literature.[165] 
 
 
N-{2-Methyl-6-[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136aa): The general 
procedure E was followed using substrate 123a (93 mg, 0.50 mmol) and 
(iodoethynyl)triisopropylsilane (61a’) (462 mg, 1.50 mmol). Isolation by column 







N-{2-Methyl-6-[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136aa): The general 
procedure E was followed using substrate 123a (93 mg, 0.50 mmol) and 
(chloroethynyl)triisopropylsilane (61a’’) (325 mg, 1.50 mmol). Isolation by column 
chromatography (n-hexane/EtOAc: 10/1) yielded 136aa (97 mg, 53%) as a yellow solid. 
 
 
N-{2-Fluoro-6-[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136ba): The general 
procedure E was followed using substrate 123b (95 mg, 0.5 mmol) and alkyne 61a (392 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 136ba (120 
mg, 65%) as a yellow solid.  
M. p. = 98–99 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.36 (d, J = 4.8 Hz, 2H), 7.69 (s, 1H), 7.33–7.28 (m, 1H), 
7.16–7.05 (m, 2H), 6.66 (t, J = 4.8 Hz, 1H).  
13C NMR (125 MHz, CDCl3) δ = 160.7 (Cq), 157.4 (Cq, 1JC-F = 249.3 Hz), 157.9 (CH), 128.5 
(CH, 4JC-F= 3.3 Hz), 128.4 (Cq, 2JC-F = 13.1 Hz), 126.1 (CH, 3JC-F= 8.7 Hz), 122.2 (Cq, 3JC-F= 
3.0 Hz), 116.6 (CH, J = 20.7 Hz), 112.6 (CH), 102.4 (Cq, 4JC-F = 4.1 Hz), 97.7 (Cq), 18.5 (CH3), 
11.1 (CH).  
19F NMR (283 MHz, CDCl3) δ = -117.3 (dd, J = 8.8, 6.5 Hz).  
IR (neat): 3229, 2941, 2862, 2157, 1583, 1446, 1413, 996, 795, 665 cm-1.  
MS (EI) m/z (relative intensity) 369 (10) [M+], 326 (100).  







N-{3-[(Triisopropylsilyl)ethynyl]-[1,1'-biphenyl]-2-yl}pyrimidin-2-amine (136da): The 
general procedure E was followed using substrate 123d (124 mg, 0.50 mmol) and alkyne 61a 
(392 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 
136da (109 mg, 51%) as a yellow solid.  
M. p. = 122–123 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.17 (d, J = 4.8 Hz, 2H), 7.56 (dd, J = 7.6, 1.7 Hz, 1H), 7.42 
– 7.30 (m, 3H), 7.30 – 7.08 (m, 4H), 6.89 (s, 1H), 6.49 (t, J = 4.8 Hz, 1H), 1.03 – 0.97 (m, 21H).  
13C NMR (75 MHz, CDCl3) δ = 160.8 (Cq), 157.7 (CH), 139.5 (Cq), 138.9 (Cq), 137.1 (Cq), 
132.7 (CH), 130.9 (CH), 128.6 (CH), 128.1 (CH), 127.1 (CH), 126.0 (CH), 122.0 (Cq), 111.8 
(CH), 104.1 (Cq), 96.2 (Cq), 18.5 (CH), 11.1 (CH3).  
IR (neat): 3057, 2942, 2863, 2157, 1570, 1512, 1430, 1406, 880, 757 cm-1.  
MS (EI) m/z (relative intensity) 427 (30) [M+], 384 (100).  
HR-MS (EI) m/z calcd for C27H33N3Si [M+] 427.2444, found 427.2454. 
 
 
N-{5-Methyl-2-[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136fa): The general 
procedure E was followed using substrate 123f (93 mg, 0.50 mmol) and alkyne 61a (392 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 123fa (110 
mg, 60%) as a colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 8.42 (d, J = 4.8 Hz, 2H), 8.37 (s, 1H), 7.99 (br s, 1H), 7.34 (d, 
J = 7.8 Hz, 1H), 6.75 (d, J = 7.8 Hz, 1H), 6.71 (t, J = 4.8 Hz, 1H), 2.38 (s, 3H), 1.17–1.13 (m, 
21H).  
13C NMR (75 MHz, CDCl3) δ 159.9 (Cq), 157.8 (CH), 141.0 (Cq), 139.9 (Cq), 131.9 (CH), 
122.2 (CH), 118.3 (CH), 112.9 (CH), 109.1 (Cq), 103.0 (Cq), 97.3 (Cq), 22.1 (CH3), 18.7 (CH3), 
11.3 (CH).  
IR (neat): 3377, 2941, 2864, 2143, 1576, 1526, 1442, 1248, 989, 795 cm-1.  





HR-MS (EI) m/z calcd for C22H31N3Si [M+] 365.2287, found 365.2280.  
The analytical data for compound 136fa was consistent with the literature.[165] 
 
 
N-{5-Methoxy-2-[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136ga): The 
general procedure E was followed using substrate 123g (101 mg, 0.50 mmol) and alkyne 61a 
(392 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 
136ga (113 mg, 59%) as a colorless liquid. 
1H NMR (300 MHz, CDCl3) δ = 8.43 (d, J = 4.8 Hz, 2H), 8.32 (d, J = 2.5 Hz, 1H), 8.08 (s, 
1H), 7.37 (d, J = 8.5 Hz, 1H), 6.72 (t, J = 4.8 Hz, 1H), 6.48 (dd, J = 8.5, 2.5 Hz, 1H), 3.84 (s, 
3H), 1.27–0.93 (m, 21H). 
13C NMR (75 MHz, CDCl3) δ = 160.6 (Cq), 159.8 (Cq), 157.8 (CH), 142.6 (Cq), 133.0 (CH), 
113.0 (CH), 106.9 (CH), 104.3 (Cq), 103.6 (CH), 102.9 (Cq), 96.5 (Cq), 55.4 (CH3), 18.7 (CH3), 
11.3 (CH).  
IR (neat): 3376, 2941, 2863, 2141, 1576, 1523, 1250, 989, 794, 675 cm-1.  
MS (EI) m/z (relative intensity) 381 (30) [M+], 338 (100).  
HR-MS (EI) m/z calcd for C22H31N3OSi [M+] 381.2236, found 381.2231.  




The general procedure E was followed using substrate 123h (120 mg, 0.50 mmol) and alkyne 
61a (392 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 15/1) 
yielded 136ha (136 mg, 65%) as a yellow solid.  





1H NMR (300 MHz, CDCl3) δ = 9.00 (s, 1H), 8.47 (d, J = 4.8 Hz, 2H), 8.15 (s, 1H), 7.53 (d, J 
= 8.8 Hz, 1H), 7.15 (ddd, J = 8.8, 1.7, 0.7 Hz, 1H), 6.79 (t, J = 4.8 Hz, 1H), 1.43 – 0.83 (m, 
21H). 
13C NMR (75 MHz, CDCl3) δ = 159.6 (Cq), 157.9 (CH), 141.6 (Cq), 132.2 (CH), 131.1 (q, 2J = 
32.9 Hz, Cq), 124.0 (q, 1J = 272.8 Hz, Cq), 117.3 (q, 3J = 4.0 Hz, CH), 114.6 (Cq), 114.3 (Cq, 3J 
= 4.0 Hz, CH), 113.7 (CH), 101.4 (Cq), 101.0 (Cq), 18.7 (CH), 11.2 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -62.8 (s).  
IR (neat): 3372, 2943, 2965, 2148, 1580, 1533, 1446, 1327, 1124, 774 cm-1.  
MS (EI) m/z (relative intensity) 419 (15) [M+], 376 (100).  
HR-MS (EI) m/z calcd for C22H28F3N3Si [M+] 419.2005, found 419.1999. 
 
 
N-{5-Chloro-2-[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136qa): The general 
procedure E was followed using substrate 123q (103 mg, 0.50 mmol) and alkyne 61a (392 mg, 
1.5 mmol). Isolation by column chromatography (n-hexane/EtOAc: 25/1) yielded 136qa (120 
mg, 62%) as a colorless liquid.  
1H NMR (400 MHz, CDCl3) δ = 8.73 (d, J = 2.1 Hz, 1H), 8.45 (d, J = 4.8 Hz, 2H), 8.07 (s, 
1H), 7.35 (d, J = 8.2 Hz, 1H), 6.89 (dd, J = 8.2, 2.1 Hz, 1H), 6.77 (t, J = 4.8 Hz, 1H), 1.24–1.09 
(m, 21H).  
13C NMR (100 MHz, CDCl3) δ = 159.5 (Cq), 157.9 (CH), 142.1 (Cq), 135.3 (Cq), 132.7 (CH), 
121.1 (CH), 117.5 (CH), 113.5 (CH), 109.9 (Cq), 101.8 (Cq), 99.3 (Cq), 18.7 (CH3), 11.3 (CH).  
IR (neat): 3375, 2942, 2864, 2146, 1574, 1515, 1443, 1243, 795, 689 cm-1.  
MS (EI) m/z (relative intensity) 385 (20) [M+], 342 (100).  







N-{5-Bromo-2-[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136ua): The general 
procedure E was followed using substrate 123u (125 mg, 0.50 mmol) and alkyne 61a (392 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 136ua (122 
mg, 57%) as a yellow solid.  
M. p. = 40–41 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.89 (d, J = 2.0 Hz, 1H), 8.45 (d, J = 4.8 Hz, 2H), 8.05 (s, 
1H), 7.29 (d, J = 8.2 Hz, 1H), 7.05 (dd, J = 8.2, 2.0 Hz, 1H), 6.76 (t, J = 4.8 Hz, 1H), 1.38–0.93 
(m, 21H).  
13C NMR (75 MHz, CDCl3) δ = 159.4 (Cq), 157.8 (CH), 142.1 (Cq), 132.8 (CH), 123.9 (CH), 
123.6 (Cq), 120.3 (CH), 113.5 (CH), 110.3 (Cq), 101.8 (Cq), 99.6 (Cq), 18.7 (CH3), 11.2 (CH). 
IR (neat): 3365, 2940, 2863, 2146, 1576, 1555, 1444, 1243, 882, 668 cm-1. 
MS (EI) m/z (relative intensity) 429 (20) [M+], 386 (100).  




The general procedure E was followed using substrate 123v (138 mg, 0.50 mmol) and alkyne 
61a (392 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) 
yielded 136va (103 mg, 45%) as a colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 9.09 (d, J = 1.6 Hz, 1H), 8.39 (d, J = 4.8 Hz, 2H), 8.09 (s, 
1H), 7.94 – 7.80 (m, 2H), 7.65 – 7.52 (m, 2H), 7.50 – 7.42 (m, 2H), 7.35 (dd, J = 8.0, 1.6 Hz, 





13C NMR (75 MHz, CDCl3) δ = 196.0 (Cq), 159.6 (Cq), 157.8 (CH), 141.1 (Cq), 137.8 (Cq), 
137.4 (Cq), 132.4 (CH), 131.7 (CH), 130.2 (CH), 128.1 (CH), 122.4 (CH), 119.5 (CH), 115.3 
(Cq), 113.4 (CH), 102.0 (Cq), 101.4 (Cq), 18.7 (CH), 11.2 (CH3).  
IR (neat): 3379, 2942, 2890, 2145, 1659, 1574, 1443, 1236, 881, 649 cm-1.  
MS (EI) m/z (relative intensity) 455 (20) [M+], 412 (100). 
HR-MS (EI) m/z calcd for C28H33N3OSi [M+] 455.2393, found 455.2384. 
 
 
tert-Butyl 3-(pyrimidin-2-ylamino)-4-[(triisopropylsilyl)ethynyl]benzoate (136ja): The 
general procedure E was followed using substrate 123j (136 mg, 0.50 mmol) and alkyne 61a 
(392 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 
136ja (127 mg, 56%) as a colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 9.21 (d, J = 1.6 Hz, 1H), 8.45 (d, J = 4.8 Hz, 2H), 8.02 (s, 
1H), 7.53 (dd, J = 8.0, 1.6 Hz, 1H), 7.45 (dd, J = 8.0, 0.5 Hz, 1H), 6.75 (s, 1H), 1.59 (s, 9H), 
1.20–1.12 (m, 21H).  
13C NMR (75 MHz, CDCl3) δ = 165.4 (Cq), 159.7 (Cq), 157.9 (CH), 141.1 (Cq), 132.5 (Cq), 
131.7 (CH), 121.9 (CH), 118.6 (CH), 115.4 (Cq), 113.3 (CH), 102.2 (Cq), 101.0 (Cq), 81.1 (Cq), 
28.1 (CH3), 18.7 (CH), 11.2 (CH3).  
IR (neat): 3380, 2942, 2865, 2146, 1713, 1575, 1523, 1444, 1292, 766 cm-1.  
MS (EI) m/z (relative intensity) 451 (15) [M+], 352 (100).  









and alkyne 61a (392 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
10/1) yielded 136wa (110 mg, 56%) as a colorless liquid.  
1H NMR (400 MHz, CDCl3) δ = 8.41 (d, J = 4.8 Hz, 2H), 8.08 (d, J = 2.5 Hz, 1H), 8.04 (br s, 
1H), 7.32 (d, J = 8.6 Hz, 1H), 6.69 (t, J = 4.8 Hz, 1H), 6.29 (dd, J = 8.6, 2.5 Hz, 1H), 3.00 (s, 
6H), 1.17–1.16 (m, 21H).  
13C NMR (100 MHz, CDCl3) δ = 160.1 (Cq), 157.7 (CH), 151.2 (Cq), 142.1 (Cq), 132.7 (CH), 
112.6 (CH), 105.5 (CH), 104.1 (Cq), 101.5 (CH), 99.7 (Cq), 95.1 (Cq), 40.3 (CH3), 18.8 (CH3), 
11.4 (CH3).  
IR (neat): 3377, 2941, 2863, 2134, 1615, 1573, 1527, 1399, 1284, 793 cm-1.  
MS (ESI) m/z (relative intensity) 395 [M+H+].  
HR-MS (ESI) m/z calcd for C23H35N4Si [M+H+] 395.2626, found 395.2624. 
 
 
The general procedure E was followed using substrate 123l (95 mg, 0.50 mmol) and alkyne 
61a (392 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 50/1) 
yielded 136la (96 mg, 52%) as a colorless liquid and 136la’(30 mg, 11%) as a white solid.  
N-{4-Fluoro-2-[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136la):  
1H NMR (600 MHz, CDCl3) δ = 8.47 (dd, J = 9.2, 5.2 Hz, 1H), 8.41 (d, J = 4.8 Hz, 2H), 7.86 
(br s, 1H), 7.13 (dd, J = 8.1, 3.0 Hz, 1H), 7.04 (ddd, J = 9.2, 8.1, 3.0 Hz, 1H), 6.72 (t, J = 4.8 
Hz, 1H), 1.23–1.07 (m, 21H).  
13C NMR (125 MHz, CDCl3) δ = 160.3 (Cq), 159.7 (Cq, 1JC-F = 235 Hz), 157.7 (CH), 137.5 (Cq), 
119.6 (CH, 3JC-F = 7.7 Hz), 118.1 (CH, 2JC-F = 24.0 Hz), 116.3 (CH, 2JC-F = 22.1 Hz), 113.2 (Cq, 
3JC-F = 9.2 Hz), 112.9 (CH), 101.6 (Cq), 99.4 (Cq), 18.8 (CH3), 11.4 (CH).  
19F NMR (283 MHz, CDCl3) δ = -121.9 (ddd, J = 8.4, 8.4, 5.4 Hz).  
IR (neat): 3382, 2943, 2865, 2144, 1569, 1523, 1449, 1417, 882, 663 cm-1.  





HR-MS (EI) m/z calcd for C21H28FN3Si [M+] 369.2037, found 369.2032. 
 
N-{4-Fluoro-2,6-bis[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136la’): 
M. p. = 99–100 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.31 (d, J = 4.8 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 6.88 (br s, 
1H), 6.62 (t, J = 4.8 Hz, 1H), 0.97–0.98 (m, 42H).  
13C NMR (100 MHz, CDCl3) δ = 160.9 (Cq), 159.2 (Cq, 1JC-F = 246.2 Hz), 157.8 (CH), 137.9 
(Cq, 4JC-F = 3.0 Hz), 123.2 (Cq, 3JC-F = 10.5 Hz), 119.9 (CH, 2JC-F = 23.8 Hz), 112.5 (CH), 102.2 
(Cq, 4JC-F = 2.9 Hz), 98.1 (Cq), 18.5 (CH3), 11.1 (CH).  
19F NMR (376 MHz, CDCl3) δ = -116.6 (t, J = 8.5 Hz).  
IR (neat): 3201, 2943, 2864, 2156, 1577, 1514, 1439, 1404, 1004, 882 cm-1.  
MS (ESI) m/z (relative intensity) 550 [M+H+].  
HR-MS (ESI) m/z calcd for C32H49FN3Si2 [M+H+] 550.3444, found 550.3440. 
 
 
The general procedure E was followed using substrate 123c (86 mg, 0.5 mmol) and alkyne 61a 
(392 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 
136ca (74 mg, 42%) as a colorless liquid and 136ca’ (50mg, 19%) as a white solid.  
N-{2-[(Triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136ca):  
1H NMR (300 MHz, CDCl3) δ = 8.56 (dd, J = 8.4, 1.0 Hz, 1H), 8.43 (d, J = 4.8 Hz, 2H), 8.06 
(br s, 1H), 7.46 (dd, J = 7.7, 1.6 Hz, 1H), 7.34 (ddd, J = 8.4, 7.6, 1.6 Hz, 1H), 6.93 (ddd, J = 
7.7, 7.6, 1.0 Hz, 1H), 6.72 (t, J = 4.8 Hz, 1H), 1.30 – 1.02 (m, 21H). 
13C NMR (75 MHz, CDCl3) δ 159.9 (Cq), 157.8 (CH), 141.1 (Cq), 132.1 (CH), 129.4 (CH), 
121.1 (CH), 117.7 (CH), 113.0 (CH), 111.8 (Cq), 102.7 (Cq), 98.1 (Cq), 18.7 (CH3), 11.3 (CH).  
IR (neat): 3379, 2942, 2864, 2145, 1715, 1576, 1518, 1437, 989, 752 cm-1.  





HR-MS (EI) m/z calcd for C21H29N3Si [M+] 351.2131, found 351.2129. 
 
N-{2,6-Bis[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136ca’):  
M. p. = 87–88 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.33 (d, J = 4.8 Hz, 2H), 7.48 (d, J = 7.8 Hz, 2H), 7.10 (t, J = 
7.8 Hz, 1H), 7.04 (br s, 1H), 6.63 (t, J = 4.8 Hz, 1H), 0.98–0.97 (m, 42H).  
13C NMR (100 MHz, CDCl3) δ = 160.7 (Cq), 157.8 (CH), 141.4 (Cq), 133.3 (CH), 125.2 (CH), 
121.1 (Cq), 112.6, 103.3 (Cq), 96.9 (Cq), 18.6 (CH3), 11.2 (CH). 
IR (neat): 3379, 2941, 2864, 2147, 1576, 1518, 1438, 1407, 981, 882 cm-1.  
MS (EI) m/z (relative intensity) 531 (25) [M+], 488 (100).  
HR-MS (EI) m/z calcd for C32H49N3Si2 [M +] 531.3465, found 531.3463. 
The analytical data for compound 136ca’ was consistent with the literature.[165] 
 
 
N-{2-[(Triisopropylsilyl)ethynyl]naphthalen-1-yl}pyrimidin-2-amine (136sa): The general 
procedure E was followed using substrate 123s (111 mg, 0.50 mmol) and alkyne 61a (392 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 136sa (169 
mg, 84%) as a yellow solid.  
M. p. = 189–190 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.28 (d, J = 4.8 Hz, 2H), 8.01(dd, J = 6.8, 2.5 Hz, 1H), 7.82 
(dd, J = 7.2, 2.5 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.55 (br s, 1H), 
7.46 (ddd, J = 7.2, 6.8, 2.5 Hz, 1H), 7.43 (ddd, J = 7.2, 6.8, 2.5 Hz, 1H), 6.60 (t, J = 4.8 Hz, 
1H), 1.02 (s, 21H). 
13C NMR (75 MHz, CDCl3) δ = 162.1 (Cq), 158.1 (CH), 137.2 (Cq), 134.0 (Cq), 130.7 (Cq), 
129.0 (CH), 128.1 (CH), 126.8 (CH), 126.7 (CH), 126.6 (CH), 124.0 (CH), 118.7 (Cq), 112.1 
(CH), 104.4 (Cq), 97.3 (Cq), 18.6 (CH), 11.2 (CH3).  





MS (EI) m/z (relative intensity) 401 (30) [M+], 358 (100).  




The general procedure E was followed using substrate 123n (102 mg, 0.5 mmol) and alkyne 
61a (392 mg, 1.5 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 
136na (136 mg, 71%) as a yellow solid.  
M. p. = 95–96 °C.  
1H NMR (500 MHz, CDCl3) δ = 8.29 (d, J = 4.8 Hz, 2H), 7.06 (dd, J = 8.5, 2.8 Hz, 1H), 6.96–
6.94 (m, 2H), 6.60 (t, J = 4.8 Hz, 1H), 2.24 (s, 3H), 1.12–0.89 (m, 21H).  
13C NMR (75 MHz, CDCl3) δ = 161.1 (d, 1JC-F = 245.6 Hz, Cq), 161.5 (Cq), 158.1 (CH), 139.0 
(d, 3JC-F = 8.9 Hz, Cq), 134.8 (d, 4JC-F = 2.9 Hz, Cq), 123.4 (d, 3JC-F = 10.6 Hz, Cq), 117.9 (d, 
2JC-F = 22.1 Hz, CH), 116.9 (d, 2JC-F = 23.6 Hz, CH), 112.0 (CH), 102.8 (d, 4JC-F = 3.2 Hz, Cq), 
96.9 (Cq), 18.9 (d, 4JC-F = 1.4 Hz, CH3), 18.5 (CH3), 11.1 (CH). 
19F NMR (283 MHz, CDCl3) δ = -116.4 (t, J = 8.8 Hz).  
IR (neat): 3372, 2944, 2865, 2151, 1580, 1533, 1446, 1327, 1123, 795 cm-1.  
MS (EI) m/z (relative intensity) 383 (15) [M+], 340 (100).  
HR-MS (EI) m/z calcd for C22H30FN3Si [M+] 383.2193, found 383.2196. 
 
 
N-{2,4-Difluoro-6-[(triisopropylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136oa): The 
general procedure E was followed using substrate 123o (104 mg, 0.50 mmol) and alkyne 61a 
(392 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 





M. p. = 102–103 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.32 (d, J = 4.8 Hz, 2H), 7.78 (br s, 1H), 7.04 (ddd, J = 8.2, 
2.9, 1.3 Hz, 1H), 6.89 (ddd, J = 9.8, 8.4, 2.9 Hz, 1H), 6.64 (d, J = 4.8 Hz, 1H), 0.98–0.97 (m, 
21H).  
13C NMR (75 MHz, CDCl3) δ = 160.8 (Cq) 159.8 (Cq, d, JC-F = 233.5, 13.0 Hz), 158.0 (CH), 
157.9 (Cq, d, JC-F = 252.2, 13.5 Hz), 125.0 (Cq, dd, JC-F = 13.3, 4.4 Hz), 123.5 (Cq, dd, JC-F = 
11.5, 4.3 Hz), 115.0 (CH, dd, JC-F = 23.2, 4.0 Hz), 112.5 (CH), 105.3 (CH, dd, JC-F = 26.4, 24.8 
Hz), 101.4 (Cq, dd, JC-F = 3.4, 3.3 Hz), 99.1 (Cq), 18.4 (CH), 11.0 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -(113.1–113.3) (m).  
IR (neat): 3224, 2961, 2942, 2863, 1584, 1532, 1446, 1128, 992, 883 cm-1.  
MS (EI) m/z (relative intensity) 387 (10) [M+], 344 (100).  
HR-MS (EI) m/z calcd for C21H27F2N3Si [M+] 387.1942, found 387.1946. 
 
 
The general procedure E was followed using substrate 123x (89 mg, 0.50 mmol) and alkyne 
61a (392 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 50/1) 
yielded 136xa (80 mg, 45%) as a colorless liquid and 136xa’ (28 mg, 10%) as a white solid. 
N-{2-[(Triisopropylsilyl)ethynyl]thiophen-3-yl}pyrimidin-2-amine (136xa):  
1H NMR (600 MHz, CDCl3) δ = 8.40 (d, J = 4.8 Hz, 2H), 7.97 (d, J = 5.5 Hz, 1H), 7.54 (br s, 
1H), 7.14 (d, J = 5.5 Hz, 1H), 6.70 (t, J = 4.8 Hz, 1H), 1.25–0.97 (m, 21H).  
13C NMR (100 MHz, CDCl3) δ = 159.1 (Cq), 158.1 (CH), 143.0 (Cq), 125.3 (CH), 121.3 (CH), 
112.9 (CH), 103.9 (Cq), 101.0 (Cq), 97.3 (Cq), 18.7 (CH3), 11.3 (CH).  
IR (neat): 3412, 3230, 2941, 2864, 2142, 1586, 1509, 1444, 1414, 882 cm-1.  
MS (ESI) m/z (relative intensity) 358 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C19H28N3SSi [M+H+] 358.1768, found 358.1768. 





M. p. = 100–101 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.35 (d, J = 4.8 Hz, 2H), 7.32 (s, 1H), 6.90 (br s, 1H), 6.64 (t, 
J = 4.8 Hz, 1H), 0.99–0.97 (m, 42H).  
13C NMR (75 MHz, CDCl3) δ = 160.4 (Cq), 158.0 (CH), 141.5 (Cq), 128.6 (CH), 120.7 (Cq), 
114.3 (Cq), 112.6 (CH), 101.2 (CH), 99.2 (CH), 97.1 (CH), 94.5 (CH), 18.5 (CH3), 18.5 (CH3), 
11.1 (CH), 11.1 (CH).  
IR (neat): 3398, 2942, 2864, 2864, 2131, 1573, 1576, 1549, 1422, 669 cm-1.  
MS (ESI) m/z (relative intensity) 538 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C30H48N3SSi2 [M+H+] 538.3102, found 538.3095. 
 
 
N-{2-Methyl-6-[(tri-n-butylsilyl)ethynyl]phenyl}pyrimidin-2-amine (136ab): The general 
procedure E was followed using substrate 123a (93 mg, 0.50 mmol) and alkyne 61b (455 mg, 
1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 136ab (101 
mg, 50%) as a brown solid.  
M. p. = 85–86 °C. 
1H NMR (400 MHz, CDCl3) δ = 8.32 (d, J = 4.8 Hz, 2H), 7.36 (dd, J = 7.6, 1.6 Hz, 1H), 7.22 
(dd, J = 7.6, 1.6 Hz, 1H), 7.10 (dd, J = 7.6, 7.6 Hz, 1H), 6.89 (s, 1H), 6.62 (t, J = 4.8 Hz, 1H), 
2.25 (s, 3H), 1.40–1.21 (m, 12H), 0.87–0.82 (m, 9H), 0.62–0.47 (m, 6H). 
13C NMR (100 MHz, CDCl3) δ = 161.4 (Cq), 158.1 (CH), 138.6 (Cq), 136.0 (Cq), 131.1 (CH), 
130.4 (CH), 123.0 (CH), 121.0 (CH), 112.0 (Cq), 103.1 (Cq), 98.0 (Cq), 26.4 (CH2), 26.0 (CH2), 
18.9 (CH3), 13.7 (CH3), 12.9 (CH2).  
IR (neat): 3223, 2955, 2921, 2869, 2153, 1577, 1521, 1463, 1409, 785 cm-1.  
MS (EI) m/z (relative intensity) 407 (60) [M+], 350 (100).  







N-{2-[(tert-Butyldimethylsilyl)ethynyl]-6-methylphenyl}pyrimidin-2-amine (136ac): The 
general procedure E was followed using substrate 123a (93 mg, 0.50 mmol) and alkyne 61c 
(455 mg, 1.50 mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 
136ac (100 mg, 62%) as a brown solid.  
M. p. = 149–150°C.  
1H NMR (300 MHz, CDCl3) δ = 8.33 (d, J = 4.8 Hz, 2H), 7.37 (ddd, J = 7.6, 1.6 Hz, 1H), 7.24 
(dd, J = 7.6, 1.6, Hz 1H), 7.19 (br s, 1H), 7.10 (dd, J = 7.6, 7.6 Hz, 1H), 6.61 (t, J = 4.8 Hz, 
1H), 2.26 (s, 3H), 0.85 (s, 9H), 0.05 (s, 6H). 
13C NMR (125 MHz, CDCl3) δ = 161.3 (Cq), 157.9 (CH), 138.6 (Cq), 136.0 (Cq), 131.0 (CH), 
130.3 (CH), 125.9 (CH), 121.1 (Cq), 111.9 (CH), 102.8 (Cq), 97.8 (Cq), 26.1 (CH3), 18.8 (CH3), 
16.5 (Cq), -4.6 (CH3).  
IR (neat): 3221, 2952, 2927, 2856, 2149, 1577, 1444, 1407, 1248, 836 cm-1.  
MS (EI) m/z (relative intensity) 323 (10) [M+], 266 (100).  




The general procedure E was followed using purine base 134a (136 mg, 0.50 mmol) and alkyne 
61a (261 mg, 1.00 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1 + 10% 
CH2Cl2) yielded 137aa (171 mg, 76%) as a white solid.  
M. p. = 107–108 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.42 (s, 1H), 7.92 (s, 1H), 7.83 (br s, 1H), 7.36–7.31 (m, 1H), 





13C NMR (76 MHz, CDCl3) δ = 157.8 (Cq, 1JC-F = 249.0 Hz), 153.0 (Cq), 152.5 (CH), 149.7 
(Cq), 138.2 (CH), 128.6 (CH, 4JC-F = 3.4 Hz), 127.4 (Cq, 3JC-F = 13.8 Hz), 127.0 (CH, 3JC-F = 8.7 
Hz), 123.3 (Cq, 4JC-F = 2.6 Hz), 120.9 (Cq), 116.6 (CH, 2J = 20.7 Hz), 102.2 (Cq, 4J = 4.0 Hz), 
97.9 (Cq), 47.0 (CH), 22.6 (CH3), 18.4 (CH3), 11.0 (CH).  
19F NMR (283 MHz, CDCl3) δ = -117.8 (dd, J = 9.3, 5.6 Hz).  
IR (neat): 3168, 2940, 2863, 2156, 1611, 1463, 1304, 1230, 985, 700 cm-1.  
MS (EI) m/z (relative intensity) 451 (15) [M+], 408 (100).  




The general procedure E was followed using purine base 5d (134 mg, 0.50 mmol) and alkyne 
61a (392 mg, 1.50 mmol) at 100 °C. Isolation by column chromatography (n-hexane/EtOAc: 
4/1) yielded 137da (145 mg, 65%) as a red solid.  
M. p. = 89–90 °C. 
1H NMR (600 MHz, CDCl3) δ = 8.64 (s, 1H), 8.56 (s, 1H), 8.49 (s, 1H), 7.83 (s, 1H), 7.37 (d, 
J = 7.8 Hz, 1H), 6.81 (dd, J = 7.8, 1.6 Hz, 1H), 4.85 (hept, J = 6.8 Hz, 1H), 2.41 (s, 3H), 1.61 
(d, J = 6.8 Hz, 6H), 1.20 – 1.12 (m, 21H).  
13C NMR (125 MHz, CDCl3) δ = 152.0 (CH), 151.9 (Cq), 149.2 (Cq), 140.1 (Cq), 139.8 (Cq), 
137.9 (CH), 132.1 (CH), 123.0 (CH), 121.4 (Cq), 119.6 (CH), 110.0 (Cq), 102.4 (Cq), 97.8 (Cq), 
47.1 (CH), 22.8 (CH3), 22.2 (CH3), 18.9 (CH), 11.4 (CH3).  
IR (neat): 3356, 2940, 2863, 2144, 1621, 1428, 1305, 1219, 1018, 881 cm-1.  
MS (EI) m/z (relative intensity) 447 (20) [M+], 404 (100). 








amine (137fa): The general procedure E was followed using purine base 134f (160 mg, 0.50 
mmol) and alkyne 61a (261 mg, 1.00 mmol) at 90 °C. Isolation by column chromatography (n-
hexane/EtOAc: 6/1) yielded 137fa (145 mg, 58%) as a white solid. 
M. p. = 147–148 °C.  
1H NMR (600 MHz, CDCl3) δ = 9.32 (d, J = 1.7 Hz, 1H), 8.64 (br s, 1H), 8.60 (s, 1H), 7.87 (s, 
1H), 7.57 (d, J = 8.0 Hz, 1H), 7.21 (dd, J = 8.0, 1.7 Hz, 1H), 4.86 (hept, J = 6.8 Hz, 1H), 1.62 
(d, J = 6.8 Hz, 6H), 1.30–1.20 (m, 3H), 1.21–1.15 (m, 18H).  
13C NMR (125 MHz, CDCl3) δ = 151.9 (CH), 151.5 (Cq), 149.5 (Cq), 140.8 (Cq), 138.4 (CH), 
132.4 (CH), 130.9 (Cq, q, 2JC-F= 32.4 Hz), 124.9 (Cq, q, 1JC-F= 272.2 Hz), 118.0 (CH, d, 3JC-F= 
4.0 Hz), 115.7 (CH, d, 3JC-F = 4.5 Hz), 115.4 (Cq), 101.7 (Cq), 100.8 (Cq), 47.2 (CH), 22.8 (CH), 
18.8 (CH3), 11.4 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -62.8 (s). 
IR (neat): 3345, 2942, 2867, 2151, 1621, 1432, 1328, 1111, 823, 660 cm-1.  
MS (EI) m/z (relative intensity) 501 (20) [M+], 458 (100).  




The general procedure E was followed using purine base 134l (160 mg, 0.50 mmol) and alkyne 
61a (261 mg, 1.00 mmol) at 120 °C. Isolation by column chromatography (n-hexane/EtOAc: 





M. p. = 156–157 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.46 (s, 1H), 7.84 (br s, 1H), 7.74 (s, 1H), 7.37–7.23 (m, 6H), 
7.21–7.10 (m, 2H), 5.36 (s, 2H), 0.88–0.87 (m, 21H). 
13C NMR (125 MHz, CDCl3) δ = 157.7 (Cq, 1JC-F = 249.1 Hz), 152.9 (CH), 152.9 (Cq), 150.2 
(Cq), 140.4 (CH), 135.5 (Cq), 128.9 (CH), 128.5 (CH, 4JC-F = 3.3 Hz), 128.3 (CH), 127.6 (CH), 
127.2 (Cq, 2JC-F = 13.8 Hz), 126.9 (CH, 3JC-F = 8.7 Hz), 123.1 (Cq, 4JC-F = 2.5 Hz), 120.3 (Cq), 
116.6 (CH, 2JC-F = 20.6 Hz), 102.1 (Cq, 4JC-F = 4.1 Hz), 98.0 (Cq), 47.2 (CH2), 18.5 (CH3), 11.1 
(CH).  
19F NMR (283 MHz, CDCl3) δ = -(102.1–135.8) (m). 
IR (neat): 3174, 2940, 2891, 2157, 1605, 1465, 1301, 1275, 992, 647 cm-1.  
MS (EI) m/z (relative intensity) 499 (10) [M+], 456 (80), 91 (100).  




Intermolecular Competition Experiments 
 
N-(m-Tolyl)pyrimidin-2-amine (123f) (93 mg, 0.5 mmol), N-[3-
(trifluoromethyl)phenyl]pyrimidin-2-amine (123h) (120 mg, 0.5 mmol), [(DME)NiCl2] (2.8 
mg, 2.5 mol %) and LiOt-Bu(80 mg, 1.0 mmol) were placed in a 25 mL Schlenk tube. The tube 
was degassed and purged with N2 for three times. Dt-BEDA (143) (5.5 µL, 5.0 mol %), alkyne 
61a (130 mg, 0.5 mmol) and 1,4-dioxane (1.5 mL) were then added, and the mixture was stirred 
at 100 °C for 16 h. At ambient temperature, CH2Cl2 (2.0 mL) was added, and the reaction 





pressure. Isolation by column chromatography on silica gel (n-hexane/EtOAc: 10/1) afforded a 




N-(3-Methoxyphenyl)pyrimidin-2-amine (123g) (101 mg, 0.50 mmol), N-[3-
(trifluoromethyl)phenyl]pyrimidin-2-amine (123h) (120 mg, 0.50 mmol), [(DME)NiCl2] (2.8 
mg, 2.5 mol %) and LiOt-Bu (80 mg, 1.00 mmol) were placed in a 25 mL Schlenk tube. The 
tube was degassed and purged with N2 for three times. Dt-BEDA (143) (5.5 µL, 5.0 mol %), 
alkyne 61a (130 mg, 0.5 mmol) and 1,4-dioxane (1.5 mL) were then added, and the mixture 
was stirred at 100 °C for 16 h. At ambient temperature, CH2Cl2 (2 mL) was added, and the 







pressure. Isolation by column chromatography on silica gel (n-hexane/EtOAc: 10/1) afforded a 




N-(m-Tolyl)pyrimidin-2-amine (123f) (93 mg, 0.5 mmol), 9-isopropyl-N-{5-methyl-2-
[(triisopropylsilyl)ethynyl]phenyl}-9H-purin-6-amine (134d) (134 mg, 0.5 mmol), 
[(DME)NiCl2] (2.8 mg, 2.5 mol %) and LiOt-Bu (80 mg, 1.0 mmol) were placed in a 25 mL 
Schlenk tube. The tube was degassed and purged with N2 for three times. Dt-BEDA (143) (5.5 
µL, 5.0 mol %), alkyne 61a (130 mg, 0.5 mmol) and 1,4-dioxane (1.5 mL) were then added, 
and the mixture was stirred at 100 °C for 16 h. At ambient temperature, CH2Cl2 (2.0 mL) was 






under reduced pressure. Isolation by column chromatography on silica gel (n-hexane/EtOAc: 





N-(o-Tolyl)pyrimidin-2-amine 123a (93 mg, 0.50 mmol), [(DME)NiCl2] (2.8 mg, 2.5 mol %), 
additive (1.0 equiv, 0.50 mmol) and LiOt-Bu (80 mg, 1.0 mmol) were placed in a 25 mL 
Schlenk tube. The tube was degassed and purged with N2 three times. Dt-BEDA (143) (5.5 µL, 
5.0 mol %), alkyne 61a (261 mg, 1.00 mmol) and 1,4-dioxane (1.5 mL) were then added, and 
the mixture was stirred at 100 °C for 16 h. After cooling to ambient temperature, CH2Cl2 (2.0 
mL) was added, and the reaction mixture was transferred into a round flask with CH2Cl2 and 
concentrated under reduced pressure, purified by column chromatography on silica gel to afford 
the desired product 136aa. 
 
H/D Exchange Experiments 
 
Following the general procedure E, [D]5-123c (88 mg, 0.5 mmol) was reacted with 61a (157 
mg, 0.6mmol). After 3.5 h or 16 h, the reaction was cooled to ambient temperature, CH2Cl2 (2.0 
mL) was added, and the reaction mixture was transferred into a round flask with CH2Cl2 and 
concentrated under reduced pressure, purified by column chromatography on silica gel to afford 









KIE Study Experiments  
 
Independent parallel reactions with 123c or [D]5-123c were run for different reaction times. 
Following general procedure E, 123c (86 mg, 0.5 mmol) or [D]5-123c (88 mg, 0.5 mmol) with 
internal standard n-dodecane (85 mg, 0.5 mmol) were reacted with 61a (157 mg, 0.6 mmol). 
After the reaction times indicated below, the conversion to the products 136ca or [D]4-136ca 







Time [h] 1.0 1.5 2.0 2.5 3.0 3.5 
136ca [%] 8.4 13.5 17.0 20.3 23.9 26.1 




Diversification to access indoles 
 
 
N-(2-Ethynyl-6-methylphenyl)pyrimidin-2-amine (136aa’): To a solution of 136aa (73 mg, 
0.2 mmol) in dry THF (1.0 mL) and H2O (0.05 mL) was added TBAF in THF (1M, 3.0 ml) at 
y = 7.0286x + 2.3857
R² = 0.9874






























23 °C and stirred for 10 minutes. H2O (5 mL) was added and the mixture was extracted with 
EtOAc (3 × 7.0 mL). The organic layer was combined, washed with brine and dried over 
anhydrous Na2SO4. The solvent was evaporated and the residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc: 4/1) to afford the desired product 136aa’ (41 
mg, 98%) as a yellow solid.  
M. p. = 105–106 °C. 
1H NMR (500 MHz, CDCl3) δ = 8.35 (d, J = 4.8 Hz, 2H), 7.39 (d, J = 7.6 Hz, 1H), 7.28 (d, J 
= 7.6 Hz, 1H), 7.13 (dd, J = 7.6, 7.6 Hz, 1H), 6.99 (s, 1H), 6.65 (t, J = 4.8 Hz, 1H), 3.19 (s, 1H), 
2.25 (s, 3H).  
13C NMR (125 MHz, CDCl3) δ = 161.2 (Cq), 158.2 (CH), 138.8 (Cq), 136.3 (Cq), 131.7 (CH), 
130.6 (CH), 126.1 (CH), 119.6 (Cq), 112.2 (CH), 82.2 (CH), 80.8 (Cq), 18.9 (CH3).  
IR (neat): 3283, 3212, 2957, 2924, 1573, 1510, 1443, 1406, 1259, 634 cm-1. 
MS (EI) m/z (relative intensity) 209 (90) [M+], 194 (100). 




amine (136aa’) (21 mg, 0.1mmol) and Cu(OAc)2 (2.0 mg, 0.01 mmol) were placed in a 10 mL 
Schlenk tube.The tube was degassed and purged with N2 three times, then DCE (2.0 mL) was 
added, and the mixture was stirred at 85 °C for 2 h. At ambient temperature, CH2Cl2 (2 mL) 
was added, and the reaction mixture was transferred into a round flask with CH2Cl2 and 
concentrated under reduced pressure, purified by column chromatography on silica gel (n-
hexane/EtOAc: 4/1) to afford the desired product 149a (17 mg, 85%) as a colorless liquid. 
1H NMR (400 MHz, CDCl3) δ = 8.73 (d, J = 4.8 Hz, 2H), 7.78 (d, J = 3.6 Hz, 1H), 7.48 (dd, J 
= 7.7, 1.5 Hz, 1H), 7.15 (dd, J = 7.7, 7.4 Hz, 1H), 7.12 (t, J = 4.8 Hz, 1H), 6.69 (dd, J = 7.4, 
1.5 Hz, 1H), 2.40 (s, 3H).  
13C NMR (100 MHz, CDCl3) δ 158.2 (CH), 158.1 (Cq), 134.7 (Cq), 131.8 (Cq), 129.8 (CH), 





IR (neat): 3042, 2965, 2926, 1697, 1561, 1412, 1348, 1227, 1078, 720 cm-1.  
MS (EI) m/z (relative intensity) 209 (85) [M+], 208 (100), 130 (20).  
HR-MS (ESI) m/z calcd for C13H11N3 [M+] 209.0953, found 209.0958.  




To a solution of 136sa (80 mg, 0.2mmol) in THF (1.0 mL) and H2O (0.05 mL) was added TBAF 
in THF (1M, 3.0 ml) at 23 °C and stirred for 10 minutes. H2O (5.0 mL) was added and the 
mixture was extracted with EtOAc (3 × 7.0 mL). The organic layer was combined, washed with 
brine and dried over anhydrous Na2SO4. The solvent was evaporated and the residue was 
purified by column chromatography on silica gel (n-hexane/EtOAc: 4/1) to afford the desired 
product 136sa’ (48 mg, 97%) as a yellow solid. 
M. p. = 181–182 °C. 
1H NMR (400 MHz, CDCl3) δ = 8.32 (d, J = 4.8 Hz, 2H), 7.99–7.92 (m, 1H), 7.87–7.80 (m, 
1H), 7.72 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.53–7.41 (m, 3H), 6.66 (t, J = 4.8 Hz, 
1H), 3.30 (s, 1H).  
13C NMR (100 MHz, CDCl3) δ = 162.2 (Cq), 158.2 (CH), 138.0 (Cq), 134.3 (Cq), 130.5 (Cq), 
128.6 (CH), 128.2 (CH), 127.0 (CH), 126.8 (CH), 126.6 (CH), 124.4 (CH), 116.8 (Cq), 112.4 
(CH), 83.3 (Cq), 81.2 (Cq).  
IR (neat): 3236, 1596, 1512, 1445, 1415, 1379, 818, 787, 557 cm-1.  
MS (EI) m/z (relative intensity) 245 (100) [M+], 218 (70).  








amine (136sa’) (25 mg, 0.10 mmol) and Cu(OAc)2 (2.0 mg, 0.01 mmol) were placed in a 10 
mL Schlenk tube. The tube was degassed and purged with N2 three times, then DCE (2.0 mL) 
was added, and the mixture was stirred at 85 °C for 2 h. At ambient temperature, CH2Cl2 (2.0 
mL) was added, and the reaction mixture was transferred into a round flask with CH2Cl2 and 
concentrated under reduced pressure, purified by column chromatography on silica gel (n-
hexane/EtOAc: 4/1) to afford the desired product 149s (21 mg, 84%) as a colorless liquid. 
1H NMR (400 MHz, CDCl3) δ = 8.81 (d, J = 4.8 Hz, 2H), 7.94 (dd, J = 8.4, 1.4 Hz, 1H), 7.91 
(dd, J = 8.0, 1.4 Hz, 1H), 7.84 (d, J = 3.4 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.65 (d, J = 8.5 Hz, 
1H), 7.39 (ddd, J = 8.0, 6.9, 1.3 Hz, 1H), 7.33 (ddd, J = 8.4, 6.9, 1.6 Hz, 1H), 7.24 (d, J = 4.8 
Hz, 1H), 6.81 (d, J = 3.4 Hz, 1H).  
13C NMR (100 MHz, CDCl3) δ = 159.1 (Cq), 158.7 (CH), 132.1 (Cq), 129.8 (Cq), 129.5 (CH), 
129.0 (CH), 128.8 (Cq), 124.3 (CH), 124.0 (CH), 123.9 (CH), 123.7 (CH), 123.1 (Cq), 120.4 
(CH), 118.3 (CH), 107.6 (CH).  
IR (neat): 3039, 1708, 1592, 1507, 1339, 1198, 805, 727cm-1.  
MS (EI) m/z (relative intensity) 245 (100) [M+], 139 (15). 
HR-MS (ESI) m/z calcd for C16H11N3 [M+] 245.0953, found 245.0957. 
 
 
N-(2-Ethynyl-5-methoxyphenyl)pyrimidin-2-amine (136ga’): To a solution of 136ga (76 mg, 
0.2 mmol) in dry THF (1.0 mL) and H2O (0.05 mL) was added TBAF in THF (1M, 3.0 ml) at 
23 °C and stirred for 10 minutes. H2O (5.0 mL) was added and the mixture was extracted with 
EtOAc (3 × 7 mL). The organic layer was combined, washed with brine and dried over 
anhydrous Na2SO4. The solvent was evaporated and the residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc: 4/1) to afford the desired product 136ga’ (44 
mg, 98%) as a light yellow solid. 





1H NMR (300 MHz, CDCl3) δ = 8.45 (d, J = 4.8 Hz, 2H), 8.32 (d, J = 2.5 Hz, 1H), 7.96 (brs, 
1H), 7.37 (d, J = 8.5 Hz, 1H), 6.76 (t, J = 4.8 Hz, 1H), 6.50 (dd, J = 8.6, 2.5 Hz, 1H), 3.84 (s, 
3H), 3.45 (s, 1H).  
13C NMR (125 MHz, CDCl3) δ = 160.8 (Cq), 159.6 (Cq), 157.8 (CH), 142.6 (Cq), 133.2 (CH), 
113.2 (CH), 107.2 (CH), 103.8 (CH), 102.6 (Cq), 83.0 (CH), 79.9 (Cq), 55.4 (CH). 
IR (neat): 3390, 3164, 1577, 1446, 1401, 1254, 858, 787, 599 cm-1.  
MS (EI) m/z (relative intensity) 225 (100) [M+], 210 (50).  




methoxyphenyl)pyrimidin-2-amine (136ga’) (23 mg, 0.10 mmol) and Cu(OAc)2 (2.0 mg, 0.01 
mmol) were placed in a 10 mL Schlenk tube. The tube was degassed and purged with N2 three 
times, then DCE (2.0 mL) was added, and the mixture was stirred at 85 °C for 2 h. At ambient 
temperature, CH2Cl2 (2.0 mL) was added, and the reaction mixture was transferred into a round 
flask with CH2Cl2 and concentrated under reduced pressure, purified by column 
chromatography on silica gel (n-hexane/EtOAc: 4/1) to afford the desired product 149g (19 mg, 
82%) as a colorless liquid.  
1H NMR (400 MHz, CDCl3) δ = 8.67 (d, J = 4.8 Hz, 2H), 8.43 (d, J = 2.4 Hz, 1H), 8.15 (d, J 
= 3.7 Hz, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.01 (t, J = 4.8 Hz, 1H), 6.88 (d, J = 8.6 Hz, 1H), 6.61 
(d, J = 3.7 Hz, 1H), 3.92 (s, 3H).  
13C NMR (100 MHz, CDCl3) δ = 158.0 (CH), 157.8 (Cq), 157.3 (Cq), 136.2 (Cq), 125.3 (Cq), 
124.7 (CH), 121.0 (CH), 115.9 (CH), 111.0 (CH), 106.7 (CH), 101.0 (CH), 55.8 (CH3).  
IR (neat): 3126, 2937, 2832, 1575, 1438, 1269, 1074, 921, 795 cm-1.  
MS (EI) m/z (relative intensity) 225 (100) [M+], 182 (60).  
HR-MS (ESI) m/z calcd for C13H11N3O [M+] 225.0902, found 225.0896.  







N-(5-Chloro-2-ethynylphenyl)pyrimidin-2-amine (136qa’): To a solution of 136qa (77 mg, 
0.20 mmol) in dry THF (1.0 mL) and H2O (0.05 mL) was added 1.0 mol/L TBAF in THF (3.0 
mL) at 23 °C and stirred for 10 minutes. H2O (5 mL) was added and the mixture was extracted 
with EtOAc (3 × 7.0 mL). The organic layer was combined, washed with brine and dried over 
anhydrous Na2SO4. The solvent was evaporatedand the residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc: 4/1) to afford the desired product 136qa’ (45 
mg, 98%) as a yellow solid.  
M. p. = 159–160 °C. 
1H NMR (400 MHz, CDCl3) δ = 8.74 (d, J = 2.1 Hz, 1H), 8.47 (d, J = 4.8 Hz, 2H), 7.95 (br s, 
1H), 7.36 (d, J = 8.3 Hz, 1H), 6.91 (dd, J = 8.3, 2.1 Hz, 1H), 6.80 (t, J = 4.8 Hz, 1H), 3.55 (s, 
1H).  
13C NMR (100 MHz, CDCl3) δ = 159.3 (Cq), 157.9 (CH), 142.2 (Cq), 135.9 (Cq), 133.0 (CH), 
121.3 (CH), 117.8 (CH), 113.7 (CH), 108.4 (Cq), 85.1 (CH), 78.9 (Cq).  
IR (neat): 3372, 3193, 1524, 1397, 1242, 941, 777, 584 cm-1.  
MS (EI) m/z (relative intensity) 229 (75) [M+], 228 (100).  




amine (136qa’) (23 mg, 0.10 mmol) and Cu(OAc)2 (2.0 mg, 0.01 mmol) were placed in a 10 
mL Schlenk tube. The tube was degassed and purged with N2 three times, then DCE (2.0 mL) 
was added, and the mixture was stirred at 85 °C for 16 h. At ambient temperature, CH2Cl2 (2.0 
mL) was added, and the reaction mixture was transferred into a round flask with CH2Cl2 and 
concentrated under reduced pressure, purified by column chromatography on silica gel (n-





1H NMR (400 MHz, CDCl3) δ = 8.86 (d, J = 2.0 Hz, 1H), 8.69 (d, J = 4.8 Hz, 2H), 8.24 (d, J 
= 3.7 Hz, 1H), 7.50 (d, J = 8.3 Hz, 1H), 7.20 (dd, J = 8.3, 2.0 Hz, 1H), 7.06 (t, J = 4.8 Hz, 1H), 
6.65 (d, J = 3.7 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ = 158.2 (CH), 157.4 (Cq), 135.6 (Cq), 129.7 (Cq), 129.4 (Cq), 
126.4 (CH), 122.6 (CH), 121.4 (CH), 116.5 (CH), 116.4 (CH), 106.6 (CH).  
IR (neat): 3145, 3116, 1574, 1521, 1437, 1201, 1146, 795 cm-1.  
MS (EI) m/z (relative intensity) 229 (100) [M+], 176 (15). 
HR-MS (ESI) m/z calcd for C12H8ClN3 [M+] 229.0407, found 229.0403.  
The analytical data are in accordance with those previously published in the literature.[168] 
 
5.3.4 Characterization Data: Manganese-Catalyzed C‒H Alkynylation: Expedient 
Peptide Synthesis and Modification of Peptides 
 
1-(Pyridin-2-yl)-2-[(triisopropylsilyl)ethynyl]-1H-indole (138aa): The general procedure F 
was followed using substrate 83a (97 mg, 0.5 mmol) and 61a (157 mg, 0.6 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/1) yielded 138aa (159 mg, 85%) as a colorless 
liquid.  
1H NMR (400 MHz, CDCl3) δ = 8.64 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.80 (ddd, J = 8.1, 7.4, 
1.9 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.68 (dd, J = 8.1, 1.0 Hz, 1H), 7.60 (dd, J = 7.9, 1.1 Hz, 
1H), 7.29–7.24 (m, 2H), 7.18 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.01 (s, 1H), 1.28–0.84 (m, 21H).  
13C NMR (100 MHz, CDCl3) δ = 151.1 (Cq), 148.8 (CH), 137.7 (CH), 136.6 (Cq), 127.7 (Cq), 
124.3 (CH), 121.6 (CH), 121.5 (CH), 120.8 (CH), 120.7 (Cq), 120.6 (CH), 112.4 (CH), 112.1 
(CH), 98.4 (Cq), 98.2 (Cq), 18.5 (CH3), 11.2 (CH).  
IR (neat): 2944, 2864, 2149, 1559, 1466, 1448, 1327, 708 cm-1.  
MS (EI) m/z (relative intensity) 374 (25) [M+], 331 (100), 289 (33).  





The analytical data are in accordance with those previously published in the literature.[158] 
 
 
1-(Pyrimidin-2-yl)-2-[(triisopropylsilyl)ethynyl]-1H-indole (138ba): The general procedure 
F was followed using substrate 83b (98 mg, 0.5 mmol) and 61a (157 mg, 0.6 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 9/1) yielded 138ba (186 mg, 99%) as a colorless 
liquid.  
1H NMR (400 MHz, CDCl3) δ = 8.75 (d, J = 4.8 Hz, 2H), 8.30 (dd, J = 8.5, 0.9 Hz, 1H), 7.58 
(dd, J = 8.0, 1.0 Hz, 1H), 7.34 (ddd, J = 8.5, 7.1, 1.3 Hz, 1H), 7.23 (ddd, J = 8.0, 7.1, 1.0 Hz, 
1H), 7.12 (t, J = 4.8 Hz, 1H), 7.10 (s, 1H), 1.15‒1.14 (m, 21H).  
13C NMR (100 MHz, CDCl3) δ = 157.9 (CH), 157.2 (Cq), 136.1 (Cq), 128.4 (Cq), 124.7 (CH), 
122.3 (CH), 120.8 (Cq), 120.6 (CH), 117.5 (CH), 115.6 (CH), 114.0 (CH), 98.7 (Cq), 97.7 (Cq), 
18.6 (CH3), 11.3 (CH).  
IR (neat): 2957, 2151, 1561, 1421, 1248, 839, 746 cm-1.  
MS (EI) m/z (relative intensity) 375 (30) [M+], 332 (100).  
HR-MS (ESI) m/z calcd for C23H30N3Si [M+H+] 375.2131, found 375.2125. 
The analytical data are in accordance with those previously published in the literature.[158] 
 
 
5-Methoxy-1-(pyrimidin-2-yl)-2-[(triisopropylsilyl)ethynyl]-1H-indole (138ca): The 
general procedure F was followed using substrate 83c (113 mg, 0.5 mmol) and 61a (157 mg, 
0.6 mmol). Isolation by column chromatography (n-pentane/EtOAc: 9/1) yielded 138ca (158 
mg, 78%) as a white solid.  





1H NMR (300 MHz, CDCl3) δ = 8.73 (d, J = 4.8 Hz, 2H), 8.22 (dd, J = 9.0, 0.7 Hz, 1H), 7.11 
(t, J = 4.8 Hz, 1H), 6.99–6.97 (m, 2H), 6.94 (dd, J = 9.0, 2.6 Hz, 1H), 3.83 (s, 3H), 1.12–1.13 
(m, 21H).  
13C NMR (75 MHz, CDCl3) δ = 157.9 (CH), 157.3 (Cq), 155.6 (Cq), 131.1 (Cq), 129.2 (Cq), 
121.2 (Cq), 117.3 (CH), 115.6 (CH), 115.3 (CH), 114.4 (CH), 102.1 (CH), 98.9 (Cq), 97.8 (Cq), 
55.6 (CH3), 18.6 (CH3), 11.4 (CH).  
IR (neat): 2941, 2864, 2144, 1561, 1417, 1207, 660 cm-1.  
MS (EI) m/z (relative intensity) 405 (35) [M+], 362 (100).  
HR-MS (EI) m/z calcd for C24H31N3OSi [M+] 405.2236, found 405.2225 
The analytical data are in accordance with those previously published in the literature.[158] 
 
 
1-(5-Methylpyridin-2-yl)-2-[(triisopropylsilyl)ethynyl]-1H-indole (138da): The general 
procedure F was followed using substrate 83d (104 mg, 0.5 mmol) and 61a (157 mg, 0.6 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 15/1) yielded 138da (190 mg, 98%) as 
a colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 8.46 (d, J = 2.5 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.63–7.57 
(m, 2H), 7.54 (d, J = 8.2 Hz, 1H), 7.26 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.16 (ddd, J = 8.0, 7.0, 
1.1 Hz, 1H), 6.99 (s, 1H), 2.40 (s, 3H), 1.06–1.05 (m, 21H).  
13C NMR (125 MHz, CDCl3) δ = 148.9 (CH), 148.8 (Cq), 138.1 (CH), 136.8 (Cq), 131.4 (Cq), 
127.5 (Cq), 124.1 (CH), 121.2 (CH), 120.8 (Cq), 120.7 (CH), 120.1 (CH), 111.8 (CH), 111.8 
(CH), 98.4 (Cq), 98.0 (Cq), 18.6 (CH3), 18.0 (CH3), 11.4 (CH).  
IR (neat): 2941, 2863, 2147, 1597, 1446, 720 cm-1.  
MS (EI) m/z (relative intensity) 388 (30) [M+], 345 (100), 303 (33).  







1-(5-Bromopyridin-2-yl)-2-[(triisopropylsilyl)ethynyl]-1H-indole (138ea): The general 
procedure F was followed using substrate 83e (136 mg, 0.5 mmol) and 61a (157 mg, 0.6 mmol). 
Isolation by column chromatography (n-pentane/EtOAc: 15/1) yielded 138ea (165 mg, 73%) 
as a colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 8.68 (dd, J = 2.5, 0.7 Hz, 1H), 7.89 (dd, J = 8.6, 2.5 Hz, 1H), 
7.75 (d, J = 8.3 Hz, 1H), 7.66–7.56 (m, 2H), 7.28 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.19 (ddd, J 
= 8.0, 7.1, 1.1 Hz, 1H), 7.02 (s, 1H), 1.08–1.07 (m, 21H).  
13C NMR (125 MHz, CDCl3) δ = 149.6 (CH), 149.5 (Cq), 140.1 (CH), 136.3 (Cq), 127.7 (Cq), 
124.5 (CH), 121.8 (CH), 121.4 (CH), 120.8 (CH), 120.4 (Cq), 117.7 (Cq), 113.1 (CH), 112.1 
(CH), 99.1 (Cq), 97.9 (Cq), 18.6 (CH3), 11.3 (CH).  
IR (neat): 2941, 2863, 2146, 1572, 1446, 1381, 714 cm-1.  
MS (EI) m/z (relative intensity) 452 (23) [M+] (79Br), 454 (25) [M+] (81Br), 411 (100) (81Br), 
409 (95) (79Br).  
HR-MS (EI) m/z calcd for C24H29BrN2Si [M+] 452.1283 (79Br), found 452.1277 (79Br). 
 
 
1-(Pyrimidin-2-yl)-2-[(triisopropylsilyl)ethynyl]-1H-indole-3-carbonitrile (138fa): The 
general procedure F was followed using substrate 83f (73 mg, 0.5 mmol) and 61a (157 mg, 0.6 
mmol) at 100 °C. Isolation by column chromatography (n-pentane/EtOAc: 9/1) yielded 138fa 
(140 mg, 70%) as a white solid.  
M. p. = 78‒80 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.83 (d, J = 4.8 Hz, 2H), 8.86 (d, J = 8.1 Hz, 1H), 7.72 (d, J 





13C NMR (125 MHz, CDCl3) δ = 158.3 (CH), 156.3 (Cq), 134.8 (Cq), 127.8 (Cq), 127.0 (Cq), 
126.3 (CH), 124.1 (CH), 119.4 (CH), 119.0 (CH), 114.7 (CH), 114.3 (Cq), 106.7 (Cq), 98.6 (Cq), 
94.8 (Cq), 18.7 (CH3), 11.3 (CH).  
IR (neat): 2940, 2862, 2226, 2156, 1566, 1414, 657 cm-1.  
MS (ESI) m/z (relative intensity) 439 (6) [M+K+], 423 (23) [M+Na+], 401(100) [M+H+].  
HR-MS (ESI) m/z calcd for C24H29N4Si [M+H+] 401.2161, found 401.2156. 
The analytical data are in accordance with those previously published in the literature.[169] 
 
 
1-(Pyrimidin-2-yl)-2-[(tri-n-butylsilyl)ethynyl]-1H-indole (138bb): The general procedure 
F was followed using substrate 83b (98 mg, 0.5 mmol) and 61b (182 mg, 0.6 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 20/1) yielded 138bb (204 mg, 98%) as a 
colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 8.80 (d, J = 4.8 Hz, 2H), 8.26 (dd, J = 8.4, 0.9 Hz, 1H), 7.58 
(dd, J = 7.7, 1.0 Hz, 1H), 7.33 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.27–7.21 (m, 1H), 7.19 (t, J = 
4.8 Hz, 1H), 7.06 (s, 1H), 1.41–1.35 (m, 12H), 0.91 (t, J = 7.1 Hz, 9H), 0.75–0.60 (m, 6H).  
13C NMR (76 MHz, CDCl3) δ = 158.0 (CH), 157.3 (Cq), 136.1 (Cq), 128.5 (Cq), 124.8 (CH), 
122.3 (CH), 120.8 (CH), 120.8 (Cq), 117.6 (CH), 115.5 (CH), 113.9 (CH), 99.6 (Cq), 97.9 (Cq), 
26.5 (CH2), 26.1 (CH2), 13.8 (CH3), 13.0 (CH2).  
IR (neat): 2955, 2869, 2153, 1577, 1447,1409, 784 cm-1.  
MS (EI) m/z (relative intensity) 417 (80) [M +], 222 (100).  
HR-MS (EI) m/z calcd for C26H35N3Si [M+] 417.2600, found 417.2599. 
 
 
2-[(tert-Butyldimethylsilyl)ethynyl]-1-(pyrimidin-2-yl)-1H-indole (138bc): The general 





Isolation by column chromatography (n-hexane/EtOAc: 20/1) yielded 138bc (143 mg, 86%) as 
a white solid.  
M. p. = 66‒67 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.77 (d, J = 4.8 Hz, 2H), 8.28 (dd, J = 8.5, 0.9 Hz, 1H), 7.57 
(dd, J = 7.8, 1.3 Hz, 1H), 7.32 (ddd, J = 8.5, 7.1, 1.3 Hz, 1H), 7.21 (ddd, J = 8.1, 7.1, 1.0 Hz, 
1H), 7.15 (t, J = 4.8 Hz, 1H), 7.06 (s, 1H), 0.98 (s, 9H), 0.19 (s, 6H).  
13C NMR (100 MHz, CDCl3) δ = 158.0 (CH), 157.2 (Cq), 136.1 (Cq), 128.4 (Cq), 124.8 (CH), 
122.4 (CH), 120.8 (CH), 120.7 (Cq), 117.6 (CH), 115.6 (CH), 114.1 (CH), 99.5 (Cq), 97.6 (Cq), 
26.1 (CH3), 16.8 (Cq), -4.72 (CH3).  
IR (neat): 2950, 2929, 2856, 2148, 1573, 1416, 1250, 835 cm-1.  
MS (EI) m/z (relative intensity) 333 (25) [M+], 276 (100).  
HR-MS (EI) m/z calcd for C20H23N3Si [M+] 333.1661, found 333.1660. 
 
 
1-(Pyrimidin-2-yl)-2-[(trimethylsilyl)ethynyl]-1H-indole (138bd): The general procedure F 
was followed using substrate 83b (98 mg, 0.5 mmol) and 61d (106 mg, 0.6 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 10/1) yielded 138bd (130 mg, 89%) as brown 
solid.  
M. p. = 75‒76 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.77 (d, J = 4.8 Hz, 2H), 8.28 (dd, J = 8.4, 0.9 Hz, 1H), 7.58 
(dd, J = 7.8, 1.2 Hz, 1H), 7.33 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.21 (ddd, J = 7.7, 7.1, 1.3 Hz, 
1H), 7.14 (t, J = 4.8 Hz, 1H), 7.06 (s, 1H), 0.25 (s, 9H).  
13C NMR (75 MHz, CDCl3) δ = 157.9 (CH), 157.1 (Cq), 136.1 (Cq), 128.3 (Cq), 124.9 (CH), 
122.3 (CH), 120.8 (CH), 120.5 (Cq), 117.6 (CH), 115.3 (CH), 114.0 (CH), 101.0 (Cq), 97.1 (Cq), 
-0.28 (CH3).  
IR (neat): 3091, 2962, 2149, 1563, 1448, 1420, 831 cm-1.  
MS (ESI) m/z (relative intensity) 314(100) [M+Na+], 292 (80) [M+H+].  





The analytical data are in accordance with those previously published in the literature.[158] 
 
 
1-(Pyrimidin-2-yl)-2-[(triphenylsilyl)ethynyl]-1H-indole (138be): The general procedure F 
was followed using substrate 83b (98 mg, 0.5 mmol) and 61e (218 mg, 0.6 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/1) yielded 138be (237 mg, 99%) as a light 
yellow solid.  
M. p. = 114‒115 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.64 (d, J = 4.8 Hz, 2H), 8.42 (dd, J = 8.5, 0.9 Hz, 1H), 7.86–
7.79 (m, 6H), 7.65 (dd, J = 7.8, 1.0 Hz, 1H), 7.54–7.37 (m, 12H), 7.32–7.28 (m, 1H), 7.27 (s, 
1H), 7.07 (t, J = 4.8 Hz, 1H).  
13C NMR (100 MHz, CDCl3) δ = 157.9 (CH), 157.1 (Cq), 136.3 (Cq), 135.6 (CH), 133.5 (Cq), 
129.9 (CH), 128.3 (Cq), 127.9 (CH), 125.2 (CH), 122.5 (CH), 120.9 (CH), 120.2 (Cq), 117.5 
(CH), 116.5 (CH), 114.4 (CH), 101.7 (Cq), 95.9 (Cq).  
IR (neat): 2943, 2865, 2148, 1563, 1447, 1112, 697 cm-1.  
MS (ESI) m/z (relative intensity) 478 (20) [M+H+].  
HR-MS (ESI) m/z calcd for C32H24N3Si [M+H+] 478.1734, found 478.1725. 
 
 
2-[(Methyldiphenylsilyl)ethynyl]-1-(pyrimidin-2-yl)-1H-indole (138bf): The general 
procedure F was followed using substrate 83b (98 mg, 0.5 mmol) and 61f (181 mg, 0.6 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 138bf (203 mg, 98%) as 
a yellow solid.  
M. p. = 99–100 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.67 (d, J = 4.8 Hz, 2H), 8.40 (dd, J = 8.5, 0.9 Hz, 1H), 7.83–
7.75 (m, 4H), 7.65 (dd, J = 7.9, 1.0 Hz, 1H), 7.49–7.37 (m, 7H), 7.29 (ddd, J = 8.0, 7.1, 1.0 Hz, 





13C NMR (100 MHz, CDCl3) δ = 157.9 (CH), 157.1 (Cq), 136.2 (Cq), 135.2 (Cq), 134.6 (CH), 
129.6 (CH), 128.3 (Cq), 127.8 (CH), 125.1 (CH), 122.5 (CH), 120.9 (CH), 120.2 (Cq), 117.5 
(CH), 116.2 (CH), 114.3 (CH), 100.4 (Cq), 97.2 (Cq), -2.2 (CH3).  
IR (neat): 3000, 2148, 1561, 1422, 1112, 806, 697 cm-1.  
MS (EI) m/z (relative intensity) 415 (73) [M+], 338 (15).  
HR-MS (EI) m/z calcd for C27H21N3Si [M+] 415.1505, found 415.1492. 
The analytical data are in accordance with those previously published in the literature.[158] 
 
 
2-(Phenylethynyl)-1-(pyrimidin-2-yl)-1H-indole (150bg): The general procedure G was 
followed using substrate 83b (98 mg, 0.5 mmol) and 61g (108 mg, 0.6 mmol) for 1 h. Isolation 
by column chromatography (n-pentane/EtOAc: 5/1) yielded 150bg (141 mg, 95%) as a 
colorless oil.  
1H NMR (500 MHz, CDCl3) δ = 8.85 (d, J = 4.9 Hz, 2H), 8.31 (d, J = 8.4 Hz, 1H), 7.60 (d, J 
= 7.6 Hz, 1H), 7.52–7.48 (m, 2H), 7.35–7.31 (m, 4H), 7.25‒7.21 (m, 1H), 7.21 (t, J = 4.9 Hz, 
1H), 7.08 (s, 1H).  
13C NMR (125 MHz, CDCl3) δ = 158.1 (CH), 157.4 (Cq), 136.4 (Cq), 131.3 (CH), 128.8 (Cq), 
128.4 (CH), 128.3 (CH), 124.8 (CH), 123.3 (Cq), 122.4 (CH), 120.9 (Cq), 120.8 (CH), 117.7 
(CH), 114.6 (CH), 114.1 (CH), 95.0 (Cq), 82.5 (Cq).  
IR (neat): 3048, 2963, 2851, 1560, 1418, 1081, 741, 686, 521 cm-1.  
MS (ESI) m/z (relative intensity) 296 (5) [M+], 214 (11), 196 (100), 173 (20), 149 (15). 
HR-MS (ESI) m/z calcd for C20H14N3 [M+H+] 296.1182, found 296.1188. 
 
 
2-[(3-Fluorophenyl)ethynyl]-1-(pyrimidin-2-yl)-1H-indole (150bh): The general procedure 





Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 150bh (130 mg, 83%) 
as a colorless liquid.  
1H NMR (400 MHz, CDCl3) δ = 8.83 (d, J = 4.8 Hz, 2H), 8.35 (d, J = 8.4 Hz, 1H), 7.61 (d, J 
= 7.8 Hz, 1H), 7.36 (d, J = 7.5 Hz, 1H), 7.31–7.22 (m, 3H), 7.21–7.15 (m, 2H), 7.11 (s, 1H), 
7.05–7.00 (m, 1H).  
13C NMR (100 MHz, CDCl3) δ = 162.3 (Cq, 1JC-F = 246.6 Hz), 158.0 (CH), 157.3 (Cq), 136.4 
(Cq), 129.9 (CH, 3JC-F = 8.7 Hz), 128.6 (Cq), 127.1 (CH, 4JC-F = 3.0 Hz), 125.1 (Cq, 3JC-F = 9.6 
Hz), 125.0 (CH), 122.5 (CH), 120.8 (CH), 120.3 (Cq), 118.0 (CH), 117.9 (CH, 2JC-F = 22.8 Hz), 
115.6 (CH, 2JC-F = 21.2 Hz), 115.1 (CH), 114.2 (CH), 93.6 (Cq, 4JC-F = 3.4 Hz), 83.5 (Cq).  
19F NMR (376 MHz, CDCl3) δ = -112.8 (ddd, J = 9.6, 9.6, 3.9 Hz).  
IR (neat): 3065, 2208, 1711, 1561, 1419, 1333, 727 cm-1.  
MS (EI) m/z (relative intensity) 313 (83) [M+], 156 (15).  
HR-MS (EI) m/z calcd for C20H13FN3 [M+H+] 313.1015, found 313.1012. 
 
 
2-[(3-Bromophenyl)ethynyl]-1-(pyrimidin-2-yl)-1H-indole (150bi): The general procedure 
G was followed using substrate 83b (98 mg, 0.5 mmol) and 61i (156 mg, 0.6 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 10/1) yielded 150bi (150 mg, 80%) as a 
colorless liquid.  
1H NMR (400 MHz, CDCl3) δ = 8.81 (d, J = 4.8 Hz, 2H), 8.36 (d, J = 8.4 Hz, 1H), 7.65 (dd, J 
= 1.8, 1.8 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.43 (dd, J = 7.6, 1.2 Hz, 2H), 7.36 (ddd, J = 8.4, 
7.0, 1.3 Hz, 1H), 7.29–7.22 (m, 1H), 7.21–7.13 (m, 2H), 7.11 (s, 1H).  
13C NMR (100 MHz, CDCl3) δ = 158.0 (CH), 157.2 (Cq), 136.4 (Cq), 133.8 (CH), 131.3 (CH), 
129.7 (CH), 129.7 (CH), 128.6 (Cq), 125.3 (Cq), 125.0 (CH), 122.5 (CH), 122.0 (Cq), 120.8 
(CH), 120.2 (Cq), 117.7 (CH), 115.2 (CH), 114.2 (CH), 93.3 (Cq), 84.0 (Cq). 
IR (neat): 3054, 2929, 1987, 1906, 1885, 1450, 810 cm-1.  
MS (ESI) m/z (relative intensity) 374 (35) [M+H+] (79Br), 376 (33) [M+H+] (81Br).  







2-(Hept-1-yn-1-yl)-1-(pyrimidin-2-yl)-1H-indole (150bj): The general procedure G was 
followed using substrate 83b (98 mg, 0.5 mmol) and 61j (105 mg, 0.6 mmol) for 1 h. Isolation 
by column chromatography (n-hexane/EtOAc: 10/1) yielded 150bj (101 mg, 70%) as a 
colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 8.79 (d, J = 4.8 Hz, 2H), 8.20 (dd, J = 8.3, 1.0 Hz, 1H), 7.55 
(d, J = 7.7 Hz, 1H), 7.28 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.22–7.19 (m, 1H), 7.16 (t, J = 4.8 Hz, 
1H), 6.91 (s, 1H), 2.45 (t, J = 7.0 Hz, 2H), 1.70–1.53 (m, 2H), 1.47–1.22 (m, 4H), 0.89 (t, J = 
7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ = 158.0 (CH), 157.3 (Cq), 136.0 (Cq), 128.6 (Cq), 124.2 (CH), 
122.2 (CH), 121.5 (Cq), 120.4 (CH), 117.6 (CH), 113.6 (CH), 113.5 (CH), 96.5 (Cq), 73.2 (Cq), 
31.0 (CH2), 28.1 (CH2), 22.2 (CH2), 19.8 (CH2), 14.0 (CH3).  
IR (neat): 3048, 2954, 2928, 2857, 1561, 1420, 801, 745 cm-1.  
MS (ESI) m/z (relative intensity) 312 (46) [M+Na+], 290 (55) [M+H+].  
HR-MS (ESI) m/z calcd for C19H20N3 [M+H+] 290.1652, found 290.1651. 
 
 
2-(6-Chlorohex-1-yn-1-yl)-1-(pyrimidin-2-yl)-1H-indole (150bk): The general procedure G 
was followed using substrate 83b (98 mg, 0.5 mmol) and 61k (117 mg, 0.6 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/1) yielded 150bk (81 mg, 52%) as a colorless 
oil.  
1H NMR (300 MHz, CDCl3) δ = 8.80 (d, J = 4.8 Hz, 2H), 8.22 (dd, J = 8.4, 0.9 Hz, 1H), 7.55 
(dd, J = 7.7, 1.0 Hz, 1H), 7.29 (ddd, J = 8.5, 7.1, 1.4 Hz, 1H), 7.21 (dd, J = 7.8, 1.1 Hz, 1H), 
7.16 (t, J = 4.8 Hz, 1H), 6.92 (s, 1H), 3.56 (t, J = 6.6 Hz, 2H), 2.51 (t, J = 6.8 Hz, 2H), 1.95 (tt, 





13C NMR (75 MHz, CDCl3) δ = 158.1 (CH), 157.2 (Cq), 136.0 (Cq), 128.5 (Cq), 124.3 (CH), 
122.2 (CH), 121.1 (Cq), 120.5 (CH), 117.6 (CH), 113.8 (CH), 113.7 (CH), 95.3 (Cq), 73.9 (Cq), 
44.5 (CH2), 31.5 (CH2), 25.5 (CH2), 19.2 (CH2).  
IR (neat): 3001, 2929, 1709, 1563, 1422, 1220, 748 cm-1.  
MS (ESI) m/z (relative intensity) 332 (18) [M+Na+], 310 (60) [M+H+].  
HR-MS (ESI) m/z calcd for C18H17ClN3 [M+H+] 310.1106, found 310.1104. 
 
 
2-(Cyclohexylethynyl)-1-(pyrimidin-2-yl)-1H-indole (150bl): The general procedure G was 
followed using substrate 83b (98 mg, 0.5 mmol) and 61l (56 mg, 0.6 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 10/1) yielded 150bl (110 mg, 73%) as a colorless 
oil.  
1H NMR (300 MHz, CDCl3) δ = 8.78 (d, J = 4.8 Hz, 2H), 8.20 (dd, J = 8.1, 0.7 Hz, 1H), 7.55 
(d, J = 7.8 Hz, 1H), 7.28 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H), 7.20 (dd, J = 7.6, 0.9 Hz, 1H), 7.15 (d, 
J = 4.8 Hz, 1H), 6.90 (d, J = 0.7 Hz, 1H), 2.67 (tt, J = 8.4, 3.7 Hz, 1H), 1.88–1.80 (m, 2H), 
1.77–1.68 (m, 2H), 1.62–1.46 (m, 3H), 1.43–1.24 (m, 3H).  
13C NMR (75 MHz, CDCl3) δ = 157.9 (CH), 157.3 (Cq), 136.0 (Cq), 128.6 (Cq), 124.1 (CH), 
122.1 (CH), 121.5 (Cq), 120.4 (CH), 117.6 (CH), 113.6 (CH), 113.2 (CH), 100.2 (Cq), 73.3 (Cq), 
32.2 (CH2), 29.9 (CH), 25.9 (CH2), 24.6 (CH2).  
IR (neat): 3046, 2926, 2851, 1561, 1418, 1217, 799, 738 cm-1.  
MS (ESI) m/z (relative intensity) 324 (12) [M+Na +], 302 (64) [M+H+].  
HR-MS (ESI) m/z calcd for C20H20N3 [M+H+] 302.1652, found 302.1652. 
 
 
2-[3-(Allyloxy)-3-phenylbut-1-yn-1-yl]-1-(pyrimidin-2-yl)-1H-indole (150bm): The general 





Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 150bm (152 mg, 80%) 
as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ = 8.76 (d, J = 4.8 Hz, 2H), 8.37 (ddd, J = 8.5, 0.8, 0.8 Hz, 1H), 
7.79–7.73 (m, 2H), 7.61 (ddd, J = 7.9, 1.3, 0.8 Hz, 1H), 7.41–7.35 (m, 3H), 7.35–7.28 (m, 1H), 
7.28–7.21 (m, 1H), 7.14 (t, J = 4.8 Hz, 1H), 7.12 (s, 1H), 5.97 (ddt, J = 17.2, 10.4, 5.6 Hz, 1H), 
5.29 (ddt, J = 17.2, 1.7, 1.3 Hz, 1H), 5.15 (ddt, J = 10.4, 1.9, 1.3 Hz, 1H), 4.25 (ddt, J = 12.2, 
5.5, 1.5 Hz, 1H), 3.76 (ddt, J = 12.2, 5.7, 1.5 Hz, 1H), 1.87 (s, 3H).  
13C NMR (100 MHz, CDCl3) δ = 158.0 (CH), 157.3 (Cq), 143.1 (Cq), 136.3 (Cq), 135.0 (CH), 
128.6 (Cq), 128.2 (CH), 127.7 (CH), 126.1 (CH), 124.8 (CH), 122.5 (CH), 120.7 (CH), 120.1 
(Cq), 117.6 (CH), 116.4 (CH), 115.1 (CH), 114.3 (Cq), 95.2 (Cq), 80.5 (Cq), 76.7 (CH2), 66.4 
(CH2), 32.6 (CH3).  
IR (neat): 3057, 2984, 2929, 2858, 1561, 1420, 1071, 698 cm-1.  
MS (ESI) m/z (relative intensity) 380 (18) [M+H+].  




yl)-3-methylbutanoate (150bn): The general procedure G was followed using substrate 83b 
(98 mg, 0.5 mmol) and 61n (235 mg, 0.6 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 3/1) yielded 150bn (304 mg, 60%) as a colorless liquid.  
1H NMR (300 MHz, CDCl3) δ = 8.78 (d, J = 4.8 Hz, 2H), 8.27 (dd, J = 8.5, 0.9 Hz, 1H), 7.87–
7.80 (m, 2H), 7.70 (dd, J = 5.5, 3.0 Hz, 2H), 7.54 (ddd, J = 7.8, 1.3, 0.7 Hz, 1H), 7.29 (ddd, J 
= 8.4, 7.1, 1.3 Hz, 1H), 7.18 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 7.14 (t, J = 4.8 Hz, 1H), 6.97 (d, J 
= 0.8 Hz, 1H), 4.54 (d, J = 8.2 Hz, 1H), 2.76 (m, 1H), 1.74 (s, 3H), 1.67 (s, 3H), 1.11 (d, J = 
6.6 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ = 167.7 (Cq), 166.7 (Cq), 158.0 (CH), 157.2 (Cq), 136.2 (Cq), 





(Cq), 117.6 (CH), 115.1 (CH), 114.1 (CH), 95.0 (Cq), 77.6 (Cq), 74.2 (Cq), 58.4 (CH), 28.9 (CH3), 
28.5 (CH3), 28.3 (CH), 20.9 (CH3), 19.6 (CH3).  
IR (neat): 2966, 2935, 1713, 1562, 1422, 1116, 716 cm-1.  
MS (ESI) m/z (relative intensity) 529 (65) [M+Na+], 507 (10) [M+H+].  
HR-MS (ESI) m/z calcd for C34H36N3O2 [M+H+] 507.2027, found 507.2016. 
 
 
2-(Pyren-1-ylethynyl)-1-(pyrimidin-2-yl)-1H-indole (150bo): The general procedure G was 
followed using substrate 83b (98 mg, 0.5 mmol) and 61o (183 mg, 0.6 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 6/1) yielded 150bo (84 mg, 40%) as a yellow solid.  
M. p. = 165‒166 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.94 (d, J = 4.8 Hz, 2H), 8.78 (d, J = 9.0 Hz, 1H), 8.43 (d, J 
= 8.4 Hz, 1H), 8.21 (d, J = 7.6 Hz, 1H), 8.19–8.18 (m, 2H), 8.15 (d, J = 9.1 Hz, 1H), 8.12–8.08 
(m, 2H), 8.04–8.00 (m, 2H), 7.66 (dd, J = 7.8, 1.0 Hz, 1H), 7.38 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 
7.29–7.27 (m, 1H), 7.28 (t, J = 4.8 Hz, 1H), 7.27–7.26 (m, 1H), 7.24 (s, 1H).  
13C NMR (125 MHz, CDCl3) δ = 158.3 (CH), 157.6 (Cq), 136.5 (Cq), 132.1 (Cq), 131.3 (Cq), 
131.2 (Cq), 131.0 (Cq), 129.3 (CH), 129.0 (Cq), 128.2 (CH), 128.1 (CH), 127.2 (CH), 126.2 
(CH), 125.8 (CH), 125.6 (CH), 125.5 (CH), 124.9 (CH), 124.6 (CH), 124.5 (Cq), 124.3 (Cq), 
122.6 (CH), 121.0 (Cq), 120.8 (CH), 117.9 (Cq), 117.7 (CH), 115.2 (CH), 114.4 (CH), 94.6 (Cq), 
88.2 (Cq).  
IR (neat): 3030, 1575, 1557, 1452, 1432, 1350, 837, 729 cm-1.  
MS (ESI) m/z (relative intensity) 442 (5) [M+Na +], 420 (15) [M+H+].  









(150bp): The general procedure G was followed using substrate 83b (98 mg, 0.5 mmol) and 
61p (242 mg, 0.6 mmol). Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 
150bp (254 mg, 98%) as a light yellow solid.  
M. p. = 140‒141 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.78 (d, J = 4.8 Hz, 2H), 8.28 (dd, J = 8.4, 0.9 Hz, 1H), 7.56 
(dd, J = 7.8, 1.0 Hz, 1H), 7.31 (ddd, J = 8.5, 7.2, 1.3 Hz, 1H), 7.25–7.20 (m, 2H), 7.17 (t, J = 
4.8 Hz, 1H), 7.03 (s, 1H), 6.70 (dd, J = 8.6, 2.8 Hz, 1H), 6.62 (d, J = 2.7 Hz, 1H), 3.76 (s, 3H), 
3.48 (s, 3H), 2.93–2.76 (m, 2H), 2.43–2.25 (m, 2H), 2.20–1.99 (m, 3H), 1.93–1.75 (m, 4H), 
1.53–1.31 (m, 4H), 0.91 (s, 3H).  
13C NMR (125 MHz, CDCl3) δ = 158.0 (CH), 157.3 (Cq), 137.8 (Cq), 136.1 (Cq), 132.5 (Cq), 
128.6 (Cq), 126.2 (CH), 124.6 (CH), 122.4 (Cq),122.3 (CH), 120.6 (Cq), 120.5 (CH), 117.5 (CH), 
114.6 (CH), 114.0 (CH), 113.7 (CH), 111.4 (CH), 96.3 (Cq), 86.6 (Cq), 80.8 (Cq), 55.2 (CH3), 
53.6 (CH3), 49.8 (CH), 48.2 (Cq), 43.6 (CH), 39.3 (CH), 36.6 (CH2), 34.4 (CH2), 29.9 (CH2), 
27.4 (CH2), 26.7 (CH2), 23.0 (CH2), 12.9 (CH3). 
IR (neat): 2930, 2867, 1562, 1449, 1422, 1091, 805, 746 cm-1.  
MS (ESI) m/z (relative intensity) 540 (48) [M+Na+], 518 (10) [M+H+].  









yl]ethynyl}-1-(pyrimidin-2-yl)-1H-indol-3-yl}propanoate (154a): The general procedure G 
was followed using substrate 153a (198 mg, 0.5 mmol) and 61p (242 mg, 0.6 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 4/1) yielded 154a (235 mg, 66%) as a light 
yellow solid.  
M. p. = 163‒164 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.77 (d, J = 4.8 Hz, 2H), 8.31 (d, J = 8.4 Hz, 1H), 7.59 (d, J 
= 7.9 Hz, 1H), 7.32 (ddd, J = 8.3, 7.1, 1.3 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.19 (d, J = 8.7 Hz, 
1H), 7.16 (t, J = 4.8 Hz, 1H), 6.69 (dd, J = 8.6, 2.8 Hz, 1H), 6.61 (d, J = 2.8 Hz, 1H), 5.19 (d, 
J = 7.7 Hz, 1H), 4.61 (q, J = 7.2 Hz, 1H), 3.76 (s, 3H), 3.64 (s, 3H), 3.51 (s, 3H), 3.38 (d, J = 
7.0 Hz, 2H), 2.94–2.75 (m, 2H), 2.49–2.37 (m, 1H), 2.33–2.30 (m, 1H), 2.19–2.16 (m, 1H), 
2.11–2.06 (m, 2H), 1.95–1.81 (m, 4H), 1.55–1.43 (m, 4H), 1.34 (s, 9H), 0.92 (s, 3H).  
13C NMR (125 MHz, CDCl3) δ = 172.7 (Cq), 158.0 (CH), 157.4 (Cq), 157.3 (Cq), 155.2 (Cq), 
137.9 (Cq), 136.0 (Cq), 132.5 (Cq), 128.4 (Cq), 126.3 (CH), 125.1 (CH), 122.4 (CH), 121.8 (Cq), 
119.6 (Cq), 119.0 (CH), 117.5 (CH), 114.2 (CH), 113.7 (CH), 111.4 (CH), 99.8 (Cq), 86.8 (Cq), 
79.8 (Cq), 79.8 (Cq), 55.2 (CH3), 54.0 (CH), 53.6 (CH3), 52.3 (CH3), 49.9 (CH), 48.1 (Cq), 43.5 
(CH), 39.2 (CH), 36.8 (CH2), 34.5 (CH2), 29.8 (CH2), 28.3 (CH2), 28.2 (CH3), 27.3 (CH2), 26.6 
(CH2), 22.9 (CH2), 12.8 (CH3).  
IR (neat): 2976, 2930, 2868, 1714, 1498, 1423, 1156, 745 cm-1.  
MS (ESI) m/z (relative intensity) 741 (32) [M+Na+].  









The general procedure F was followed using substrate 153b (156 mg, 0.25 mmol) and 61a (78 
mg, 0.3 mmol). Isolation by column chromatography (n-hexane/EtOAc: 1/2) yielded 154b (141 
mg, 70%) as a white solid.  
M. p. = 207–208 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.77 (d, J = 4.8 Hz, 2H), 8.30 (d, J = 8.4 Hz, 1H), 7.52 (d, J 
= 7.9 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.38 (t, J = 5.9 Hz, 1H), 7.31 (ddd, J = 8.5, 7.1, 1.3 Hz, 
1H), 7.23–7.19 (m, 2H), 6.14 (d, J = 5.5 Hz, 1H), 5.82 (d, J = 2.2 Hz, 1H), 4.51 (m, 1H), 4.34 
(td, J = 5.8, 2.2 Hz, 1H), 4.19 (dd, J = 17.6, 6.4 Hz, 1H), 3.92 (dd, J = 17.7, 5.2 Hz, 1H), 3.89 
(dd, J = 5.6, 3.5 Hz, 1H), 3.72 (s, 3H), 3.54–3.41 (m, 2H), 2.07–2.03 (m, 1H), 1.41 (d, J = 7.4 
Hz, 3H), 1.36 (s, 9H), 1.19–1.08 (m, 21H), 0.64 (d, J = 7.0 Hz, 3H), 0.29 (d, J = 6.9 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 173.1 (Cq), 172.8 (Cq), 170.4 (Cq), 169.9 (Cq), 158.0 (CH), 
157.0 (Cq), 156.6 (Cq), 135.8 (Cq), 127.9 (Cq), 125.8 (CH), 122.9 (CH), 122.5 (Cq), 119.8 (Cq), 
119.3 (CH), 117.7 (CH), 114.5 (CH), 102.4 (Cq), 98.1 (Cq), 81.6 (Cq), 59.6 (CH), 57.8 (CH), 
52.0 (CH3), 49.1 (CH), 41.3 (CH2), 28.5 (CH3), 28.2 (CH), 26.5 (CH2), 18.8 (CH3), 18.5 (CH3), 
17.3 (CH3), 16.7 (CH3), 11.5 (CH).  
IR (neat): 3285, 2940, 2865, 1721, 1634, 1451, 1339, 1161, 678 cm-1.  
MS (ESI) m/z (relative intensity): 826 (80) [M+Na+].  









The general procedure F was followed using substrate 153c (346 mg, 0.5 mmol) and 61a (157 
mg, 0.6 mmol). Isolation by column chromatography (n-hexane/EtOAc: 1/1 → 1/2) yielded 
154c (230 mg, 53%) as a white solid.  
M. p. = 190–191 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.78 (d, J = 4.8 Hz, 2H), 8.31 (d, J = 8.5 Hz, 1H), 7.51 (d, J 
= 8.0 Hz, 1H), 7.44–7.42 (m, 2H), 7.32 (ddd, J = 8.4, 7.1, 1.2 Hz, 1H), 7.25–7.20 (m, 1H), 7.20 
(d, J = 4.8 Hz, 1H), 6.12 (d, J = 5.4 Hz, 1H), 5.84 (d, J = 1.9 Hz, 1H), 4.52–4.47 (m, 1H), 4.33 
(td, J = 5.0, 2.1 Hz, 1H), 4.26–4.18 (m, 2H), 4.13 (dd, J = 17.6, 6.1 Hz, 1H), 3.98 (dd, J = 17.6, 
5.6 Hz, 1H), 3.86 (dd, J = 5.4, 3.4 Hz, 1H), 3.52–3.43 (m, 2H), 3.44–3.37 (m, 2H), 2.08–2.03 
(m, 1H), 1.91 (tt, J = 6.5, 6.5 Hz, 2H), 1.42 (d, J = 7.4 Hz, 3H), 1.36 (s, 9H), 1.18–1.11 (m, 
21H), 0.63 (d, J = 7.0 Hz, 3H), 0.27 (d, J = 7.0 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 173.2 (Cq), 172.9 (Cq), 170.3 (Cq), 169.4 (Cq), 158.0 (CH), 
157.0 (Cq), 156.7 (Cq), 135.8 (Cq), 127.9 (Cq), 125.9 (CH), 122.9 (CH), 122.4 (Cq), 119.8 (Cq), 
119.2 (CH), 117.7 (CH), 114.6 (CH), 102.4 (Cq), 98.1 (Cq), 81.7 (Cq), 61.8 (CH2), 59.7 (CH), 
57.9 (CH), 49.2 (CH), 48.1 (CH2), 41.5 (CH2), 28.5 (CH3), 28.3 (CH2), 28.2 (CH), 26.5 (CH2), 
18.8 (CH3), 18.5 (CH3), 17.3 (CH3), 16.7 (CH3), 11.5 (CH).  
IR (neat): 3283, 2941, 2864, 2141, 1634, 1451, 1164, 675 cm-1.  
MS (ESI) m/z (relative intensity): 895 (20). [M+Na+]  









tryptophanate (154d): The general procedure F was followed using substrate 153d (203 mg, 
0.25 mmol) and 61a (78 mg, 0.30 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 1/2 → 0/1) yielded 154d (181 mg, 73%) as a white solid.  
M. p. = 219–220 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.78 (d, J = 4.8 Hz, 2H), 8.57 (br s, 1H), 8.31 (d, J = 8.4 Hz, 
1H), 7.60 (t, J = 6.2 Hz, 1H), 7.53–7.50 (m, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.30 (ddd, J = 8.3, 
7.0, 1.2 Hz, 2H), 7.20 (t, J = 4.8 Hz, 1H), 7.19–7.15 (m, 2H), 7.14 (d, J = 2.5 Hz, 1H), 7.11 
(ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.05 (ddd, J = 7.9, 6.9, 1.0 Hz, 1H), 6.14 (d, J = 5.1 Hz, 1H), 
5.86 (d, J = 2.1 Hz, 1H), 4.88 (dt, J = 8.1, 5.7 Hz, 1H), 4.53–4.48 (m, 1H), 4.35 (ddd, J = 6.4, 
4.6, 2.0 Hz, 1H), 4.12 (dd, J = 16.5, 6.5 Hz, 1H), 3.91 (dd, J = 16.4, 5.7 Hz, 1H), 3.80 (dd, J = 
5.1, 3.6 Hz, 1H), 3.54 (s, 3H), 3.50–3.41 (m, 2H), 3.38–3.25 (m, 2H), 2.03–1.98 (m, 1H), 1.38 
(d, J = 7.3 Hz, 3H), 1.30 (s, 9H), 1.21–1.10 (m, 21H), 0.65 (d, J = 7.0 Hz, 3H), 0.30 (d, J = 7.0 
Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 173.6 (Cq), 173.2 (Cq), 171.6 (Cq), 170.8 (Cq), 169.0 (Cq), 
158.0 (CH), 157.0 (Cq), 156.9 (Cq), 135.9 (Cq), 135.8 (Cq), 127.9 (Cq), 127.4 (Cq), 125.9 (CH), 
123.8 (CH), 123.0 (CH), 122.3 (Cq), 121.5 (CH), 119.7 (Cq), 119.1 (CH), 119.0 (CH), 118.4 
(CH), 117.7 (CH), 114.6 (CH), 111.0 (CH), 109.7 (Cq), 102.4 (Cq), 98.1 (Cq), 81.7 (Cq), 59.9 
(CH), 58.0 (CH), 52.5 (CH), 52.1 (CH3), 49.3 (CH), 43.9 (CH2), 28.5 (CH3), 28.1 (CH), 27.5 
(CH2), 26.4 (CH2), 18.8 (CH3), 18.4 (CH3), 17.4 (CH3), 16.8 (CH3), 11.5 (CH).  
IR (neat): 3274, 2953, 2863, 2161, 1626, 1423, 1214, 794 cm-1.  
MS (ESI) m/z (relative intensity): 1012 (90) [M+Na+].  







Cyclic peptide 10: The general procedure G was followed using substrate 155 (84 mg, 0.10 
mmol) and MnBr(CO)5 (5.5 mg, 20 mol %) in DCE (10 mL). Isolation by column 
chromatography (EtOAc/CH2Cl2: 4/1) yielded 156 (40 mg, 53%) as a light yellow solid. 
M. p. = 160 °C (decomp.).  
1H NMR (500 MHz, CDCl3) δ = 8.79 (d, J = 4.8 Hz, 2H), 8.29 (d, J = 8.4 Hz, 1H), 7.61 (d, J 
= 7.8 Hz, 1H), 7.39 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.33 (ddd, J = 7.8, 7.1, 1.1 Hz, 1H), 7.23 (t, 
J = 4.8 Hz, 1H), 7.22–7.18 (m, 1H), 7.07 (d, J = 5.7 Hz, 1H), 6.68 (d, J = 6.1 Hz, 1H), 5.05 (d, 
J = 2.6 Hz, 1H), 4.44–4.40 (m, 2H), 4.39–4.32 (m, 2H), 4.31–4.24 (m, 1H), 4.14–4.09 (m, 1H), 
4.02 (dt, J = 9.9, 6.5 Hz, 1H), 3.94 (dt, J = 9.9, 6.1 Hz, 1H), 3.73 (dd, J = 17.8, 3.3 Hz, 1H), 
3.54 (dd, J = 14.5, 5.1 Hz, 1H), 3.10 (dd, J = 14.5, 10.6 Hz, 1H), 2.45 (ddt, J = 10.1, 7.1, 2.6 
Hz, 1H), 2.05–1.95 (m, 2H), 1.68–1.61 (m, 4H), 1.55–1.44 (m, 4H), 1.41 (d, J = 7.4 Hz, 3H), 
1.34 (s, 9H), 1.01 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 6.9 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 172.7 (Cq), 171.9 (Cq), 170.2 (Cq), 169.1 (Cq), 158.0 (CH), 
156.8 (Cq), 156.4 (Cq), 135.7 (Cq), 128.6 (Cq), 125.4 (CH), 122.9 (CH), 119.8 (Cq), 119.5 (Cq), 
118.0 (CH), 117.6 (CH), 114.6 (CH), 101.3 (Cq), 81.5 (Cq), 74.8 (Cq), 64.0 (Cq), 61.3 (CH2), 
59.7 (CH), 56.9 (CH), 49.5 (CH), 41.8 (CH2), 37.1 (CH2), 37.0 (CH2), 28.8 (CH), 28.1 (CH3), 
27.2 (CH2), 25.4 (CH2), 22.6 (CH2), 19.6 (CH3), 17.1 (CH3).  
MS (ESI) m/z (relative intensity): 780 (90) [M+Na+].  










C–H Alkynylations with Cyclometalated Complex 152 
 
 
Following a modification of a reported procedure,[106] 1-(pyrimidin-2-yl)-1H-indole (83b) (195 
mg, 1.0 mmol), MnBr(CO)5 (274 mg, 1.0 mmol), Cy2NH (362 mg, 2.0 mmol) and DCE (2.0 
mL) were placed in a 25 mL Schlenk tube under N2 and then stirred at 80 °C for 30 min. At 
ambient temperature, the mixture was diluted with EtOAc (20 ml) and filtered through a short 
pad of celite. The solvent was removed by rotary evaporation and the residue was purified by 
column chromatography on silica gel (n-hexane/EtOAc: 20/1) afforded 152 (279 mg, 77%) as 
a yellow solid. 
M. p. = 150–151 °C.  
1H NMR (300 MHz, CDCl3) δ = 8.69 (dd, J = 4.8, 2.4 Hz, 1H), 8.57 (dd, J = 5.6, 2.4 Hz, 1H), 
8.50 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 7.5 Hz, 1H), 7.20 (dd, J = 7.5, 7.3 Hz, 1H), 7.12 (dd, J = 
7.5, 7.2, 1H), 6.85 (t, J = 5.2 Hz, 1H), 6.79 (s, 1H).  
13C NMR (125 MHz, CDCl3) δ = 218.4 (Cq), 213.1 (Cq), 210.7 (Cq), 162.2 (CH), 161.3 (Cq), 
160.9 (Cq), 160.1 (CH), 138.5 (Cq), 136.0 (Cq), 122.9 (CH), 120.7 (CH), 119.3 (CH), 117.5 
(CH), 114.1 (CH), 113.6 (CH).  
IR (neat): 2078, 1974, 1937, 1920, 1575, 1491, 1380, 787, 639 cm-1.  
MS (EI) m/z (relative intensity): 360 (5) [M +], 249 (35), 195 (100).  








Complex 152 (72 mg, 0.2 mmol), bromoalkyne 61a (62 mg, 0.24 mmol), and DCE (0.5 mL) 
were placed in a 25 mL Schlenk tube under N2 and were then stirred at 80 °C for 30 min. At 
ambient temperature, CH2Cl2 (2 mL) was added, and the reaction mixture was transferred into 
a round bottom flask with CH2Cl2 and concentrated under reduced pressure. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 10/1) afforded 138ba (64 mg, 84%). 
 
 
1-(Pyrimidin-2-yl)-1H-indole (83b) (98 mg, 0.5 mmol), bromoalkyne 61a (157 mg, 0.6 mmol), 
152 (9 mg, 5.0 mol %), Cy2NH (181 mg, 1.0 mmol) and DCE (1.0 mL) were placed in a 25 mL 
Schlenk tube under N2 and then stirred at 80 °C for 16 h. At ambient temperature, the mixture 
was diluted with EtOAc (20 ml) and filtered through a short pad of celite. The solvent was 
removed by rotary evaporation and the residue was purified by column chromatography on 
silica gel (n-hexane/EtOAc: 10/1) afforded 138ba (197 mg, 99% based on 0.525 mmol). 
 
Reactions under air or in the presence of radical scavenger 
 
 
(a) 1-(Pyrimidin-2-yl)-1H-indole (83b) (98 mg, 0.5 mmol), MnBr(CO)5 (6.9 mg, 5.0 mol %), 
bromoalkyne (61a) (157 mg, 0.6 mmol), Cy2NH (181 mg, 1.0 mmol) and DCE (1.0 mL) were 





temperature, the reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (3 
× 15 mL). The combined organic layer was dried with Na2SO4 and concentrated under reduced 
pressure. Purification by column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded 
138ba (99 mg, 53%). 
 
(b) 1-(Pyrimidin-2-yl)-1H-indole (83b) (98 mg, 0.5 mmol), MnBr(CO)5 (6.9 mg, 5.0 mol %), 
bromoalkyne (61a) (157 mg, 0.6 mmol), Cy2NH (181 mg, 1.0 mmol), TEMPO (78 mg, 0.5 
mmol) and DCE (1.0 mL) were placed in a 25 mL Schlenk tube under N2 and were then stirred 
at 80 °C for 16 h. At ambient temperature, the reaction mixture was diluted with H2O (10 mL) 
and extracted with EtOAc (3 × 15 mL). The combined organic layer was dried with Na2SO4 
and concentrated under reduced pressure. Purification by column chromatography on silica gel 
(n-hexane/EtOAc: 10/1) yielded 138ba (17 mg, 9%). 
 
Intermolecular Competition Experiment 
 
 
5-Methoxy-1-(pyrimidin-2-yl)-1H-indole (83c) (113 mg, 0.5 mmol), 5-fluoro-1-(pyrimidin-2-
yl)-1H-indole (83g) (107 mg, 0.5 mmol), bromoalkyne 61a (157 mg, 0.6 mmol), MnBr(CO)5 
(6.9 mg, 5.0 mol %), Cy2NH (181.3 mg, 1.0 mmol), and DCE (1.0 mL) were placed in a 25 mL 
Schlenk tube under N2 and were then stirred at 80 °C for 16 h. At ambient temperature, CH2Cl2 
(2.0 mL) was added, and the reaction mixture was transferred into a round flask with CH2Cl2 
and concentrated under reduced pressure. Purification by column chromatography on silica gel 






H/D Exchange experiments 
 
 
1-(Pyrimidin-2-yl)-1H-indole (83b) (98 mg, 0.5 mmol), MnBr(CO)5 (6.9 mg, 5.0 mol %), 
bromoalkyne 61a (157 mg, 0.6 mmol), Cy2NH (181 mg, 1.0 mmol), DCE (0.9 mL) and D2O 
(0.1 mL) were placed in a 25 mL Schlenk tube under N2 and were then stirred at 80 °C for 3 h. 
At ambient temperature, the reaction mixture was diluted with H2O (10 mL) and extracted with 
EtOAc (3 × 15 mL). The combined organic layer was dried with Na2SO4 and concentrated 
under reduced pressure. Purification by column chromatography on silica gel (n-hexane/EtOAc: 
10/1) yielded [D]n-83b (71 mg, 72%) and [D]n-138ba (50 mg, 27%). The D incorporation was 









H/D Exchange experiments in the absence of MnBr(CO)5 
 
 
1-(Pyrimidin-2-yl)-1H-indole (83b) (49 mg, 0.25 mmol), bromoalkyne 61a (77 mg, 0.3 mmol), 
Cy2NH (93 mg, 0.5 mmol), DCE (0.9 mL) and D2O (0.1 mL) were placed in a 25 mL Schlenk 
tube under N2 and were then stirred at 80 °C for 3 h. At ambient temperature, the reaction 
mixture was diluted with H2O (10 mL) and extracted with EtOAc (3 × 15 mL). The combined 
organic layer was dried with Na2SO4 and concentrated under reduced pressure. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded [D]n-83b (47 mg, 95%). 








1-(Pyrimidin-2-yl)-2-[(triisopropylsilyl)ethynyl]-1H-indole (138ba) (95 mg, 0.25 mmol), 
Cy2NH (190 mg, 0.5 mmol), DCE (0.9 mL) and D2O (0.1 mL) were placed in a 25 mL Schlenk 
tube under N2 and were then stirred at 80 °C for 3 h. At ambient temperature, the reaction 
mixture was diluted with H2O (10 mL) and extracted with EtOAc (3 × 15 mL). The combined 
organic layer was dried with Na2SO4 and concentrated under reduced pressure. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded [D]n-138ba (91 mg, 









Seven independent reactions of 83b or [D]1-83b with 61a were performed to determine the 
corresponding KIE value. 83b (98 mg, 0.50 mmol) or [D]1-83b (98 mg, 0.50 mmol), 61a (157 
mg, 0.6 mmol), MnBr(CO)5 (6.9 mg, 5.0 mol %), and DCE (1.0 mL) were placed in 25 mL 
Schlenk tubes. The mixtures were stirred at 80 °C. After cooling to ambient temperature, the 
GC conversions were determined by using n-dodecane as internal standard:  
 
T [min] 30 50 70 90 110 130 150 
138ba/% 22 32 40 48 54 60 67 







Removal of the Directing Group 
 
2-(Phenylethynyl)-1H-indole (151): To a solution of 150bg (59 mg, 0.2 mmol) in dry DMSO 
(1.5 mL) and dry MeOH (0.5 mL), NaOEt (41mg, 0.6 mmol, 3.0 equiv) was added and stirred 
for 3 h at 80 °C. Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 151 (35 
mg, 81%) as a yellow solid.  
M. p. = 160–161 °C.  
1H NMR (400 MHz, CDCl3) δ = 8.21 (br s, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.58–7.51 (m, 2H), 
7.38–7.35 (m, 3H), 7.32 (dd, J = 8.2, 1.0 Hz, 1H), 7.28–7.20 (m, 1H), 7.14 (ddd, J = 8.2, 7.0, 
1.2 Hz, 1H), 6.84 (dd, J = 2.3, 1.1 Hz, 1H).  
13C NMR (100 MHz, CDCl3) δ = 136.1 (Cq), 131.4 (CH), 128.6 (CH), 128.4 (CH), 127.8 (Cq), 
123.5 (CH), 122.6 (Cq), 120.8 (CH), 120.5 (CH), 118.8 (Cq), 110.7 (CH), 108.8 (CH), 92.5 (Cq), 
81.8 (Cq).  
IR (neat): 3368, 1594, 1351, 1305, 795, 745, 689, 657 cm-1.  
MS (ESI) m/z (relative intensity): 218 [M+H+] (30).  
HR-MS (ESI) m/z calcd for C16H12N [M+H+] 218.0964, found 218.0963. 
The analytical data are in accordance with those previously published in the literature.[170] 
y = 0.3661x + 13.196
R² = 0.9921





































5.3.5 Characterization Data: Ruthenium(II)-Catalyzed meta-C–H Mono- and 
Difluoromethylations by Phosphine/Carboxylate Cooperation 
 
Ethyl 2,2-difluoro-2-[3-(pyridin-2-yl)phenyl]acetate (140aa): The general procedure H was 
followed using substrate 95a (78 mg, 0.50 mmol) and 139a (304 mg, 1.5 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 9/1) yielded 140aa (99 mg, 71%) as a colorless oil. 
A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 yielded 140aa (100 mg, 
72%).  
1H NMR (300 MHz, CDCl3) δ = 8.71 (ddd, J = 4.8, 1.6, 1.1 Hz, 1H), 8.24 (ddt, J = 1.9, 1.3, 
0.7 Hz, 1H), 8.16 (dddt, J = 7.6, 1.9, 1.4, 0.7 Hz, 1H), 7.83–7.73 (m, 2H), 7.66 (ddd, J = 7.8, 
1.9, 1.3 Hz, 1H), 7.57 (dd, J = 7.8, 7.6 Hz, 1H), 7.30–7.25 (m, 1H), 4.31 (q, J = 7.1 Hz, 2H), 
1.31 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 164.0 (t, 2JC-F = 35.2 Hz, Cq), 156.0 (Cq), 149.7 (CH), 139.8 
(Cq), 136.8 (CH), 133.3 (t, 2JC-F = 25.5 Hz, Cq), 129.4 (t, 4JC-F = 1.7 Hz, CH), 129.1 (CH), 125.8 
(t, 3JC-F = 6.0 Hz, CH), 123.9 (t, 3JC-F = 6.3 Hz, CH), 122.6 (CH), 120.6 (CH), 113.3 (t, 1JC-F = 
252.0 Hz, Cq), 63.2 (CH2), 14.0 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -103.7 (s). 
IR (neat): 2986, 1761, 1585, 1463, 1290, 1100, 777 cm-1.  
MS (ESI) m/z (relative intensity) 278 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C15H14F2NO2 [M+H+] 278.0987, found 278.0994. 
 
 
Ethyl 2,2-difluoro-2-[2-fluoro-5-(pyridin-2-yl)phenyl]acetate (140ba): The general 
procedure H was followed using substrate 95b (87 mg, 0.50 mmol) and 139a (304 mg, 1.5 





72%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 140ba (110 mg, 75%).  
1H NMR (300 MHz, CDCl3) δ = 8.60 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.21 (dd, J = 7.0, 2.2 Hz, 
1H), 8.06 (dddt, J = 8.8, 4.9, 2.2, 0.8 Hz, 1H), 7.81–7.49 (m, 2H), 7.21–7.16 (m, 1H), 7.15–
7.11 (m, 1H), 4.28 (q, J = 7.1 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ =162.9 (t, 2JC-F = 33.9 Hz, Cq), 160.1 (dt, 1, 3JC-F = 254.5, 4.6 
Hz, Cq), 155.0 (Cq), 149.6 (CH), 136.9 (CH), 135.7 (d, 4JC-F = 3.5 Hz, Cq), 131.3 (d, 3JC-F = 8.7 
Hz, CH), 125.6 (td, 3, 3JC-F = 7.1, 2.6 Hz, CH), 122.5 (CH), 121.1 (td, 2, 2JC-F = 25.7, 12.9 Hz, 
Cq), 120.2 (CH), 116.6 (d, 2JC-F = 21.1 Hz, CH), 111.5 (t, 1JC-F = 251.1 Hz, Cq), 63.4 (CH2), 13.8 
(CH3).  
19F NMR (283 MHz, CDCl3) δ = -102.0 (d, J = 7.5 Hz), -114.8 (s).  
IR (neat): 2987, 1763, 1589, 1465, 1218, 1088, 779 cm-1.  
MS (ESI) m/z (relative intensity) 318 (20) [M+Na+], 296 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C15H13F3NO2 [M+H+] 296.0893, found 296.0902. 
 
 
Ethyl 2,2-difluoro-2-[2-methoxy-5-(pyridin-2-yl)phenyl]acetate (140ca): The general 
procedure H was followed using substrate 95c (93 mg, 0.50 mmol) and 139a (304 mg, 1.5 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 140ca (77 mg, 
50%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 140ca (108 mg, 70%).  
1H NMR (600 MHz, CDCl3) δ = 8.69 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.85 (ddd, J = 7.8, 1.7, 
0.8 Hz, 1H), 7.75 (dd, J = 7.9, 1.0 Hz, 1H), 7.72–7.65 (m, 2H), 7.29 (dd, J = 7.7, 7.7 Hz, 1H), 
7.24–7.22 (m, 1H), 4.34 (q, J = 7.1 Hz, 2H), 3.37 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 163.6 (t, 2JC-F = 33.7 Hz, Cq), 155.5 (t, 3JC-F = 5.2 Hz, Cq), 
154.9 (Cq), 149.8 (CH), 136.2 (CH), 134.3 (t, 4JC-F = 1.8 Hz, CH), 133.5 (Cq), 127.7 (t, 2JC-F = 
24.5 Hz, Cq), 126.6 (t, 3JC-F = 7.2 Hz, CH), 124.2 (CH), 124.1 (CH), 122.3 (CH), 112.2 (t, 1JC-F 





19F NMR (283 MHz, CDCl3) δ = -100.8 (s).  
IR (neat): 2986, 1772, 1586, 1457, 1304, 1091, 765 cm-1.  
MS (ESI) m/z (relative intensity) 330 (10) [M+Na+], 308 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C16H16F2NO3 [M+H+] 308.1093, found 308.1094. 
 
 
Ethyl 2-[2-chloro-5-(pyridin-2-yl)phenyl]-2,2-difluoroacetate (140da): The general 
procedure H was followed using substrate 95d (95 mg, 0.50 mmol) and 139a (304 mg, 1.5 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 5/1) yielded 140da (120 mg, 
77%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 140da (120 mg, 77%).  
1H NMR (500 MHz, CDCl3) δ = 8.69 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.36 (d, J = 2.3 Hz, 1H), 
8.08 (dd, J = 8.4, 2.3 Hz, 1H), 7.83–7.70 (m, 2H), 7.52 (d, J = 8.4 Hz, 1H), 7.27 (ddd, J = 7.3, 
4.8, 1.5 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ = 162.9 (t, 2JC-F = 33.9 Hz, Cq), 155.0 (Cq), 149.8 (CH), 138.2 
(Cq), 136.9 (CH), 132.4 (t, 3JC-F = 4.3 Hz, Cq), 131.5 (t, 2JC-F = 24.2 Hz, Cq), 130.9 (CH), 130.1 
(CH), 125.7 (t, 3JC-F = 8.6 Hz, CH), 122.8 (CH), 120.4 (CH), 112.1 (t, 1JC-F = 250.8 Hz, Cq), 
63.4 (CH2), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -102.3 (s).  
IR (neat): 2986, 1772, 1588, 1460, 1304, 1080, 778 cm-1.  
MS (ESI) m/z (relative intensity) 334 (5) [M+Na+], 312 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C15H13ClF2NO2 [M+H+] 312.0597, found 312.0602. 
 
 
Ethyl 2,2-difluoro-2-[3-(4-methylpyridin-2-yl)phenyl]acetate (140ea): The general 
procedure H was followed using substrate 95e (85 mg, 0.50 mmol) and 139a (304 mg, 1.5 





70%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 140ea (108 mg, 74%).  
1H NMR (500 MHz, CDCl3) δ = 8.56 (d, J = 5.0 Hz, 1H), 8.20 (d, J = 1.8 Hz, 1H), 8.15 (d, J 
= 7.8 Hz, 1H), 7.64 (dd, J = 7.9, 1.8 Hz, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.55 (dd, J = 7.9, 7.8 
Hz, 1H), 7.09 (dd, J = 5.0, 1.8 Hz, 1H), 4.31 (q, J = 7.1 Hz, 2H), 2.43 (s, 3H), 1.30 (t, J = 7.1 
Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 164.0 (t, 2JC-F = 35.2 Hz, Cq), 155.9 (Cq), 149.4 (CH), 147.9 
(Cq), 134.0 (Cq), 133.2 (t, 2JC-F = 25.5 Hz, Cq), 129.4 (t, 4JC-F = 1.8 Hz, CH), 129.0 (CH), 125.7 
(t, 3JC-F = 6.1 Hz, CH), 123.8 (t, 3JC-F = 6.2 Hz, CH), 123.6 (CH), 121.5 (CH), 113.3 (t, 1JC-F = 
251.9 Hz, Cq), 63.2 (CH2), 21.2 (CH3), 13.9 (CH3).  
19F NMR (376 MHz, CDCl3) δ = -103.7 (s).  
IR (neat): 2986, 1761, 1603, 1244, 1099, 1025, 803 cm-1.  
MS (ESI) m/z (relative intensity) 314 (5) [M+Na+], 292 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C16H15F2NO2Na [M+Na+] 314.0963, found 314.0959. 
 
 
Ethyl 2,2-difluoro-2-[3-(4-methylpyridin-2-yl)phenyl]acetate (140fa): The general 
procedure H was followed using substrate 95f (93 mg, 0.50 mmol) and 139a (304 mg, 1.5 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 140fa (132 mg, 
86%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 140fa (126 mg, 82%).  
1H NMR (300 MHz, CDCl3) δ = 8.50 (d, J = 5.7 Hz, 1H), 8.17 (ddt, J = 1.9, 1.3, 0.7 Hz, 1H), 
8.10 (ddd, J = 7.7, 1.9, 1.3 Hz, 1H), 7.63 (dddt, J = 7.8, 1.9, 1.3, 0.6 Hz, 1H), 7.53 (dd, J = 7.8, 
7.7 Hz, 1H), 7.22 (d, J = 2.4 Hz, 1H), 6.79 (dd, J = 5.7, 2.4 Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 
3.90 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 166.4 (Cq), 164.0 (t, 2JC-F = 35.1 Hz, Cq), 157.7 (Cq), 150.9 





(t, 3JC-F = 6.1 Hz, CH), 123.9 (t, 3JC-F = 6.3 Hz, CH), 113.3 (t, 2JC-F = 251.9 Hz, Cq), 108.5 (CH), 
107.1 (CH), 63.2 (CH2), 55.3 (CH3), 14.0 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -103.7.  
IR (neat): 2985, 1761, 1592, 1474, 1300, 1098, 805 cm-1.  
MS (ESI) m/z (relative intensity) 308 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C16H16F2NO3 [M+H+] 308.1093, found 308.1097. 
 
 
Ethyl 2,2-difluoro-2-[3-(5-fluoropyridin-2-yl)phenyl]acetate (140ga): The general 
procedure H was followed using substrate 95g (87 mg, 0.50 mmol) and 139a (304 mg, 1.5 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 140ga (111 mg, 
75%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 140ga (114 mg, 77%).  
1H NMR (600 MHz, CDCl3) δ = 8.52 (d, J = 2.9 Hz, 1H), 8.17 (s, 1H), 8.06 (d, J = 7.8 Hz, 
1H), 7.72 (dd, J = 8.8, 4.2 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.53 (dd, J = 7.8, 7.8 Hz, 1H), 
7.46 (ddd, J = 8.9, 8.0, 2.9 Hz, 1H), 4.29 (q, J = 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 163.9 (t, 2JC-F = 35.1 Hz, Cq), 158.9 (d, 1JC-F = 256.8 Hz, Cq), 
152.2 (d, 4JC-F = 4.0 Hz, Cq), 138.8 (Cq), 137.8 (d, 2JC-F = 23.6 Hz, CH), 133.4 (t, 2JC-F = 25.5 
Hz, Cq), 129.1 (CH), 129.0 (CH), 125.7 (t, 3JC-F = 6.0 Hz, CH), 123.7 (t, 3JC-F = 6.3 Hz, CH), 
123.5 (d, 2JC-F = 18.6 Hz, CH), 121.3 (d, 3JC-F = 4.4 Hz, CH), 113.2 (t, 1JC-F = 252.0 Hz, Cq), 
63.2 (CH2), 13.9 (CH3).  
19F NMR (376 MHz, CDCl3) δ = -103.7 (s, 2F), -128.6 (dd, J = 8.0, 4.3 Hz, 1F).  
IR (neat): 2986, 1761, 1470, 1286, 1226, 1084, 837 cm-1.  
MS (ESI) m/z (relative intensity) 318 (30) [M+Na+], 296 (100) [M+H+].  







Ethyl 2,2-difluoro-2-[3-(5-methylpyridin-2-yl)phenyl]acetate (140ha): The general 
procedure H was followed using substrate 95h (85 mg, 0.50 mmol) and 139a (304 mg, 1.5 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 140ha (99 mg, 
68%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 140ha (97 mg, 67%).  
1H NMR (600 MHz, CDCl3) δ = 8.50 (s, 1H), 8.18 (s, 1H), 8.10 (d, J = 7.7 Hz, 1H), 7.62 (d, J 
= 7.8 Hz, 1H), 7.61 (d, J = 7.7 Hz, 1H), 7.55 (d, J = 8.0, 1H), 7.52 (dd, J = 8.0, 7.8 Hz, 1H), 
4.28 (q, J = 7.1 Hz, 2H), 2.35 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 164.0 (t, 2JC-F = 35.2 Hz, Cq), 153.3 (Cq), 150.1 (CH), 139.9 
(Cq), 137.3 (CH), 133.2 (t, 2JC-F = 25.5 Hz, Cq), 132.2 (Cq), 129.1 (t, 4JC-F = 1.8 Hz, CH), 128.9 
(CH), 125.4 (t, 3JC-F = 6.0 Hz, CH), 123.6 (t, 3JC-F = 6.2 Hz, CH), 120.0 (CH), 113.3 (t, 1JC-F = 
251.8 Hz, Cq), 63.1 (CH2), 18.2 (CH3), 13.9 (CH3).  
19F NMR (376 MHz, CDCl3) δ = -103.7 (s).  
IR (neat): 2986, 1761, 1471, 1289, 1216, 1099, 802 cm-1.  
MS (ESI) m/z (relative intensity) 314 (5) [M+Na+], 292 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C16H16F3NO2 [M+H+] 292.1144, found 292.1151. 
 
 
Ethyl 2,2-difluoro-2-[3-(pyrimidin-2-yl)phenyl]acetate (140ia): The general procedure H 
was followed using substrate 95i (78 mg, 0.50 mmol) and 139a (304 mg, 1.5 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 8/1) yielded 140ia (107 mg, 77%) as a white 
solid. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 yielded140ia (100 
mg, 72%).  





1H NMR (600 MHz, CDCl3) δ = 8.80 (d, J = 4.8 Hz, 2H), 8.72 (s, 1H), 8.56 (dd, J = 7.9, 1.8 
Hz, 1H), 7.71 (dd, J = 7.8, 1.8 Hz, 1H), 7.56 (dd, J = 7.9, 7.8 Hz, 1H), 7.20 (t, J = 4.8 Hz, 1H), 
4.29 (q, J = 7.1, 2H), 1.28 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 164.0 (t, 2JC-F = 35.1 Hz, Cq), 163.4 (Cq), 157.2 (CH), 138.1 
(Cq), 133.3 (t, 2JC-F = 25.6 Hz, Cq), 130.5 (t, 4JC-F = 1.9 Hz, CH), 128.9 (CH), 127.5 (t, 3JC-F = 
6.0 Hz, CH), 125.3 (t, 3JC-F = 6.3 Hz, CH), 119.5 (CH), 113.3 (t, 1JC-F = 251.9 Hz, Cq), 63.2 
(CH2), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -103.6 (s).  
IR (neat): 2996, 1766, 1557, 1410, 1132, 1021, 806 cm-1.  
MS (ESI) m/z (relative intensity) 301 (50) [M+Na+], 279 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C14H13F2N2O2 [M+H+] 279.0940, found 279.0946. 
 
 
Ethyl 2-[5-(1H-indazol-1-yl)-2-methylphenyl]-2,2-difluoroacetate (140ja): The general 
procedure H was followed using substrate 95j (104 mg, 0.50 mmol) and 139a (304 mg, 1.5 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 140ja (69 mg, 
42%) as a white solid. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 140ja (68 mg, 41%).  
M. p. = 77–78 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.20 (s, 1H), 7.98 (d, J = 2.3 Hz, 1H), 7.79 (d, J = 8.1 Hz, 
1H), 7.74 (dd, J = 8.2, 2.4 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.46–7.42 (m, 1H), 7.39 (d, J = 
8.2 Hz, 1H), 7.23 (m, 1H), 4.33 (q, J = 7.1 Hz, 2H), 2.48 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 163.6 (t, 2JC-F = 34.8 Hz, Cq), 138.6 (Cq), 138.2 (Cq), 135.6 
(CH), 134.5 (t, 3JC-F = 3.1 Hz, Cq), 132.9 (CH), 132.2 (t, 2JC-F = 23.7 Hz, Cq), 127.3 (CH), 125.3 
(Cq), 124.5 (t, 4JC-F = 1.4 Hz, CH), 121.6 (CH), 121.3 (CH), 120.2 (t, 3JC-F = 9.3 Hz, CH), 113.6 
(t, 1JC-F = 252.1 Hz, Cq), 110.1 (CH), 63.3 (CH2), 19.3 (t, 4JC-F = 2.7 Hz, CH3), 13.9 (CH3).  
19F NMR (376 MHz, CDCl3) δ = -101.6 (d, J = 2.3 Hz).  





MS (ESI) m/z (relative intensity) 353 (50) [M+Na+], 331 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C18H17F2N2O2 [M+H+] 331.1253, found 331.1255. 
 
 
Ethyl 2,2-difluoro-2-[2-fluoro-5-(1H-pyrazol-1-yl)phenyl]acetate (140ka): The general 
procedure H was followed using substrate 95k (81 mg, 0.50 mmol) and 139a (304 mg, 1.5 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 140ka (107 mg, 
75%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 140ka (101 mg, 71%).  
1H NMR (600 MHz, CDCl3) δ = 7.96 (dd, J = 6.1, 2.8 Hz, 1H), 7.91 (d, J = 2.5, 1H), 7.84 (ddd, 
J = 8.7, 4.2, 2.8 Hz, 1H), 7.73 (d, J = 1.8 Hz, 1H), 7.23 (dd, J = 9.8, 8.9 Hz, 1H), 6.49 (dd, J = 
2.5, 1.8 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 1.32 (t, J = 7.1 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ = 162.6 (t, 2JC-F = 33.6 Hz, Cq), 157.6 (dt, 1, 3JC-F = 251.8, 4.6 
Hz, Cq), 141.5 (CH), 136.6 (d, 4JC-F = 3.0 Hz, Cq), 126.8 (CH), 123.4 (d, 3JC-F = 8.5 Hz, CH), 
121.9 (td, 2, 2JC-F = 25.9, 14.1 Hz, Cq), 117.8 (td, 3JC-F = 7.4, 2.5 Hz, CH), 117.3 (d, 2JC-F = 22.4 
Hz, CH), 111.1 (t, 1JC-F = 252.0 Hz, Cq), 108.2 (CH), 63.5 (CH2), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -102.3 (d, J = 7.6 Hz, 2F), -117.6 (t, J = 7.6 Hz, 1F).  
IR (neat): 2987, 1764, 1504, 1224, 1088, 1016, 748 cm-1.  
MS (ESI) m/z (relative intensity) 307 (60) [M+Na+], 285 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C13H12F3N2O2 [M+H+] 285.0845, found 285.0848. 
 
 
Ethyl 2,2-difluoro-2-[2-methyl-5-(1H-pyrazol-1-yl)phenyl]acetate (140la): The general 
procedure H was followed using substrate 95l (79 mg, 0.50 mmol) and 139a (304 mg, 1.5 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 10/1) yielded 140la (116 mg, 
83%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 





1H NMR (300 MHz, CDCl3) δ = 7.94–7.87 (m, 2H), 7.75–7.65 (m, 2H), 7.30 (d, J = 8.3 Hz, 
1H), 6.46 (dd, J = 2.5, 1.8 Hz, 1H), 4.31 (q, J = 7.1 Hz, 2H), 2.41 (s, 3H), 1.29 (t, J = 7.1 Hz, 
3H).  
13C NMR (125 MHz, CDCl3) δ = 163.5 (t, 2JC-F = 34.8 Hz, Cq), 141.1 (CH), 138.2 (Cq), 134.2 
(t, 3JC-F = 3.2 Hz, Cq), 132.8 (CH), 132.2 (t, 2JC-F = 23.6 Hz, Cq), 126.6 (CH), 121.1 (t, 4JC-F = 
1.6 Hz, CH), 116.8 (t, 3JC-F = 9.5 Hz, CH), 113.5 (t, 1JC-F = 252.0 Hz, Cq), 107.7 (CH), 63.2 
(CH2), 19.1 (t, 4JC-F = 2.7 Hz, CH3), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -101.8 (s).  
IR (neat): 2985, 1761, 1521, 1282, 1226, 1085, 747 cm-1.  
MS (ESI) m/z (relative intensity) 303 (20) [M+Na+], 281 (100) [M+H+]. 
HR-MS (ESI) m/z calcd for C14H15F2N2O2 [M+H+] 281.1096, found 281.1100. 
 
 
Ethyl 2-(2-acetyl-5-(1H-pyrazol-1-yl)phenyl)-2,2-difluoroacetate (140ma): The general 
procedure H was followed using substrate 95m (93 mg, 0.50 mmol) and 139a (304 mg, 1.5 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 4/1) yielded 140ma (43 mg, 
28%) as a brown solid. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 140ma (83 mg, 53%).  
M. p. = 106–107 °C.  
1H NMR (600 MHz, CDCl3) δ = 8.18 (d, J = 1.9 Hz, 1H), 8.04 (d, J = 2.7 Hz, 1H), 7.99–7.93 
(m, 2H), 7.77 (d, J = 1.7 Hz, 1H), 6.52 (dd, J = 2.6, 1.7 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 2.60 
(s, 3H), 1.33 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 197.9 (Cq), 162.7 (t, 2JC-F = 32.9 Hz, Cq), 142.6 (Cq), 142.4 
(CH), 134.6 (t, 2JC-F = 23.7 Hz, Cq), 133.0 (t, 3JC-F = 2.8 Hz, Cq), 131.9 (CH), 126.9 (CH), 119.8 
(CH), 117.3 (t, 3JC-F = 11.4 Hz, CH), 112.9 (t, 1JC-F = 250.5 Hz, Cq), 109.0 (CH), 62.8 (CH2), 
28.0 (CH3), 13.9 (CH3).  





IR (neat): 3130, 2923, 1762, 1387, 1268, 1120, 1006, 742 cm-1.  
MS (ESI) m/z (relative intensity) 331 (85) [M+Na+], 309 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C15H15F2N2O3 [M+H+] 309.1045, found 309.1048. 
 
 
Ethyl 2-[3-(9-n-butyl-9H-purin-6-yl)phenyl]-2,2-difluoroacetate (141aa): The general 
procedure I was followed using substrate 131a (63 mg, 0.25 mmol) and 139a (152 mg, 0.75 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 3/1) yielded 141aa (73 mg, 
78%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 141aa (73 mg, 78%).  
1H NMR (600 MHz, CDCl3) δ = 9.06 (t, J = 1.9 Hz, 1H), 9.00 (s, 1H), 8.97 (dd, J = 7.9, 1.9 
Hz, 1H), 8.10 (s, 1H), 7.73 (ddt, J = 7.8, 1.9, 1.2 Hz, 1H), 7.62 (dd, J = 7.9, 7.8 Hz, 1H), 4.38–
4.24 (m, 4H), 1.98–1.87 (m, 2H), 1.43–1.32 (m, 2H), 1.29 (t, J = 7.1 Hz, 3H), 0.95 (t, J = 7.4 
Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 163.9 (t, 2JC-F = 35.1 Hz, Cq), 153.0 (Cq), 152.6 (Cq), 152.1 
(CH), 144.5 (CH), 136.3 (Cq), 133.3 (t, 2JC-F = 25.6 Hz, Cq), 132.3 (CH), 131.1 (Cq), 128.8 (CH), 
127.6 (t, 3JC-F = 5.9 Hz, CH), 126.7 (t, 3JC-F = 6.3 Hz, CH), 113.3 (t, 1JC-F = 252.0 Hz, Cq), 63.2 
(CH2), 43.8 (CH2), 32.0 (CH2), 20.0 (CH2), 13.9 (CH3), 13.5 (CH3). 
19F NMR (283 MHz, CDCl3) δ = -103.5 (s).  
IR (neat): 2962, 1761, 1572, 1323, 1084, 800, 645 cm-1.  
MS (ESI) m/z (relative intensity) 397 (40) [M+Na+], 375 (100) [M+H+].  







Ethyl 2-[2-chloro-5-(9-isopropyl-9H-purin-6-yl)phenyl]-2,2-difluoroacetate (141ba): The 
general procedure I was followed using substrate 131b (68 mg, 0.25 mmol) and 139a (152 mg, 
0.75 mmol). Isolation by column chromatography (n-hexane/EtOAc: 1/1) yielded 141ba (82 
mg, 83%) as a brown solid. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 141ba (80 mg, 81%) as a brown solid.  
M. p. = 78–79 °C.  
1H NMR (400 MHz, CDCl3) δ = 9.26 (d, J = 2.1 Hz, 1H), 9.01 (s, 1H), 8.99 (dd, J = 8.4, 2.1 
Hz, 1H), 8.21 (s, 1H), 7.61 (d, J = 8.5 Hz, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.35 (q, J = 7.1 Hz, 
2H), 1.67 (d, J = 6.8 Hz, 6H), 1.30 (t, J = 7.1 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ = 163.0 (t, 2JC-F = 33.8 Hz, Cq), 152.4 (Cq), 152.0 (Cq), 151.9 
(CH), 142.5 (CH), 134.8 (Cq), 134.4 (t, 3JC-F = 5.0 Hz, Cq), 133.2 (CH), 131.6 (t, 2JC-F = 25.2 
Hz, Cq), 131.4 (Cq), 130.8 (CH), 128.6 (t, 3JC-F = 8.7 Hz, CH), 112.1 (t, 1JC-F = 251.2 Hz, Cq), 
63.3 (CH2), 47.4 (CH), 22.5 (CH3), 13.8 (CH3).  
19F NMR (376 MHz, CDCl3) δ = -102.2 (s).  
IR (neat): 3113, 2983, 1757, 1682, 1228, 1078, 837, 635 cm-1.  
MS (ESI) m/z (relative intensity) 417 (10) [M+Na+], 395 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C18H18ClF2N4O2 [M+H+] 395.1081, found 395.1081. 
 
 
Ethyl 2,2-difluoro-2-[5-(9-isopropyl-9H-purin-6-yl)-2-methoxyphenyl]acetate (141ca): 
The general procedure I was followed using substrate 131c (67 mg, 0.25 mmol) and 139a (152 





(80 mg, 82%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-
C6H4CF3)3 yielded 141ca (87 mg, 89%).  
1H NMR (600 MHz, CDCl3) δ = 9.15 (d, J = 2.1 Hz, 1H), 9.01 (dd, J = 8.7, 2.1 Hz, 1H), 8.93 
(s, 1H), 8.14 (s, 1H), 7.07 (d, J = 8.7 Hz, 1H), 4.93 (hept, J = 6.8 Hz, 1H), 4.29 (q, J = 7.1 Hz, 
2H), 3.87 (s, 3H), 1.62 (d, J = 6.8 Hz, 6H), 1.25 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 163.7 (t, 2JC-F = 33.9 Hz, Cq), 158.5 (t, 3JC-F = 4.6 Hz, Cq), 
152.9 (Cq), 151.8 (Cq), 151.7 (CH), 141.7 (CH), 134.1 (CH), 130.8 (Cq), 128.4 (Cq), 128.0 (t, 
3JC-F = 7.6 Hz, CH), 122.1 (t, 2JC-F = 24.1 Hz, Cq), 112.0 (t, 1JC-F = 248.5 Hz, Cq), 111.1 (CH), 
62.6 (CH2), 55.9 (CH3), 47.2 (CH), 22.5 (CH3), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -102.8 (s).  
IR (neat): 2981, 1758, 1575, 1507, 1274, 1022, 645 cm-1.  
MS (ESI) m/z (relative intensity) 413 (25) [M+Na+], 319 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C19H21F2N4O3 [M+H+] 391.1576, found 391.1576. 
 
 
Ethyl 2-[2-acetyl-5-(9-isopropyl-9H-purin-6-yl)phenyl]-2,2-difluoroacetate (141da): The 
general procedure I was followed using substrate 131d (70 mg, 0.25 mmol) and 139a (152 mg, 
0.75 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1) yielded 141da (20 
mg, 20%) as a brown solid. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 141da (60 mg, 60%).  
M. p. = 125–126 °C.  
1H NMR (600 MHz, CDCl3) δ = 9.33 (d, J = 1.6 Hz, 1H), 9.12 (dd, J = 8.1, 1.6 Hz, 1H), 9.04 
(s, 1H), 8.22 (s, 1H), 7.97 (d, J = 8.1 Hz, 1H), 4.98 (hept, J = 6.8 Hz, 1H), 4.35 (q, J = 7.1 Hz, 





13C NMR (125 MHz, CDCl3) δ = 199.5 (Cq), 163.0 (t, 2JC-F = 33.5 Hz, Cq), 152.5 (Cq), 151.9 
(CH), 151.7 (Cq), 142.8 (CH), 139.2 (Cq), 137.5 (t, 3JC-F = 3.8 Hz, Cq), 132.6 (t, 2JC-F = 23.8 Hz, 
Cq), 131.9 (CH), 131.8 (Cq), 129.8 (CH), 128.3 (t, 3JC-F = 10.4 Hz, CH), 113.3 (t, 1JC-F = 250.0 
Hz, Cq), 62.7 (CH2), 47.6 (CH), 28.5 (CH3), 22.6 (CH3), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -99.3 (s). 
IR (neat): 2985, 1773, 1582, 1224, 1109, 1022, 764 cm-1.  
MS (ESI) m/z (relative intensity) 425 (40) [M+Na+], 403 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C20H21F2N4O3 [M+H+] 403.1576, found 403.1576. 
 
 
Ethyl 2,2-difluoro-2-[3-(9-phenyl-9H-purin-6-yl)phenyl]acetate (141ea): The general 
procedure I was followed using substrate 131e (68 mg, 0.25 mmol) and 139a (152 mg, 0.75 
mmol). Isolation by column chromatography (n-hexane/EtOAc: 4/1) yielded 141ea (62 mg, 
63%) as a white solid. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 
yielded 141ea (74 mg, 75%).  
M. p. = 81–82 °C.  
1H NMR (400 MHz, CDCl3) δ = 9.12 (d, J = 1.8 Hz, 1H), 9.07 (s, 1H), 9.02 (dd, J = 7.9, 1.7 
Hz, 1H), 8.39 (s, 1H), 7.77 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H), 7.75–7.71 (m, 2H), 7.66 (dd, J = 7.9, 
7.8 Hz, 1H), 7.62–7.56 (m, 2H), 7.51–7.45 (m, 1H), 4.32 (q, J = 7.1 Hz, 2H), 1.31 (t, J = 7.1 
Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ = 164.0 (t, 2JC-F = 35.1 Hz, Cq), 153.8 (Cq), 153.0 (CH), 152.4 
(Cq), 143.6 (CH), 136.1 (Cq), 134.2 (Cq), 133.4 (t, 2JC-F = 25.7 Hz, Cq), 132.4 (t, 4JC-F = 1.7 Hz, 
CH), 131.6 (Cq), 123.0 (CH), 129.0 (CH), 128.6 (CH), 127.9 (t, 3JC-F = 6.0 Hz, CH), 126.8 (t, 
3JC-F = 6.4 Hz, CH), 123.7 (CH), 113.3 (t, 1JC-F = 252.4 Hz, Cq), 63.2 (CH2), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -103.5 (s).  





MS (ESI) m/z (relative intensity) 417 (10) [M+Na+], 395 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C21H17F2N4O2 [M+H+] 395.1314, found 395.1314. 
 
 
Ethyl 2-{3-[9-(4-acetylphenyl)-9H-purin-6-yl]phenyl}-2,2-difluoroacetate (141fa): The 
general procedure I was followed using substrate 131f (79 mg, 0.25 mmol) and 139a (152 mg, 
0.75 mmol). Isolation by column chromatography (n-hexane/EtOAc: 2/1) yielded 141fa (83 
mg, 76%) as a light yellow solid. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-
C6H4CF3)3 yielded 141fa (69 mg, 63%).  
M. p. = 134–135 °C.  
1H NMR (600 MHz, CDCl3) δ = 9.11 (d, J = 1.8 Hz, 1H), 9.10 (s, 1H), 9.01 (d, J = 8.2 Hz, 1H), 
8.47 (s, 1H), 8.19 (d, J = 8.6 Hz, 2H), 7.95 (d, J = 8.6 Hz, 2H), 7.79 (dd, J = 7.6, 1.4 Hz, 1H), 
7.67 (dd, J = 8.2, 7.6 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 2.66 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 196.3 (Cq), 163.9 (t, 2JC-F = 35.3 Hz, Cq), 154.1 (Cq), 153.1 
(CH), 152.2 (Cq), 142.7 (CH), 138.0 (Cq), 136.5 (Cq), 135.8 (Cq), 133.4 (t, 2JC-F = 25.7 Hz, Cq), 
132.4 (CH), 131.7 (Cq), 130.1 (CH), 129.0 (CH), 128.0 (t, 3JC-F = 5.9 Hz, CH), 126.9 (t, 3JC-F = 
6.3 Hz, CH), 123.0 (CH), 113.2 (t, 1JC-F = 251.5 Hz, Cq), 63.3 (CH2), 26.7 (CH3), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -103.6 (s).  
IR (neat): 3078, 2982, 1757, 1682, 1572, 1227, 1099, 836 cm-1.  
MS (ESI) m/z (relative intensity) 475 (55) [M+K+], 437 (40) [M+H+].  








(141ga): The general procedure I was followed using substrate 131g (70 mg, 0.25 mmol) and 
139a (152 mg, 0.75 mmol). Isolation by column chromatography (n-hexane/EtOAc: 8/1) 
yielded 141ga (56 mg, 56%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead 
of P(4-C6H4CF3)3 yielded 141ga (82 mg, 81%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ = 9.07 (d, J = 1.9 Hz, 1H), 9.03 (s, 1H), 9.00 (dd, J = 7.8, 1.9 
Hz, 1H), 8.35 (s, 1H), 7.77 (ddd, J = 7.8, 1.9, 1.3 Hz, 1H), 7.65 (dd, J = 7.8, 7.8 Hz, 1H), 5.86 
(dd, J = 10.0, 2.8 Hz, 1H), 4.33 (q, J = 7.1 Hz, 2H), 4.25–4.09 (m, 1H), 3.82 (td, J = 11.5, 3.0 
Hz, 1H), 2.27–1.99 (m, 3H), 1.91–1.70 (m, 3H), 1.32 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 163.9 (t, 2JC-F = 35.1 Hz, Cq), 153.1 (Cq), 152.2 (CH), 151.8 
(Cq), 142.4 (CH), 136.1 (Cq), 133.3 (t, 2JC-F = 25.6 Hz, Cq), 132.4 (CH), 131.1 (Cq), 128.9 (CH), 
127.7 (t, 3JC-F = 5.9 Hz, CH), 126.7 (t, 3JC-F = 6.3 Hz, CH), 113.2 (t, 1JC-F = 252.0 Hz, Cq), 82.0 
(CH), 68.9 (CH2), 63.2 (CH2), 31.9 (CH2), 24.9 (CH2), 22.8 (CH2), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -103.5 (d, J = 2.0 Hz).  
IR (neat): 2945, 1761, 1572, 1217, 1081, 728, 575 cm-1.  
MS (ESI) m/z (relative intensity) 425 (50) [M+Na+], 403 (100) [M+H+].  








purin-9-yl}tetrahydrofuran-3,4-diyl diacetate (141ha): The general procedure I was 
followed using substrate 131h (114 mg, 0.25 mmol) and 139a (152 mg, 0.75 mmol). Isolation 
by column chromatography (n-hexane/EtOAc: 1/1) yielded 141ha (81 mg, 56%) as a colorless 
oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) instead of P(4-C6H4CF3)3 yielded 141ha (88 mg, 
61%).  
1H NMR (300 MHz, CDCl3) δ = 9.06 (d, J = 1.8 Hz, 1H), 9.02 (s, 1H), 8.96 (dd, J = 7.9, 1.9 
Hz, 1H), 8.29 (s, 1H), 7.76 (ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 7.64 (dd, J = 7.9, 7.8 Hz, 1H), 6.29 
(d, J = 5.3 Hz, 1H), 6.00 (dd, J = 5.4 Hz, 1H), 5.69 (dd, J = 5.6, 4.4 Hz, 1H), 4.51–4.35 (m, 
3H), 4.31 (q, J = 7.1 Hz, 2H), 2.15 (s, 3H), 2.12 (s, 3H), 2.07 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 170.1 (Cq), 169.4 (Cq), 169.2 (Cq), 163.9 (t, 2JC-F = 35.1 Hz, 
Cq), 153.6 (Cq), 152.4 (CH), 152.1 (Cq), 142.8 (CH), 135.9 (Cq), 133.3 (t, 2JC-F = 25.7 Hz, Cq), 
132.3 (CH), 131.6 (Cq), 128.9 (CH), 127.8 (t, 3JC-F = 5.9 Hz, CH), 126.7 (t, 3JC-F = 6.3 Hz, CH), 
113.2 (t, 1JC-F = 252.0 Hz, Cq), 86.4 (CH), 80.4 (CH), 73.0 (CH), 70.6 (CH), 63.2 (CH2), 63.0 
(CH2), 20.8 (CH3), 20.5 (CH3), 20.4 (CH3), 13.9 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -103.6 (s).  
IR (neat): 2987, 1745, 1209, 1095, 910, 800, 729 cm-1.  
MS (ESI) m/z (relative intensity) 599 (50) [M+Na+], 577 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C26H27F2N4O9 [M+H+] 577.1741, found 577.1734. 
 
 
Ethyl 2-fluoro-2-[3-(pyridin-2-yl)phenyl]acetate (162a): The general procedure H was 
followed using substrate 95a (78 mg, 0.50 mmol) and 161 (278 mg, 1.5 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 8/1) yielded 162a (78 mg, 60%) as a colorless oil.  
1H NMR (600 MHz, CDCl3) δ = 8.68 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.08 (s, 1H), 8.04–7.98 
(m, 1H), 7.77–7.67 (m, 2H), 7.50–7.49 (m, 2H), 7.27–7.19 (m, 1H), 5.84 (d, J = 47.7 Hz, 1H), 





13C NMR (125 MHz, CDCl3) δ = 168.3 (d, 2JC-F = 27.5 Hz, Cq), 156.4 (Cq), 149.6 (CH), 139.9 
(Cq), 136.7 (CH), 134.8 (d, 2JC-F = 20.5 Hz, Cq), 129.1 (CH), 128.0 (d, 4JC-F = 2.1 Hz, CH), 
126.9 (d, 3JC-F = 5.9 Hz, CH), 125.2 (d, 3JC-F = 6.3 Hz, CH), 122.4 (CH), 120.5 (CH), 89.3 (d, 
1JC-F = 185.5 Hz, CH), 61.9 (CH2), 14.1 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -180.3 (d, J = 47.5 Hz).  
IR (neat): 2983, 1754, 1585, 1462, 1205, 1055, 769 cm-1.  
MS (ESI) m/z (relative intensity) 282 (10) [M+Na+], 260 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C15H14FNO2 [M+H+] 260.1081, found 260.1086. 
 
 
Ethyl 2-fluoro-2-[3-(pyrimidin-2-yl)phenyl]acetate (162b): The general procedure H was 
followed using substrate 95i (78 mg, 0.50 mmol) and 161 (278 mg, 1.5 mmol). Isolation by 
column chromatography (n-hexane/EtOAc: 8/1) yielded 162b (74 mg, 57%) as a colorless oil.  
1H NMR (500 MHz, CDCl3) δ = 8.80 (d, J = 4.8 Hz, 2H), 8.56 (d, J = 1.6 Hz, 1H), 8.47 (dd, J 
= 7.8, 1.5 Hz, 1H), 7.58 (dd, J = 7.7, 1.5 Hz, 1H), 7.52 (dd, J = 7.8, 7.7 Hz, 1H), 7.20 (t, J = 
4.8 Hz, 1H), 5.86 (d, J = 47.6 Hz, 1H), 4.44–4.01 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 168.4 (d, 2JC-F = 27.5 Hz, Cq), 163.9 (Cq), 157.3 (CH), 138.1 
(Cq), 134.8 (d, 2JC-F = 20.5 Hz, Cq), 129.2 (d, 4JC-F = 2.1 Hz, CH), 129.1 (CH), 128.7 (d, 3JC-F = 
5.8 Hz, CH), 126.7 (d, 3JC-F = 6.5 Hz, CH), 119.4 (CH), 89.3 (d, 1JC-F = 185.8 Hz, CH), 61.9 
(CH2), 14.0 (CH3).  
19F NMR (471 MHz, CDCl3) δ = -180.1 (d, J = 47.8 Hz).  
IR (neat): 2983, 1754, 1567, 1410, 1204, 1054, 775 cm-1.  
MS (ESI) m/z (relative intensity) 283 (100) [M+Na+], 261 (90) [M+H+].  







Ethyl 2-[3-(1H-pyrazol-1-yl)phenyl]-2-fluoroacetate (162c): The general procedure H was 
followed using 1-phenyl-1H-pyrazole (95p) (72 mg, 0.50 mmol) and 161 (278 mg, 1.5 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 8/1) yielded 162c (96 mg, 77%) as a 
colorless oil.  
1H NMR (500 MHz, CDCl3) δ = 7.93 (dd, J = 2.5, 0.6 Hz, 1H), 7.80 (s, 1H), 7.73 (dd, J = 8.2, 
1.1 Hz, 1H), 7.70 (d, J = 1.8 Hz, 1H), 7.46 (dd, J = 8.2, 7.6 Hz, 1H), 7.36 (dd, J = 7.6, 1.2 Hz, 
1H), 6.45 (dd, J = 2.5, 1.8 Hz, 1H), 5.81 (d, J = 47.6 Hz, 1H), 4.36–4.09 (m, 2H), 1.24 (t, J = 
7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 168.1 (d, 2JC-F = 27.2 Hz, Cq), 141.3 (CH), 140.4 (Cq), 135.7 
(d, 2JC-F = 20.7 Hz, Cq), 129.9 (CH), 126.7 (CH), 124.2 (d, 3JC-F = 6.3 Hz, CH), 120.0 (d, 4JC-F 
= 1.9 Hz, CH), 117.0 (d, 3JC-F = 6.9 Hz, CH), 107.9 (CH), 88.8 (d, 1JC-F = 186.7 Hz, CH), 62.0 
(CH2), 14.0 (CH3).  
19F NMR (471 MHz, CDCl3) δ = -181.8 (d, J = 47.2 Hz).  
IR (neat): 2984, 1754, 1596, 1392, 1204, 1042, 749 cm-1.  
MS (ESI) m/z (relative intensity) 271 (100) [M+Na+], 249 (90) [M+H+].  
HR-MS (ESI) m/z calcd for C13H14FN2O2 [M+H+] 249.1034, found 249.1037.  
 
Ethyl 2-[3-(9-n-butyl-9H-purin-6-yl)phenyl]-2-fluoroacetate (162d): The general procedure 
I was followed using substrate 131a (63 mg, 0.25 mmol) and 161 (139 mg, 0.75 mmol). 
Isolation by column chromatography (n-hexane/EtOAc: 2/1) yielded 162d (54 mg, 60%) as a 
colorless oil.  
1H NMR (500 MHz, CDCl3) δ = 9.01 (s, 1H), 8.90 (d, J = 1.6 Hz, 1H), 8.88 (d, J = 7.3 Hz, 
1H), 8.11 (s, 1H), 7.67–7.55 (m, 2H), 5.91 (d, J = 47.6 Hz, 1H), 4.50–4.01 (m, 4H), 1.97–1.82 
(m, 2H), 1.43–1.33 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ = 168.4 (d, 2JC-F = 27.4 Hz, Cq), 153.6 (Cq), 152.6 (Cq), 152.2 





Hz, CH), 129.1 (CH), 128.7 (d, 3JC-F = 5.8 Hz, CH), 128.2 (d, 3JC-F = 6.3 Hz, CH), 89.3 (d, 1JC-
F = 186.0 Hz, Cq), 61.9 (CH2), 43.7 (CH2), 31.9 (CH2), 19.9 (CH2), 14.0 (CH3), 13.5 (CH3).  
19F NMR (471 MHz, CDCl3) δ = -180.3 (d, J = 48.0 Hz).  
IR (neat): 2961, 2935, 1754, 1572, 1204, 1057, 700 cm-1.  
MS (ESI) m/z (relative intensity) 379 (30) [M+Na+], 357 (100) [M+H+].  




(a) Intermolecular competition between arenes 95 
 
 
2-(4-Fluorophenyl)pyridine (95b) (87 mg, 0.5 mmol), 2-phenylpyridine (95a) (78 mg, 0.5 
mmol), 139a (102 mg, 0.5 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), P(4-
C6H4CF3)3 (46.7 mg, 20 mol %), Na2CO3 (106 mg, 1.0 mmol) and 1,4-dioxane (2.0 mL) were 
placed in a 25 mL Schlenk tube under N2. The mixture was stirred at 60 °C for 18 h. At ambient 
temperature, CH2Cl2 (3 mL) was added, and the reaction mixture was transferred into a round 
flask with CH2Cl2 and concentrated under reduced pressure. Isolation of the residue by column 
chromatography (n-hexane/EtOAc: 10/1) afforded the mixture 140aa and 140ba (86 mg). 
Careful 19F NMR analysis disclosed the ratio of 140aa /140ba to be 1.0/1.0. Their spectral data 








2-(4-Fluorophenyl)pyridine (95b) (87 mg, 0.5 mmol), 2-(4-methoxyphenyl)pyridine (95c) (93 
mg, 0.5 mmol), 139a (102 mg, 0.5 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), 
P(4-C6H4CF3)3 (46.7 mg, 20 mol %), Na2CO3 (106 mg, 1.0 mmol) and 1,4-dioxane (2.0 mL) 
were placed in a 25 mL Schlenk tube under N2. The mixture was stirred at 60 °C for 18 h. At 
ambient temperature, EtOAc (20 mL) was added, and the mixture was filtered through a short 
pad of silica gel and concentrated in vacuo. Yields of products were determined by crude 19F 
NMR spectroscopy using C6F6 (37.2 mg, 0.20 mmol) as internal standard. Their spectral data 
were identical to those reported above. 









2-(4-Fluorophenyl)pyridine (95b) (87 mg, 0.50 mmol), 2-(p-tolyl)pyridine (95n) (85 mg, 0.50 
mmol), 139a (102 mg, 0.50 mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), P(4-
C6H4CF3)3 (46.7 mg, 20 mol %), Na2CO3 (106 mg, 1.0 mmol) and 1,4-dioxane (2.0 mL) were 
placed in a 25 mL Schlenk tube under N2. The mixture was stirred at 60 °C for 18 h. At ambient 
temperature, EtOAc (20 mL) was added, and the mixture was filtered through a short pad of 
silica gel and concentrated in vacuo. Conversions of products were determined by crude 19F 
NMR spectroscopy using C6F6 (37.2 mg, 0.20 mmol) as internal standard.  
 
 






Ethyl 2,2-difluoro-2-[2-methyl-5-(pyridin-2-yl)phenyl]acetate (140na): 
1H NMR (500 MHz, CDCl3) δ = 8.67 (ddd, J = 4.8, 1.3, 1.2 Hz, 1H), 8.21 (d, J = 1.9 Hz, 1H), 
8.00 (dd, J = 7.9, 1.9 Hz, 1H), 7.77–7.67 (m, 2H), 7.31 (d, J = 7.9 Hz, 1H), 7.21 (ddd, J = 6.2, 
4.8, 2.3 Hz, 1H), 4.30 (q, J = 7.1 Hz, 2H), 2.44 (t, J = 2.1 Hz, 3H), 1.28 (t, J = 7.1 Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ = 164.0 (t, 2JC-F = 35.1 Hz, Cq), 156.1 (Cq), 149.6 (CH), 137.2 
(Cq), 137.1 (t, 3JC-F = 3.1 Hz, Cq), 136.8 (CH), 132.4 (CH), 131.5 (t, 2JC-F = 23.3 Hz, Cq), 129.0 
(t, 4JC-F = 1.5 Hz, CH), 124.6 (t, 3JC-F = 9.0 Hz, CH), 122.3 (CH), 120.3 (CH), 114.1 (t, 1JC-F = 
251.9 Hz, Cq), 63.1 (CH2), 19.4 (t, 3JC-F = 2.6 Hz, CH2), 13.8 (CH3).  
19F NMR (471 MHz, CDCl3) δ = -101.3 (s).  
IR (neat): 2985, 1761, 1465, 1294, 1227, 1015, 779 cm-1.  
MS (ESI) m/z (relative intensity) 314 (10) [M+Na+], 292 (100) [M+H+].  




-CF2CO2Et of 140ba 







1-[4-(Trifluoromethyl)phenyl]-1H-pyrazole (95o) (106 mg, 0.50 mmol), 1-(p-tolyl)-1H-
pyrazole (95l) (79 mg, 0.50 mmol), 139a (102 mg, 0.50 mmol), [Ru(O2CMes)2(p-cymene)] 
(28.1 mg, 10 mol %), P(4-C6H4CF3)3 (46.7 mg, 20 mol %), Na2CO3 (106 mg, 1.0 mmol) and 
1,4-dioxane (2.0 mL) were placed in a 25 mL Schlenk tube under N2. The mixture was stirred 
at 60 °C for 18 h. At ambient temperature, EtOAc (20 mL) was added, and the mixture was 
filtered through a short pad of silica gel and concentrated in vacuo. Conversions of products 
were determined by crude 19F NMR spectroscopy using C6F6 (37.2 mg, 0.20 mmol) as internal 
standard.  
 
Ethyl 2-[5-(1H-pyrazol-1-yl)-2-(trifluoromethyl)phenyl]-2,2-difluoroacetate (140oa):  
1H NMR (300 MHz, CDCl3) δ = 8.19 (d, J = 2.3 Hz, 1H), 8.05 (dd, J = 2.6, 0.6 Hz, 1H), 7.98 
(d, J = 8.6 Hz, 1H), 7.87 (dd, J = 8.6, 2.3 Hz, 1H), 7.79 (dd, J = 1.8, 0.6 Hz, 1H), 6.55 (dd, J = 
2.6, 1.8 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H).  
13C NMR (100 MHz, CDCl3) δ = 162.8 (t, 2JC-F = 34.0 Hz, Cq), 142.5 (CH), 140.1 (Cq), 132.8 
(t, 2JC-F = 25.8 Hz, Cq), 129.3 (q, 3JC-F = 5.7 Hz, CH), 126.9 (CH), 125.0 (qt, 2,3JC-F = 33.0, 2.7 
Hz, Cq), 123.2 (q, 1JC-F = 271.3 Hz, Cq), 120.2 (CH), 118.0 (t, 3JC-F = 10.8 Hz, CH), 112.4 (t, 
1JC-F = 253.8 Hz, Cq), 109.1 (CH), 63.6 (CH2), 13.7 (CH3).  
19F NMR (283 MHz, CDCl3) δ = -58.0 (t, J = 11.1 Hz, 3F), -98.9 (q, J = 11.1 Hz, 2F). 
IR (neat): 2988, 1775, 1619, 1310, 1132, 1035, 751 cm-1.  
MS (ESI) m/z (relative intensity) 357 [M+Na+] (40), 335 [M+H+] (100).  







(b) Intermolecular competition between bromides  
 
 
Ethyl 2-bromo-2,2-difluoroacetate (139a) (102 mg, 0.50 mmol), ethyl 2-bromo-2-
methylpropanoate (124a) (98 mg, 0.50 mmol), 2-phenylpyridine (95a) (78 mg, 0.50 mmol), 
[Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), P(4-C6H4CF3)3 (46.7 mg, 20 mol %), Na2CO3 
(106 mg, 1.0 mmol) and 1,4-dioxane (2.0 mL) were placed in a 25 mL Schlenk tube under N2 
and were then stirred at 60 °C for 18 h. At ambient temperature, CH2Cl2 (3.0 mL) was added, 
and the reaction mixture was transferred into a round flask with CH2Cl2 and concentrated under 
reduced pressure. Purification by column chromatography on silica gel (n-hexane/EtOAc: 8/1) 
yielded 157aa (97 mg, 72%) as a colorless oil.  
-CF2CO2Et of 140oa 






1H NMR (300 MHz, CDCl3) δ = 8.69 (ddd, J = 4.8, 1.7, 1.1 Hz, 1H), 8.00 (dd, J = 1.8, 1.7 Hz, 
1H), 7.84 (ddd, J = 7.1, 1.8, 1.8 Hz, 1H), 7.80–7.64 (m, 2H), 7.49–7.33 (m, 2H), 7.22 (ddd, J 
= 6.7, 4.8, 1.7 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 1.64 (s, 6H), 1.18 (t, J = 7.1 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ = 176.7 (Cq), 157.5 (Cq), 149.6 (CH), 145.4 (Cq), 139.5 (Cq), 
136.7 (CH), 128.7 (CH), 126.5 (CH), 125.3 (CH), 124.2 (CH), 122.1 (CH), 120.7 (CH), 60.8 
(Cq), 46.6 (CH2), 26.6 (CH3), 14.1 (CH3).  
IR (neat): 2977, 1723, 1584, 1462, 1251, 1142, 769 cm-1.  
MS (ESI) m/z (relative intensity) 270 (100) [M+H+].  
HR-MS (ESI) m/z calcd for C17H19NO2 [M+H+] 270.1489, found 270.1493.  
The analytical data are in accordance with those previously reported in the literature.[126] 
 
(c) H/D Exchange experiment 
 
 
2-Phenylpyridine (95a) (78 mg, 0.50 mmol), 139a (304 mg, 1.5 mmol), [Ru(O2CMes)2(p-
cymene)] (28.1 mg, 10 mol %), P(4-CF3C6H4)3 (46.7 mg, 20 mol %), Na2CO3 (106 mg, 1.0 
mmol), D2O (50 µL, 2.75 mmol) and 1,4-dioxane (2.0 mL) were placed in a 25 mL Schlenk 
tube under N2 and were then stirred at 60 °C for 1 h. At ambient temperature, the reaction 
mixture was diluted with H2O (10 mL) and extracted with EtOAc (3 × 15 mL). The combined 
organic layer was dried with Na2SO4 and concentrated under reduced pressure. Purification by 
column chromatography on silica gel (n-hexane/EtOAc: 10/1) yielded [D]n-95a (24 mg, 31%) 














(d) meta-C–H Difluoromethylation in the presence of TEMPO 
 
 
2-Phenylpyridine (95a) (78 mg, 0.50 mmol), 139a (304 mg, 1.5 mmol), TEMPO (78 mg, 0.50 
mmol), [Ru(O2CMes)2(p-cymene)] (28.1 mg, 10 mol %), P(4-C6H4CF3)3 (46.7 mg, 20 mol %), 
Na2CO3 (106 mg, 1.0 mmol) and 1,4-dioxane (2.0 mL) were placed in a 25 mL Schlenk tube 
under N2 and were then stirred at 60 °C for 18 h. After completion of the reaction, CH2Cl2 (3.0 
mL) was added at ambient temperature and the volatiles were removed in vacuo. Purification 
by column chromatography on silica gel (n-hexane/EtOAc: 50/1) yielded 95a (74 mg, 95%) as 
a colorless oil and 158 (21 mg, 15%) as a colorless oil. A reaction using Ni(PPh3)2Cl2 (10 mol %) 
instead of P(4-C6H4CF3)3 yielded 158 (17 mg, 12%). 
1H NMR (600 MHz, CDCl3) δ = 4.35 (q, J = 7.1 Hz, 2H), 1.63–1.51 (m, 6H), 1.37 (t, J = 7.1 
Hz, 3H), 1.19 (t, J = 2.6 Hz, 6H), 1.17 (s, 6H).  
13C NMR (125 MHz, CDCl3) δ = 160.6 (t, 2JC-F = 42.6 Hz, Cq), 115.4 (t, 1JC-F = 271.1 Hz, Cq), 
63.0 (CH2), 61.4 (Cq), 40.3 (CH2), 33.5 (t, 5JC-F = 4.3 Hz, CH3), 20.8 (CH3), 17.0 (CH2), 14.0 
(CH3).  
19F NMR (283 MHz, CDCl3) δ = -73.5.  
IR (neat): 2980, 2938, 1772, 1467, 1323, 1120, 688 cm-1.  
MS (ESI) m/z (relative intensity) 280 [M+H+] (100).  
HR-MS (ESI) m/z calcd for C13H24F2NO3 [M+H+] 280.1719, found 280.1721. 








(e) meta-C–H Difluoromethylation with complexes 159 and 160 
 
2-Phenylpyridine (95a) (31 mg, 0.20 mmol), ethyl 2-bromo-2,2-difluoroacetate (139a) (122 mg, 
0.60 mmol), complex 159 (11.0 mg, 10 mol %), P(4-C6H4CF3)3 (19.0 mg, 20 mol %), Na2CO3 
(43 mg, 0.40 mmol) and 1,4-dioxane (1.0 mL) were placed in a 25 mL Schlenk tube under N2 
and were then stirred at 60 °C for 18 h. At ambient temperature, CH2Cl2 (3.0 mL) was added, 
and the reaction mixture was transferred into a round flask with CH2Cl2 and concentrated under 
reduced pressure. Purification by column chromatography on silica gel (n-hexane/EtOAc: 9/1) 
yielded 140aa (15 mg, 27%) as a colorless oil and 95a (21 mg, 70%) as a colorless oil. 
 
 
2-Phenylpyridine (95a) (78 mg, 0.50 mmol), ethyl 2-bromo-2,2-difluoroacetate (139a) (304 mg, 
1.5 mmol), complex 160 (39.0 mg, 10 mol %), MesCO2H (16.4 mg, 20 mol %), Na2CO3 (106 
mg, 1.0 mmol) and 1,4-dioxane (2.0 mL) were placed in a 25 mL Schlenk tube under N2 and 
were then stirred at 60 °C for 18 h. At ambient temperature, CH2Cl2 (3 mL) was added, and the 
reaction mixture was transferred into a round flask with CH2Cl2 and concentrated under reduced 
pressure. Purification by column chromatography on silica gel (n-hexane/EtOAc: 9/1) yielded 
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